EBMに基づく脳神経疾患の基本治療指針　第4版

出版社： メジカルビュー社
著者：
発行日： 2016-04-01
分野： 臨床医学：内科  >  脳神経科学/神経内科学
ISBN： 9784758315562
電子書籍版： 2016-04-01 （第4版第2刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

14,300 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

14,300 円(税込)

購入する

商品紹介

脳神経外科、神経内科で扱う疾患を網羅した本書は、2002年に初版を刊行して以来、各疾患の概念から治療までをエビデンスに基づきコンパクトにまとめて好評を得てきた。2010年に改訂第3版を刊行したが，その後改訂されたガイドライン，新たに追加されたガイドラインの情報を盛り込み，また新たにいくつか項目を追加し，進歩の著しい脳神経疾患の日常診療に対応できるよう内容を一新した。脳外科医，神経内科医の日常診療に是非役立てていただきたい一冊である。

目次

  • EBMに基づく脳神経疾患の基本治療指針　第4版

    ―目次―

    第1章 脳血管障害
    第2章 脳腫瘍
    第3章 頭部外傷
    第4章 小児・先天奇形
    第5章 脊椎・脊髄疾患
    第6章 機能的脳神経外科疾患
    第7章 頭部外傷
    第8章 頭痛
    第9章 感染症
    第10章 炎症性疾患
    第11章 変性疾患
    第12章 後天性／先天性代謝疾患
    第13章 末梢神経障害
    第14章 筋疾患
    第15章 その他の脳神経疾患・治療
    第16章 遺伝子診断と遺伝相談

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 脳血管障害

P.6 掲載の参考文献
1) van Gijn J, Rinkel GJ. Subarachnoid haemorrhage : diagnosis, causes and management. Brain 2001 ; 124 : 249-78.
PubMed
2) 小林祥泰, 他. くも膜下出血の実態. In ; 小林祥泰 編集. 脳卒中データバンク 2015, 中山書店, 東京, 2015, p154-79.
 
3) de Rooij NK, Linn FH, van der Plas JA, et al. Incidence of subarachnoid haemorrhage : a systematic review with emphasis on region, age, gender and time trends. J Neurol Neurosurg Psychiatry 2007 ; 78 : 1365-72.
PubMed
4) Kassell NF, Torner JC, Jane JA, et al. The International Cooperative Study on the Timing of Aneurysm Surgery. Part 2 : Surgical results. J Neurosurg 1990 ; 73 : 37-47.
 
5) Hunt WE, Kosnik EJ. Timing and perioperative care in intracranial aneurysm surgery, Clin Neurosurg 1974 ; 21 : 79-89.
PubMed
6) Drake CG. Report of World Federation of Neurological Surgeons Committee on a Universal Subarachnoid Hemorrhage Grading Scale. J Neurosurg 1988 ; 68 : 985-6.
 
7) Sundt TM Jr, Whisnant JP. Subarachnoid hemorrhage from intracranial aneurysms. Surgical management and natural history of disease. N Engl J Med 1978 ; 299 : 116-22.
PubMed
8) Nieuwkamp DJ, Setz LE, Algra A, et al. Changes in case fatality of aneurysmal subarachnoid haemorrhage over time, according to age, sex, and region : a meta-analysis. Lancet Neurol 2009 ; 8 : 635-42.
PubMed
9) Mayberg MR, Batjer HH, Dacey R, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage. A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 1994 ; 25 : 2315-28.
PubMed
10) Kurth T, Kase C, Berger K, et al. Smoking and risk of hemorrhagic stroke in women, Stroke 2003 ; 34 : 2792-5.
PubMed
11) Vlak MH, Algra A, Brandenburg R, et al. Prevalence of unruptured intracranial aneurysms, with emphasis on sex, age, comorbidity, country, and time period : a systematic review and meta-analysis. Lancet Neurol 2011 ; 10 : 626-36.
PubMed
12) Yamada S, Koizumi A, Iso H, et al. Risk factors for fatal subarachnoid hemorrhage : the Japan Collaborative Cohort Study. Stroke 2003 ; 34 : 2781-7.
PubMed
13) Okamoto K, Horisawa R, Kawamura T, et al. Family history and risk of subarachnoid hemorrhage : a case-control study in Nagoya, Japan. Stroke 2003 ; 34 : 422-6.
PubMed
14) The Magnetic Resonance Angiography in Relatives of Patients with Subarachnoid Hemorrhage Study Group, Risks and benefits of screening for intracranial aneurysms in first-degree relatives of patients with sporadic subarachnoid hemorrhage. N Engl J Med 1999 ; 341 : 1344-50.
 
15) de Steenhuijsen Piters WA, Algra A, van den Broek MF, et al. Seasonal and meteorological determinants of aneurysmal subarachnoid hemorrhage : a systematic review and meta-analysis. J Neurol 2013 ; 260 : 614-9.
PubMed
16) Bassi P, Bandera R, Loiero, M, et al. Warning signs in subarachnoid hemorrhage : a cooperative study. Acta Neurol Scand 1991 ; 84 : 277-81.
PubMed
17) Mayer PL, Awad IA, Todor R, et al. Misdiagnosis of symptomatic cerebral aneurysm. Prevalence and correlation with outcome at four institutions. Stroke 1996 ; 27 : 1558-63.
PubMed
18) 吉峰俊樹, 他. 科学的根拠に基づくくも膜下出血診療ガイドライン. 脳卒中の外科 2003 ; 31 (増刊号 (I)) : 1-60.
 
19) 日本脳卒中学会 脳卒中ガイドライン委員会 編. 脳卒中治療ガイドライン 2015, 協和企画, 東京, 2015.
 
20) van der Wee N, Rinkel GJ, Hasan D, et al. Detection of subarachnoid haemorrhage on early CT : is lumbar puncture still needed after a negative scan? J Neurol Neurosurg Psychiatry 1995 ; 58 : 357-9.
PubMed
21) Wintermark M, Uske A, Chalaron M, et al. Multislice computerized tomography angiography in the evaluation of intracranial aneurysms : a comparison with intraarterial digital subtraction angiography. J Neurosurg 2003 ; 98 : 828-36.
PubMed
22) van Gijn J, van Dongen KJ, Vermeulen M, et al. Perimesencephalic hemorrhage : a nonaneurysmal and benign form of subarachnoid hemorrhage. Neurology 1985 ; 35 : 493-7.
PubMed
23) Andaluz N, Zuccarello M. Yield of further diagnostic work-up of cryptogenic subarachnoid hemorrhage based on bleeding patterns on computed tomographic scans. Neurosurgery 2008 ; 62 : 1040-6.
PubMed
24) Johnston SC, Selvin S, Gress DR. The burden, trends, and demographics of mortality from subarachnoid hemorrhage, Neurology 1998 ; 50 : 1413-8.
PubMed
25) Kassell NF, Drake CG. Timing of aneurysm surgery. Neurosurgery 1982 ; 10 : 514-9.
PubMed
26) Kassell NF, Torner JC, Haley EC, et al. The International Cooperative Study on the Timing of Aneurysm Surgery. Part 1 : Overall management results. J Neurosurg 1990 ; 73 : 18-36.
 
27) Molyneux A, Kerr R, Stratton I, et al. International Subarachnoid Aneurysm Tria (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms : a randomised trial. Lancet 2002 ; 360 : 1267-74.
 
28) Molyneux AJ, Kerr RS, Yu LM, et al. International subarachnoid aneurysm tria (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms : a randomised comparison of effects on survival, dependency, seizures, rebleeding, subgroups, and aneurysm occlusion. Lancet 2005 ; 366 : 809-17.
 
29) Molyneux AJ, Kerr RS, Birks J, et al. Risk of recurrent subarachnoid haemorrhage, death, or dependence and standardised mortality ratios after clipping or coiling of an intracranial aneurysm in the International Subarachnoid Aneurysm Tria (ISAT) : long-term follow-up. Lancet Neurol 2009 ; 8 : 427-33.
 
30) Spetzler RF, McDougall CG, Albuquerque FC, et al. The Barrow Ruptured Aneurysm Trial : 3-year results. J Neurosurg 2013 ; 119 : 146-57.
PubMed
31) Li H, Pan R, Wang H, Rong X, et al. Clipping versus coiling for ruptured intracranial aneurysms : a systematic review and meta-analysis. Stroke 2013 ; 44 : 29-37.
PubMed
32) Johnston SC, Dowd CF, Higashida RT, et al ; Predictors of rehemorrhage after treatment of ruptured intracranial aneurysms : the Cerebral Aneurysm Rerupture After Treatment (CARAT) study. Stroke 2008 ; 39 : 120-5.
PubMed
33) Dorsch NW, King MT. A review of cerebral vasospasm in aneurysmal subarachnoid haemorrhage Part I : Incidence and effects. J Clin Neurosci 1994 ; 1 : 19-26.
 
34) Adams HP Jr, Kassell NF, Torner JC, et al. Predicting cerebral ischemia after aneurysmal subarachnoid hemorrhage : influences of clinical condition, CT results, and antifibrinolytic therapy. A report of the Cooperative Aneurysm Study, Neurology 1987 ; 37 : 1586-91.
PubMed
35) Goddard AJ, Raju PP, Gholkar A : Does the method of treatment of acutely ruptured intracranial aneurysms influence the incidence and duration of cerebral vasospasm and clinical outcome?, J Neurol Neurosurg Psychiatry 2004 ; 75 : 868-72.
PubMed
36) Rabinstein AA, Pichelmann MA, Friedman JA, et al. Symptomatic vasospasm and outcomes following aneurysmal subarachnoid hemorrhage : a comparison between surgical repair and endovascular coil occlusion. J Neurosurg 2003 ; 98 : 319-25.
PubMed
37) Dehdashti AR, Mermillod B, Rufenach DA, et al. Does treatment modality of intracranial ruptured aneurysms influence the incidence of cerebral vasospasm and clinical outcome? Cerebrovasc Dis 2004 ; 17 : 53-60.
 
38) Findlay JM, Kassell NF, Weir BK, et al. A randomized trial of intraoperative, intracisternal tissue plasminogen activator for the prevention of vasospasm. Neurosurgery 1995 ; 37 : 168-78.
PubMed
39) Kodama N, Sasaki T, Kawakami M, et al. Cisternal irrigation therapy with urokinase and ascorbic acid for prevention of vasospasm after aneurysmal subarachnoid hemorrhage. Outcome in 217 patients. Surg Neurol 2000 ; 53 : 110-118.
PubMed
40) Saito I, Asano T, Ochiai C, et al. A double-blind clinical evaluation of the effect of Nizofenone (Y-9179) on delayed ischemic neurological deficits following aneurysmal rupture. Neurol Res 1983 ; 5 : 29-47.
PubMed
41) Shibuya M, Suzuki Y, Sugita K, et al. Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Results of a prospective placebo-controlled double-blind trial. J Neurosurg 1992 ; 76 : 571-7.
 
42) Suzuki S, Sano K, Handa H, et al. Clinical study of OKY-046, a thromboxane synthetase inhibitor, in prevention of cerebral vasospasms and delayed cerebral ischaemic symptoms after subarachnoid haemorrhage due to aneurysmal rupture : a randomized double-blind study. Neurol Res 1989 ; 11 : 79-88.
PubMed
43) Allen, GS, Ahn, HS, Preziosi, TJ, et al. Cerebral arterial spasm-a controlled trial of nimodipine in patients with subarachnoid hemorrhage, N Engl J Med 1983 ; 308 : 619-24.
PubMed
44) Tseng MY, Czosnyka M, Richard H, et al. Effects of acute treatment with pravastatin on cerebral vasospasm, autoregulation, and delayed ischemic deficits after aneurysmal subarachnoid hemorrhage : a phase II randomized placebocontrolled trial. Stroke 2005 ; 36 : 1627-32.
 
45) Sen J, Belli A, Albon H, et al. Triple-H therapy in the management of aneurysmal subarachnoid haemorrhage. Lancet Neurol 2003 ; 2 : 614-21.
PubMed
46) Amin-Hanjani S, Ogilvy CS, Barker FG 2nd : Does intracisternal thrombolysis prevent vasospasm after aneurysmal subarachnoid hemorrhage? A meta-analysis. Neurosurgery 2004 ; 54 : 326-34 ; discussion 334-5.
 
47) Gruber A, Reinprecht A, Bavinzski G, et al. Chronic shuntdependent hydrocephalus after early surgical and early endovascular treatment of ruptured intracranial aneurysms. Neurosurgery 1999 ; 44 : 503-9 ; discussion 509-12.
 
48) Sethi H, Moore A, Dervin J, et al. Hydrocephalus : comparison of clipping and embolization in aneurysm treatment. J Neurosurg 2000 ; 92 : 991-4.
PubMed
P.14 掲載の参考文献
1) Vlak MH, Algra A, Brandenburg R, et al. Prevalence of unruptured intracranial aneurysms, with emphasis on sex, age, comorbidity, country, and time period : a systematic review and meta-analysis. Lancet Neurol 2011 ; 10 : 626-36. Epub 2011/06/07.
 
2) Vlak MH, Rinkel GJ, Greebe P, et al. Independent risk factors for intracranial aneurysms and their joint effect : a case-control study. Stroke 2013 ; 44 : 984-7. Epub 2013/02/21.
 
3) Weir B. Unruptured intracranial aneurysms : a review. J Neurosurg 2002 ; 96 : 3-42. Epub 2002/01/17.
 
4) Wiebers DO, Whisnant JP, Huston J, 3rd, et al. Unruptured intracranial aneurysms : natural history, clinical outcome, and risks of surgical and endovascular treatment. Lancet 2003 ; 362 : 103-10. Epub 2003/07/18.
 
5) Otawara Y, Ogasawara K, Ogawa A, et al. Cognitive function before and after surgery in patients with unruptured intracranial aneurysm. Stroke 2005 ; 36 : 142-3. Epub 2004/12/01.
 
6) Morita A, UCAS II Investigators. Management Outcome in the Unruputred Cerebral Aneurysm Study II (UCAS II : Interim Report. Jpn J Neurosurg 2011 ; 20 : 484-90.
 
7) Shigematsu T, Fujinaka T, Yoshimine T, et al. Endovascular therapy for asymptomatic unruptured intracranial aneurysms : JR-NET and JR-NET2 findings. Stroke 2013 ; 44 : 2735-42. Epub 2013/08/01.
 
8) Johnston SC, Dudley RA, Gress DR, et al. Surgical and endovascular treatment of unruptured cerebral aneurysms at university hospitals. Neurology 1999 ; 52 : 1799-805. Epub 1999/06/17.
 
9) McDonald JS, McDonald RJ, Fan J, et al. Comparative effectiveness of unruptured cerebral aneurysm therapies : propensity score analysis of clipping versus coiling. Stroke 2013 ; 44 : 988-94. Epub 2013/03/02.
 
10) Wermer MJ, van der Schaaf IC, Algra A, et al. Risk of rupture of unruptured intracranial aneurysms in relation to patient and aneurysm characteristics : an updated meta-analysis. Stroke 2007 ; 38 : 1404-10.
PubMed
11) Ishibashi T, Murayama Y, Urashima M, et al. Unruptured intracranial aneurysms : incidence of rupture and risk factors. Stroke 2009 ; 40 : 313-6. Epub 2008/10/11.
 
12) Sonobe M, Yamazaki T, Yonekura M, et al. Small unruptured intracranial aneurysm verification study : SUAVe study, Japan. Stroke 2010 ; 41 : 1969-77. Epub 2010/07/31.
 
13) Morita A, Kirino T, Hashi K, et al. The natural course of unruptured cerebral aneurysms in a Japanese cohort. N Engl J Med 2012 ; 366 : 2474-82. Epub 2012/06/29.
 
14) Greving JP, Wermer MJ, Brown RD, Jr, et al. Development of the PHASES score for prediction of risk of rupture of intracranial aneurysms : a pooled analysis of six prospective cohort studies. Lancet Neurol 2014 ; 13 : 59-66. Epub 2013/12/03.
 
15) Tominari S, Morita A, Ishibashi T, et al. Prediction model for 3-year rupture risk of unruptured cerebral aneurysms in Japanese patients. Ann Neurol 2015 ; 77 : 1050-9. Epub 2015/03/11.
 
16) Inoue T, Shimizu H, Fujimura M, et al. Annual rupture risk of growing unruptured cerebral aneurysms detected by magnetic resonance angiography. J Neurosurg 2012 ; 117 : 20-5. Epub 2012/05/01.
 
17) Juvela S, Lehto H. Risk factors for all-cause death after diagnosis of unruptured intracranial aneurysms. Neurology 2015 ; 84 : 456-63. Epub 2015/01/09.
 
18) Pyysalo L, Luostarinen T, Keski-Nisula L, et al. Long-term excess mortality of patients with treated and untreated unruptured intracranial aneurysms. J Neurol Neurosurg Psychiatry 2013 ; 84 : 888-92. Epub 2013/02/21.
 
19) Yoshimoto Y, Tanaka Y. Risk perception of unruptured intracranial aneurysms. Acta Neurochir (Wien) 2013 ; 155 : 2029-36. Epub 2013/08/08.
 
20) King JT Jr, Yonas H, Horowitz MB, et al. A failure to communicate : patients with cerebral aneurysms and vascular neurosurgeons. J Neurol Neurosurg Psychiatry 2005 ; 76 : 550-4. Epub 2005/03/19.
 
P.17 掲載の参考文献
1) Spetzler RF, Zabramski JM. Grading and staged resection of cerebral arteriovenous malformations. Clin Neurosurg 1990 ; 36 : 318-37.
PubMed
2) Han PP, Ponce FA, Spetzler RF. Intention-to-treat analysis of Spetzler-Martin grades IV and V arteriovenous malformations : natural history and treatment paradigm. J Neurosurg 2003 ; 98 : 3-7.
PubMed
3) Ogilvy CS, Stieg PE, Awad I, et al. AHA Scientific Statement : Recommendations for the management of intracranial arteriovenous malformations : a statement for healthcare professionals from a special writing group of the Stroke Council, American Stroke Association. Stroke 2001 ; 32 : 1458-71.
PubMed
4) Lawton MT, Kim H, McCulloch CE, et al. A supplementary grading scale for selecting patients with brain arteriovenous malformations for surgery. Neurosurgery 2010 ; 66 : 702-13.
PubMed
5) Pollock BE, Flickinger JC. Modification of the radiosurgery-based arteriovenous malformation grading system. Neurosurgery 2008 ; 63 : 239-43.
PubMed
6) Starke RM, Yen CP, Ding D, et al. A practical grading scale for predicting outcome after radiosurgery for arteriovenous malformations : analysis of 1012 treated patients. J Neurosurg 2013 ; 119 : 981-7.
PubMed
7) Meyers PM, Schumacher HC, Higashida RT, et al. Indications for the performance of intracranial endovascular neurointerventional procedures : a scientific statement from the American Heart Association Council on Cardiovascular Radiology and Intervention, Stroke Council, Council on Cardiovascular Surgery and Anesthesia, Interdisciplinary Council on Peripheral Vascular Disease, and Interdisciplinary Council on Quality of Care and Outcomes Research. Circulation 2009 ; 119 : 2235-49.
PubMed
8) Kondo R, Matsumoto Y, Endo H, et al. Endovascular embolization of cerebral arteriovenous malformations : results of the Japanese Registry of Neuroendovascular Therapy (JR-NET) 1 and 2. Neurol Med Chir (Tokyo) 2014 ; 54 : 54-62.
 
9) Jessurun GA, Kamphuis DJ, van der Zande FH, et al. Cerebral arteriovenous malformations in The Netherlands Antilles. High prevalence of hereditary hemorrhagic telangiectasia-related single and multiple cerebral arteriovenous malformations. Clin Neurol Neurosurg 1993 ; 95 : 193-8.
PubMed
10) Brown RD Jr, Wiebers DO, Torner JC, et al. Incidence and prevalence of intracranial vascular malformations in Olmsted County, Minnesota, 1965 to 1992. Neurology 1996 ; 46 : 949-52.
PubMed
11) Hillman J. Population-based analysis of arteriovenous malformation treatment. J Neurosurg 2001 ; 95 : 633-7.
PubMed
12) Gross BA, Du R. Natural history of cerebral arteriovenous malformations : a meta-analysis. J Neurosurg 2013 ; 118 : 437-43.
PubMed
13) Crawford PM, West CR, Chadwick DW, et al. Arteriovenous malformations of the brain : natural history in unoperated patients. J Neurol Neurosurg Psychiatry 1986 ; 49 : 1-10.
PubMed
14) Brown RD Jr, Wiebers DO, Forbes G, et al. The natural history of unruptured intracranial arteriovenous malformations. J Neurosurg 1988 ; 68 : 352-7.
PubMed
15) Mast H, Young WL, Koennecke HC, et al. Risk of spontaneous haemorrhage after diagnosis of cerebral arteriovenous malformation. Lancet 1997 ; 350 : 1065-6.
PubMed
16) Patel MC, Hodgson TJ, Kemeny AA, et al. Spontaneous obliteration of pial arteriovenous malformations : a review of 27 cases. AJNR Am J Neuroradiol 2001 ; 22 : 531-6.
PubMed
17) van Beijnum J, Lovelock CE, Cordonnier C, et al. SIVMS Steering Committee and the Oxford Vascular Study : Outcome after spontaneous and arteriovenous malformation-related intracerebral haemorrhage : population-based studies. Brain 2009 ; 132 (Pt 2) : 537-43.
 
18) Yamada S, Takagi Y, Nozaki K, et al. Risk factors for subsequent hemorrhage in patients with cerebral arteriovenous malformations. J Neurosurg 2007 ; 107 : 965-72.
PubMed
19) Hernesniemi JA, Dashti R, Juvela S, et al. Natural history of brain arteriovenous malformations : a long-term follow-up study of risk of hemorrhage in 238 patients. Neurosurgery 2008 ; 63 : 823-9.
PubMed
20) Heros RC, Korosue K, Diebold PM : Surgical excision of cerebral arteriovenous malformations : late results. Neurosurgery 1990 ; 26 : 570-7.
PubMed
21) Hamilton MG, Spetzler RF. The prospective application of a grading system for arteriovenous malformations. Neurosurgery 1994 ; 34 : 2-6.
PubMed
22) Lawton MT. UCSF Brain Arteriovenous Malformation Study Project : Spetzler-Martin Grade III arteriovenous malformations : surgical results and a modification of the grading scale. Neurosurgery 2003 ; 52 : 740-8.
 
23) Korja M, Bervini D, Assaad N, et al. Role of surgery in the management of brain arteriovenous malformations : prospective cohort study. Stroke 2014 ; 45 : 3549-55.
PubMed
24) Lawton MT, Du R, Tran MN, et al. Effect of presenting hemorrhage on outcome after microsurgical resection of brain arteriovenous malformations. Neurosurgery 2005 ; 56 : 485-93.
PubMed
25) Miyamoto S, Hashimoto N,Nagata I, et al. Posttreatment sequelae of palliatively treated cerebral arteriovenous malformations. Neurosurgery 2000 ; 46 : 589-95.
PubMed
26) Mohr JP, Parides MK, Stapf C, et al. international ARUBA investigators : Medical management with or without interventional therapy for unruptured brain arteriovenous malformations (ARUBA) : a multicentre, non-blinded, randomised trial. Lancetv ; 383 (9917) : 614-21.
 
27) FloresBC, Klinger DR, RickertKL, et al. Management of intracranial aneurysms associated with arteriovenous malformations. Neurosurg Focus2014 ; 37 : E11.
PubMed
28) Spetzler RF, Wilson CB, Weinstein P, et al. Normal perfusion pressure breakthrough theory. Clin Neurosurg 1978 ; 25 : 651-72.
PubMed
29) al-Rodhan NR, Sundt TM Jr, Piepgras DG, et al. Occlusive hyperemia : a theory for the hemodynamic complications following resection of intracerebral arteriovenous malformations. J Neurosurg 1993 ; 78 : 167-75.
PubMed
30) Loh Y, Duckwiler GR. A prospective, multicenter, randomized trial of the Onyx liquid embolic system and N-butyl cyanoacrylate embolization of cerebral arteriovenous malformations. J Neurosurg 2010 ; 113 : 733-41.
 
31) Hartmann A, Pile-Spellman J, Stapf C, et al. Risk of endovascular treatment of brain arteriovenous malformations. Stroke 2002 ; 33 : 1816-20.
PubMed
32) Taylor CL, Dutton K, Rappard G, et al. Complications of preoperative embolization of cerebral arteriovenous malformations. J Neurosurg 2004 ; 100 : 810-2.
PubMed
33) Englot DJ, Young WL, Han SJ, et al. Seizure predictors and control after microsurgical resection of supratentorial arteriovenous malformations. Neurosurgery 2012 ; 71 : 572-80.
PubMed
34) Yeh HS, Tew JM Jr, Gartner M. Seizure control after surgery on ce ebral arteriovenous malformations. J Neurosurg 1993 ; 78 : 12-8.
 
35) Schauble B, Cascino GD, Pollock BE, et al. Seizure outcomes after stereotactic radiosurgery for cerebral arteriovenous malformations. Neurology 2004 ; 63 : 683-7.
PubMed
36) Yang SY, Kim DG, Chung HT, et al. Radiosurgery for unruptured cerebral arteriovenous malformations : long-term seizure outcome. Neurology 2012 ; 78 : 1292-8.
PubMed
37) Josephson CB, Bhattacharya JJ, Counsell CE, et al. Seizure risk with AVM treatment or conservative management : prospective, population-based study. Neurology 2012 ; 79 : 500-7.
PubMed
P.24 掲載の参考文献
1) 日本脳卒中学会 脳卒中ガイドライン委員会. 脳卒中治療ガイドライン 2015, 協和企画, 東京, 2015, p138-80.
 
2) Hemphill JC 3rd, Greenberg SM, Anderson CS, et al. Guideline for the Management of Spontaneous Intracerebral Hemorrhage : A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2015 ; 46 : 2032-60.
PubMed
3) 大根田玄寿. 脳出血の原理, 文光堂, 東京, 1974, p20-75.
 
4) 小林祥泰. 脳卒中データバンク 2015, 中山書店, 東京, 2015.
 
5) Qureshi AI, Mendelow AD, Hanley DF. Intracerebral haemorrhage. Lancet 2009 ; 373 : 1632-44.
PubMed
6) Ariesen MJ, Claus SP, Rinkel GJ, et al. Risk factors for intracerebral hemorrhage in the general population : a systematic review. Stroke 2003 ; 34 : 2060-5.
PubMed
7) Hackam DG, Woodward M, Newby LK, et al. Statins and intracerebral hemorrhage : collaborative systematic review and meta-analysis. Circulation 2011 ; 124 : 2233-42.
PubMed
8) Wang X, Dong Y, Qi X, et al. Cholesterol levels and risk of hemorrhagic stroke : a systematic review and meta-analysis. Stroke 2013 ; 44 : 1833-9.
PubMed
9) Sarwar N, Gao P, Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease : a collaborative meta-analysis of 102 prospective studies. Lancet 2010 ; 375 : 2215-22.
PubMed
10) Yatsuya H, Toyoshima H, Yamagishi K, et al. Body mass index and risk of stroke and myocardial infarction in a relatively lean population : meta-analysis of 16 Japanese cohorts using individual data. Circ Cardiovasc Qual Outcomes 2010 ; 3 : 498-505.
 
11) Reynolds K, Lewis B, Nolen JD, et al. Alcohol consumption and risk of stroke : a meta-analysis. JAMA 2003 ; 289 : 579-88.
PubMed
12) Iso H, Date C, Yamamoto A, Toyoshima H, et al. Smoking cessation and mortality from cardiovascular disease among Japanese men and women : the JACC Study. Am J Epidemiol 2005 ; 161 : 170-9.
PubMed
13) Gomori JM, Grossman RI, Goldberg HI, et al. Intracranial hematomas : imaging by high-field MR. Radiology 1985 ; 157 : 87-93.
 
14) Kwak R, Kadoya S, Suzuki T. Factors affecting the prognosis in thalamic hemorrhage. Stroke 1983 ; 14 : 493-500.
PubMed
15) Hemphill JC 3rd, Bonovich DC, Besmertis L, et al. The ICH score : a simple, reliable grading scale for intracerebral hemorrhage. Stroke 2001 ; 32 : 891-7.
 
16) 金谷春之, 湯川英機, 神野哲夫, 他. 高血圧性脳出血における新しいNeurological GradingおよびCTによる血腫分類とその予後について. 高血圧性脳出血の外科 III, ニューロン社, 東京, 1978, p256-70.
 
17) Anderson CS, Heeley E, Huang Y, et al. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med 2013 ; 368 : 2355-65.
PubMed
18) Koga M, Toyoda K, Yamagami H, et al. Systolic blood pressure lowering to 160mmHg or less using nicardipine in acute intracerebral hemorrhage : a prospective, multicenter, observational study (the Stroke Acute Management with Urgent Risk-factor Assessment and Improvement-Intracerebral Hemorrhage study). J Hypertens 2012 ; 30 : 2357-64.
PubMed
19) Arakawa S, Saku Y, Ibayashi S, et al. Blood pressure control and recurrence of hypertensive brain hemorrhage. Stroke 1998 ; 29 : 1806-9.
PubMed
20) Arima H, Chalmers J, Woodward M, et al. Lower target blood pressures are safe and effective for the prevention of recurrent stroke : the PROGRESS trial. J Hypertens 2006 ; 24 : 1201-8.
 
21) Lovelock CE, Cordonnier C, Naka H, et al. Antithrombotic drug use, cerebral microbleeds, and intracerebral hemorrhage : a systematic review of published and unpublished studies. Stroke 2010 ; 41 : 1222-8.
PubMed
22) Kollmar R, Staykov D, Dorfler A, et al. Hypothermia reduces perihemorrhagic edema after intracerebral hemorrhage. Stroke 2010 ; 41 : 1684-9.
PubMed
23) Dennis M, Sandercock PA, Reid J, et al. Effectiveness of thighlength graduated compression stockings to reduce the risk of deep vein thrombosis after stroke (CLOTS trial 1) : a multicentre, randomised controlled trial. Lancet 2009 ; 373 : 1958-65.
PubMed
24) Dennis M, Sandercock P, Reid J, et al. Effectiveness of intermittent pneumatic compression in reduction of risk of deep vein thrombosis in patients who have had a stroke (CLOTS 3) : a multicentre randomised controlled trial. Lancet 2013 ; 382 : 516-24.
PubMed
25) Paciaroni M, Agnelli G, Venti M, at al. Efficacy and safety of anticoagulants in the prevention of venous thromboembolism in patients with acute cerebral hemorrhage : a meta-analysis of controlled studies. J Thromb Haemost 2011 ; 9 : 893-8.
 
26) Mendelow AD, Gregson BA, Fernandes HM, et al. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH) : a randomised trial. Lancet 2005 ; 365 : 387-97.
 
27) Mendelow AD, Gregson BA, Rowan EN, et al. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial lobar intracerebral haematomas (STICH II) : a randomised trial. Lancet 2013 ; 382 : 397-408.
 
28) Prasad K, Mendelow AD, Gregson B. Surgery for primary supratentorial intracerebral haemorrhage. Cochrane Database Syst Rev, 2008
PubMed
29) Gregson BA, Broderick JP, Auer LM, et al. Individual patient data subgroup meta-analysis of surgery for spontaneous supratentorial intracerebral hemorrhage. Stroke 2012 ; 43 : 1496-504.
PubMed
30) Hattori N, Katayama Y, Maya Y, et al. Impact of stereotactic hematoma evacuation on activities of daily living during the chronic period following spontaneous putaminal hemorrhage : a randomiIzed study. J Neurosurg 2004 ; 101 : 417-20.
PubMed
31) Mould WA, Carhuapoma JR, Muschelli J, et al. Minimally invasive surgery plus recombinant tissue-type plasminogen activator for intracerebral hemorrhage evacuation decreases perihematomal edema. Stroke 2013 ; 44 : 627-34.
PubMed
32) Morgan T, Awad I, Keyl P, et al. Preliminary report of the clot lysis evaluating accelerated resolution of intraventricular hemorrhage (CLEAR-IVH) clinical trial. Acta Neurochir Suppl 2008 ; 105 : 217-20.
PubMed
33) 金谷春之. 高血圧性脳出血の治療の現況-全国調査の成績より-. 脳卒中 1990 ; 12 : 509-24.
 
34) Toyoda K, Yasaka M, Iwade K, et al. Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease : a prospective, multicenter, observational study. Stroke 2008 ; 39 : 1740-5.
PubMed
P.40 掲載の参考文献
1) 日本脳卒中学会 脳卒中ガイドライン委員会. 脳卒中治療ガイドライン 2015, 協和企画, 2015.
 
2) 小林祥泰 編. 脳卒中データバンク 2015, 中山書店, 2015.
 
3) 木村和美, 数井誠司, 峰松一夫, 他. 発症後3時間以内に受診した脳梗塞の入院時NIHSSスコアと退院時転帰脳梗塞急性期医療の実態に関する研究グループ (J-MUSIC). 脳卒中 2003 ; 25 : 312-21.
 
4) National Institute of Neurological Disorders and Stroke Ad Hoc Committee. Stroke 1990 ; 21 : 637-76.
 
5) 日本脳卒中学会脳卒中医療向上・社会保険委員会, rt-PA (アルテプラーゼ) 静注療法指針改訂部会. rt-PA (アルテプラーゼ) 静注療法適正治療指針 第二版, 2012.
 
6) Brott T, Adams HP Jr, Olinger CP, et al. Measurements of acute cerebral infarction : a clinical examination scale. Stroke 1989 ; 20 : 864-70.
PubMed
7) The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995 ; 333 : 1581-7.
 
8) Van Swieten JC, Koudstaal PJ, Visser MC, et al. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988 ; 19 : 604-7.
 
9) Barber PA, Demchuk AM, Zhang J, et al. Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Programme Early CT Score. Lancet 2000 ; 355 : 1670-4.
 
10) Wardlaw JM, Mielke O. Early signs of brain infarction at CT : Observer reliability and outcome after thrombolytic treatment-systematic review. Radiology 2005 ; 235 : 444-53.
PubMed
11) Nezu T, Koga M, Kimura K, et al. Pretreatment ASPECTS on DWI predicts 3-month outcome following rt-PA : SAMURAI rt-PA Registry. Neurology 2010 ; 75 : 555-61.
PubMed
12) Cho KH, Kim JS, Kwon SU, et al. Significance of susceptibility vessel sign on T2*-weighted gradient echo imaging for identification of stroke subtypes. Stroke 2005 ; 36 : 2379-83.
PubMed
13) Marks MP, Tong DC, Beaulieu C, et al. Evaluation of early reperfusion and i.v. tPA therapy using diffusion-and perfusion-weighted MRI. Neurology 1999 ; 52 : 1792-8.
 
14) Iso H, Sato S, Kitamura A, et al. metabolic syndrome and the risk of ischemic heart disease and stroke among Japanese men and women. Stroke 2007 ; 38 : 1744-51.
PubMed
15) Kaptoge S, Di Angelantonio E, Lowe G, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality : an individual participant meta-analysis. Lancet 2010 ; 375 : 132-40.
 
16) 日本高血圧学会ガイドライン作成委員会 編. 高血圧治療ガイドライン 2014, 21, 2014.
 
17) 日本動脈硬化学会 編. 動脈硬化性疾患予防ガイドライン 2012, 33, 2012.
 
18) 日本糖尿病学会 編. 糖尿病治療ガイド 2014-2015, 20, 2014.
 
19) Lawers CM, Rodgers A, Bennett DA, et al. Asia Pacific Cohort Studies Collaboration. Blood pressure and cardiovascular disease in the Asia pacific region. J Hypertens 2003 ; 21 : 707-16.
 
20) Woodward M, Zhang X, Barzi F, et al. Asia Pacific Cohort Studies Collaboration. The effect of diabetes on the risk of major cardiovascular disease and death in the Asia-pacific region. Diabetes Care 2003 ; 26 360-6.
 
21) 大村隆夫, 上田一雄, 清原裕, 他. 一般住民の22年間追跡調査における耐糖能異常と脳卒中発症の関連 久山朝研究. 糖尿病 1993 ; 36 : 17-24.
 
22) Zhang X, Patel A, Horibe H, et al. Asia Pacific Cohort Studies Collaboration. Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. Int J Epidemiol 2003 ; 32 : 563-72.
 
23) Imamura T, Doi Y, Arima H, et al. Low-density lipoprotein cholesterol and the development of stroke subtypes and coronary heart disease in a general Japanese population : the Hisayama Study. Stroke 2009 ; 40 : 382-8.
 
24) Nakaya N, Kita T, Mabuchi H, et al. Large-scale cohort study on the relationship between serum lipid concentrations and risk of cerebrovascular disease under low-dose simvastatin in Japanese patients with hypercholesterolemia : Sub-Analysis of the Japan Lipid Intervention Trial (J-LIT). Circ J 2005 ; 69 : 1016-21.
 
25) Tanizaki Y, Kiyohara Y, Kato I, et al. Incidence and risk factors for subtypes of cerebral infarction in a general population : the Hisayama study. Stroke 2000 ; 31 : 2616-22.
 
26) Hohnloser SH, Pajitnev D, Poque J, et al. ACTIVE W investigators. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy : an ACTIVE W Substudy. J Am Coll Cardiol 2007 ; 50 : 2156-61.
PubMed
27) Go AS, Hylek EM, Chang Y, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation : how well do randomized trials translate into clinical practice? JAMA 2003 ; 290 : 2685-92.
PubMed
28) Gage BF, van Walraven C, Pearce L, et al. Selecting patients with atrial fibrillation for anticoagulation : stroke risk stratification in patients taking aspirin. Circulation 2004 ; 110 : 2287-92.
PubMed
29) Camm AJ, Lip GY, De Caterina R, et al. ESC Committee for Practice Guidelines (CGP). Eur Heart J 2012 ; 33 : 2719-47.
 
30) Shinton R, Beevers G. Meta-analysis of relation between cigarette smoking and stroke. BMJ 1989 ; 298 : 789-94.
PubMed
31) Mannami T, Iso H, Baba S, et al. Japan Public Health Center-based Prospective Study on Cancer and Cardiovascular Disease Group. Cigarette smoking and risk of stroke and its subtypes among middle-aged Japanese men and women : the JPHC Study Cohort I. Stroke 2004 ; 35 : 1248-53.
PubMed
32) Oono IP, Mackay DF, Pell JP. Mata-analysis of the association between second hand smoke exposure and stroke. J public Health 2011 ; 33 : 496-502.
 
33) Hata J, Doi Y, Ninomiya T, et al. The effect of metabolic syndrome defined by various criteria on the development of ischemic stroke subtypes in general Japanese population. Atherosclerosis, 2010 ; 210 : 249-55.
PubMed
34) 社団法人 日本腎臓病学会 編. CKD診療ガイド 2012, 株式会社東京医学社, 2012.
 
35) Ninomiya T, Kiyohara Y, Tokuda Y, et al. Japan Arteriosclerosis Longitudinal Study Group. Circulation 2008 ; 118 : 2694-701.
PubMed
36) Davies DP, Rodgers H, Walshaw D, et al. Snoring, daytime sleepiness and stroke : a case-control study of first-ever stroke. J Sleep Res 2003 ; 12 : 313-8.
PubMed
37) Wu CM, McLaughlin K, Lorenzetti DL, et al. Early risk of stroke after transient ischemic attack : a systematic review and meta-analysis. Arch Intern Med 2007 ; 167 : 2417-22.
PubMed
38) Johnson SC, Rothwell PM, Nguyen-Huynh MN, et al. Validation and refinement of scores to predict very early stroke risk after transient ischemic attack. Lancet 2007 ; 369 : 283-92.
 
39) 峰松一夫. TIA診療マニュアル. 厚生労働科学研究費補助金 一過性脳虚血発作 (TIA) の診断基準の再検討, ならびにわが国の医療環境に則した適切な診断・治療システムの確立に関する研究, 2012.
 
40) Rothwell PM, Giles MF, Chandratheva A, et al. Effect of urgent treatment for transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study) : a prospective population-based sequential comparison. Lancet 2007 ; 370 : 1432-42.
PubMed
41) 金浩澤. 医学のあゆみ 脳梗塞超急性期 Brain attack 時代の診断と治療. ペナンブラとは, 医歯薬出版株式会社, 2001.
 
42) The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995 ; 333 : 1581-7.
 
43) Yamaguchi T, Mori E, Minematsu K, et al. Alteplase at 0.6mg/kg for acute ischemic stroke within 3 hours of onset : Japan Alteplase Clinical Trial. Stroke 2006 ; 37 : 1810-5.
 
44) Hache W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008 ; 359 : 1317-29.
 
45) Lee KR, Bluhmki E, von Kummer R, et al. Time to treatment with intravenous alteplase and outcome in stroke : an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010 ; 375 : 1695-703.
 
46) Broderick JP, Palesch YY, Demchuk AM, et al. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med 2013 ; 368 : 893-903.
PubMed
47) Ciccone A, Valvassori L, Nichelatti M, et al. Endovascular treatment for acute ischemic stroke. N Engl J Med 2013 ; 368 : 904-13.
PubMed
48) Kidwell CS, Jahan R, Gornbein J, et al. A trial of imaging selection and endovascular treatment for ischemic stroke. N Engl J Med 2013 ; 368 : 914-23.
 
49) Berkhemer OA, Fransen PS, Beumer D, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med 2015 ; 372 : 11-20.
PubMed
50) Goyal M, Demchuk AM, Menon BK, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med 2015 ; 372 : 1019-30.
PubMed
51) Campbell BC, Mitchell PJ, Kleinig TJ, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med. 2015 ; 372 : 1009-18.
PubMed
52) Saver JL, Goyal M, Bonafe A, et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med 2015 ; 372 : 2285-95.
PubMed
53) Yoshimura S, Sakai N, Okada Y, et al. Efficacy of endovascular treatment for acute cerebral large-vessel occlusion : analysis of nationwide prospective registry. J Stroke Cerebrovasc Dis 2014 ; 23 : 1183-90.
PubMed
54) Mazighi M, Chaudhry SA, Ribo M, et al. Impact of onset-to-reperfusion time on stroke mortality : A collaborative pooled analysis. Circulation 2013 ; 127 : 1980-5.
PubMed
55) Wang Y, Zhao X, Liu L, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Eng J Med 2013 ; 369 : 11-9.
 
56) Wong KS, Wang Y, Leng X, et al. Early dual versus mono antiplatelet therapy for acute non-cardioembolic ischemic stroke or transient ischemic attack : an updated systematic review and meta-analysis. Circulation 2013 ; 128 : 1656-66.
 
57) Paciaroni M, Agnelli G, Micheli S, et al. Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke : a meta-analysis of ramdomized controlled trials. Stroke 2007 ; 38 : 423-30.
 
58) Kulshreshtha A, VaccarinoV, Judd SE, et al. Life's Simple 7 and risk of incident stroke : the reasons for geographic and racial differences in stroke study. Stroke 2013 ; 44 : 1909-14.
 
59) Staessen JA, Li Y, Thijs L, et al. Blood pressure reduction and cardiovascular prevention : an update including the 2003-2004 secondary prevention trials. Hypertens Res 2005 ; 28 : 385-407.
PubMed
60) Lawes CM, Bennett DA, Feigin VL, et al. Blood pressure and stroke : an overview of published reviews. Stroke 2004 ; 35 : 1024.
PubMed
61) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes : UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998 ; 317 : 703-13.
Medical*Online
62) Calhoun HM, Betterridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS) : multicentre randomized placebo-controlled trial. Lancet 2004 ; 364 : 685-96.
 
63) MRC/BHF Heart Protection Study of Cholesterol lowering with simvastatin in 20,536 high-risk individuals : a randomized placebo-controlled trial. Lancet 2002 ; 360 : 7-22.
PubMed
64) Zhang X, Patel A, Horibe H, et al. Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. Int J Epidemiol 2003 ; 32 : 563-72.
 
65) Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study) : a prospective randomized controlled trial. Lancet 2006 ; 368 : 1155-63.
PubMed
66) Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than- average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial- Lipid Lowering Arm (SCOT-LLA) : a multicenter randomized controlled trial. Lancet 2003 ; 361 : 1149-58.
 
67) January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation : executive summary : a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014 ; 130 : 2071-104.
 
68) Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation : an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012 ; 33 : 2719-47.
PubMed
69) Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009 ; 361 : 1139-51.
PubMed
70) Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011 ; 365 : 1557-9.
 
71) Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011 ; 365 : 981-92.
PubMed
72) Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013 ; 369 : 2093-104.
PubMed
73) Hart RG, Pearce LA, Aguilar MI. Meta-analysis : antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007 ; 146 : 857-67.
PubMed
74) Sato H, Ishikawa k, Kitabatake A. Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation : Japan Atrial Fibrillation Stroke Trial. Stroke 2006 ; 37 ; 447-51.
PubMed
75) Pisters R, Lane DA, Nieuwlatt R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation : the Euro Heart Survey. Chest 2010 ; 138 : 1093-100.
 
76) Iso H, Date C, Yamamoto A, et al. Smoking cessation and mortality from cardiovascular disease among Japanese men and women : the JACC Study. Am J Epidemiol 2005 ; 161 : 170-9.
PubMed
77) Everett BM, Glynn RJ, MacFadyen JG. Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein : justification for the Use of Statins in Prevention : an Intervention Trial Evaluating Rosuvastatin (JUPITER). Circulation 2010 ; 121 : 143-50.
PubMed
78) PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001 ; 358 : 1033-41.
PubMed
79) Wilcox R, Bousser MG, Betteridge DJ, et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke : results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 2007 ; 38 : 865-73.
PubMed
80) Amarenco P, Bogousslavsky J, Callahan, A 3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006 ; 355 : 549-59.
PubMed
81) 日本動脈硬化学会 編. 動脈硬化性疾患予防ガイドライン 2012年版. 日本動脈硬化学会, 杏林社, 2012.
 
82) Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002 ; 324 : 71-86.
PubMed
83) CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996 ; 348 : 1329-39.
 
84) Shinohara Y, Katayama Y, Uchiyama S, et al. Cilostazol for prevention of secondary stroke (CSPS 2) : an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 2010 ; 9 : 959-68.
PubMed
85) Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH) : randomised, double-blind, placebo-controlled trial. Lancet 2004 ; 364 : 331-7.
PubMed
86) Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006 ; 354 : 1706-17.
PubMed
87) Hankey GJ, Johnston SC, Easton JD, et al. Effect of clopidogrel plus ASA vs. ASA early after TIA and ischaemic stroke : a substudy of the CHARISMA trial. Int J Stroke 2011 ; 6 : 3-9.
PubMed
88) Toyoda K, Yasaka M, Iwade K, et al. Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease : a prospective, multicenter, observational study. Stroke 2008 ; 39 : 1740-5.
PubMed
89) 藤元一眞, 藤城光弘, 加藤元嗣, 他. 抗血栓薬服用者に対する消化器内視鏡診療ガイドライン. 日本消化器内視鏡学会雑誌 2012 ; 54 : 2073-102.
 
90) Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group Lancet, 1993 ; 342 : 1255-62.
 
91) Hart RG, Benavente O, McBride R, et al. antithrombotic therapy to prevent stroke in patients with atrial fibrillation : a meta-analysis. Ann Intern Med 1999 ; 131 : 492-501.
PubMed
92) 日本有病者歯科医療学会, 日本口腔外科学会, 日本老年歯科医学会 編. 科学的根拠に基づく抗血栓療法患者の抜歯に関するガイドライン 2010年版, 学術社, 東京, 2010.
 
93) Yadas JS, Wholey MH, Kuntz RE, et al. Protected carotid-artery stenting versus endarterectomy in high-risk patients. N Engl J Med 2004 ; 351 : 1493-501.
 
94) Mas JL, Chatellier G, Beyssen B, et al. Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. N Engl J Med 2006 ; 355 : 1660-71.
PubMed
95) SPACE Collaborative Group, Ringleb PA, Allenberg J, et al. 30 day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients : a randomised non-inferiority trial. Lancet 2006 ; 368 : 1239-47.
 
96) International Carotid Stenting Study investigators, Ederle J, Dobson J, et al., Carotid artery stenting compared with endarterectomy in patients with symptomatic carotid stenosis (International Carotid Stenting Study) : an interim analysis of a randomised controlled trial. Lancet 2010 ; 375 : 985-7.
 
97) Arya S, Pipinos II, Garg N, et al. Carotid endarterectomy is superior to carotid angioplasty and stenting for perioperative and long-term results. Vasc Endovascular Surg 2011 ; 45 : 490-8.
PubMed
98) Brott TG, Hobson RW 2nd, Howard G, et al. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med 2010 ; 363 : 11-23.
PubMed
99) Chimowitz MI, Lynn MJ, Derdeyn CP, et al. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med 2011 ; 365 : 993-1003.
PubMed
100) Derdeyn CP, Chimowitz MI, Lynn MJ, et al. Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS) : the final results of a randomized trial. Lancet 2014 ; 383 : 333-41.
 
101) JET Study Group. Japanese EC-IC Bypass Trial (JET Study) 中間解析結果 (第二報). 脳卒中の外科 2002 ; 30 : 434-7.
 
102) The EC/IC Bypass Study Group. Failure of extracranial-intracranial arterial bypass to reduce the risk of ischemic stroke. Results of an international randomized study. N Engl J Med 1985 ; 313 : 1191-200.
 
103) Powers WJ, Clarke WR, Grubb RL Jr, et al. Exracranial-intracranial bypass surgery for stroke prevention in hemodynamic cerebral ischemia : Carotid Occlusion Surgery Study randomized trial. JAMA 2011 ; 306 : 1983-92.
 
104) Bernick C, Kuller L, Dulberg C, et al. Silent MRI infarcts and the risk of future stroke : the cardiovascular health study. Neurology 2001 ; 57 : 1222-9.
PubMed
105) Vermeer SE, Hollander M, van Dijk EJ, et al. Silent brain infarcts and white matter lesions increase stroke risk in the general population : the Rotterdam Scan Study. Stroke 2003 ; 34 : 1126-9.
PubMed
106) Debette S, Beiser A, DeCarli C, et al. Association of MRI markers of vascular brain injury with incident stroke, mild cognitive impairment, dementia, and mortality : the Framingham Offspring Study. Stroke 2010 ; 41 : 600-6.
PubMed
107) Putaala J, Haapaniemi E, Kurkinen M, et al. Silent brain infarcts, leukoaraiosis, and long-term prognosis in young ischemic stroke patients. Neurology 2011 ; 76 : 1742-9.
PubMed
108) Kobayashi S, Okada K, Koide H, et al. Subcortical silent brain infarction as a risk factor for clinical stroke. Stroke 1997 ; 28 : 1932-9.
PubMed
109) Mok VC, Lam WW, Fan YH, et al. Effects of statins on the progression of cerebral white matter lesion : Post hoc analysis of the ROCAS (Regression of Cerebral Artery Stenosis) study. J Neurol 2009 ; 256 : 750-7.
PubMed
110) Ni J, Yao M, Gao S, et al. Stroke risk and prognostic factors of asymptomatic middle cerebral artery atherosclerotic stenosis. J Neurol Sco 2011 ; 301 : 63-5.
 
111) 新名主宏一, 岡崎智治, 新名主泰文. 低用量シロスタゾール (プレタール) の症候性頭蓋内主幹動脈有意狭窄病変における狭窄改善効果およびその作用機序に関する検討. Progress in Medicine 2013 ; 33 : 631-5.
Medical*Online
112) Abbott AL. Medical (nonsurgical) intervention alone is now best for prevention of stroke associated with asymptomatic severe carotid stenosis : results of a systematic review and analysis. Stroke 2009 ; 40 : 573-83.
 
113) LeFevre ML. Screening for asymptomatic carotid artery stenosis : U. S. preventive services task force recommendation statement. Ann Intern Med 2014 ; 161 : 356-62.
PubMed
114) Goldstein LB, Bushnell CD, Adams RJ, et al. Guidelines for the primary prevention of stroke : a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011 ; 42 : 517-84.
PubMed
P.46 掲載の参考文献
1) Suzuki J, Takaku A. Cerebrovascular 'moyamoya' disease. Disease showing abnormal net-like vessels in base of brain. Arch Neurol 1969 ; 20 : 288-99.
PubMed
2) Kuriyama S, Kusaka Y, Fujimura M, et al. Prevalence and clinicopathological features of moyamoya disease in Japan : Findings from a national epidemiological survey. Stroke 2008 ; 39 : 42-7.
 
3) Fujimura M, Tominaga T. Current Status of Revascularization Surgery for Moyamoya Disease : Special Consideration for Its 'Internal Carotid-External Carotid (IC-EC) Conversion' as the Physiological Reorganization System. Tohoku J Exp Med 2015 ; 236 : 45-53.
PubMed
4) 厚生労働省 ウイリス動脈輪閉塞症における病態・治療に関する研究班 もやもや病 (ウイリス動脈輪閉塞症) 診断・治療ガイドライン. 脳卒中の外科 2009 ; 37 : 321-37.
 
5) Sonobe S, Fujimura M, Niizuma K, et al. Temporal profile of the vascular anatomy evaluated by 9.4-T magnetic resonance angiography and histopathological analysis in mice lacking RNF213 : A susceptibility gene for moyamoya disease. Brain Res 2014 ; 1552 : 64-71.
 
6) Fukui M. Guidelines for the diagnosis and treatment of spontaneous occlusion of the circle of Willis ('moyamoya' disease). Research Committee on Spontaneous Occlusion of the Circle of Willis (Moyamoya Disease) of the Ministry of Health and Welfare, Japan. Clin Neurol Neurosurg 1997 ; 99 Suppl 2 : S238-40.
 
7) Miyamoto S, Yoshimoto T, Hashimoto N, et al. JAM Trial Investigators. Effects of Extracranial-Intracranial Bypass for Patients With Hemorrhagic Moyamoya Disease : Results of the Japan Adult Moyamoya Trial. Stroke 2014 ; 45 : 1415-21.
PubMed
8) Hayashi T, Shirane R, Fujimura M, et al. Postoperative neurological deterioration in pediatric moyamoya disease. Watershed shift and hyperperfusion. J Neurosurg Pediatr 2010 ; 6 : 73-81.
PubMed
9) Fujimura M, Kaneta T, Shimizu H, et al. Cerebral ischemia owing to compression of the brain by swollen temporal muscle used for encephalo-myo-synangiosis in moyamoya disease. Neurosurg Rev 2009 ; 32 : 245-9.
PubMed
10) Fujimura M, Kaneta T, Mugikura S, et al. Temporary neurologic deterioration due to cerebral hyperperfusion after superficial temporal artery-middle cerebral artery anastomosis in patients with adult-onset moyamoya disease. Surg Neurol 2007 ; 67 : 273-82.
PubMed
11) Fujimura M, Shimizu H, Inoue T, et al. Significance of focal cerebral hyperperfusion as a cause of transient neurologic deterioration after EC-IC bypass for moyamoya disease : Comparative study with non-moyamoya patients using 123I-IMP-SPECT. Neurosurgery 2011 ; 68 : 957-65.
 
12) Kuroda S. AMORE Study Group. Asymptomatic moyamoya disease : literature review and ongoing AMORE study. Neurol Med Chir (Tokyo) 2015 ; 55 : 194-8.
 
13) Kuroda S, Hashimoto N, Yoshimoto T, et al. Research Committee on Moyamoya Disease in Japan. Radiological findings, clinical course, and outcome in asymptomatic moyamoya disease : results of multicenter survey in Japan. Stroke 2007 ; 38 : 1430-5.
PubMed
14) Kuroda S, Ishikawa T, Houkin K, et al. Incidence and clinical features of disease progression in adult moyamoya disease. Stroke 2005 ; 36 : 2148-53.
PubMed
15) Mori N, Mugikura S, Higano S, et al. The leptomeningeal "ivy sign" on fluid-attenuated inversion recovery MR imaging in Moyamoya disease. AJNR Am J Neuroradiol 2009 ; 30 : 930-5.
PubMed
P.50 掲載の参考文献
1) Mizutani T, Kojima H, Asamoto S, et al. Pathological mechanism and three-dimensional structure of cerebral dissecting aneurysms. J Neurosurg 2001 ; 94 : 712-7.
PubMed
2) Day AL, Gaposchkin CG, Yu CJ, et al. Spontaneous fusiform middle cerebral artery aneurysms : characteristics and a proposed mechanism of formation. J Neurosurg 2003 ; 99 : 228-40.
 
3) Verny C, Marc G, Pasco A, et al. Middle cerebral artery dissection gives rise to giant serpentine aneurysm. Cerebrovasc Dis 2008 ; 25 : 283-5.
PubMed
4) Debette S, Compter A, Labeyrie MA, et al. Epidemiology, pathophysiology, diagnosis, and management of intracranial artery dissection. Lancet Neurol 2015 ; 14 : 640-54.
PubMed
5) Yamaura A, Ono J, Hirai S. Clinical picture of intracranial non-traumatic dissecting aneurysm. Neuropathology 2000 ; 20 : 85-90.
PubMed
6) Han M, Rim NJ, Lee JS, et al. Feasibility of high-resolution MR imaging for the diagnosis of intracranial vertebrobasilar artery dissection. Eur Radiol 2014 ; 24 : 3017-24.
 
7) Takano K, Yamashita S, Takemoto K, et al. MRI of intracranial vertebral artery dissection : evaluation of intramural haematoma using a black blood, variable-flip-angle 3D turbo spin-echo sequence. Neuroradiology 2013 ; 55 : 845-51.
PubMed
8) Kim TW, Choi HS, Koo J, et al. Intramural hematoma detection by susceptibility-weighted imaging in intracranial vertebral artery dissection. Cerebrovasc Dis 2013 ; 36 : 292-8.
PubMed
9) Ono H, Nakatomi H, Tsutsumi K, et al. Symptomatic recurrence of intracranial arterial dissections : follow-up study of 143 consecutive cases and pathological investigation. Stroke 2013 ; 44 : 126-31.
PubMed
10) Mizutani T, Aruga T, Kirino T, et al. Recurrent subarachnoid hemorrhage from untreated ruptured vertebrobasilar dissecting aneurysms. Neurosurgery 1995 ; 36 : 905-11 ; discussion 12-3.
 
11) Mizutani T, Kojima H, Asamoto S. Healing process for cerebral dissecting aneurysms presenting with subarachnoid hemorrhage. Neurosurgery 2004 ; 54 : 342-7 ; discussion 7-8.
 
12) Hamada J, Kai Y, Morioka M, et al. Multimodal treatment of ruptured dissecting aneurysms of the vertebral artery during the acute stage. J Neurosurg 2003 ; 99 : 960-6.
 
13) Iihara K, Sakai N, Murao K, et al. Dissecting aneurysms of the vertebral artery : a management strategy. J Neurosurg 2002 ; 97 : 259-67.
PubMed
14) Kim BM, Shin YS, Kim SH, et al. Incidence and risk factors of recurrence after endovascular treatment of intracranial vertebrobasilar dissecting aneurysms. Stroke 2011 ; 42 : 2425-30.
PubMed
15) Martin AR, Cruz JP, Matouk CC, et al. The pipeline flow-diverting stent for exclusion of ruptured intracranial aneurysms with difficult morphologies. Neurosurgery 2012 ; 70 (1 Suppl Operative) : 21-8 ; discussion 8.
 
16) Ishikawa T, Nakamura N, Houkin K, et al. Pathological consideration of a "blister-like" aneurysm at the superior wall of the internal carotid artery : case report. Neurosurgery 1997 ; 40 : 403-5 ; discussion 5-6.
 
17) Satoh A, Sugiyama T, Hongo K, et al. Nationwide surveillance of IC anterior (or dorsal) wall aneurysm : with special reference to its dissecting nature. Acta Neurochir Suppl 2008 ; 103 : 51-5.
PubMed
18) Ishikawa T, Mutoh T, Nakayama N, et al. Universal external carotid artery to proximal middle cerebral artery bypass with interposed radial artery graft prior to approaching ruptured blood blister-like aneurysm of the internal carotid artery. Neurol Med Chir (Tokyo) 2009 ; 49 : 553-8.
PubMed
19) Lim YC, Kim BM, Suh SH, et al. Reconstructive treatment of ruptured blood blister-like aneurysms with stent and coil. Neurosurgery 2013 ; 73 : 480-8.
PubMed
20) Lee BH, Kim BM, Park MS, et al. Reconstructive endovascular treatment of ruptured blood blister-like aneurysms of the internal carotid artery. J Neurosurgery 2009 ; 110 : 431-6.
 
21) Meckel S, Singh TP, Undren P, et al. Endovascular treatment using predominantly stent-assisted coil embolization and antiplatelet and anticoagulation management of ruptured blood blister-like aneurysms. AJNR Am J Neuroradiol 2011 ; 32 : 764-71.
PubMed
22) Chalouhi N, Zanaty M, Tjoumakaris S, et al. Treatment of blister-like aneurysms with the pipeline embolization device. Neurosurgery 2014 ; 74 : 527-32 ; discussion 32.
 
23) Naito I, Iwai T, Sasaki T. Management of intracranial vertebral artery dissections initially presenting without subarachnoid hemorrhage. Neurosurgery 2002 ; 51 : 930-7 ; discussion 7-8.
 
24) Metso TM, Metso AJ, Helenius J, et al. Prognosis and safety of anticoagulation in intracranial artery dissections in adults. Stroke 2007 ; 38 : 1837-42.
PubMed
25) Engelter ST, Brandt T, Debette S, et al. Antiplatelets versus anticoagulation in cervical artery dissection. Stroke 2007 ; 38 : 2605-11.
PubMed
P.53 掲載の参考文献
1) Dulli DA, et al. Cerebral venous thrombosis and activated protein C resistance. Stroke 1996 ; 27 : 1731-3.
PubMed
2) Bousser MG, et al. Cerebral venous thrombosis : an update. Lancet Neurol 2007 ; 6 : 162-70.
PubMed
3) Stam J, et al. Thrombosis of the cerebral vein and sinuses. N Engl J Med 2005 ; 352 : 1791-8.
PubMed
4) 日本脳卒中学会, 脳卒中ガイドライン委員会編集. 脳卒中治療ガイドライン 2015, 協和企画, 2015.
 
5) Ferro JM, et al. Prognosis of cerebral vein and dural sinus thrombosis : results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke 2004 ; 35 : 664-70.
 
6) Lowe GD. Virchow's tried revisited : abnormal flow. Pathophysiol Haemost Thromb 2004 ; 33 : 455-7.
 
7) Nakase H, Heimann A, Kempski O. Local cerebral blood flow in a rat cortical vein occlusion model. J Cereb Blood Flow Metab 1996 ; 16 : 720-8.
 
8) Nakase H, Kakizaki T, Miyamoto K, et al. Use of local cerebral blood flow monitoring to predict brain damage after disturbance to the venous circulation : Cortical vein occlusion model by photochemical dye. Neurosurgery 1995 ; 37 : 280-6.
 
9) Bousser MG. Cerebral venous thrombosis : diagnosis and management. J Neurol 2000 ; 247 : 252-8.
PubMed
10) Paciaroni M, et al. Clinical presentations of cerebral vein and sinus thrombosis. In ; Caso V, et al. ed. Handbook on Cerebral Venous Thromhosis, Front Neurol Neurosci, Karger, Bassel, 2008, p77-88.
 
11) Rodallec MH, et al. Cerebral venous thrombosis and multidetector CT angiography : Tips and tricks. Radio Graphics 2006 ; 26 : S5-18.
 
12) Idbaih A, et al. MRI of clot in cerebral venous thrombosis : high diagnosis value of susceptibility-weighted images. Stroke 2006 ; 37 : 991-5.
PubMed
13) Einhaupl KM, et al. Heparin treatment in sinus, venous thrombosis. Lancet 1991 ; 338 : 597-600.
PubMed
14) de Bruijn SF, Stem J. Randomized, placebo-controlled trial of anticoagulant treatment with low-molecular-weight heparin for cerebral sinus thrombosis. Stroke 1999 ; 30 : 484-8.
 
15) Coutinho J, de Bruijn SF, Deveber G, et al. Anticoagulation for cerebral venous sinus thrombosis. Cochrane Database Syst Rev 2011 ; 10 : CD002005.
 
16) Einhaupl K, Stam J, Bousser MG, et al. European Federation of Neurological Societies. EFNS guideline on the treatment of cerebral venous and sinus thrombosis in adult patients. Eur J Neurol. 2010 ; 17 : 1229-35.
PubMed
17) Siddiqui FM, Dandapat S, Banerjee C, et al. Mechanical thrombectomy in cerebral venous thrombosis : systematic review of 185 cases. Stroke 2015 ; 46 : 1263-8.
PubMed
18) Einhaupl K, Bousser MG, de Bruijn SF, egt al. EFNS guideline on the treatment of cerebral venous and sinus thrombosis. Eur J Neurol. 2006 ; 13 : 553-9.
 
19) Hon SF, Li HL, Cheng PW. Use of direct thrombin inhibitor for treatment of cerebral venous thrombosis. J Stroke Cerebrovasc Dis 2012 ; 21 : 915.e11-5.
PubMed
20) Morales H, Jones BV, Leach JL, et al. Documented development of a dural arteriovenous fistula in an infant subsequent to sinus thrombosis : case report and review of the literature. Neuroradiology 2010 ; 52 : 225-9.
 
P.57 掲載の参考文献
1) Acciarri N, Galassi E, Giulioni M, et al. Cavernous malformations of the central nervous system in the pediatric age group. Pediatr Neurosurg 2009 ; 45 : 81-104.
PubMed
2) Al-Holou WN, O'Lynnger TM, Pandey AS, et al. Natural history and imaging prevalence of cavernous malformations in children and young adults. J Neurosurg Pediatrics 2012 ; 9 : 198-205.
 
3) Awad IA, Robinson JR, Mohanty S, et al. Mixed vascular malformations of the brain : clinical and pathogenetic considerations. Neurosurgery 1993 ; 33 : 179-88.
PubMed
4) Barker FG 2nd, Amin-Hanjani S, Butler WE, et al. Temporal clustering of hemorrhage from untreated cavernous malformations of the central nervous system. Neurosurgery 2001 ; 49 : 15-24.
PubMed
5) Batra S, Lin D, Recinos PF, et al. Cavernous malformations : natural history, diagnosis and treatment. Nat Rev Neurol 2009 ; 5 : 659-70.
PubMed
6) Boukobza M, Enjolras O, Guichard JP, et al. Cerebral developmental venous anomalies associated with head and neck venous malformations. AJNR Am J Neuroradiol 1996 ; 17 : 987-94.
PubMed
7) Campbell PG, Jabbour P, Yadla S, et al. Emerging clinical imaging techniques for cerebral cavernous malformations : a systemic review. Neurosurg Focus 2010 ; 29 : E6.
 
8) Campeau NG, Lane JI. De novo development of a lesion with the appearance of a cavernous malformation adjacent to an existing developmental venous anomaly. AJNR Am J Neuroradiol 2005 ; 26 : 156-9.
 
9) Churchyard A, Khangure M, Grainger K. Cerebral cavernous angioma : a potentially benign condition? Successful treatment in 16 cases. J Neurol Neurosurg Psychiatry 1992 ; 55 : 1040-5.
 
10) Curling OD, Kelly DL, Elster AD, et al. An analysis of the natural history of cavernous angiomas. J Neurosurg 1991 ; 75 : 702-8.
 
11) Dalyai RT, Ghobrial G, Awad I, et al. Management of incidental cavernous malformations : a review. Neurosurg Focus 2011 ; 31 : E5.
PubMed
12) Englot DJ, Han SJ, Lawton MT, et al. Predictors of seizure freedom in the surgical treatment of supratentorial cavernous malformations. J Neurosurg 2011 ; 115 : 1169-74.
PubMed
13) Garner TB, Curling OD, Kelly DL, et al. The natural history of intracranial venous angiomas. J Neurosurg 1991 ; 75 : 715-22.
 
14) Gross B, Batjer H, Awad I, et al. Brainstem cavernous malformations : 1390 surgical cases from the literature. World Neurosurg 2013 ; 80 : 89-93.
PubMed
15) Hon JM, Bhattacharya JJ, Counsell CE, et al. The presentation and clinical course of intracranial developmental venous anomalies in adults : a systemic review and prospective, population-bases study. Stroke 2009 ; 40 : 1980-5.
 
16) Kida Y, Hasegawa T, Iwai Y, et al. Radiosurgery for symptom cavernous malformations : a multi-institutional retrospective study in Japan. Surg Neurol Int 2015 ; 6 : S249-57.
 
17) Komiyama M, Yamanaka K, Iwai Y, et al. Venous angiomas with arteriovenous shunts : Report of three cases and review of the literature. Neurosurgery 1999 ; 44 : 1328-34.
PubMed
18) Kondziolka D, Lunsford LD, Kestle JR. The natural history of cerebral cavernous malformations. J Neurosurg 1995 ; 83 : 820-4.
PubMed
19) Lasjaunias P, Burrows P, Planet C. Developmental venous anomalies (DVA) : the so-called venous angioma. Neurosurg Rev 1986 ; 9 : 233-44.
PubMed
20) Lee CC, Pan DHC, Chung WY, et al. Brainstem cavernous malformations : the role of Gamma knife surgery. J Neurosurg 2012 ; (Suppl) 117 : 164-9.
 
21) Lindquist C, Guo WY, Karlsson B, Steiner L. Radiosurgery for venous angiomas. J Neurosurg 1993 ; 78 : 531-6.
PubMed
22) Maraine JN, Awad IA. Intracranial cavernous malformations : lesion behavior and management strategies. Neurosurgery 1995 ; 37 : 591-605.
 
23) McCormick WF. The pathology of vascular ("arteriovenous") malformations. J Neurosurg 1966 ; 24 : 807-16.
PubMed
24) McLaughlin MR, Kondzioka D, Flickinger JC, et al. The prospective natural history of cerebral venous malformations. Neurosurgery 1998 ; 43 : 195-200.
 
25) Monaco EA, Khan AA, Niranjan A, et al. Stereotactic radiosurgery for the treatment of symptom brainstem cavernous malformations. Neurosurg Focus 2010 ; 29 : E11.
 
26) Moore AS, Brown RD, Christianson TJH, et al. Long-term natural history of incidentally discovered cavernous malformations in a single-center cohort. J Neurosurg 2014 ; 120 : 1188-92.
 
27) Naff NJ, Wemmer JR, Hoenig-Rigamonti K, et al. A longitude study of patients with venous malformations : demonstration of a negligible hemorrhage risk and benign natural history. Neurology 1998 ; 50 : 1709-14.
 
28) Nagy G, Kemeny AA. Radiosurgery for cerebral cavernomas. J Neurosurg Science 2015 ; 59 : 295-306.
 
29) 日本脳卒中学会脳卒中ガイドライン委員会. 脳卒中ガイドライン 2015, 協和企画, 東京, 2015.
 
30) Noto S, Fujii M, Akimura T, et al. Management of patients with cavernous angiomas presenting epileptic seizures. Surg Neurol 2005 ; 64 : 495-8.
PubMed
31) Petersen TA, Morrison LA, Schrader RM, et al. Familial versus sporadic cavernous malformations : differences in developmental venous anomaly association and lesion phenotype. AJNR Am J Neuroradiol 2010 ; 31 : 377-82.
PubMed
32) Pham M, Gross B, Bendok B, et al. Radiosurgey for angiographically occult vascular malformations. Neurosurg Focus 2009 ; 26 : E16.
 
33) Rammos SK, Raffella M, Gluseppe L. Developmental venous anomalies : current concepts and implications for management. Neurosurgery 2009 ; 65 : 20-30.
 
34) Revencu N, Vikkula M. Cerebral cavernous malformation : new molecular and clinical insights. J Med Genet 2006 ; 43 : 716-21.
PubMed
35) Rigamonti D, Drayer BP, Johnson PC, et al. The MRI appearance of cavernous malformations (angiomas). J Neurosurg 1987 ; 67 : 518-24.
PubMed
36) Robinson JR, Awad IA, Little JR. Natural history of the cavernous angioma. J Neurosurg 75 : 709-714, 1991
PubMed
37) Ruiz DSM, Delavelle J, Yilmaz H, et al. Parenchymal abnormalities associated with developmental venous anomalies. Neuroradiology 2007 ; 49 : 987-95.
 
38) Schneble HM, Soumare A, Herve D, et al. Antithrombotic therapy and bleeding risk in a prospective cohort study of patients with cerebral cavernous malformations. Stroke 2012 ; 43 : 3196-9.
 
39) Washington CW, McCoy KE, Zipfel GJ. Update on the history of cavernous malformations and factors predicting aggressive clinical presentation. Neurosurg Focus 2010 ; 29 : E7.
PubMed
40) Witiw CD, Abou-Hamden A, Kulkarn A, et al. Cerebral cavernous malformations and pregnancy : hemorrhagic risk and influence on obstetrical management. Neurosurgery 2012 ; 71 : 626-31.
 
P.62 掲載の参考文献
1) Masuda J, Tanaka K, Ueda K, et al. Autopsy study of incidence and distribution of cerebral amyloid angiopathy in Hisayama, Japan. Stroke 1988 ; 19 : 205-10.
 
2) Mandybur TI. Cerebral amyloid angiopathy : The vascular pathology and complications. J Neuropathol Exp Neurol 1986 ; 45 : 79-90.
PubMed
3) Cosgrove GR, Leblanc R, Meagher-Villemure K, et al. Cerebral amyloid angiopathy. Neurology 1985 ; 35 : 625-31.
PubMed
4) Wakai S, Kumakura N, Nagai M. Lobar intracerebral hemorrhage. a clinical, radiographic, and pathological study of 29 consecutive operated cases with negative angiography. J Neurosurg 1992 ; 76 : 231-8.
PubMed
5) Itoh Y, Yamada M, Hayakawa M, et al. Cerebral amyloid angiopathy : a significant cause of cerebellar as well as lobar cerebral hemorrhage in the elderly. J Neurol Sci 1993 ; 116 : 135-41.
PubMed
6) Knudsen KA, Rosand J, Karluk D, et al. Clinical diagnosis of cerebral amyloid angiopathy : Validation of the boston criteria. Neurology 2001 ; 56 : 537-9.
PubMed
7) 山田正仁, 他. 厚生労働科学研究費補助会, 難治性疾患克服研究事業. 平成17年度総括・分担研究報告書. 2006, p66-70.
 
8) Shimode K, Kobayashi S, Imaoka K, et al. Leukoencephalopathyrelated cerebral amyloid angiopathy with cystatin C deposition. Stroke 1996 ; 27 : 1417-9.
PubMed
9) Pfeifer LA, White LR, Ross GW, et al. Cerebral amyloid angiopathy and cognitive function : the HAAS autopsy study. Neurology 2002 ; 58 : 1629-34.
PubMed
10) Okazaki H, Reagan TJ, Campbell RJ. Clinicopathologic studies of primary cerebral amyloid angiopathy. Mayo Clin Proc 1979 ; 54 : 22-31.
PubMed
11) Fazekas F, Kleinert R, Roob G, et al. Histopathologic analysis of foci of signal loss on gradient-echo T2*-weighted MR images in patients with spontaneous intracerebral hemorrhage : evidence of microangiopathy-related microbleeds. AJNR Am J Neuroradiol 1999 ; 20 : 637-42.
PubMed
12) Greenberg SM, O'Donnell HC, Schaefer PW, et al. MRI detection of new hemorrhages : potential marker of progression in cerebral amyloid angiopathy. Neurology 1999 ; 53 : 1135-8.
 
13) van Rooden S, van der Grond J, van den Boom R, et al. Descriptive analysis of the Boston criteria applied to a Dutch-type cerebral amyloid angiopathy population. Stroke 2009 ; 40 : 3022-7.
PubMed
14) Rosand J, Hylek EM, O'Donnell HC, et al. Warfarin-associated hemorrhage and cerebral amyloid angiopathy : a genetic and pathologic study. Neurology 2000 ; 55 : 947-51.
 
15) Haan J, Algra PR, Roos RA. Hereditary cerebral hemorrhage with amyloidosis-dutch type. Clinical and computed tomographic analysis of 24 cases. Arch Neurol 1990 ; 47 : 649-53.
PubMed
16) Brett M, Persey MR, Reilly MM, et al. Transthyretin Leu12pro is associated with systemic, neuropathic and leptomeningeal amyloidosis. Brain 1999 ; 122 (Pt 2) : 183-90.
 
17) Nakamura M, Yamashita T, Ueda M, et al. Neuroradiologic and clinicopathologic features of oculoleptomeningeal type amyloidosis. Neurology 2005 ; 65 : 1051-6.
PubMed
18) O'Donnell HC, Rosand J, Knudsen KA, et al. Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage. N Engl J Med 2000 ; 342 : 240-5.
 
19) Hamaguchi T, Okino S, Sodeyama N, et al. Association of a polymorphism of the transforming growth factor-beta1 gene with cerebral amyloid angiopathy. J Neurol Neurosurg Psychiatry 2005 ; 76 : 696-9.
PubMed
20) Nagai A, Kobayashi S, Shimode K, et al. No mutations in cystatin C gene in cerebral amyloid angiopathy with cystatin C deposition. Mol Chem Neuropathol 1998 ; 33 : 63-78.
PubMed
21) Shimode K, Fujihara S, Nakamura M, et al. Diagnosis of cerebral amyloid angiopathy by enzyme-linked immunosorbent assay of cystatin C in cerebrospinal fluid. Stroke 1991 ; 22 : 860-6.
PubMed
22) Izumihara A, Ishihara T, Iwamoto N, et al. Postoperative outcome of 37 patients with lobar intracerebral hemorrhage related to cerebral amyloid angiopathy. Stroke 1999 ; 30 : 29-33.
PubMed
23) Rosand J, Hylek EM, O'Donnell HC, et al. Warfarin-associated hemorrhage and cerebral amyloid angiopathy : A genetic and pathologic study. Neurology 2000 ; 55 : 947-51.
 
P.67 掲載の参考文献
1) Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996 ; 334 : 494-500.
 
2) Williams O, Brust JC. Hypertensive encephalopathy. Curr Treat Options Cardiovasc Med 2004 ; 6 : 209-16.
PubMed
2) North American Symptomatic Carotid Endarterectomy Trial Collaborators. Benefical effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 1991 ; 325 : 445-53.
 
3) Barnett HJM, Taylor DW, Eliasziw M, et al. for the North American Symptomatic Carotid Endarterectomy Trial Collaborators. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. N Engl J Med 1998 ; 339 : 1415-25.
PubMed
3) Williams G. Hypertensive vascular disease. In ; Braunwald E, Fauci A, Kasper D, et al. eds. Harrison's principles of internal medicine. New York, McGraw-Hill, 2001, p1428-9.
 
4) European Carotid Surgery Trialist's Collaborative Group. MRC European Carotid Surgery Trial : interim results for symptomatic patients with severe (70-99%) stenosis. Lancet 1991 ; 337 : 1235-43.
 
4) Zampaglione B, Pascale C, Marchisio M, et al. Hypertensive urgencies and emergencies. Prevalence and clinical presentation. Hypertension 1996 ; 27 : 144-7.
PubMed
5) Wright RR, Mathews KD. Hypertensive encephalopathy in childhood. J Child Neurol 1996 ; 11 : 193-6.
PubMed
5) 日本脳卒中学会 脳卒中治療ガイドライン委員会編. 脳卒中治療ガイドライン 2015.
 
6) Hallidy A, Mansfield A, Marro J, et al. MRC Asymptomatic Carotid Surgery Trial (ACST) Collaborative Group : Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms : Randomised controlled trial. Lancet 2004 ; 363 : 1491-502.
 
6) Sheth RD, Riggs JE, Bodenstenier JB, et al. Parietal occipital edema in hypertensive encephalopathy : a pathogenic mechanism. Eur Neurol 1996 ; 36 : 25-8.
PubMed
7) Okada T, Hiyoshi K, Noto N, et al. A case of guillain-barre syndrome accompanied by sympathetic overactivity and hypertensive encephalopathy. Acta Paediatr 1996 ; 85 : 1006-8.
PubMed
7) Yadav JS, et al. 2004.V patients with Carotid ications such as for the stenting and angioplasty with protection in patients at high risk for endarterectomy investigators : Protected carotid-artery stenting versus endarterectomy in high-risk patients. N Engl J Med 2004 ; 351 : 1493-501.
 
8) Brott TG, et al. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med 2010 ; 363 : 11-23.
PubMed
8) Amin-Hanjani S, Schwartz RB, Sathi S, et al. Hypertensive encephalopathy as a complication of hyperdynamic therapy for vasospasm : report of two cases. Neurosurgery 1999 ; 44 : 1113-6.
PubMed
9) Ille O, Woimant F, Pruna A, et al. Hypertensive encephalopathy after bilateral carotid endarterectomy. Stroke 1995 ; 26 : 488-91.
PubMed
10) Sharma A1, Whitesell RT, Moran KJ. Imaging pattern of intracranial hemorrhage in the setting of posterior reversible encephalopathy syndrome. Neuroradiology 2010 ; 52 : 855-63.
 
11) Weingarten K, Barbut D, Filippi C, et al. Acute hypertensive encephalopathy : findings on spin-echo and gradient-echo MR imaging. AJR Am J Roentgenol 1994 ; 162 : 665-70.
PubMed
12) Schwartz RB, Feske SK, Polak JF, et al. Preeclampsiaeclampsia : clinical and neuroradiographic correlates and insights into the pathogenesis of hypertensive encephalopathy. Radiology 2000 ; 217 : 371-6.
 
13) Zunker P, Ley-Pozo J, Louwen F, et al. Cerebral hemodynamics in pre-eclampsia/eclampsia syndrome. Ultrasound Obstet Gynecol 1995 ; 6 : 411-5.
PubMed
14) Schwartz RB, Jones KM, Kalina P, et al. Hypertensive encephalopathy : Findings on CT, MR imaging, and spect imaging in 14 cases. AJR Am J Roentgenol 1992 ; 159 : 379-83.
 
15) Schwartz RB, Mulkern RV, Gudbjartsson H, et al. Diffusion-weighted MR imaging in hypertensive encephalopathy : clues to pathogenesis. AJNR Am J Neuroradiol 1998 ; 19 : 859-62.
 
16) Chu K, Kang DW, Lee SH, et al. Diffusion-weighted MR findings in brain stem hypertensive encephalopathy : a possibility of cytotoxic edema? Eur Neurol 2001 ; 46 : 220-2.
PubMed
17) Kinoshita T, Moritani T, Shrier DA, et al. Diffusion-weighted mr imaging of posterior reversible leukoencephalopathy syndrome : a pictorial essay. Clin Imaging 2003 ; 27 : 307-15.
PubMed
18) Leonard MB, Kasner SE, Feldman HI, et al. Adverse neurologic events associated with rebound hypertension after using short-acting nifedipine in childhood hypertension. Pediatr Emerg Care 2001 ; 17 : 435-7.
PubMed
19) 高橋一夫, 福田準, 木谷光博. 眼で見る神経内科 高血圧性脳症のMRI所見. 神経内科 1998 ; 49 : 193-5.
 
20) 日本脳卒中学会脳卒中ガイドライン委員会編. 高血圧性脳症. 脳卒中治療ガイドライン 2015, 協和企画, 東京, p264.
 
21) McNair A, Krogsgaard AR, Hilden T, et al. Severe hypertension with cerebral symptoms treated with furosemide, fractionated diazoxide or dihydralazine. Danish Multicenter Study. Acta Med Scand 1986 ; 220 : 15-23.
PubMed
22) Blumenfeld JD, Laragh JH. Management of hypertensive crises : The scientific basis for treatment decisions. Am J Hypertens 2001 ; 14 : 1154-67.
PubMed
23) 三島香津子, 浦川博史, 時澤佳子, 他. 眼で見る神経内科 腎血管性高血圧による高血圧性脳症. 神経内科 2001 ; 54 : 92-4.
 
24) Wang MC, Escott EJ, Breeze RE. Posterior fossa swelling and hydrocephalus resulting from hypertensive encephalopathy : Case report and review of the literature. Neurosurgery 1999 ; 44 : 1325-7.
PubMed
25) Nakano H, Tomita Y, Bandoh K, et al. Malignant hypertension associated with obstructive hydrocephalus--case report. Neurol Med Chir (Tokyo) 1997 ; 37 : 265-9.
PubMed
26) Verrees M, Fernandes Filho JA, et al. Primary hypertension-induced cerebellar encephalopathy causing obstructive hydrocephalus. Case report. J Neurosurg 2003 ; 98 : 1307-11.
PubMed
27) Duley L, Mahomed K. Magnesium sulphate in eclampsia. Lancet 1998 ; 351 : 1061-2.
PubMed
P.71 掲載の参考文献
1) Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. Endarterectomy for asymptomatic carotid artery stenosis. JAMA 1995 ; 273 : 1421-8.
PubMed
P.75 掲載の参考文献
1) James AH, Bushnell CD, Jamison MG, et al. Incidence and risk factors for stroke in pregnancy and the puerperium. Obstet Gynecol 2005 ; 106 : 509-16.
PubMed
2) Tang CH, Wu CS, Lee TH, et al. Preeclampsia-eclampsia and the risk of stroke among peripartum in taiwan. Stroke 2009 ; 40 : 1162-8.
PubMed
3) Ikeda T, Ikenoue T, Mori N, et al. Effect of early pregnancy on maternal regional cerebral blood flow. Am J Obstet Gynecol 1993 ; 168 : 1303-8.
PubMed
4) el-Roeiy A, Myers SA, Gleicher N. The relationship between autoantibodies and intrauterine growth retardation in hypertensive disorders of pregnancy. Am J Obstet Gynecol 1991 ; 164 : 1253-61.
PubMed
5) Carreras LO, Defreyn G, Machin SJ, et al. Arterial thrombosis, intrauterine death and "lupus" antiocoagulant : Detection of immunoglobulin interfering with prostacyclin formation. Lancet 1981 ; 1 : 244-6.
PubMed
6) Rodgers GM, Taylor RN, Roberts JM. Preeclampsia is associated with a serum factor cytotoxic to human endothelial cells. Am J Obstet Gynecol 1988 ; 159 : 908-14.
PubMed
7) 真木正博. 胎盤における抗血栓機序 新しいタイプの胎盤性抗凝固物質. 産婦血液 1988 ; 12 : 41-8.
 
8) 安達知子. 妊娠に伴う凝固・線溶系の変化. 産婦の実際 2004 ; 53 : 497-502.
 
9) Rappaport VJ, Hirata G, Yap HK, et al. Anti-vascular endothelial cell antibodies in severe preeclampsia. Am J Obstet Gynecol 1990 ; 162 : 138-46.
PubMed
10) 平成8年度厚生省心身障害研究 妊産婦死亡の防止に関する研究妊産婦死亡の原因の究明に関する研究. 分担研究報告書, 1997.
 
11) 妊婦関連の脳血管障害の発生に関する研究. 厚生労働科学研究費補助金 子ども家庭総合研究事業 乳幼児死亡と妊産婦死亡の分析と提言に関する研究 平成19年度総括・分担研究報告書, 2008.
 
12) Takahashi JC, Iihara K, Ishii A, et al. Pregnancy-associated intracranial hemorrhage : Results of a survey of neurosurgical institutes across japan. Journal of stroke and cerebrovascular diseases 2014 ; 23 : e65-71.
PubMed
13) Liang CC, Chang SD, Lai SL, et al. Stroke complicating pregnancy and the puerperium. Eur J Neurol 2006 ; 13 : 1256-60.
PubMed
14) Scott CA, Bewley S, Rudd A, et al. Incidence, risk factors, management, and outcomes of stroke in pregnancy. Obstet Gynecol 2012 ; 120 : 318-24.
PubMed
15) Simolke GA, Cox SM, Cunningham FG. Cerebrovascular accidents complicating pregnancy and the puerperium. Obstetrics and gynecology. 1991 ; 78 : 37-42.
PubMed
16) Kizilkilic O, Albayram S, Adaletli I, et al. Endovascular treatment of ruptured intracranial aneurysms during pregnancy : Report of three cases. Arch Gynecol Obstet 2003 ; 268 : 325-8.
PubMed
17) Marshman LA, Rai MS, Aspoas AR. Comment to "endovascular treatment of ruptured intracranial aneurysms during pregnancy : Report of three cases". Arch Gynecol Obstet 2005 ; 272 : 93.
PubMed
18) Marshman LA, Aspoas AR, Rai MS, et al. The implications of isat and isuia for the management of cerebral aneurysms during pregnancy. Neurosurg Rev 2007 ; 30 : 177-80 ; discussion 180.
 
19) 江面正幸, 他. 妊娠分娩とAVM. The Mt. Fuji WS on CVD講演集 2013 ; 31 : 48-51.
 
20) Takahashi JC, Ikeda T, Iihara K, et al. Pregnancy and delivery in moyamoya disease : Results of a nationwide survey in japan. Neurol Med Chi (Tokyo) 2012 ; 52 : 304-10.
 

第2章 脳腫瘍

P.83 掲載の参考文献
1) 公益財団法人パブリックヘルスリサーチセンター がん臨床研究支援事業 (CSPOR) 教育研修小委員会. がん臨床試験テキストブック 考え方から実践まで, 医学書院, 東京, 2013.
 
2) 田村晃, 松谷雅生, 清水輝夫 編. EBMに基づく脳神経疾患の基本治療指針 改訂第3版, メジカルビュー社, 東京, 2010.
 
3) JCOGデータセンター訳. 米国SWOGに学ぶ がん臨床試験の実践 第2版, 医学書院, 東京, 2013.
 
4) 沖田典子, 成田善孝. 神経膠腫患者の認知機能・QOL研究の現状と課題 (総説). 脳外誌 2014 ; 23 : 46-58.
 
5) Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas : response assessment in neuro-oncology working group. J Clin Oncol 2010 ; 28 : 1963-72.
 
6) 里見清一. 誰も教えてくれなかった癌臨床試験の正しい解釈, 中外医学社, 東京, 2011.
 
7) Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study : 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009 ; 10 : 459-66.
 
8) 相原守夫, 他 監訳. 医学文献ユーザーズガイド 第2版, 凸版メディア, 2010.
 
9) 折笠秀樹 監訳. 臨床研究を正しく評価するには Dr. ファーバーグが教える26のポイント第2版, ライフサイエンス出版, 東京, 2013.
 
P.89 掲載の参考文献
1) 成田善孝, 渋井壮一郎. 脳腫瘍の治療結果を可視化する大規模データの収集・臨床試験の必要性-脳腫瘍全国集計調査報告の活用について-. 脳外誌 2015 ; 24 : 699-704.
 
2) Committee of Brain Tumor Registry of Japan. Report of Brain Tumor Registry of Japan (2001-2004) vol.13. Neurol Med Chir (Tokyo) 2014 ; 54 (Suppl) : 1-102.
 
3) Narita Y, Shibui S ; Committee of Brain Tumor Registry of Japan Supported by the Japan Neurosurgical S. Trends and Outcomes in the Treatment of Gliomas Based on Data during 2001-2004 from the Brain Tumor Registry of Japan. Neurol Med Chir (Tokyo) 2015 ; 55 Suppl 1 : 286-95.
 
4) Ostrom QT, Gittleman H, Fulop J, et al. CBTRUS Statistical Report : Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012. Neuro Oncol 2015 ; 17 Suppl 4 : iv1-iv62.
 
5) Makino K, Nakamura H, Yano S, et al. Population-based epidemiological study of primary intracranial tumors in childhood. Childs Nerv Syst 2010 ; 26 : 1029-34.
PubMed
6) Nakamura H, Makino K, Yano S, et al. Epidemiological study of primary intracranial tumors : a regional survey in Kumamoto prefecture in southern Japan-20-year study. Int J Clin Oncol 2011 ; 16 : 314-21.
PubMed
P.95 掲載の参考文献
1) National Institute for Health and Clinical Excellence (NICE). Improving Outcomes for People with Brain and Other CNS Tumours. National Institute for Health and Clinical Excellence (NICE) ; 2006 ; Available from : https://www.nice.org.uk/guidance/csg10.
 
2) National Comprehensive Cancer Network. Central Nervous System Cancers (Version 1.2015). 2015 ; Available from : http://www.nccn.org.
 
3) Preusser M, de Ribaupierre S, Wohrer A, et al. Current concepts and management of glioblastoma. Ann Neurol 2011 ; 70 : 9-21.
PubMed
4) Metcalfe SE, Grant R. Biopsy versus resection for malignant glioma. Cochrane Database Syst Rev 2001 (3) : CD002034.
PubMed
5) Ammirati M, Vick N, Liao YL, et al. Effect of the extent of surgical resection on survival and quality of life in patients with supratentorial glioblastomas and anaplastic astrocytomas. Neurosurgery 1987 ; 21 : 201-6.
PubMed
6) Fadul C, Wood J, Thaler H, et al. Morbidity and mortality of craniotomy for excision of supratentorial gliomas. Neurology 1988 ; 38 : 1374-9.
PubMed
7) Keles GE, Anderson B, Berger MS. The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere. Surg Neurol 1999 ; 52 : 371-9.
PubMed
8) Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme : prognosis, extent of resection, and survival. J Neurosurg 2001 ; 95 : 190-8.
PubMed
9) Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008 ; 62 : 753-64 ; discussion 264-6.
 
10) Ryken TC, Frankel B, Julien T, et al. Surgical management of newly diagnosed glioblastoma in adults : role of cytoreductive surgery. J Neurooncol 2008 ; 89 : 271-86.
PubMed
11) Vuorinen V, Hinkka S, Farkkila M, et al. Debulking or biopsy of malignant glioma in elderly people - a randomised study. Acta Neurochir (Wien) 2003 ; 145 : 5-10.
PubMed
12) Woodworth G, McGirt MJ, Samdani A, et al. Accuracy of frameless and frame-based image-guided stereotactic brain biopsy in the diagnosis of glioma : comparison of biopsy and open resection specimen. Neurol Res 2005 ; 27 : 358-62.
 
13) Hall WA. The safety and efficacy of stereotactic biopsy for intracranial lesions. Cancer 1998 ; 82 : 1749-55. Epub 1998/05/12.
 
14) Kickingereder P, Willeit P, Simon T, et al. Diagnostic value and safety of stereotactic biopsy for brainstem tumors : a systematic review and meta-analysis of 1480 cases. Neurosurgery 2013 ; 72 : 873-81 ; discussion 82 ; quiz 82. Epub 2013/02/22.
 
15) Brell M, Ibanez J, Caral L, et al. Factors influencing surgical complications of intra-axial brain tumours. Acta Neurochir (Wien) 2000 ; 142 : 739-50.
PubMed
16) Chang SM, Parney IF, McDermott M, et al. Perioperative complications and neurological outcomes of first and second craniotomies among patients enrolled in the Glioma Outcome Project. J Neurosurg 2003 ; 98 : 1175-81.
PubMed
17) Sacko O, Lauwers-Cances V, Brauge D, et al. Awake craniotomy vs surgery under general anesthesia for resection of supratentorial lesions. Neurosurgery 2011 ; 68 : 1192-8 ; discussion 8-9.
 
18) Sawaya R, Hammoud M, Schoppa D, et al. Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchymal tumors. Neurosurgery 1998 ; 42 : 1044-55 ; discussion 55-6.
 
19) Taylor MD, Bernstein M. Awake craniotomy with brain mapping as the routine surgical approach to treating patients with supratentorial intraaxial tumors : a prospective trial of 200 cases. J Neurosurg 1999 ; 90 : 35-41.
 
20) Vorster SJ, Barnett GH. A proposed preoperative grading scheme to assess risk for surgical resection of primary and secondary intraaxial supratentorial brain tumors. Neurosurg Focus 1998 ; 4 : e2.
PubMed
21) Lassen B, Helseth E, Ronning P, et al. Surgical mortality at 30 days and complications leading to recraniotomy in 2630 consecutive craniotomies for intracranial tumors. Neurosurgery 2011 ; 68 : 1259-68 ; discussion 68-9.
 
22) Trinh VT, Davies JM, Berger MS. Surgery for primary supratentorial brain tumors in the United States, 2000-2009 : effect of provider and hospital caseload on complication rates. J Neurosurg 2015 ; 122 : 280-96.
PubMed
23) Hervey-Jumper SL, Li J, Lau D, et al. Awake craniotomy to maximize glioma resection : methods and technical nuances over a 27-year period. J Neurosurg 2015 ; 123 : 325-39.
 
24) Paldor I, Drummond KJ, Awad M, et al. Is a wake-up call in order? Review of the evidence for awake craniotomy. J Clin Neurosci 2016 ; 23 : 1-7.
PubMed
25) Sanai N, Mirzadeh Z, Berger MS. Functional outcome after language mapping for glioma resection. N Engl J Med 2008 ; 358 : 18-27.
PubMed
26) Laperriere N, Zuraw L, Cairncross G, Cancer Care Ontario Practice Guidelines Initiative Neuro-Oncology Disease Site G. Radiotherapy for newly diagnosed malignant glioma in adults : a systematic review. Radiother Oncol 2002 ; 64 : 259-73.
 
27) Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party. Br J Cancer 1991 ; 64 : 769-74.
PubMed
28) Walker MD, Alexander E Jr, Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 1978 ; 49 : 333-43.
PubMed
29) Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005 ; 352 : 987-96.
PubMed
30) Hochberg FH, Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology 1980 ; 30 : 907-11.
PubMed
31) Halperin EC, Burger PC. Conventional external beam radiotherapy for central nervous system malignancies. Neurol Clin 1985 ; 3 : 867-82.
PubMed
32) Tsao MN, Mehta MP, Whelan TJ, et al. The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma. Int J Radiat Oncol Biol Phys 2005 ; 63 : 47-55.
 
33) Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme : report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys 2004 ; 60 : 853-60.
PubMed
34) Waters JD, Rose B, Gonda DD, et al. Immediate post-operative brachytherapy prior to irradiation and temozolomide for newly diagnosed glioblastoma. J Neurooncol 2013 ; 113 : 467-77.
PubMed
35) Stupp R, Hegi ME, Gilbert MR, et al. Chemoradiotherapy in malignant glioma : standard of care and future directions. J Clin Oncol 2007 ; 25 : 4127-36.
PubMed
36) Chi AS, Wen PY. Inhibiting kinases in malignant gliomas. Expert Opin Ther Targets 2007 ; 11 : 473-96.
PubMed
37) Duda DG, Jain RK, Willett CG. Antiangiogenics : the potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J Clin Oncol 2007 ; 25 : 4033-42.
PubMed
38) Rodrigus P. Motexafin gadolinium : a possible new radiosensitiser. Expert Opin Investig Drugs 2003 ; 12 : 1205-10.
PubMed
39) van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults : the EORTC 22845 randomised trial. Lancet 2005 ; 366 : 985-90.
PubMed
40) Karim AB, Afra D, Cornu P, et al. Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult : European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4 : an interim analysis. Int J Radiat Oncol Biol Phys 2002 ; 52 : 316-24.
PubMed
41) Ryken TC, Parney I, Buatti J, et al. The role of radiotherapy in the management of patients with diffuse low grade glioma : A systematic review and evidence-based clinical practice guideline. J Neurooncol 2015 ; 125 : 551-83.
PubMed
42) Field KM, Rosenthal MA, Khasraw M, et al. Evolving management of low grade glioma : No consensus amongst treating clinicians. J Clin Neurosci 2016 ; 23 : 81-7.
PubMed
43) Ryu S, Buatti JM, Morris A, et al. The role of radiotherapy in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline. J Neurooncol 2014 ; 118 : 489-99.
PubMed
44) Diaz AZ, Choi M. Radiation-associated toxicities in the treatment of high-grade gliomas. Semin Oncol 2014 ; 41 : 532-40.
PubMed
45) Laack NN, Brown PD. Cognitive sequelae of brain radiation in adults. Semin Oncol 2004 ; 31 : 702-13.
PubMed
46) Sheline GE, Wara WM, Smith V. Therapeutic irradiation and brain injury. Int J Radiat Oncol Biol Phys 1980 ; 6 : 1215-28.
PubMed
47) Armstrong C, Mollman J, Corn BW, et al. Effects of radiation therapy on adult brain behavior : evidence for a rebound phenomenon in a phase 1 trial. Neurology 1993 ; 43 : 1961-5.
 
48) Armstrong C, Ruffer J, Corn B, et al. Biphasic patterns of memory deficits following moderate-dose partial-brain irradiation : neuropsychologic outcome and proposed mechanisms. J Clin Oncol 1995 ; 13 : 2263-71.
PubMed
49) Vigliani MC, Sichez N, Poisson M, et al. A prospective study of cognitive functions following conventional radiotherapy for supratentorial gliomas in young adults : 4-year results. Int J Radiat Oncol Biol Phys 1996 ; 35 : 527-33.
 
50) Kramer S. The hazards of therapeutic iradiation of the central nervous system. Clin Neurosurg 1968 ; 15 : 301-18.
PubMed
51) Schultheiss TE, Kun LE, Ang KK, et al. Radiation response of the central nervous system. Int J Radiat Oncol Biol Phys 1995 ; 31 : 1093-112.
PubMed
52) Parvez K, Parvez A, Zadeh G. The diagnosis and treatment of pseudoprogression, radiation necrosis and brain tumor recurrence. Int J Mol Sci 2014 ; 15 : 11832-46.
PubMed
53) Kim HS, Goh MJ, Kim N, et al. Which combination of MR imaging modalities is best for predicting recurrent glioblastoma? Study of diagnostic accuracy and reproducibility. Radiology 2014 ; 273 : 831-43.
PubMed
54) Belka C, Budach W, Kortmann RD, et al. Radiation induced CNS toxicity--molecular and cellular mechanisms. Br J Cancer 2001 ; 85 : 1233-9.
PubMed
55) Brown WR, Blair RM, Moody DM, et al. Capillary loss precedes the cognitive impairment induced by fractionated whole-brain irradiation : a potential rat model of vascular dementia. J Neurol Sci 2007 ; 257 : 67-71.
PubMed
56) Brown WR, Moody DM, Thore CR, et al. Vascular dementia in leukoaraiosis may be a consequence of capillary loss not only in the lesions, but in normal-appearing white matter and cortex as well. J Neurol Sci 2007 ; 257 : 62-6.
PubMed
57) Moretti R, Torre P, Antonello RM, et al. Neuropsychological evaluation of late-onset post-radiotherapy encephalopathy : a comparison with vascular dementia. J Neurol Sci 2005 ; 229-30 : 195-200.
 
58) Bellinzona M, Gobbel GT, Shinohara C, et al. Apoptosis is induced in the subependyma of young adult rats by ionizing irradiation. Neurosci Lett 1996 ; 208 : 163-6.
PubMed
59) Kurita H, Kawahara N, Asai A, et al. Radiation-induced apoptosis of oligodendrocytes in the adult rat brain. Neurol Res 2001 ; 23 : 869-74.
PubMed
60) Shinohara C, Gobbel GT, Lamborn KR, et al. Apoptosis in the subependyma of young adult rats after single and fractionated doses of X-rays. Cancer Res 1997 ; 57 : 2694-702.
PubMed
61) Tsai PF, Yang CC, Chuang CC, et al. Hippocampal dosimetry correlates with the change in neurocognitive function after hippocampal sparing during whole brain radiotherapy : a prospective study. Radiat Oncol 2015 ; 10 : 253.
PubMed
62) Marks LB, Yorke ED, Jackson A, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys 2010 ; 76 (3 Suppl) : S10-9.
 
63) Appelman-Dijkstra NM, Kokshoorn NE, Dekkers OM, et al. Pituitary dysfunction in adult patients after cranial radiotherapy : systematic review and meta-analysis. J Clin Endocrinol Metab 2011 ; 96 : 2330-40.
PubMed
64) Lam KS, Tse VK, Wang C, et al. Effects of cranial irradiation on hypothalamic-pituitary function--a 5-year longitudinal study in patients with nasopharyngeal carcinoma. Q J Med 1991 ; 78 : 165-76.
PubMed
65) Samaan NA, Schultz PN, Yang KP, et al. Endocrine complications after radiotherapy for tumors of the head and neck. J Lab Clin Med 1987 ; 109 : 364-72.
PubMed
66) Hudgins PA, Newman NJ, Dillon WP, et al. Radiation-induced optic neuropathy : characteristic appearances on gadolinium-enhanced MR. AJNR Am J Neuroradiol 1992 ; 13 : 235-8.
PubMed
67) Roden D, Bosley TM, Fowble B, et al. Delayed radiation injury to the retrobulbar optic nerves and chiasm. Clinical syndrome and treatment with hyperbaric oxygen and corticosteroids. Ophthalmology 1990 ; 97 : 346-51.
 
68) Ross HS, Rosenberg S, Friedman AH. Delayed radiation necrosis of the optic nerve. Am J Ophthalmol 1973 ; 76 : 683-6.
PubMed
69) Elsamadicy AA, Babu R, Kirkpatrick JP, et al. Radiation-induced malignant gliomas : a current review. World Neurosurg 2015 ; 83 : 530-42.
PubMed
70) Cahan WG, Woodard HQ, et al. Sarcoma arising in irradiated bone ; report of 11 cases. Cancer 1948 ; 1 : 3-29.
PubMed
71) 成田善孝. 抗悪性腫瘍薬 Temozolomide. 腫瘍内科 2009 ; 4 : 280-7.
 
72) Ohno M, Narita Y, Miyakita Y, et al. Reactivation of Hepatitis B Virus After Glioblastoma Treatment With Temozolomide-Case Report. Neurol Med Chir (Tokyo) 2011 ; 51 : 728-31.
PubMed
73) Okita Y, Narita Y, Miyakita Y, et al. Reactivation of cytomegalovirus following treatment of malignant glioma with temozolomide : A case report. Int Canc Conf J 2012 ; 1 : 53-7. Epub 2012/03/27.
 
74) 朝比奈 靖, 泉並, 桶谷眞, 他. B型肝炎治療ガイドライン (第1.1版). 肝臓 2013 ; 54 : 402-72.
 
75) Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014 ; 370 : 709-22.
PubMed
76) Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014 ; 370 : 699-708.
PubMed
77) Nagane M, Nishikawa R, Narita Y, et al. Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma. Jpn J Clin Oncol 2012 ; 42 : 887-95. Epub 2012/07/31.
 
78) Narita Y. Bevacizumab for glioblastoma. Ther Clin Risk Manag 2015 ; 11 : 1759-65.
PubMed
79) Aoki T, Nishikawa R, Sugiyama K, et al. A multicenter phase I/II study of the BCNU implant (Gliadel ((R)) Wafer) for Japanese patients with malignant gliomas. Neurol Med Chir (Tokyo) 2014 ; 54 : 290-301.
PubMed
80) Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma : a randomised phase III trial of a novel treatment modality. Eur J Cancer 2012 ; 48 : 2192-202.
 
81) Stupp R, Taillibert S, Kanner AA, et al. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma : A Randomized Clinical Trial. JAMA 2015 ; 314 : 2535-43.
PubMed
P.99 掲載の参考文献
1) Burkhard C, Di Patre PL, Schuler D, et al. A population-based study of the incidence and survival rates in patients with pilocytic astrocytoma. J Neurosurg 2003 ; 98 : 1170-4.
 
2) Committee_of_Brain_Tumor_Registry_of_Japan. Report of Brain Tumor Registry of Japan (2001-2004). Neurol Med Chir (Tokyo) 2014 ; suppl (1).
 
3) Tomita T, Grahovac G. Cerebellopontine angle tumors in infants and children. Childs Nerv Syst 2015 ; 31 : 1739-50.
PubMed
4) Stuer C, Vilz B, Majores M, et al. Frequent recurrence and progression in pilocytic astrocytoma in adults. Cancer 2007 ; 110 : 2799-808.
PubMed
5) Cin H, Meyer C, Herr R, et al. Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. Acta Neuropathol 2011 ; 121 : 763-74.
PubMed
6) Schindler G, Capper D, Meyer J, et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 2011 ; 121 : 397-405.
PubMed
7) Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005 ; 64 : 479-89.
PubMed
8) Johnson DR, Brown PD, Galanis E, et al. Pilocytic astrocytoma survival in adults : analysis of the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute. J Neurooncol 2012 ; 108 : 187-93.
PubMed
9) Bian SX, McAleer MF, Vats TS, et al. Pilocytic astrocytoma with leptomeningeal dissemination. Childs Nerv Syst 2013 ; 29 : 441-50.
PubMed
10) Rodriguez FJ, Scheithauer BW, Burger PC, et al. Anaplasia in pilocytic astrocytoma predicts aggressive behavior. Am J Surg Pathol 2010 ; 34 : 147-60.
PubMed
11) Ogiwara H, Bowman RM, Tomita T. Long-term follow-up of pediatric benign cerebellar astrocytomas. Neurosurgery 2012 ; 70 : 40-7 ; discussion 7-8.
 
12) Fisher BJ, Leighton CC, Vujovic O, et al. Results of a policy of surveillance alone after surgical management of pediatric low grade gliomas. Int J Radiat Oncol Biol Phys 2001 ; 51 : 704-10.
PubMed
13) Shaw EG, Wisoff JH. Prospective clinical trials of intracranial lowgrade glioma in adults and children. Neuro Oncol 2003 ; 5 : 153-60.
 
14) Sievert AJ, Fisher MJ. Pediatric low-grade gliomas. J Child Neurol 2009 ; 24 : 1397-408.
PubMed
15) Steinbok P, Poskitt K, Hendson G. Spontaneous regression of cerebellar astrocytoma after subtotal resection. Childs Nervous Syst 2006 ; 22 : 572-6.
 
16) Brown MT, Friedman HS, Oakes WJ, et al. Chemotherapy for pilocytic astrocytomas. Cancer 1993 ; 71 : 3165-72.
PubMed
17) Massimino M, Spreafico F, Cefalo G, et al. High response rate to cisplatin/etoposide regimen in childhood low-grade glioma. J Clin Oncol 2002 ; 20 : 4209-16.
PubMed
18) Lafay-Cousin L, Sung L, Carret AS, et al. Carboplatin hypersensitivity reaction in pediatric patients with low-grade glioma : a Canadian Pediatric Brain Tumor Consortium experience. Cancer 2008 ; 112 : 892-9.
PubMed
19) Yu DY, Dahl GV, Shames RS, et al. Weekly dosing of carboplatin increases risk of allergy in children. J Pediat Hematol Oncol 2001 ; 23 : 349-52.
 
20) Ater JL, Zhou T, Holmes E, et al. Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children : a report from the Children's Oncology Group. J Clin Oncol 2012 ; 30 : 2641-7.
 
21) Sardi I, Bresci C, Schiavello E, et al. Successful treatment with a low-dose cisplatin-etoposide regimen for patients with diencephalic syndrome. J Neurooncol 2012 ; 109 : 375-83.
PubMed
22) Brokinkel B, Peetz-Dienhart S, Ligges S, et al. A comparative analysis of MAPK pathway hallmark alterations in pilocytic astrocytomas : age-related and mutually exclusive. [corrected]. Neuropathol Appl Neurobiol 2015 ; 41 : 258-61.
PubMed
23) Kilday JP, Bartels UK, Bouffet E. Targeted therapy in pediatric low-grade glioma. Curr Neurol Neurosci Rep 2014 ; 14 : 441.
PubMed
24) Bouffet E, Jakacki R, Goldman S, et al. Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma. J Clin Oncol 2012 ; 30 : 1358-63.
PubMed
25) Gururangan S, Fisher MJ, Allen JC, et al. Temozolomide in children with progressive low-grade glioma. Neuro Oncol 2007 ; 9 : 161-8.
PubMed
26) Hwang EI, Jakacki RI, Fisher MJ, et al. Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas. Pediatr Blood Cancer 2013 ; 60 : 776-82.
PubMed
27) Gururangan S, Fangusaro J, Poussaint TY, et al. Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas-a Pediatric Brain Tumor Consortium study. Neuro Oncol 2014 ; 16 : 310-7.
PubMed
28) Pollack IF, Claassen D, al-Shboul Q, et al. Low-grade gliomas of the cerebral hemispheres in children : an analysis of 71 cases. J Neurosurg 1995 ; 82 : 536-47.
 
29) Blumcke I, Wiestler OD. Gangliogliomas : an intriguing tumor entity associated with focal epilepsies. J Neuropathol Exp Neurol 2002 ; 61 : 575-84.
PubMed
30) Haddad SF, Moore SA, Menezes AH, et al. Ganglioglioma : 13 years of experience. Neurosurgery 1992 ; 31 : 171-8.
PubMed
31) Hakim R, Loeffler JS, Anthony DC, et al. Gangliogliomas in adults. Cancer 1997 ; 79 : 127-31.
PubMed
32) Lang FF, Epstein FJ, Ransohoff J, et al. Central nervous system gangliogliomas. Part 2 : Clinical outcome. J Neurosurg 1993 ; 79 : 867-73.
PubMed
33) Zentner J, Wolf HK, Ostertun B, et al. Gangliogliomas : clinical, radiological, and histopathological findings in 51 patients. J Neurol Neurosurg Psychiatry 1994 ; 57 : 1497-502.
PubMed
34) Luyken C, Blumcke I, Fimmers R, et al. Supratentorial gangliogliomas : histopathologic grading and tumor recurrence in 184 patients with a median follow-up of 8 years. Cancer 2004 ; 101 : 146-55.
PubMed
35) Selch MT, Goy BW, Lee SP, et al. Gangliogliomas : experience with 34 patients and review of the literature. Am J Clin Oncol 1998 ; 21 : 557-64.
PubMed
36) Ulutin HC, Onguru O, Pak Y. Postoperative radiotherapy for ganglioglioma ; report of three cases and review of the literature. Minim Invasive Neurosurg 2002 ; 45 : 224-7.
PubMed
37) Rumana CS, Valadka AB. Radiation therapy and malignant degeneration of benign supratentorial gangliogliomas. Neurosurgery 1998 ; 42 : 1038-43.
PubMed
38) Liauw SL, Byer JE, Yachnis AT, et al. Radiotherapy after subtotally resected or recurrent ganglioglioma. Int J Radiat Oncol Biol Phys 2007 ; 67 : 244-7.
PubMed
39) Wallner KE, Gonzales MF, Edwards MS, et al. Treatment results of juvenile pilocytic astrocytoma. J Neurosurg 1988 ; 69 : 171-6.
PubMed
40) Steinberg GK, Shuer LM, Conley FK, et al. Evolution and outcome in malignant astroglial neoplasms of the cerebellum. J Neurosurg 1985 ; 62 : 9-17.
PubMed
41) Miller DC, Lang FF, Epstein FJ. Central nervous system gangliogliomas. Part 1 : Pathology. J Neurosurg 1993 ; 79 : 859-66.
PubMed
42) Wolf HK, Muller MB, Spanle M, et al. Ganglioglioma : a detailed histopathological and immunohistochemical analysis of 61 cases. Acta Neuropathol 1994 ; 88 : 166-73.
PubMed
43) Selvanathan SK, Hammouche S, Salminen HJ, et al. Outcome and prognostic features in anaplastic ganglioglioma : analysis of cases from the SEER database. J Neurooncol 2011 ; 105 : 539-45.
PubMed
44) Varlet P, Soni D, Miquel C, et al. New variants of malignant glioneuronal tumors : a clinicopathological study of 40 cases. Neurosurgery 2004 ; 55 : 1377-91 : discussion 91-2.
 
45) Rades D, Zwick L, Leppert J, et al. The role of postoperative radiotherapy for the treatment of gangliogliomas. Cancer 2010 ; 116 : 432-42.
PubMed
46) Schneider C, Vosbeck J, Grotzer MA, et al. Anaplastic ganglioglioma : a very rare intramedullary spinal cord tumor. Pediatr Neurosurg 2012 ; 48 : 42-7.
PubMed
47) Lucas JT Jr, Huang AJ, Mott RT, et al. Anaplastic ganglioglioma : a report of three cases and review of the literature. J Neurooncol 2015 ; 123 : 171-7.
PubMed
48) Chamberlain MC. Recurrent ganglioglioma in adults treated with BRAF inhibitors. CNS Oncol 2016 ; 5 : 27-9.
PubMed
P.108 掲載の参考文献
1) Louis DN, Ohgaki H, Wiestler OD, et al. WHO Classification of Tumours of the Central Nervous System, 4th edition. Fourth Edition ed. Lyon, IARC Press, 2007.
 
2) 日本脳神経外科学会, 日本病理学会. 脳腫瘍取り扱い規約 第3版, 金原出版, 東京, 2010.
 
3) Ostrom QT, Gittleman H, Fulop J, et al. CBTRUS Statistical Report : Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012. Neuro Oncol 2015 ; 17 Suppl 4 : iv1-62.
 
4) Committee of Brain Tumor Registry of Japan. Report of Brain Tumor Registry of Japan (2001-2004) vol.13. Neurol Med Chir (Tokyo) 2014 ; 54 (Suppl) : 1-102.
 
5) Chang EF, Potts MB, Keles GE, et al. Seizure characteristics and control following resection in 332 patients with low-grade gliomas. J Neurosurg 2008 ; 108 : 227-35.
PubMed
6) Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 2002 ; 20 : 2076-84.
PubMed
7) Smits A, Duffau H. Seizures and the natural history of World Health Organization Grade II gliomas : a review. Neurosurgery 2011 ; 68 : 1326-33.
PubMed
8) van Breemen MS, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours : epidemiology, mechanisms, and management. Lancet Neurol 2007 ; 6 : 421-30.
PubMed
9) Klein M. Neurocognitive functioning in adult WHO grade II gliomas : impact of old and new treatment modalities. Neuro Oncol 2012 ; 14 Suppl 4 : iv17-24.
 
10) Bauchet L, Rigau V, Mathieu-Daude H, et al. French brain tumor data bank : methodology and first results on 10,000 cases. J Neuro Oncol 2007 ; 84 : 189-99.
 
11) Kamiguchi H, Shiobara R, Toya S. Accidentally detected brain tumors : clinical analysis of a series of 110 patients. Clin Neurol Neurosurg 1996 ; 98 : 171-5.
PubMed
12) Potts MB, Smith JS, Molinaro AM, et al. Natural history and surgical management of incidentally discovered low-grade gliomas. J Neurosurg 2012 ; 116 : 365-72.
PubMed
13) Narita Y, Shibui S, Committee of Brain Tumor Registry of Japan Supported by the Japan Neurosurgical S. Trends and Outcomes in the Treatment of Gliomas Based on Data during 2001-2004
 
14) Bauman G, Fisher B, Watling C, et al. Adult supratentorial low-grade glioma : long-term experience at a single institution. Int J Radiat Oncol Bio Phys 2009 ; 75 : 1401-7.
 
15) Schomas DA, Laack NN, Rao RD, et al. Intracranial low-grade gliomas in adults : 30-year experience with long-term follow-up at Mayo Clinic Neuro Oncol 2009 ; 11 : 437-45.
 
16) Coons SW, Pearl DK. Mitosis identification in diffuse gliomas : implications for tumor grading. Cancer 1998 ; 82 : 1550-5.
PubMed
17) Giannini C, Burger PC, Berkey BA, et al. Anaplastic oligodendroglial tumors : refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathol 2008 ; 18 : 360-9.
PubMed
18) Watanabe T, Nobusawa S, Kleihues P, et al. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 2009 ; 174 : 1149-53.
PubMed
19) Mukasa A, Takayanagi S, Saito K, et al. Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients. Cancer Sci 2012 ; 103 : 587-92.
PubMed
20) Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. New Engl J Med 2009 ; 360 : 765-73.
PubMed
21) Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009 ; 462 : 739-44.
PubMed
22) 市村幸一, 有田英之, 成田善孝. 遺伝子変異からみた神経膠腫の発生機序. 脳外誌 2014 ; 23 : 532-40.
 
23) Camelo-Piragua S, Jansen M, Ganguly A, et al. Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis. Acta Neuropathol 2010 ; 119 : 509-11.
PubMed
24) Arita H, Narita Y, Fukushima S, et al. Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. Acta Neuropathol 2013 ; 126 : 267-76.
PubMed
25) Liu XY, Gerges N, Korshunov A, et al. Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathol 2012 ; 124 : 615-25.
PubMed
26) Reuss DE, Sahm F, Schrimpf D, et al. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol 2015 ; 129 : 133-46.
PubMed
27) Ichimura K, Narita Y, Hawkins CE. Diffusely infiltrating astrocytomas : pathology, molecular mechanisms and markers. Acta Neuropathol 2015 ; 129 : 789-808.
PubMed
28) Kim YH, Nobusawa S, Mittelbronn M, et al. Molecular classification of low-grade diffuse gliomas. Am J Pathol 2010 ; 177 : 2708-14.
PubMed
29) Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 2009 ; 11 : 341-7.
PubMed
30) Suzuki H, Aoki K, Chiba K, et al. Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet 2015 ; 47 : 458-68.
PubMed
31) van den Bent MJ. Interobserver variation of the histopathological diagnosis in clinical trials on glioma : a clinician's perspective. Acta Neuropathol 2010 ; 120 : 297-304.
 
32) Cancer Genome Atlas Research N, Brat DJ, Verhaak RG, et al. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. New Engl J Med 2015 ; 372 : 2481-98.
PubMed
33) Eckel-Passow JE, Lachance DH, Molinaro AM, et al. Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. New Engl J Med 2015 ; 372 : 2499-508.
PubMed
34) Ellison DW. Multiple Molecular Data Sets and the Classification of Adult Diffuse Gliomas. New Engl J Med 2015 ; 372 : 2555-7.
PubMed
35) Louis DN, Perry A, Burger P, et al. International Society Of Neuropathology-Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol 2014 ; 24 : 429-35.
PubMed
36) Asari S, Makabe T, Katayama S, et al. Assessment of the pathological grade of astrocytic gliomas using an MRI score. Neuroradiology 1994 ; 36 : 308-10.
PubMed
37) Pallud J, Capelle L, Taillandier L, et al. Prognostic significance of imaging contrast enhancement for WHO grade II gliomas. Neuro Oncol 2009 ; 11 : 176-82.
PubMed
38) Sonoda Y, Shibahara I, Kawaguchi T, et al. Association between molecular alterations and tumor location and MRI characteristics in anaplastic gliomas. Brain Tumor Pathol 2015 ; 32 : 99-104.
PubMed
39) Tortosa A, Vinolas N, Villa S, et al. Prognostic implication of clinical, radiologic, and pathologic features in patients with anaplastic gliomas. Cancer 2003 ; 97 : 1063-71.
PubMed
40) van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group) : assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol. 2011 ; 12 : 583-93.
PubMed
41) Pallud J, Fontaine D, Duffau H, et al. Natural history of incidental World Health Organization grade II gliomas. Ann Neurol 2010 ; 68 : 727-33.
PubMed
42) Mandonnet E, Pallud J, Fontaine D, et al. Inter- and intrapatients comparison of WHO grade II glioma kinetics before and after surgical resection. Neurosurg Rev 2010 ; 33 : 91-6.
PubMed
43) Jaeckle KA, Decker PA, Ballman KV, et al. Transformation of low grade glioma and correlation with outcome : an NCCTG database analysis. J Neuro Oncology 2011 ; 104 : 253-9.
 
44) Ohno M, Narita Y, Miyakita Y, et al. Histopathological malignant progression of grade II and III gliomas correlated with IDH1/2 mutation status. Brain Tumor Pathol 2012 ; 29 : 183-91.
PubMed
45) Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol 2008 ; 26 : 1338-45.
 
46) van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults : the EORTC 22845 randomised trial. Lancet 2005 ; 366 : 985-90.
PubMed
47) Jakola AS, Myrmel KS, Kloster R, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas. JAMA 2012 ; 308 : 1-8.
 
48) Shaw EG, Berkey B, Coons SW, et al. Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma : results of a prospective clinical trial. J Neurosurg 2008 ; 109 : 835-41.
PubMed
49) Duffau H, Peggy Gatignol ST, Mandonnet E, et al. Intraoperative subcortical stimulation mapping of language pathways in a consecutive series of 115 patients with Grade II glioma in the left dominant hemisphere. J Neurosurg 2008 ; 109 : 461-71.
 
50) Muragaki Y, Iseki H, Maruyama T, et al. Information-guided surgical management of gliomas using low-field-strength intraoperative MRI. Acta Neurochir Suppl 2011 ; 109 : 67-72.
PubMed
51) Nimsky C, Ganslandt O, Buchfelder M, et al. Intraoperative visualization for resection of gliomas : the role of functional neuronavigation and intraoperative 1.5 T MRI. Neurol Res 2006 ; 28 : 482-7.
 
52) De Witt Hamer PC, Robles SG, Zwinderman AH, et al. Impact of intraoperative stimulation brain mapping on glioma surgery outcome : a meta-analysis. J Clin Oncol 2012 ; 30 : 2559-65.
PubMed
53) Singer JM. Supratentorial low grade gliomas in adults. A retrospective analysis of 43 cases treated with surgery and radiotherapy. Eur J Surg Oncol 1995 ; 21 : 198-200.
PubMed
54) Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma : European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Rad Oncol Biol Phys 1996 ; 36 : 549-56.
 
55) Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma : initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol 2002 ; 20 : 2267-76.
 
56) Crossen JR, Garwood D, Glatstein E, et al. Neurobehavioral sequelae of cranial irradiation in adults : a review of radiation-induced encephalopathy. J Clin Oncol 1994 ; 12 : 627-42.
PubMed
57) Lee AW, Kwong DL, Leung SF, et al. Factors affecting risk of symptomatic temporal lobe necrosis : significance of fractional dose and treatment time. Int J Rad Oncol Biol Phys 2002 ; 53 : 75-85.
 
58) Surma-aho O, Niemela M, Vilkki J, et al. Adverse long-term effects of brain radiotherapy in adult low-grade glioma patients. Neurology 2001 ; 56 : 1285-90.
PubMed
59) Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas : a comparative study. Lancet 2002 ; 360 : 1361-8.
 
60) Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma : long-term follow-up. Lancet Neurol 2009 ; 8 : 810-8.
PubMed
61) Klein M, Engelberts NH, van der Ploeg HM, et al. Epilepsy in low-grade gliomas : the impact on cognitive function and quality of life. Ann Neurol 2003 ; 54 : 514-20.
PubMed
62) Marsh JC, Godbole R, Diaz AZ, et al. Sparing of the hippocampus, limbic circuit and neural stem cell compartment during partial brain radiotherapy for glioma : a dosimetric feasibility study. J Med Imaging Radiat Oncol. 2011 ; 55 : 442-9.
PubMed
63) Gehring K, Sitskoorn MM, Gundy CM, et al. Cognitive rehabilitation in patients with gliomas : a randomized, controlled trial. J Clin Oncol 2009 ; 27 : 3712-22.
PubMed
64) Shibui S, Narita Y, Mizusawa J, et al. Randomized trial of chemoradiotherapy and adjuvant chemotherapy with nimustine (ACNU) versus nimustine plus procarbazine for newly diagnosed anaplastic astrocytoma and glioblastoma (JCOG0305). Cancer Chemother Pharmacol 2013 ; 71 : 511-21.
PubMed
65) Buckner JC, Shaw EG, Pugh S, et al. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine (PCV) in low-grade glioma : results by histologic type. Neuro Oncol 2014 ; 16 (Suppl 5) : v11.
 
66) van den Bent MJ. Practice changing mature results of RTOG study 9802 : another positive PCV trial makes adjuvant chemotherapy part of standard of care in low-grade glioma. Neuro Oncol 2014 ; 16 : 1570-4.
PubMed
67) Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma : initial results of RTOG 9802. J Clin Oncol 2012 ; 30 : 3065-70.
PubMed
68) Fisher BJ, Hu C, Macdonald DR, et al. Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas : preliminary results of Radiation Therapy Oncology Group 0424. Int J Rad Oncol Biol Phys 2015 ; 91 : 497-504.
 
69) Baumert BG, Mason WP, Ryan G. Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss) low-grade glioma : A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033). J Clin Oncol 2013 ; 31 (Suppl) : abstract 2007.
 
70) Brandes AA, Nicolardi L, Tosoni A, et al. Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma. Neuro Oncol 2006 ; 8 : 253-60.
PubMed
71) van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas : a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 2006 ; 24 : 2715-22.
 
72) van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma : long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 2013 ; 31 : 344-50.
 
73) Cairncross G, Berkey B, Shaw E, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma : Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 2006 ; 24 : 2707-14.
PubMed
74) Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma : long-term results of RTOG 9402. J Clin Oncol 2013 ; 31 : 337-43.
PubMed
75) Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 2009 ; 27 : 5874-80.
PubMed
76) Wick W, Wiestler B, Platten M. Treatment of anaplastic glioma. Cancer Treat Res 2015 ; 163 : 89-101.
PubMed
77) Chang EF, Smith JS, Chang SM, et al. Preoperative prognostic classification system for hemispheric low-grade gliomas in adults. J Neurosurg 2008 ; 109 : 817-24.
PubMed
78) Hartmann C, Hentschel B, Tatagiba M, et al. Molecular markers in low-grade gliomas : predictive or prognostic? Clin Cancer Res 2011 ; 17 : 4588-99.
 
79) Houillier C, Wang X, Kaloshi G, et al. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 2010 ; 75 : 1560-6.
PubMed
80) van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors : a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res 2010 ; 16 : 1597-604.
 
from the Brain Tumor Registry of Japan. Neurol Med Chir (Tokyo) 2015 ; 55 : 286-95.
 
P.115 掲載の参考文献
1) Ohgaki H, Kleihues P. The definition of primary and secondary glioblastoma. Clin Cancer Res 2013 ; 19 : 764-72.
 
2) Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009 ; 360 : 765-73.
PubMed
3) Ohno M, Narita Y, Miyakita Y, et al. Glioblastomas with IDH1/2 mutations have a short clinical history and have a favorable clinical outcome. Jpn J Clin Oncol 2016 ; 46 : 31-9.
PubMed
4) Committee_of_Brain_Tumor_Registry_of_Japan. Report of Brain Tumor Registry of Japan (2001-2004). Neurol Med Chir (Tokyo) 2014 ; suppl (1).
 
5) Narita Y, Shibui S. Trends and Outcomes in the Treatment of Gliomas Based on Data during 2001-2004 from the Brain Tumor Registry of Japan. Neurol Med Chir (Tokyo) 2015 ; 55 Suppl 1 : 286-95.
PubMed
6) Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme : prognosis, extent of resection, and survival. J Neurosurg 2001 ; 95 : 190-8.
PubMed
7) Sanai N, Polley MY, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 2011 ; 115 : 3-8.
PubMed
8) Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma : a randomised controlled multicentre phase III trial. Lancet Oncol 2006 ; 7 : 392-401.
PubMed
9) Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme : identification of and adjustment for bias. Neurosurgery 2008 ; 62 : 564-76 ; discussion 564-76.
 
10) Senft C, Bink A, Franz K, et al. Intraoperative MRI guidance and extent of resection in glioma surgery : a randomised, controlled trial. Lancet Oncol 2011 ; 12 : 997-1003.
PubMed
11) Schucht P, Beck J, Abu-Isa J, et al. Gross Total Resection Rates in Contemporary Glioblastoma Surgery : Results of an Institutional Protocol Combining 5-ALA Intraoperative Fluorescence Imaging and Brain Mapping. Neurosurgery 2012.
PubMed
12) Westphal M, Ram Z, Riddle V, et al. Gliadel wafer in initial surgery for malignant glioma : long-term follow-up of a multicenter controlled trial. Acta Neurochir 2006 ; 148 : 269-75 ; discussion 75.
 
13) Gutenberg A, Lumenta CB, Braunsdorf WE, et al. The combination of carmustine wafers and temozolomide for the treatment of malignant gliomas. A comprehensive review of the rationale and clinical experience. J Neurooncol 2013 ; 113 : 163-74.
PubMed
14) Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005 ; 352 : 987-96.
PubMed
15) Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study : 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009 ; 10 : 459-66.
 
16) Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005 ; 352 : 997-1003.
PubMed
17) Stupp R, Taillibert S, Kanner AA, et al. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma : A Randomized Clinical Trial. JAMA 2015 ; 314 : 2535-43.
PubMed
18) Gilbert MR, Wang M, Aldape KD, et al. Dose-dense temozolomide for newly diagnosed glioblastoma : a randomized phase III clinical trial. J Clinical Oncol 2013 ; 31 : 4085-91.
 
19) Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014 ; 370 : 709-22.
PubMed
20) Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014 ; 370 : 699-708.
PubMed
21) Henriksson R, Bottomley A, Mason W, et al. Progression-free survival (PFS) and health-related quality of life (HRQoL) in AVAglio, a phase III study of bevacizumab (Bv), temozolomide (T), and radiotherapy (RT) in newly diagnosed glioblastoma (GBM). J Clin Oncol, 2013 ASCO Annual Meeting Abstracts 2013 ; 31 (15_suppl) : 2013 : 05.
 
22) Wefel JS, Pugh SL, Armstrong TS, et al. Neurocognitive function (NCF) outcomes in patients with glioblastoma (GBM) enrolled in RTOG 0825. J Clin Oncol 2013 ASCO Annual Meeting Abstracts. 2013 ; 31 (15_suppl) : 2013 : 04.
 
23) Wick W, Cloughesy TF, Nishikawa R, et al. Tumor response based on adapted Macdonald criteria and assessment of pseudoprogression (PsPD) in the phase III AVAglio trial of bevacizumab (Bv) plus temozolomide (T) plus radiotherapy (RT) in newly diagnosed glioblastoma (GBM). J Clin Oncol 2013 ASCO Annual Meeting Abstracts. 2013 ; 31 (15_suppl) : 2013 : 02.
 
24) Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study) : a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2014 ; 15 : 1100-8.
PubMed
25) Nabors LB, Fink KL, Mikkelsen T, et al. Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter : results of the open-label, controlled, randomized phase II CORE study. Neuro Oncol 2015 ; 17 : 708-17.
PubMed
26) Wakabayashi T, Natsume A, Mizusawa J, et al. JCOG0911 : phase II trial of interferon and temozolomide versus temozolomide alone followed by radiotherapy for newly-diagnosed glioblastoma (Japan Clinical Oncology Group : INTEGRA study). 19th Annual Scientific Meeting of Society of Neuro-Oncology. 2014 ; Meeting abstract.
 
27) Keime-Guibert F, Chinot O, Taillandier L, et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med. 2007 ; 356 (15) : 1527-35.
PubMed
28) Scott JG, Suh JH, Elson P, et al. Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or older : a retrospective review of 206 cases. Neuro-oncology. 2011 ; 13 (4) : 428-36.
PubMed
29) Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme : a prospective randomized clinical trial. J Clin Oncol 2004 ; 22 : 1583-8.
PubMed
30) Roa W, Kepka L, Kumar N, et al. International Atomic Energy Agency Randomized Phase III Study of Radiation Therapy in Elderly and/or Frail Patients With Newly Diagnosed Glioblastoma Multiforme. J Clin Oncol 2015 ; 33 : 4145-50.
 
31) Malmstrom A, Gronberg BH, Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma : the Nordic randomised, phase 3 trial. Lancet Oncol 2012 ; 13 : 916-26.
PubMed
32) Narita Y. Bevacizumab for glioblastoma. Ther clin Risk Manag 2015 ; 11 : 1759-65.
PubMed
33) Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009 ; 27 : 4733-40.
PubMed
34) Nagane M, Nishikawa R, Narita Y, et al. Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma. Jpn J Clinical Oncol 2012 ; 42 : 887-95.
 
35) Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial) : a randomised controlled phase 2 trial. Lancet Oncol 2014 ; 15 : 943-53.
 
36) Wick A, Brandes AA, Gorlia T, et al. Phase III trial exploring the combination of bevacizumab and lomustine in patients with first recurrence of a glioblastoma : the EORTC 26101 trial. Neuro Oncol 2014 ; 17 (supple 5) : v1.
 
37) Field KM, Simes J, Nowak AK, et al. Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma. Neuro Oncol 2015 ; 17 : 1504-13.
PubMed
38) Levin VA, Bidaut L, Hou P, et al. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Rad Oncol Biol Phys 2011 ; 79 : 1487-95.
 
39) Back M, Gzell CE, Kastelan M, et al. Large volume re-irradiation with bevacizumab is a feasible salvage option for patients with refractory high-grade glioma. Neurooncol Pract 2015 ; 2 : 48-53.
PubMed
40) Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma : a randomised phase III trial of a novel treatment modality. Eur J Cancer 2012 ; 48 : 2192-202.
 
41) Hamza MA, Mandel JJ, Conrad CA, et al. Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma. Journal of neuro-oncology. 2014 ; 119 (1) : 135-40.
PubMed
42) Reardon DA, Herndon JE, 2nd, Peters KB, et al. Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients. Brit J Cancer 2012 ; 107 : 1481-7.
PubMed
43) Hovey EJ, Field KM, Rosenthal MA, et al. Continuing or ceasing bevacizumab at disease progression : Results from the CABARET study, a prospective randomized phase II trial in patients with recurrent glioblastoma. J Clin Oncol, 2013 ASCO Annual Meeting Abstracts. 2015 ; 33 (15_suppl) : 2015 : 03.
PubMed
44) Curran WJ, Jr., Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993 ; 85 : 704-10.
PubMed
45) Li J, Wang M, Won M, et al. Validation and simplification of the Radiation Therapy Oncology Group recursive partitioning analysis classification for glioblastoma. Int J Radiat Oncol Biol Phys 2011 ; 81 : 623-30.
 
46) Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma : recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 2006 ; 24 : 2563-9.
 
47) Carson KA, Grossman SA, Fisher JD, et al. Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials. J Clin Oncol 2007 ; 25 : 2601-6.
PubMed
P.118 掲載の参考文献
1) Merchant TE. Current management of childhood ependymoma Oncology 2002 ; 16 : 629-42, 644 ; discussion 645-6, 648.
 
2) Gajjar A, Packer RJ, Foreman NK, et al. Children's Oncology Group's 2013 Blueprint for Research : Central Nervous System Tumors. Pediatric Blood Cancer 2013 ; 60 : 1022-6.
 
3) Massimino M, Solero CL, Garre ML, et al. Second-look surgery for ependymoma : the Italian experience. J Neurosurg Pediatr. 2011 ; 8 : 246-50.
PubMed
4) Merchant TE, Li C, Xion X, et al. Conformal radiotherapy after for paediatric ependymoma. Lancet Oncol 2009 ; 10 : 258-66.
 
5) Merchant TE, Kiehna EN, Li C, et al. Radiation dosimetry predicts IQ after conformal radiation therapy in pediatric patients with localized ependymoma. Int. J Radiat Oncol Biol Phys 2005 ; 63 : 1546-54.
PubMed
6) Grundy RG, Wilne SA, Weston CL, et al. Primary postoperative chemotherapy without radiotherapy for intracranial ependymoma in children : The UKCCSG/SIOP prospective study. Lancet 2007 ; 8 : 696-705.
PubMed
7) Bouffet E, Hawkins CE, Ballourah W, et al. Survival benefit for pediatric patients with recurrent ependymoma treated with reirradiation. Int J Radiation Oncol Biol Phys 2012 ; 83 : 1541-8.
 
P.120 掲載の参考文献
1) 柳澤隆昭. 小児脳腫瘍に対する化学療法-治療の進化. 脳神経外科 2015 ; 43 : 183-98.
 
2) Gudrunardottir T, Lannering B, Remke M, et al. Treatment developments and the unfolding of the quality of life discussion in childhood medulloblastoma : a review. Childs Nerv Syst 2014 ; 30 : 979-90.
PubMed
3) Northcott PA, Korshunov A, Pfister SM, et al. The clinical implications of medulloblastoma subgroups. Nat Rev Neurol 2012 ; 12 : 340-51.
 
4) Martin AM1, Raabe E, Eberhart C, et al. Management of pediatric and adult patients with medulloblastoma. Curr Treat Options Oncol 2014 ; 15 : 581-94.
 
5) Samkari A, White JC, Packer RJ. Medulloblastoma : toward biologically based management. Semin Pediatr Neurol 2015 ; 22 : 6-13.
PubMed
6) Moxon-Emre I, Bouffet E, Taylor MD, et al. Impact of craniospinal dose, boost volume, and neurologic complications on intellectual outcome in patients with medulloblastoma. J Clin Oncol 2014 ; 32 : 1760-8.
PubMed
P.122 掲載の参考文献
1) Burger PC. Supratentorial primitive neuroectodermal tumor (sPNET). Brain Pathol 2006 ; 6 : 86.
 
2) Picard D, Miller S, Hawkins CE, et al. Markers of survival and metastatic potential in childhood CNS primitive neuro-ectodermal brain tumours : an integrative genomic analysis. The Lancet Oncology 2012 ; 13 : 838-48.
PubMed
3) Reddy AT, James AJ, Phillips PC, et al. Outcome for children with supratentorial primitive neuroectodermal tumors treated with surgery, radiation, and chemotherapy. Cancer 2000 ; 88 : 2189-93.
 
4) Cohen BH, Zeltzer PM, Boyett JM, et al. Prognostic factors and treatment results for supratentorial primitive neuroectodermal tumors in children using radiation and chemotherapy ; a Childrens Cancer Group randomized trial. J Clin Oncol 1995 ; 13 : 1687-96.
 
5) Albright AL, Wisoff JH, Zeltzer P, et al. Prognostic factors in children with supratentorial (nonpineal) primitive neuroectodermal tumors. A neurosurgical perspective from the Children's Cancer Group. Pediatr Neurosurg 1995 ; 22 : 1-7.
 
6) Timmermann R, Kortmann RD, Kuel J, et al. Role of radiotherapy in the treatment of supratentorial primitive neuroectodermal tumors in childhood : results of the prospective German brain tumor trials HIT88/89 and 91. J Clin Oncol 2002 ; 20 : 842-9.
 
7) Jakacki RI, Zeltzer PM, Boyett JM, et al. Survival and prognostic factors following radiation and/or chemotherapy for primitive neuroectodermal tumors of the pineal region in infants and children : report of the Children's Cancer Group. J Clin Oncol 1995 ; 13 : 1377-83.
PubMed
8) Pizer BL, Weston CL, Robinson KJ, et al. Analysis of patients with supratentorial primitive neuroectodermal tumors entered into SIOP/UKCCSG PNET3 study. Eur J Cancer 2006 ; 42 : 1120-8.
 
9) Chintagumpala M, Hassall T, Paimer S, al. A pilot study of risk-adapted radiotherapy and chemotherapy in patients with supratentorial PNET. Neuro Oncol 2009 ; 11 : 33-40.
 
10) Massimino M, Gandola L, Biassoni V, et al. Evolving of therapeutic strategies for CNS-PNET. Pediatr Blood Cancer 2013 ; 60 : 2031-5.
PubMed
11) Geyer JR, Sposto R, Jennings M, et al. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumor : a report from the Children's Cancer Group. J Clin Oncol 2005 ; 23 : 7621-31.
 
12) Timmermann B, Kortmann RD, Kuel J, et al. Role of radiotherapy in supratentorial primitive neuroectodermal tumor in young children : results of the German HIT-SKK87 and HIT-SKK92 trials. J Clin Oncol 2006 ; 24 : 1554-60.
 
P.125 掲載の参考文献
1) Hilden JM, Meerbaum S, Burger P, et al. Central nervous system atypical teratoid/rahbdoid tumor : results of therapy in children enrolled in registry. J Clin Oncol 2004 ; 22 : 2877-84.
 
2) Lafay-Cousin L, Hawkins C, Carret AS, et al. Central nervous system atypical teratoid rhabdoid tumours : The Canadian Paediatric Brain Tumour Consortium experience. Eur J Cancer 2012 ; 48 : 353-9.
PubMed
3) Biegel JA, et al. Alterations of the hSNF5/INI1 gene in central nervous system atypical teratoid/rhabdoid tumors and renal and extrarenal rhabdoid tumors. Clin Cancer Res 2002 ; 8 : 3461-7.
PubMed
4) Zimmmerman MA, Goumnerova LC, Proctor M et al. Continuous remission of newly diagnosed and relapsed central nervous system atypical teratoid/rhaboid tumor. J Neuro-Oncol 2005 ; 72 : 77-84.
 
5) Seeringer A, Bartelheim K, Kerl K, et al. easibility of intensive multimodal therapy in infants affected by rhabdoid tumors-experience of the EU-RHAB registry. Klin Padiatr 2014 ; 226 : 143-8.
 
6) Wetmore C, Boyett J, Li S, et al. Alisertib is active as single agent in recurrent atypical teratoid rhabdoid tumors in 4 children. Neuro Oncol 2015 ; 17 : 882-8.
PubMed
7) Schrey D, Carceller Lechon F, Malietzis G, et al. Multimodal therapy in children and adolescents with newly diagnosed atypical teratoid rhabdoid tumor : individual pooled data analysis and review of the literature. J Neurooncol 2016 ; 126 : 81-90.
PubMed
8) Fruhwald MC, Biegel JA, Bourdeaut F, et al. Atypical teratoid/rhabdoid tumors-current concepts, advances in biology, and potential future therapies. Neuro Oncol 2016 ; pii : nov264. [Epub ahead of print]
 
P.135 掲載の参考文献
1) The Committee of Brain Tumor Registry of Japan. Report of Brain Tumor Registry of Japan (2001-2004) 13th Edition. Neurol Med Chir (Tokyo) 2014 ; 54 (Suppl 1) : 9-102.
 
2) Nakamura T, Tateishi K, Niwa T, et al. Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas. Neuropathol Appl Neurobiol 2015.
PubMed
3) Pasqualucci L, Trifonov V, Fabbri G, et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet 2011 ; 43 : 830-7.
PubMed
4) Fukumura K, Kawazu M, Ueno T, et al. Genomic characterization of primary central nervous system lymphoma. Acta Neuropathol. omline 2016 Jan 12, DOI 10.1007/s00401-016-1536-2.
 
5) 永根基雄. 脳神経外科医が解説する血液腫瘍 : 悪性リンパ腫. 脳外速報 2014 ; 24 : 658-68.
Medical*Online
6) Ferreri AJ, Marturano E. Primary CNS lymphoma. Best Prac Res Clin Haematol 2012 ; 25 : 119-30.
 
7) Camilleri-Broet S, Criniere E, Broet P, et al. A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas : analysis of 83 cases. Blood 2006 ; 107 : 190-6.
PubMed
8) Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004 ; 103 : 275-82.
PubMed
9) Abrey LE, Batchelor TT, Ferreri AJ, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 2005 ; 23 : 5034-43.
PubMed
10) Kreher S, Strehlow F, Martus P, et al. Prognostic impact of intraocular involvement in primary CNS lymphoma : experience from the G-PCNSL-SG1 trial. Ann Hematol 2015 ; 94 : 409-14.
 
11) Omuro AM, Ben-Porat LS, Panageas KS, et al. Delayed neurotoxicity in primary central nervous system lymphoma. Arch Neurol 2005 ; 62 : 1595-600.
PubMed
12) Correa DD, Maron L, Harder H, et al. Cognitive functions in primary central nervous system lymphoma : literature review and assessment guidelines. Ann Oncol 2007 ; 18 : 1145-51.
PubMed
13) Reni M, Ferreri AJ, Garancini MP, et al. Therapeutic management of primary central nervous system lymphoma in immunocompetent patients : results of a critical review of the literature. Ann Oncol 1997 ; 8 : 227-34.
PubMed
14) Weller M, Martus P, Roth P, et al. Surgery for primary CNS lymphoma? Challenging a paradigm. Neuro Oncol 2012 ; 14 : 1481-4.
PubMed
15) Schultz C, Scott C, Sherman W, et al. Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas : initial report of radiation therapy oncology group protocol 88-06. J Clin Oncol 1996 ; 14 : 556-64.
 
16) Mead GM, Bleehen NM, Gregor A, et al. A medical research council randomized trial in patients with primary cerebral non-Hodgkin lymphoma : cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy. Cancer 2000 ; 89 : 1359-70.
PubMed
17) Glass J, Gruber ML, Cher L, et al. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma : long-term outcome. J Neurosurg 1994 ; 81 : 188-95.
PubMed
18) O'Brien PC, Roos DE, Pratt G, et al. Combined-modality therapy for primary central nervous system lymphoma : long-term data from a Phase II multicenter study (Trans-Tasman Radiation Oncology Group). Int J Radiat Oncol Biol Phys 2006 ; 64 : 408-13.
 
19) Hiraga S, Arita N, Ohnishi T, et al. Rapid infusion of high-dose methotrexate resulting in enhanced penetration into cerebrospinal fluid and intensified tumor response in primary central nervous system lymphomas. J Neurosurg 1999 ; 91 : 221-30.
PubMed
20) Ferreri AJ, Reni M, Foppoli M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma : a randomised phase 2 trial. Lancet 2009 ; 374 : 1512-20.
PubMed
21) Ferreri AJ, Reni M, Pasini F, et al. A multicenter study of treatment of primary CNS lymphoma. Neurology 2002 ; 58 : 1513-20.
PubMed
22) Batchelor TT, Grossman SA, Mikkelsen T, et al. Rituximab monotherapy for patients with recurrent primary CNS lymphoma. Neurology 2011 ; 76 : 929-30.
PubMed
23) Birnbaum T, Stadler EA, von Baumgarten L, et al. Rituximab significantly improves complete response rate in patients with primary CNS lymphoma. J Neurooncol 2012 ; 109 : 285-91.
PubMed
24) Gregory G, Arumugaswamy A, Leung T, et al. Rituximab is associated with improved survival for aggressive B cell CNS lymphoma. Neuro Oncol 2013 ; 15 : 1068-73.
PubMed
25) Morris PG, Correa DD, Yahalom J, et al. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma : final results and long-term outcome. J Clin Oncol 2013 ; 31 : 3971-9.
PubMed
26) Shah GD, Yahalom J, Correa DD, et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol 2007 ; 25 : 4730-5.
PubMed
27) Abrey LE, Yahalom J, DeAngelis LM. Treatment for primary CNS lymphoma : the next step. J Clin Oncol 2000 ; 18 : 3144-50.
PubMed
28) DeAngelis LM, Seiferheld W, Schold SC, et al. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma : Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 2002 ; 20 : 4643-8.
 
29) Rubenstein JL, Hsi ED, Johnson JL, et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma : CALGB 50202 (Alliance 50202). J Clin Oncol. 2013 ; 31 : 3061-8.
PubMed
30) Reni M, Mason W, Zaja F, et al. Salvage chemotherapy with temozolomide in primary CNS lymphomas : preliminary results of a phase II trial. Eur J Cancer 2004 ; 40 : 1682-8.
PubMed
31) Ferreri AJ, Crocchiolo R, Assanelli A, et al. High-dose chemotherapy supported by autologous stem cell transplantation in patients with primary central nervous system lymphoma : facts and opinions. Leuk Lymphoma 2008 ; 49 : 2042-7.
PubMed
32) Soussain C, Hoang-Xuan K, Taillandier L, et al. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma : Societe Francaise de Greffe de Moelle Osseuse-Therapie Cellulaire. J Clin Oncol 2008 ; 26 : 2512-8.
PubMed
33) Kasenda B, Schorb E, Fritsch K, et al. Prognosis after high-dosechemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma--a long-term follow-up study. Ann Oncol 2012 ; 23 : 2670-5.
 
34) Omuro A, Correa DD, DeAngelis LM, et al. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood 2015 ; 125 : 1403-10.
PubMed
35) Shibamoto Y, Hayabuchi N, Hiratsuka J, et al. Is whole-brain irradiation necessary for primary central nervous system lymphoma? Patterns of recurrence after partial-brain irradiation. Cancer 2003 ; 97 : 128-33.
PubMed
36) Ferreri AJ, Verona C, Politi LS, et al. Consolidation radiotherapy in primary central nervous system lymphomas : impact on outcome of different fields and doses in patients in complete remission after upfront chemotherapy. Int J Radiat Oncol Biol Phys 2011 ; 80 : 169-75.
PubMed
37) Reni M, Ferreri AJ, Guha-Thakurta N, et al. Clinical relevance of consolidation radiotherapy and other main therapeutic issues in primary central nervous system lymphomas treated with upfront high-dose methotrexate. Int J Radiat Oncol Biol Phys 2001 ; 51 : 419-25.
PubMed
38) Korfel A, Thiel E, Martus P, et al. Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma. Neurology 2015 ; 84 : 1242-8.
PubMed
39) Thiel E, Korfel A, Martus P, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1) : a phase 3, randomised, non-inferiority trial. Lancet Oncol 2010 ; 11 : 1036-47.
 
40) Correa DD, Rocco-Donovan M, DeAngelis LM, et al. Prospective cognitive follow-up in primary CNS lymphoma patients treated with chemotherapy and reduced-dose radiotherapy. J Neurooncol 2009 ; 91 : 315-21.
PubMed
41) Jahnke K, Korfel A, Martus P, et al. High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma. Ann Oncol 2005 ; 16 : 445-9.
PubMed
42) Omuro AM, Taillandier L, Chinot O, et al. Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. J Neurooncol 2007 ; 85 : 207-11.
PubMed
43) Welch MR, Omuro A, Deangelis LM. Outcomes of the oldest patients with primary CNS lymphoma treated at Memorial Sloan-Kettering Cancer Center. Neuro Oncol 2012 ; 14 : 1304-11.
PubMed
44) Kasenda B, Ferreri AJ, Marturano E, et al. First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL) --a systematic review and individual patient data meta-analysis. Ann Oncol 2015 ; 26 : 1305-13.
PubMed
45) Omuro A, Chinot O, Taillandier L, et al. Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population : an intergroup ANOCEF-GOELAMS randomised phase 2 trial. Lancet Haematol 2015 ; 2 : e251-9.
 
46) Pulczynski EJ, Kuittinen O, Erlanson M, et al. Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance : results from a phase II study by the Nordic Lymphoma Group. Haematologica 2015 ; 100 : 534-40.
 
47) Plotkin SR, Betensky RA, Hochberg FH, et al. Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res 2004 ; 10 : 5643-6.
PubMed
48) Ferreri AJ, Blay JY, Reni M, et al. Prognostic scoring system for primary CNS lymphomas : the International Extranodal Lymphoma Study Group experience. J Clin Oncol 2003 ; 21 : 266-72.
 
49) Abrey LE, Ben-Porat L, Panageas KS, et al. Primary central nervous system lymphoma : the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 2006 ; 24 : 5711-5.
 
P.141 掲載の参考文献
1) Calaminus G, Kortmann R, Worch J, et al. final report of outcome of a prospective, multinational nonrandomized trial for children and adults with intracranial germinoma, comparing craniospinal irradiation alone with chemotherapy followed by focal primary site irradiation for patients with localized disease. Neuro Oncol 2013 ; 15 : 788-96.
PubMed
2) The Committee of Brain Tumor Registry of Japan : Report of Brain Tumor Registry of Japan (2001-2004), 13th Edition. Neurol Med Chir (Tokyo) 2014 ; 54, Suppl 1.
 
3) Fujimaki T, Matsutani M, Funada N, et al. CT and MRI features of intracranial germ cell tumors. J Neuro Oncol 1994 ; 19 : 217-26.
 
4) Jennings MT, Gelman R, Hochberg F. Intracranial germ-cell tumors : natural history and pathogenesis. J Neurosurg 1985 ; 63 : 155-67.
PubMed
5) Kellie SJ, Boyce H, Dunkel IJ, et al. Primary Chemotherapy for intracranial nongerminomatous germ cell tumors : results of the second international CNS germ cell study group protocol. J Clin Oncol 2004 ; 22 : 846-53.
 
6) Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, eds. WHO classification of tumours of the central nervous system. 4th Ed. International Agency for Reserach on Cancer (IARC), Lyon, 2007, p309.
 
7) Matsutani M, Sano K, Takakura K, et al. Primary intracranial germ cell tumors : A clinical analysis of 153 histologically verified cases. J Neurosurg 1997 ; 86 : 446-55.
 
8) Matsutani M, Ushio Y, Abe H, et al. Combined chemotherapy and radiation therapy for central nervous system germ cell tumors : preliminary results f a Phase II study of the Japanese Pediatric Brain Tumor Study Group. Neurosurg Focus 1998 ; 5 : Article 7.
 
9) Matsutani M, The Japanese CNS Germ Cell Study Group. Natural history of intracranial germ cell tumors and its implications for treatment. Br J Neurosurg 2013 ; 27 : e1.
 
10) Saeki N, Tamaki K, Murai H, et al. Long-term outcome of endocrine function in patients with neurohypophyseal germinomas. Endocr J 2000 ; 47 : 83-8.
 
11) Sawamura Y, de Triboulet N, Ishii N, et al. Management of primary intracranial germinomas : diagnostic surgery or radical resection? J Neurosurg 1997 ; 87 : 262-6.
PubMed
12) Sawamura Y, Ikeda J, Shirato H, et al. Germ cell tumours of the central nervous system : treatment consideration based on 111 cases and their long-term clinical outcomes. Eur J Cancer 1998 ; 34 : 104-10.
PubMed
13) Shibamoto Y, Takahashi M, Abe M. Reduction of the radiation dose for intracranial germinoma : a prospective study. Br J Cancer 1994 ; 70 : 984-9.
PubMed
14) Takami H, Fukushima S, Fukuoka K, et al. Human chorionic gonadotropin is expressed virtually in all intracranial germ cell tumors. J Neurooncol 2015 ; 124 : 23-32.
PubMed
15) Yoshida J, Sugita K, Kobayashi K, et al. Prognosis of intracranial germ cell tumours : effectiveness of chemotherapy with cisplatin and etoposide (CDDP and VP-16). Acta Neurochir (Wien) 1993 ; 120 : 111-7.
 
P.143 掲載の参考文献
1) Aldape KD, Plate KH, Vortmeyer AO, et al. Haemangioblastoma. In ; Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, eds. WHO Classification of Tumours of the Central Nervous System. Lyon, IARCPress, 2007, p184-6.
 
2) Japan TCoBTro. Report of brain tumor registry of Japan (2001-2004). Neurol Med Chir (Tokyo) 2014 ; 54 (Suppl).
 
3) Capitanio JF, Mazza E, Motta M,et al. Mechanisms, indications and results of salvage systemic therapy for sporadic and von Hippel-Lindau related hemangioblastomas of the central nervous system. Criti Rev Oncol Hematol 2013 ; 86 : 69-84.
 
4) Conway JE, Chou D, Clatterbuck RE, et al. Hemangioblastomas of the central nervous system in von Hippel-Lindau syndrome and sporadic disease. Neurosurgery 2001 ; 48 : 55-62 ; discussion-3.
 
5) 「フォン・ヒッペルリンドウ病の病態調査と診断治療系確立の研究」班. フォン・ヒッペルリンドウ (VHL) 病診療ガイドライン, 2011.
 
6) Sakamoto N, Ishikawa E, Nakai Y, et al. Preoperative endovascular embolization for hemangioblastoma in the posterior fossa. Neurol Med Chir (Tokyo) 2012 ; 52 : 878-84.
PubMed
7) Montano N, Doglietto F, Pedicelli A, et al. Embolization of hemangioblastomas. J Neurosurg 2008 ; 108 : 1063-4 ; author reply 4-5.
 
8) Kano H, Shuto T, Iwai Y, et al. Stereotactic radiosurgery for intracranial hemangioblastomas : a retrospective international outcome study. J Neurosurg 2015 ; 122 : 1469-78.
PubMed
9) Hanakita S, Koga T, Shin M, et al. The long-term outcomes of radiosurgery for intracranial hemangioblastomas. Neuro Oncol 2014 ; 16 : 429-33.
 
P.146 掲載の参考文献
1) Clark AJ, Sughrue ME, Ivan ME, et al. Factors influencing overall survival rates for patients with pineocytoma. J Neurooncol 2010 ; 100 : 255-60.
PubMed
2) Clark AJ, Ivan ME, Sughrue ME, et al. Tumor control after surgery and radiotherapy for pineocytoma. J Neurosurg 2010 ; 113 : 319-24.
PubMed
3) The Committee of Brain Tumor Registry of Japan : Report of Brain Tumor Registry of Japan (2001-2004), 13th Edition. Neurol Med Chir (Tokyo) 2014 ; 54 : Suppl 1.
 
4) Cuccia V, Rodriguez F, Palma F, et al. Pinealoblastomas in children. Childs Nerv Syst 2006 ; 22 : 577-85.
PubMed
5) D'Andrea AD, Packer RJ, Rorke LB, et al. Pineocytomas of childhood A reappraisal of natural history and response to therapy. Cancer 1987 ; 59 : 1353-7.
 
6) Fauchon F, Jouvet A, Paquis P, et al. Parenchymal pineal tumors : a clinicopathological study of 76 cases. Int J Radiat Oncol Biol Phys 2000 ; 46 : 959-68.
PubMed
7) Fauchon F, Hasselblatt M, Jouvet A, et al. Role of surgery, radiotherapy and chemotherapy in papillary tumors of the pineal region : a multicenter study. J Neurooncol 2013 ; 112 : 223-31.
PubMed
8) Ganti SR, Hilal SK, Stein Bm, et al. CT of pineal region tumors. AJNR Am J Neuroradiol 1986 ; 7 : 97-104.
 
9) Gerber NU, von Hoff K, Resch A, et al. Treatment of children with central nervous system primitive neuroectodermal tumors/pinealoblastomas in the prospective multicentric trial HIT 2000 using hyperfractionated radiation therapy followed by maintenance chemotherapy. Int J Radiat Oncol Biol Phys 2014 ; 89 : 863-71.
 
10) Gururangan S, McLaughlin C, Quinn J, et al. High-dose chemotherapy with autologous stem-cell rescue in children and adults with newly diagnosed pineoblastomas. J Clin Oncol 2003 ; 21 : 2187-91.
PubMed
11) Hinkes BG, von Hoff K, Deinlein F, et al. Childhood pineoblastoma : experiences from the prospective multicenter trials HIT-SKK87, HIT-SKK92 and HIT91. J Neurooncol 2007 ; 81 : 217-23.
PubMed
12) Ito T, Kanno H, Sato KI, et al. Clinicopathologic study of pineal parenchymal tumors of intermediate differentiation (PPTID). World Neurosurg 2014 ; 81 : 783-9.
 
13) Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, eds. WHO classification of tumours of the central nervous system. 4th Ed. International Agency for Reserach on Cancer (IARC), Lyon, 2007, p309.
 
14) Nakamura M, Saeki N, Iwadate Y, et al. Neuroradiological characteristics of pineocytoma and pineoblastoma. Neuroradiology 2000 ; 42 : 509-14.
PubMed
15) Ostrom QT, Gittleman H, Farah P, et al. CBTRUS statistical report : Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol 2013 ; 15 Suppl 2 : ii1-56.
 
16) Park JH, Kim JH, Kwon DH, et al. Upfront Stereotactic Radiosurgery for Pineal Parenchymal Tumors in Adults. J Korean Neurosurg Soc 2015 ; 58 : 334-40.
PubMed
17) Poulgrain K1, Gurgo R, Winter C, et al. Papillary tumour of the pineal region. J Clin Neurosci 2011 ; 18 : 1007-17.
 
18) Stoiber EM, Schaible B, Herfarth K, et al. Long term outcome of adolescent and adult patients with pineal parenchymal tumors treated with fractionated radiotherapy between 1982 and 2003-a single institution's experience. Radiat Oncol 2012 ; 5 : 122.
 
19) Tate M, Sughrue ME, Rutkowski MJ, et al. The long-term postsurgical prognosis of patients with pineoblastoma. Cancer 2012 ; 118 : 173-9.
 
20) Yi JW, Kim HJ, Choi YJ, S et al. Successful treatment by chemotherapy of pineal parenchymal tumor with intermediate differentiation : a case report. Cancer Res Treat 2013 ; 45 : 244-9.
 
P.148 掲載の参考文献
1) Aleksic S, Budzilovich G, Greco MA, et al. Intracranial lipomas, hydrocephalus and other CNS anomalies in oculoauriculo-vertebral dysplasia (Goldenhar-Gorlin syndrome). Childs Brain 1984 ; 11 : 285-97.
PubMed
2) Bakshi R, Shaikh ZA, Kamran S, et al. MRI findings in 32 consecutive lipomas using conventional and advanced sequences. J Neuroimaging 1999 ; 9 : 134-40.
PubMed
3) Celik SE, Kocaeli H, Cordan T, et al. Trigeminal neuralgia due to cerebellopontine angle lipoma. Case illustration. J Neurosurg 2000 ; 92 : 889.
PubMed
4) Christensen WN, Long DM, Epstein JI. Cerebellopontine angle lipoma. Hum Pathol 1986 ; 17 : 739-43.
PubMed
5) Donati F, Vassella F, Kaiser G, et al. Intracranial lipomas. Neuropediatrics 1992 ; 23 : 32-8.
PubMed
6) Eghwrudjakpor PO, Kurisaka M, Fukuoka M, et al. Intracranial lipomas : current perspectives in their diagnosis and treatment. Br J Neurosurg 1992 ; 6 : 139-44.
PubMed
7) Friedman RB, Segal R, Latchaw RE : Computerized tomographic and magnetic resonance imaging of intracranial lipoma. Case report. J Neurosurg 1986 ; 65 : 407-10.
PubMed
8) Gerber SS, Plotkin R : Lipoma of the corpus callosum. Case report. J Neurosurg 1982 ; 57 : 281-5.
PubMed
9) Haga HJ, Thomassen E, Johannesen A, et al. Neural compressive symptoms appearing during steroid treatment in a patient with intracranial lipoma. Scand J Rheumatol 1999 ; 28 : 184-6.
 
10) Ichikawa T, Kumazaki T, Mizumura S, et al. Intracranial lipomas (Demonstration by computed tomography and magnetic resonance imaging). J Nippon Med Sch 2000 ; 67 : 388-91.
PubMed
11) Inoue T, Maeyama R, Ogawa H. Hemifacial spasm resulting from cerebellopontine angle lipoma : case report. Neurosurgery 1995 ; 36 : 846-50.
PubMed
12) Kazner E, Stochdorph O, Wende S, et al. Intracranial lipoma. Diagnostic and therapeutic considerations. J Neurosurg 1980 ; 52 : 234-45.
PubMed
13) Levin JM, Lee JE : Hemifacial spasm due to cerebellopontine angle lipoma : case report. Neurology 1987 ; 37 : 337-9.
PubMed
14) Maiuri F, Cirillo S. Intracranial lipomas. Acta Neurol (Napoli) 1988 ; 10 : 29-82.
PubMed
15) Maiuri F, Cirillo S, Simonetti L, et al. Intracranial lipomas. Diagnostic and therapeutic considerations. J Neurosurg Sci 1988 ; 32 : 161-7.
PubMed
16) Maiuri F, Corriero G, Gallicchio B, et al. Lipoma of the ambient cistern causing obstructive hydrocephalus. J Neurosurg Sci 1987 ; 31 : 53-8.
PubMed
17) Steimle R, Pageaut G, Jacquet G, et al. Lipoma in the cerebellopontine angle. Surg Neurol 1985 ; 24 : 73-6.
PubMed
18) Tahmouresie A, Kroll G, Shucart W. Lipoma of the corpus callosum. Surg Neurol 11 : 31-34, 1979.
PubMed
19) Truwit CL, Barkovich AJ : Pathogenesis of intracranial lipoma : an MR study in 42 patients. AJR Am J Roentgenol 1990 ; 155 : 855-64 ; discussion 865.
 
20) Uchino A, Hasuo K, Matsumoto S, et al. MRI of dorsal mesencephalic lipomas. Clin Imaging 1993 ; 17 : 12-6.
PubMed
21) Zimmermann M, Kellermann S, Gerlach R, et al. Cerebellopontine angle lipoma : case report and review of the literature. Acta Neurochir 1999 ; 141 : 1347-51.
PubMed
22) Spallone A, Pitskhelauri DI. Lipomas of the pineal region. Surg Neurol 2004 ; 62 : 52-8.
PubMed
23) Yilmaz N, Unal O, Kiymaz N, et al. Intracranial lipomas--a clinical study. Clin Neurol Neurosurg 2006 ; 108 : 363-8.
PubMed
24) Elgamal EA, El-Dawlatly AA, Murshid WR et al. Endoscopic thirs ventriculostomy for hydrocephalus in children younger than 1 year of age. Cholds Nerv Syst 2011 ; 27 : 111-6.
 
P.151 掲載の参考文献
1) Abla AA, Shetter AG, Chang SW, et al. Gamma Knife surgery for hypothalamic hamartomas and epilepsy : patient selection and outcomes. J Neurosurg 2010 ; 113 Suppl : 207-14.
PubMed
2) Albright AL, Lee PA. Neurosurgical treatment of hypothalamic hamartomas causing precocious puberty. J Neurosurg 1993 ; 78 : 77-82.
PubMed
3) Arita K, Ikawa F, Kurisu K, et al. The relationship between magnetic resonance imaging findings and clinical manifestations of hypothalamic hamartoma. J Neurosurg 1999 ; 91 : 212-20.
PubMed
4) Arroyo S, Santamaria J, Sanmarti F, et al. Ictal laughter associated with paroxysmal hypothalamopituitary dysfunction. Epilepsia 1997 ; 38 : 114-7.
PubMed
5) Calisto A, Dorfmuller G, Fohlen M, et al. Endoscopic disconnection of hypothalamic hamartomas : safety and feasibility of robot-assisted, thulium laser-based procedures. J Neurosurg Pediatr 2014 ; 14 : 563-72.
PubMed
6) Cascino GD, Andermann F, Berkovic SF, et al. Gelastic seizures and hypothalamic hamartomas : evaluation of patients undergoing chronic intracranial EEG monitoring and outcome of surgical treatment. Neurology 1993 ; 43 : 747-50.
PubMed
7) Culler FL, James HE, Simon ML, et al. Identification of gonadotropin-releasing hormone in neurons of a hypothalamic hamartoma in a boy with precocious puberty. Neurosurgery 1985 ; 17 : 408-12.
 
8) Date I, Yagyu Y, Mino S, et al. Hypothalamic hamartoma with precocious puberty-a case report. No Shinkei Geka 1985 ; 13 : 633-8.
PubMed
9) De Sanctis V, Corrias A, Rizzo V, et al. Etiology of central precocious puberty in males : the results of the Italian Study Group for Physiopathology of Puberty. J Pediatr Endocrinol Metab 2000 ; 13 (Suppl 1) : 687-93.
 
10) Hibi I, Fujiwara K. Precocious puberty of cerebral origin : a cooperative study in Japan. Prog Exp Tumor Res 1987 ; 30 : 224-38.
PubMed
11) Hochman HI, Judge DM, Reichlin S : Hypothalamic hamartoma and precocious puberty. Pediatrics 1981 ; 67 : 236-44.
PubMed
12) Judge DM, Kulin HE, Page R, et al. Hypothalamic hamartoma : a source of luteinizing-hormone-releasing factor in precociouspuberty. N Engl J Med 1977 ; 296 : 7-10.
PubMed
13) Kameyama S, Murakami H, Masuda H, et al. Minimally invasive magnetic resonance imaging-guided stereotactic radiofrequency thermocoagulation for epileptogenic hypothalamic hamartomas. Neurosurgery 2009 ; 65 : 438-49.
PubMed
14) Kameyama S, Shirozu H, Masuda H. MRI-guided stereotactic radiofrequency thermocoagulation for 100 hypothalamic hamartomas. J Neurosurg 2015 ; 20 : 1-10.
 
15) Kornreich L, Horev G, Blaser S, et al. Central precocious puberty : evaluation by neuroimaging. Pediatr Radiol 1995 ; 25 : 7-11.
PubMed
16) Kuzniecky R, Guthrie B, Mountz J, et al. Intrinsic epileptogenesis of hypothalamic hamartomas in gelastic epilepsy. Ann Neuro 1997 ; 142 : 60-7.
 
17) Kyuma Y, Kato E, Sekido K, et al. Hypothalamic hamartoma successfully treated by operation. Case report. J Neurosurg 1985 ; 62 : 288-90.
PubMed
18) Li CD, Luo SQ, Gong J, et al. Surgical treatment of hypothalamic hamartoma causing central precocious puberty : long-term follow-up. J Neurosurg Pediatr 2013 ; 12 : 151-4.
PubMed
19) Likavec AM, Dickerman RD, Heiss JD, et al. Retrospective analysis of surgical treatment outcomes for gelastic seizures : a review of the literature. Seizure 2000 ; 9 : 204-7.
PubMed
20) Machado HR, Hoffman HJ, Hwang PA. Gelastic seizures treated by resection of a hypothalamic hamartoma. Childs Nerv Syst 1991 ; 7 : 462-5.
PubMed
21) Mottolese C, Stan H, Bret P, et al. Hypothalamic hamartoma : the role of surgery in a series of eight patients. Childs Nerv Syst 2001 ; 17 : 229-36 ; discussion 237-8.
 
22) Ng YT, Rekate HL, Prenger EC, et al. Transcallosal resection of hypothalamic hamartoma for intractable epilepsy. Epilepsia 2006 ; 47 : 1192-202.
PubMed
23) Northfield DW, Russell DS. Pubertas praecox due to hypothalamic hamartoma : report of two cases surviving surgical removal of the tumour. J Neurol Neurosurg Psychiatry 1967 ; 30 : 166-73.
PubMed
24) Pallini R, Bozzini V, Colicchio G, et al. Callosotomy for generalized seizures associated with hypothalamic hamartoma. Neurol Res 1993 ; 15 : 139-41.
PubMed
25) Parrent AG : Stereotactic radiofrequency ablation for the treatment of gelastic seizures associated with hypothalamic hamartoma. Case report. J Neurosurg 1999 ; 91 : 881-4.
PubMed
26) Pasquier B, Bost F, Peoc'h M, et al. Neuropathologic data in drug-resistant partial epilepsy. Report of a series of 195 cases. Ann Pathol 1996 ; 16 : 174-81.
 
27) Price RA, Lee PA, Albright AL, et al. Treatment of sexual precocity by removal of a luteinizing hormone-releasing hormone secreting hamartoma. JAMA 1984 ; 251 : 2247-9.
PubMed
28) Rieth KG, Comite F, Dwyer AJ, et al. CT of cerebral abnormalities in precocious puberty. AJR Am J Roentgenol 1987 ; 148 : 1231-8.
PubMed
29) Robben SG, Oostdijk W, Drop SL, et al. Idiopathic isosexual central precocious puberty : magnetic resonance findings in 30 patients. Br J Radiol 1995 ; 68 : 34-8.
PubMed
30) Rosenfeld JV, Feiz-Erfan I. Hypothalamic hamartoma treatment : surgical resection with the transcallosal approach. Semin Pediatr Neurol 2007 ; 14 : 88-98.
PubMed
31) Selch MT, Gorgulho A, Mattozo C, et al. Linear accelerator stereotactic radiosurgery for the treatment of gelastic seizures due to hypothalamic hamartoma. Minim Invasive Neurosurg 2005 ; 48 : 310-4.
PubMed
32) Styne DM, Harris DA, Egli CA, et al. Treatment of true precocious puberty with a potent luteinizing hormone-releasing factor agonist : effect on growth, sexual maturation, pelvic sonography, and the hypothalamic-pituitary-gonadal axis. J Clin Endocrinol Metab 1985 ; 61 : 142-51.
 
33) Takahashi M, Takekawa S, Matsutani M, et al. Application of reconstruction computed tomography in a case of tuber cinereum hamartoma. Radiat Med 1983 ; 1 : 117-20.
 
34) Takeuchi J, Handa H, Miki Y, et al. Precocious puberty due to a hypothalamic hamartoma. Surg Neurol 1979 ; 11 : 456-60.
PubMed
35) Turjman F, Xavier JL, Froment JC, et al. Late MR follow-up of hypothalamic hamartomas. Childs Nerv Syst 1996 ; 12 : 63-8.
PubMed
36) Unger F, Schrottner O, Haselsberger K, et al. Gamma knife radiosurgery for hypothalamic hamartoma in patients with medically intractable epilepsy and precocious puberty. Report of two cases. J Neurosurg 2000 ; 92 : 726-31.
 
37) Valdueza JM, Cristante L, Dammann O, et al. Hypothalamic hamartomas : with special reference to gelastic epilepsy and surgery. Neurosurgery 1994 ; 34 : 949-58 ; discussion 958.
 
38) Wilfong AA, Curry DJ. Hypothalamic hamartomas : optimal approach to clinical evaluation and diagnosis. Epilepsia. 2013 Dec ; 54 Suppl 9 : 109-14.
PubMed
P.155 掲載の参考文献
1) Amagasa M, Yuda F, Sato S, Kojima H. Central neurocytoma with remarkably large rosette formation and rapid malignant progression : a clinicopathological follow-up study with autopsy report. Clin Neuropathol 2008 ; 27 : 252-7.
PubMed
2) Amini E, Roffidal T, Lee A, et al. Central neurocytoma responsive to topotecan, ifosfamide, carboplatin. Pediatr Blood Cancer 2008 ; 51 : 137-40.
PubMed
3) Balko MG, Schultz DL. Sudden death due to a central neurocytoma. Am J Forensic Med Pathol 1999 ; 20 : 180-3.
PubMed
4) Brandes AA, Amist P, Gardiman M, et al. Chemotherapy in patients with recurrent and progressive central neurocytoma. Cancer 2000 ; 88 : 169-74.
 
5) Cai DX, Mafra M, Schmidt RE, et al. Medulloblastomas with extensive posttherapy neuronal maturation. Report of two cases. J Neurosurg 2000 ; 93 : 330-4.
 
6) Cobery ST, Noren G, Friehs GM, et al. Gamma knife surgery for treatment of central neurocytomas. Report of four cases. J Neurosurg 2001 ; 94 : 327-30.
 
7) Dodds D, Nonis J, Mehta M, et al. Central neurocytoma : a clinical study of response to chemotherapy. J Neurooncol 1997 ; 34 : 279-83.
PubMed
8) Elek G, Slowik F, Eross L, et al. Central neurocytoma with malignant course. Neuronal and glial differentiation and craniospinal dissemination. Pathol Oncol Res 1999 ; 5 : 155-9.
PubMed
9) Eng DY, DeMonte F, Ginsberg L, et al. Craniospinal dissemination of central neurocytoma. Report of two cases. J Neurosurg 1997 ; 86 : 547-52.
 
10) Favereaux A, Vital A, Loiseau H, et al. Histopathological variants of central neurocytoma : Report of 10 cases. Ann Pathol 2000 ; 20 : 558-63.
PubMed
11) Fujimaki T, Matsuno A, Sasaki T, et al. Proliferative activity of central neurocytoma : measurement of tumor volume doubling time, MIB-1 staining index and bromodeoxyuridine labeling index. J Neurooncol 1997 ; 32 : 103-9.
PubMed
12) 藤巻高光, 成田善孝, 淺井昭雄, 他. Central neurocytomaのclinical behavior. Neuro-Oncology 1998 ; 8 : 62-63.
 
13) Hassoun J, Gambarelli D, Grisoli F, et al. Central neurocytoma. An electron-microscopic study of two cases. Acta Neuropathol 1982 ; 56 : 151-6.
PubMed
14) Hassoun J, Soylemezoglu F, Gambarelli D, et al. Central neurocytoma : a synopsis of clinical and histological features. Brain Pathol 1993 ; 3 : 297-306.
PubMed
15) Kim DG, Chi JG, Park SH, et al. Intraventricular neurocytoma : clinicopathological analysis of seven cases. J Neurosurg 1992 ; 76 : 759-65.
 
16) Kim DG, Kim JS, Chi JG, et al. Central neurocytoma : proliferative potential and biological behavior. J Neurosurg 1996 ; 84 : 742-7.
PubMed
17) Kim DG, Paek SH, Kim IH, et al. Central neurocytoma : the role of radiation therapy and long term outcome. Cancer 1997 ; 79 : 1995-2002.
PubMed
18) Kim JW, Kim DG, Kim IK, et al. Central neurocytoma : long-term outcomes of multimodal treatments and management strategies based on 30 years' experience in a single institute. Neurosurgery 2013 ; 72 : 407-13.
 
19) Mackenzie IR. Central neurocytoma : histologic atypia, proliferation potential, and clinical outcome. Cancer 1999 ; 85 : 1606-10.
PubMed
20) Metellus P, Dufour H, Fuentes S, et al. Central neurocytoma revealed by intraventricular hemorrhage. A case report and review of the literature. Neurochirurgie 2001 ; 47 : 445-7.
PubMed
21) 峯浦一喜. Central neurocytoma. No Shinei Geka 2000 ; 28 : 583-97.
 
22) Nishio S, Takeshita I, Kaneko Y, et al. Cerebral neurocytoma. A new subset of benign neuronal tumors of the cerebrum. Cancer 1992 ; 70 : 529-37.
PubMed
23) Pollock BE, Stafford SL. Stereotactic radiosurgery for recurrent central neurocytoma : case report. Neurosurgery 2001 ; 48 : 441-3.
PubMed
24) Rades D, Schild SE, Ikezaki K, et al. Defining the optimal dose of radiation after incomplete resection of central neurocytomamas. Int J Radiat Oncol Biol Phys 2003 ; 55 : 373-7.
PubMed
25) Salvati M, Cervoni L, Caruso R, et al. Central neurocytoma : clinical features of 8 cases. Neurosurg Rev 1997 ; 20 : 39-43.
PubMed
26) Schild SE, Scheithauer BW, Haddock MG, et al. Central neurocytomas. Cancer 1997 ; 79 : 790-5.
PubMed
27) Sgouros S, Carey M, Aluwihare N, et al. Central neurocytoma : a correlative clinicopathologic and radiologic analysis. Surg Neurol 1998 ; 49 : 197-204.
PubMed
28) Soylemezoglu F, Scheithauer BW, Esteve J, et al. Atypical central neurocytoma. J Neuropathol Exp Neurol 1997 ; 56 : 551-6.
PubMed
29) Tacconi L, Thom M, Symon L. Central neurocytoma : a clinicopathological study of five cases. Br J Neurosurg 1997 ; 11 : 286-91.
 
30) Tomura N, Hirano H, Watanabe O, et al. Central neurocytoma with clinically malignant behavior. AJNR Am J Neuroradiol 1997 ; 18 : 1175-8.
PubMed
31) Valdueza JM, Westphal M, Vortmeyer A, et al. Central neurocytoma : clinical, immunohistologic, and biologic findings of a human neuroglial progenitor tumor. Surg Neurol 1996 ; 45 : 49-56.
PubMed
32) Vallat-Decouvelaere AV, Gauchez P, Varlet P, et al. So-called malignant and extra-ventricular neurocytomas : reality or wrong diagnosis? A critical review about two overdiagnosed cases. J Neurooncol 2000 ; 48 : 161-72.
PubMed
33) Vaquero J, Coca S, Oya S, et al. Clinicopathological experience with intraventricular neurocytomas. J Neurosurg Sci 1992 ; 36 : 31-8.
PubMed
34) von Koch CS, Schmidt MH, Uyehara-Lock JH, et al. The role of PCV chemotherapy in the treatment of central neurocytoma : illustration of a case and review of the literature. Surg Neurol 2003 ; 60 : 560-5.
PubMed
35) Yasargil MG, von Ammon K, von Deimling A, et al. Central neurocytoma : histopathological variants and therapeutic approaches. J Neurosurg 1992 ; 76 : 32-7.
PubMed
36) Yen CP, Sheehan J, Patterson G, Steiner L : Gamma knife surgery for neurocytoma. J Neurosurg 2007 ; 107 : 7-12.
PubMed
P.160 掲載の参考文献
1) Hashiba T, Hashimoto N, Izumoto S, et al. Serial volumetric assessment of the natural history and growth pattern of incidentally discovered meningiomas. J Neurosurg 2009 ; 110 : 675-84.
PubMed
2) Oya S, Kim S-H, Sade B, et al. The natural history of intracranial meningiomas. J Neurosurg 2011 ; 114 : 1250-6.
PubMed
3) Nakasu S, Nakasu Y, Fukami T, et al. Growth curve analysis of asymptomatic and symptomatic meningiomas. J Neurooncol 2011 ; 102 : 303-10.
PubMed
4) Claus EB, Calvocoressi L, Bondy ML, et al. Exogenous hormone use, reproductive factors, and risk of intracranial meningioma in females. J Neurosurg 2013 ; 118 : 649-56.
PubMed
5) Hishikawa T, Sugiu K, Hiramatsu M, et al. Nationwide survey of the nature and risk factors of complications in embolization of meningiomas and other intracranial tumors : Japanese Registry of NeuroEndovascular Therapy 2 (JR-NET2). Neuroradiology 2014 ; 56 : 139-44.
PubMed
6) Claus EB, Bondy ML, Schildkraut JM, et al. Epidemiology of intracranial meningioma. Neurosurgery 2005 ; 57 : 1088-95.
PubMed
7) Backer-Grodahl T, Moen BH, Torp SH. The histopathological spectrum of human meningiomas. Int J Clin Exp Pathol 2012 ; 5 : 231-42.
 
8) Shibuya M. Pathology and molecular genetics of meningioma : recent advances. Neurol Med Chir (Tokyo) 2015 ; 55 : 14-27.
 
9) Clark VE, Erson-Omay EZ, Serin A, et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 2013 ; 339 : 1077-80.
PubMed
10) Hasseleid BF, Meling TR, Roning P, et al. Surgery for convexity meningioma : Simpson Grade I resection as the goal. J Neurosurg 2012 ; 117 : 999-1006.
 
11) Ichinose T, Goto T, Ishibashi K, et al. The role of radical microsurgical resection in multimodal treatment for skull base meningioma. J Neurosurg 2010 ; 113 : 1072-8.
PubMed
12) Oya S, Kawai K, Nakatomi H, et al. Significance of Simpson grading system in modern meningioma surgery : integration of the grade with MIB-1 labeling index as a key to predict the recurrence of WHO Grade I meningiomas. J Neurosurg 2012 ; 117 : 121-8.
 
13) Rogers L, Barani I, Chamberlain M, et al. Meningiomas : knowledge base, treatment outcomes, and uncertainties. A RANO review. J Neurosurg 2015 ; 122 : 4-23.
PubMed
14) Kondziolka D, Flickinger JC, Perez B. Judicious resection and/or radiosurgery for parasagittal meningiomas : outcomes from a multicenter review. Gamma Knife Meningioma Study Group. Neurosurgery 1998 ; 43 : 405-13 ; discussion 413.
PubMed
15) Stafford SL, Pollock BE, Foote RL, et al. Meningioma radiosurgery : tumor control, outcomes, and complications among 190 consecutive patients. Neurosurgery 2001 ; 49 : 1029-37.
PubMed
16) Kondziolka D, Mathieu D, Lunsford LD, et al. Radiosurgery as definitive management of intracranial meningiomas. Neurosurgery 2008 ; 62 : 53-8.
PubMed
17) Hasegawa T, Kida Y, Yoshimoto M, et al. Gamma Knife surgery for convexity, parasagittal, and falcine meningiomas. J Neurosurg 2011 ; 114 : 1392-8.
PubMed
18) Tanaka S, Pollock BE, Stafford SL, et al. Stereotactic radiosurgery for trigeminal pain secondary to benign skull base tumors. World Neurosurg 2013 ; 80 : 371-7.
PubMed
19) Komotar RJ, Iorgulescu JB, Raper DMS, et al. The role of radiotherapy following gross-total resection of atypical meningiomas. J Neurosurg. 2012 ; 117 : 679-86.
 
20) Sun SQ, Hawasli AH, Huang J, et al. An evidence-based treatment algorithm for the management of WHO Grade II and III meningiomas. Neurosurg Focus 2015 ; 38 : E3.
PubMed
P.168 掲載の参考文献
1) Report of brain tumor registry of Japan (2001-2004), 13th Edition. Neurol Med Chir (Tokyo) 2014 ; Supplement 1 : 54.
 
2) Chahal J, Schlechte J. Hyperprolactinemia. Pituitary 2008 ; 11 : 141-6.
PubMed
3) Teramoto A, Yoshida Y, Sanno N, et al. Cavernous sinus sampling in patients with adrenocorticotrophic hormone-dependent Cushing's syndrome with emphasis on inter- and intracavernous adrenocorticotrophic hormone gradients. J Neurosurg 1998 ; 89 : 762-8.
 
4) Sanno N, Teramoto A, Osamura RY. Long-term surgical outcome in 16 patients with thyrotropin pituitary adenoma. J Neurosurg 2000 ; 93 : 194-200.
PubMed
5) Beck-Peccoz P, Brucker-Davis F, Persani L, et al. Thyrotropin-secreting pituitary tumors. Endocr Rev 1996 ; 17 : 610-38.
PubMed
6) Teramoto A, Hirakawa K, Sanno N, et al. Incidental pituitary lesions in 1,000 unselected autopsy specimens. Radiology 1994 ; 193 : 161-4.
PubMed
7) Molitch ME, Russell EJ. The pituitary "incidentaloma". Ann Intern Med 1990 ; 112 : 925-31.
PubMed
8) Arvat E, di Vito L, Maccagno B, et al. Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH. Peptides 1997 ; 18 : 885-91.
PubMed
9) JK, Markou KD, Georgalas C. Endoscopic versus microscopic trans-sphenoidal pituitary surgery : a systematic review and meta-analysis. Clin Otolaryngol 2011 ; 36 : 212-20.
 
10) Kim EH, Ku CR, Lee EJ, et al. Extracapsular en bloc resection in pituitary adenoma surgery. Pituitary 2015 ; 18 : 397-404.
PubMed
11) Monteith SJ, Starke RM, Jane JA Jr, et al. Use of the histological pseudocapsule in surgery for Cushing disease : rapid postoperative cortisol decline predicting complete tumor resection. J Neurosurg 2012 ; 116 : 721-7.
 
12) Oldfield EH, Vortmeyer AO. Development of a histological pseudocapsule and its use as a surgical capsule in the excision of pituitary tumors. J Neurosurg 2006 ; 104 : 7-19.
PubMed
13) Kawamata T, Kubo O, Hori T. Surgical removal of growth hormone-secreting pituitary adenomas with intensive microsurgical pseudocapsule resection results in complete remission of acromegaly. Neurosurg Rev 2005 ; 28 : 201-8.
PubMed
14) Farnoud MR, Kujas M, Derome P, et al. Interactions between normal and tumoral tissues at the boundary of human anterior pituitary adenomas. An immunohistochemical study. Virchows Arch 1994 ; 424 : 75-82.
PubMed
15) Lee CC, Vance ML, Xu Z, et al. Stereotactic radiosurgery for acromegaly. J Clin Endocrinol Metab 2014 ; 99 : 1273-81.
PubMed
16) Colao A, Auriemma RS, Pivonello R. The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly. Pituitary 2015. [Epub ahead of print]
 
17) Fougner SL, Bollerslev J, Svartberg J, et al. Preoperative octreotide treatment of acromegaly : long-term results of a randomised controlled trial. Eur J Endocrinol 2014 ; 171 : 229-35.
PubMed
18) Katznelson L, Laws ER Jr, Melmed S, et al ; Endocrine Society. Acromegaly : an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014 ; 99 : 3933-51
 
19) Melmed S, Jackson I, Kleinberg D, et al. Current treatment guidelines for acromegaly. J Clin Endocrinol Metab 1998 ; 83 : 2646-52.
PubMed
20) Tutuncu Y, Berker D, Isik S, et al. Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly. Pituitary 2012 ; 15 : 398-404.
PubMed
21) Gadelha MR, Bronstein MD, Brue T, et al ; Pasireotide C2402 Study Group. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA) : a randomised, phase 3 trial. Lancet Diabetes Endocrinol 2014 ; 2 : 875-84.
 
22) Stewart PM. Pegvisomant : an advance in clinical efficacy in acromegaly. Eur J Endocrinol 2003 ; 148 : S27-32.
PubMed
23) Freda PU, Gordon MB, Kelepouris N, et al. Long-term treatment with pegvisomant as monotherapy in patients with acromegaly : experience from acrostudy. Endocr Pract 2015 ; 21 : 264-74.
PubMed
24) Beck-Peccoz P, Persani L, Mannavola D, et al. Pituitary tumours : TSH-secreting adenomas. Best Pract Res Clin Endocrinol Metab 2009 ; 23 : 597-606.
PubMed
25) Gatto F, Grasso LF, Nazzari E, et al. Clinical outcome and evidence of high rate post-surgical anterior hypopituitarism in a cohort of TSH-secreting adenoma patients : Might somatostatin analogs have a role as first-line therapy? Pituitary 2015 ; 18 : 583-91.
 
26) Losa M, Mortini P, Barzaghi R, et al. Early results of surgery in patients with nonfunctioning pituitary adenoma and analysis of the risk of tumor recurrence. J Neurosurg 2008 ; 108 : 525-32.
PubMed
27) Laws ER Jr, Thapar K. Recurrent pituitary adenomas. In ; Landolt AM, et al, eds. Pituitary adenomas, Churchill Livingstone (New York), 1996, p385-93.
 
28) Biller BM, Grossman AB, Stewart PM, et al. Treatment of adrenocorticotropin-dependent Cushing's syndrome : a consensus statement. J Clin Endocrinol Metab 2008 ; 93 : 2454-62.
 
29) Brucker-Davis F, Oldfield EH, Skarulis MC, et al. Thyrotropin-secreting pituitary tumors : diagnostic criteria, thyroid hormone sensitivity, and treatment outcome in 25 patients followed at the National Institutes of Health. J Clin Endocrinol Metab 1999 ; 84 : 476-86.
PubMed
P.174 掲載の参考文献
1) Louis DN, Ohgaki H, Wiestler OD, et al. World Health Organization Histological Classification of Tumours of the Central Nervous System. Lyon, International Agency for Research on Cancer, 2007.
 
2) Report of Brain Tumor Registry of Japan (1984-2000). Neurol Med Chir (Tokyo) 2009 ; 49 Suppl : i-iii, 1-96.
 
3) Khrais T, Romano G, Sanna M. Nerve origin of vestibular schwannoma : a prospective study. J Laryngol Otol 2008 ; 122 : 128-31.
PubMed
4) Konovalov AN, Spallone A, Mukhamedjanov DJ, et al. Trigeminal neurinomas. A series of 111 surgical cases from a single institution. Acta Neurochir (Wien) 1996 ; 138 : 1027-35.
PubMed
5) Samii M, Migliori MM, Tatagiba M, et al. Surgical treatment of trigeminal schwannomas. J Neurosurg 1995 ; 82 : 711-8.
PubMed
6) Tan LC, Bordi L, Symon L, et al. Jugular foramen neuromas : a review of 14 cases. Surg Neurol 1990 ; 34 : 205-11.
PubMed
7) Samii M, Babu RP, Tatagiba M, et al. Surgical treatment of jugular foramen schwannomas. J Neurosurg 1995 ; 82 : 924-32.
PubMed
8) Symon L, Cheesman AD, Kawauchi M, et al. Neuromas of the facial nerve : a report of 12 cases. Br J Neurosurg 1993 ; 7 : 13-22.
PubMed
9) Kida Y, Yoshimoto M, Hasegawa T. Radiosurgery for facial schwannoma. J Neurosurg 2007 ; 106 : 24-9.
PubMed
10) Tos M, Stangerup SE, Caye-Thomasen P, et al. What is the real incidence of vestibular schwannoma? Arch Otolaryngol Head Neck Surg 2004 ; 130 : 216-20.
PubMed
11) Stangerup SE, Tos M, Caye-Thomasen P, et al. Increasing annual incidence of vestibular schwannoma and age at diagnosis. J Laryngol Otol 2004 ; 118 : 622-7.
PubMed
12) Ahlbom A, Feychting M, Green A, et al. Epidemiologic evidence on mobile phones and tumor risk : a review. Epidemiology 2009 ; 20 : 639-52.
 
13) Antinheimo J, Sankila R, Carpen O, et al. Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas. Neurology 2000 ; 54 : 71-6.
PubMed
14) Evans DG, Moran A, King A, et al. Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period : higher incidence than previously thought. Otol Neurotol 2005 ; 26 : 93-7.
 
15) Evans DG, Huson SM, Donnai D, et al. A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. J Med Genet 29 : 841-846, 1992.
PubMed
16) Trofatter JA, MacCollin MM, Rutter JL, et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 1993 ; 75 : 826.
PubMed
17) Rouleau GA, Merel P, Lutchman M, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 1993 ; 363 : 515-21.
 
18) Martuza RL, Eldridge R. Neurofibromatosis 2 (bilateral acoustic neurofibromatosis). N Engl J Med 1988 ; 318 : 684-8.
PubMed
19) Mautner VF, Lindenau M, Baser ME, et al. The neuroimaging and clinical spectrum of neurofibromatosis 2. Neurosurgery 1996 ; 38 : 880-5 ; discussion 885-6.
 
20) Asthagiri AR, Parry DM, Butman JA, et al. Neurofibromatosis type 2. Lancet 373 : 2009 ; 1974-86.
PubMed
21) Evans DG, Huson SM, Donnai D, et al. A clinical study of type 2 neurofibromatosis. Q J Med 1992 ; 84 : 603-18.
PubMed
22) Baser ME, Friedman JM, Aeschliman D, et al. Predictors of the risk of mortality in neurofibromatosis 2. Am J Hum Genet 2002 ; 71 : 715-23.
PubMed
23) Matthies C, Samii M. Management of 1000 vestibular schwannomas (acoustic neuromas) : clinical presentation. Neurosurgery 1997 ; 40 : 1-9 ; discussion 9-10.
 
24) Masuda A, Fisher LM, Oppenheimer ML, et al. Hearing changes after diagnosis in neurofibromatosis type 2. Otol Neurotol 2004 ; 25 : 150-4.
PubMed
25) Lunardi P, Missori P, Mastronardi L, et al. Cystic acoustic schwannomas. Acta Neurochir (Wien) 1991 ; 110 : 120-3.
PubMed
26) Shaffer KA, Haughton VM, Wilson CR. High resolution computed tomography of the temporal bone. Radiology 1980 ; 134 : 409-14.
PubMed
27) Ozgen B, Oguz B, Dolgun A. Diagnostic accuracy of the constructive interference in steady state sequence alone for follow-up imaging of vestibular schwannomas. AJNR Am J Neuroradiol 2009 ; 30 : 985-91.
PubMed
28) House JW, Brackmann DE. Facial nerve grading system. Otolaryngol Head Neck Surg 1985 ; 93 : 146-7.
PubMed
29) Hart RG, Davenport J. Diagnosis of acoustic neuroma. Neurosurgery 1981 ; 9 : 450-63.
PubMed
30) Gardner G, Robertson JH. Hearing preservation in unilateral acoustic neuroma surgery. Ann Otol Rhinol Laryngol 1988 ; 97 : 55-66.
PubMed
31) Kanzaki J, Tos M, Sanna M, et al. New and modified reporting systems from the consensus meeting on systems for reporting results in vestibular schwannoma. Otol Neurotol 2003 ; 24 : 642-8 ; discussion 648-9.
 
32) Tanaka Y, Hongo K, Tada T, et al. What is the best method for reporting tumor diameter in vestibular schwannoma? Neurosurgery 2003 ; 53 : 634-7 ; discussion 637-8.
 
33) Mendenhall WM, Friedman WA, Amdur RJ, et al. Management of acoustic schwannoma. Am J Otolaryngol 2004 ; 25 : 38-47.
PubMed
34) Yamakami I, Uchino Y, Kobayashi E, et al. Conservative management, gamma-knife radiosurgery, and microsurgery for acoustic neurinomas : a systematic review of outcome and risk of three therapeutic options. Neurol Res 2003 ; 25 : 682-90.
PubMed
35) Yoshimoto Y. Systematic review of the natural history of vestibular schwannoma. J Neurosurg 2005 ; 103 : 59-63.
PubMed
36) Caye-Thomasen P, Hansen S, Dethloff T, et al. Sublocalization and volumetric growth pattern of intracanalicular vestibular schwannomas. Laryngoscope 2006 ; 116 : 1131-5.
PubMed
37) Pennings RJ1, Morris DP, Clarke L et al.Natural history of hearing deterioration in intracanalicular vestibular schwannoma. Neurosurgery 2011 ; 68 : 68-77.
 
38) Lee JD, Park MK, Kim JS, et al. The Factors Associated With Tumor Stability Observed With Conservative Management of Intracanalicular Vestibular Schwannoma. Otology & Neurotology 2014 ; 35 : 918-21.
PubMed
39) Sughrue ME, Yang I, Aranda D, et al. The natural history of untreated sporadic vestibular schwannomas : a comprehensive review of hearing outcomes. J Neurosurg 2009 ; 112 : 163-7.
 
40) Sughrue ME, Kane AJ, Kaur R, et al. A prospective study of hearing preservation in untreated vestibular schwannomas. J Neurosurg 2011 ; 114 : 381-5.
 
41) Bakkouri WE, Kania RE, Guichard JP, et al. Conservative management of 386 cases of unilateral vestibular schwannoma : tumor growth and consequences for treatment. J Neurosurg 2009 ; 110 : 662-9.
PubMed
42) Kaylie DM, Horgan MJ, Delashaw JB, et al. A meta-analysis comparing outcomes of microsurgery and gamma knife radiosurgery. Laryngoscope 2000 ; 110 : 1850-6.
PubMed
43) Jacob A, Robinson LL Jr, Bortman JS, et al. Nerve of origin, tumor size, hearing preservation, and facial nerve outcomes in 359 vestibular schwannoma resections at a tertiary care academic center. Laryngoscope 2007 ; 117 : 2087-92.
 
44) Bloch DC, Oghalai JS, Jackler RK, et al. The fate of the tumor remnant after less-than-complete acoustic neuroma resection. Otolaryngol Head Neck Surg 2004 ; 130 : 104-12.
PubMed
45) Chen Z, Prasad SC, Lella FD, et al. The behavior of residual tumors and facial nerve outcomes after incomplete excision of vestibular schwannomas. J Neurosurg 2014 ; 120 : 1278-87.
 
46) Fukuda M, Oishi M, Hiraishi T et al. Clinicopathological factors related to regrowth of vestibular schwannoma after incomplete resection. J Neurosurg 2011 ; 114 : 1224-31.
PubMed
47) Darrouzet V, Martel J, Enee V, et al. Vestibular schwannoma surgery outcomes : our multidisciplinary experience in 400 cases over 17 years. Laryngoscope 2004 ; 114 : 681-8.
PubMed
48) Amano M, Kohno M, Nagata O, et al. Intraoperative continuous monitoring of evoked facial nerve electromyograms in acoustic neuroma surgery. Acta Neurochir 2011 ; 153 : 1059-67.
PubMed
49) Nakatomi H, Miyazaki H, Tanaka M, et al. Improved preservation of function during acoustic neuroma surgery. J neurosurg 2015 ; 122 : 24-33.
PubMed
50) Yamakami I, Uchino Y, Kobayashi E, et al. Removal of large acoustic neurinomas (vestibular schwannomas) by the retrosigmoid approach with no mortality and minimal morbidity. J Neurol Neurosurg Psychiatry 2004 ; 75 : 453-8.
PubMed
51) Magliulo G, D'Amico R, Di Cello P. Delayed facial palsy after vestibular schwannoma resection : clinical data and prognosis. J Otolaryngol 2003 ; 32 : 400-4.
 
52) Kwiek SJ, Bierzynska-Macyszyn G, Luszawski J, et al. Correlation of facial nerve paresis and histopathological type of vestibular schwannoma. Folia Neuropathol 2003 ; 41 : 237-9.
PubMed
53) Yamakami I, Yoshinori H, Saeki N, et al. Hearing preservation and intraoperative auditory brainstem response and cochlear nerve compound action potential monitoring in the removal of small acoustic neurinoma via the retrosigmoid approach. J Neurol Neurosurg Psychiatry 2009 ; 80 : 218-27.
PubMed
54) Kameda K, Shono T, Hashiguchi K, et al. Effect of tumor removal on tinnitus in patients with vestibular schwannoma. J Neurosurg 2010 ; 112 : 152-7.
PubMed
55) Watanabe K, Saito N, Taniguchi M, et al. Analysis of taste disturbance before and after surgery in patients with vestibular schwannoma. J Neurosurg 2003 ; 99 : 999-1003.
PubMed
56) Gharabaghi A, Samii A, Koerbel A, et al. Preservation of function in vestibular schwannoma surgery. Neurosurgery 2007 ; 60 : ONS124-7 ; discussion ONS127-8.
 
57) Iwai O, Ishibashi K, Watanabe Y, et al. Functional Preservation After Planned Partial Resection Followed by Gamma Knife Radiosurgery for Large Vestibular Schwannomas. World Neurosurg 2015 ; 84 : 292-300.
 
58) Meyer TA, Canty PA, Wilkinson EP, et al. Small acoustic neuromas : surgical outcomes versus observation or radiation. Otol Neurotol 2006 ; 27 : 380-92.
PubMed
59) Martin TP, Tzifa K, Kowalski C, et al. Conservative versus primary surgical treatment of acoustic neuromas : a comparison of rates of facial nerve and hearing preservation. Clin Otolaryngol 2008 ; 33 : 228-35.
PubMed
60) Rowe J, Radatz M, Kemeny A. Radiosurgery for type II neurofibromatosis. Prog Neurol Surg 2008 ; 21 : 176-82.
PubMed
61) Chan AW, Black P, Ojemann RG, et al. Stereotactic radiotherapy for vestibular schwannomas : favorable outcome with minimal toxicity. Neurosurgery 2005 ; 57 : 60-70 ; discussion 60-70.
 
62) Hasegawa T, Kida Y, Kobayashi T, et al. Long-term outcomes in patients with vestibular schwannomas treated using gamma knife surgery : 10-year follow up. J Neurosurg 2005 ; 102 : 10-6.
PubMed
63) Flickinger JC, Kondziolka D, Niranjan A, et al. Results of acoustic neuroma radiosurgery : an analysis of 5 years' experience using current methods. J Neurosurg 2001 ; 94 : 1-6.
PubMed
64) Prasad D. Vestibular schwannomas : radiosurgery. J Neurosurg 2001 ; 94 : 141-2.
PubMed
65) Friedman WA. Linear accelerator radiosurgery for vestibular schwannomas. Prog Neurol Surg 2008 ; 21 : 228-37.
PubMed
66) Weber DC, Chan AW, Bussiere MR, et al. Proton beam radiosurgery for vestibular schwannoma : tumor control and cranial nerve toxicity. Neurosurgery 2003 ; 53 : 577-86 ; discussion 586-8.
 
67) Flickinger JC, Kondziolka D, Niranjan A, et al. Acoustic neuroma radiosurgery with marginal tumor doses of 12 to 13 Gy. Int J Radiat Oncol Biol Phys 2004 ; 60 : 225-30.
PubMed
68) Yang I, Aranda D, Han SJ, et al. Hearing preservation after stereotactic radiosurgery for vestibular schwannoma : a systematic review. J Clin Neurosci 2009 ; 16 : 742-7.
PubMed
69) Sun S, Liu A. Long-term follow-up studies of Gamma Knife surgery with a low margin dose for vestibular schwannoma. J Neurosurg 2012 ; (Suppl) 117 : 57-62.
PubMed
70) Carlson ML, Jacob JT, Pollock BE, et al. Long-term hearing outcomes following stereotactic radiosurgery for vestibular schwannoma : patterns of hearing loss and variables influencing audiometric decline. J Neurosurg 2013 ; 118 : 579-87.
 
71) Hasegawa T, Kida Y, Kato T, et al. Long-term safety and efficacy of stereotactic radiosurgery for vestibular schwannomas : evaluation of 440 patients more than 10 years after treatment with Gamma Knife surgery. J Neurosurg 2013 ; 118 : 557-65.
PubMed
72) Pollock BE, Link MJ, Foote RL. Failure rate of contemporary lowdose radiosurgical technique for vestibular schwannoma. J Neurosurg 2009 ; 111 : 840-4.
 
73) Thomas C, Di Maio S, Ma R, et al. Hearing preservation following fractionated stereotactic radiotherapy for vestibular schwannomas : prognostic implications of cochlear dose. J Neurosurg 2007 ; 107 : 917-26.
 
74) Massager N, Nissim O, Delbrouck C, et al. Irradiation of cochlear structures during vestibular schwannoma radiosurgery and associated hearing outcome. J Neurosurg 2007 ; 107 : 733-9.
PubMed
75) Brown M, Ruckenstein M, Bigelow D, et al. Predictors of Hearing Loss After Gamma Knife Radiosurgery for Vestibular Schwannomas : Age, Cochlear Dose, and Tumor Coverage. Neurosurgery 2011 ; 69 : 605-14
 
76) Fukuoka S, Takanashi M, Hojyo A, et al. Gamma knife radiosurgery for vestibular schwannomas. Prog Neurol Surg 2009 ; 22 : 45-62.
PubMed
77) Friedman RA, Brackmann DE, Hitselberger WE, et al. Surgical salvage after failed irradiation for vestibular schwannoma. Laryngoscope 2005 ; 115 : 1827-32.
PubMed
78) Rowe J, Grainger A, Walton L, et al. Risk of malignancy after gamma knife stereotactic radiosurgery. Neurosurgery 2007 ; 60 : 60-5 ; discussion 65-6.
 
79) Shin M, Ueki K, Kurita H, et al. Malignant transformation of a vestibular schwannoma after gamma knife radiosurgery. Lancet 2002 ; 360 : 309-10.
PubMed
80) Loeffler JS, Niemierko A, Chapman PH. Second tumors after radiosurgery : tip of the iceberg or a bump in the road? Neurosurgery 2003 ; 52 : 1436-40 ; discussion 1440-2.
PubMed
81) Pollock BE. Vestibular schwannoma management : an evidencebased comparison of stereotactic radiosurgery and microsurgical resection. Prog Neurol Surg 2008 ; 21 : 222-7.
 
82) Pollock BE, Driscoll CL, Foote RL, et al. Patient outcomes after vestibular schwannoma management : a prospective comparison of microsurgical resection and stereotactic radiosurgery. Neurosurgery 2006 ; 59 : 77-85 ; discussion 77-85.
 
83) Myrseth E, Moller P, Pedersen PH, et al. Vestibular schwannoma : surgery or gamma knife radiosurgery? A prospective, nonrandomized study. Neurosurgery 2009 ; 64 : 654-61 ; discussion 661-3.
 
84) Brackmann DE, Fayad JN, Slattery WH, 3rd, et al. Early proactive management of vestibular schwannomas in neurofibromatosis type 2. Neurosurgery 2001 ; 49 : 274-80 ; discussion 280-3.
 
85) Samii M, Matthies C, Tatagiba M. Management of vestibular schwannomas (acoustic neuromas) : auditory and facial nerve function after resection of 120 vestibular schwannomas in patients with neurofibromatosis 2. Neurosurgery 1997 ; 40 : 696-705 ; discussion 705-6.
 
86) Phi JH, Kim DG, Chung HT, et al. Radiosurgical treatment of vestibular schwannomas in patients with neurofibromatosis type 2 : tumor control and hearing preservation. Cancer 2009 ; 115 : 390-8.
PubMed
87) Mathieu D, Kondziolka D, Flickinger JC, et al. Stereotactic radiosurgery for vestibular schwannomas in patients with neurofibromatosis type 2 : an analysis of tumor control, complications, and hearing preservation rates. Neurosurgery 2007 ; 60 : 460-8 ; discussion 468-70.
 
88) Plotkin SR, Stemmer-Rachamimov AO, Barker FG, 2nd, et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 2009 ; 361 : 358-67.
PubMed
89) Scoles DR. The merlin interacting proteins reveal multiple targets for NF2 therapy. Biochim Biophys Acta 2008 ; 1785 : 32-54.
PubMed
P.179 掲載の参考文献
1) Nomura K. Report of brain tumor registry of Japan (1969-1993). Neurol Med Chir (Tokyo) 2000 ; 40 : Suppl.
 
2) Shibui S. Report of brain tumor registry of Japan (1984-2000). Neurol Med Chir (Tokyo) 2009 ; 49 : Suppl.
 
3) Shibui S. Report of brain tumor registry of Japan (1984-2000). Neurol Med Chir (Tokyo) 2014 ; 49 : Suppl.
 
4) Kassam AB, Gardner PA, Snyderman CH, et al. Expanded endonasal approach, a fully endoscopic transnasal approach for the resection of midline suprasellar craniopharyngiomas : a new classification based on the infundibulum. J Neurosurg 2008 ; 108 : 715-28.
PubMed
5) 松谷雅生. 頭蓋咽頭腫. In ; 太田富雄, 松谷雅生, 編集. 脳神経外科学 第8版, 金芳堂, 京都, 2000, p638-48.
 
6) Mapstone TB. Craniopharyngiomas in children. Comptemporary Neurosurgery 1998 ; 20 : 1-6.
 
7) Nagahata M, Hosoya T, Kayama T, et al. Edema along the optic tract : useful MR finding for the diagnosis of craniopharyngiomas. AJNR Am J Neuroradiol 1998 ; 19 : 1753-7.
 
8) Saeki N, Uchino Y, Murai H, et al. MR imaging study of edemalike change along the optic tract in patients with pituitary region tumors. AJNR Am J Neuroradiol 2003 ; 24 : 336-42.
 
9) Satoretti-Scefer S, Wichmann W, Aguzzi A, et al. MR differentiation of admantinomatous and squamous-papillary craniopharyngioma. AJNR Am J Neuroradiol 1997 ; 18 : 7-87.
 
10) Chung WY, Pan DH, Shiau CY, et al. Gamma knife radiosurgery for craniopharyngiomas. J Neurosurg 2000 ; 93 Suppl 3 : 47-56.
PubMed
11) Fahlbusch R, Honegger J, Pallus W, et al. Surgical treatment of craniopharyngiomas : experience with 168 patients. J Neurosurg 1999 ; 90 : 237-50.
 
12) Duff JM, Meyer FB, Ilstrup DM, et al. Long-term outcomes for surgically resected craniopharyngiomas. Neurosurgery 2000 ; 46 : 291-305.
 
13) Maria G, Anile C, Albanese A, et al. The role of transsphenoidal surgery in the treatment of craniopharyngioma. J Neurosurgery 2004 ; 100 : 445-51.
 
14) Komotar RJ, Starke RM, Raper DM, et al. Endoscopic endonasal compared with microscopic transsphenoidal and open transcranial resection of craniopharyngiomas. World Neurosurg 2012 ; 77 : 329-41.
PubMed
15) Kato T, Sawamura Y, Abe H, et al. Transsphenoidal-transtttuberculum sellae approach for supradiaphragmatic tumors : technical note. Acta Neurochir 1998 ; 140 : 715-9.
PubMed
16) Kouri JG, Chen MY, Watson JC, et al. Resection of suprasellar tumors by using a modified transsphenoidal approach. Report of four cases. J Neurosurg 2000 ; 92 : 1028-35.
 
17) Jho HD, Carrau RL. Endoscopic endonasal transsphenoidal surgery : experience with 50 patients. J Neurosurg 1997 ; 87 : 44-51.
PubMed
18) Gardner PA, Kassam AB, Snyderman CH, et al. Outcomes following endoscopic, expanded endonasal resection of suprasellar craniopharyngiomas : a case series. J Neurosurg 2008 ; 109 : 6-16.
 
19) Baldauf J, Hosemann W, Schroeder HW. Endoscopic endonasal approach for craniopharyngiomas. Neurosurg Clin N Am 2015 ; 26 : 363-75.
PubMed
20) Saeki N, Horiguchi K, Murai H, et al. Endoscopic endonasal pituitary and skull base surgery. Neurol Med Chir (Tokyo) 2010 ; 50 : 756-64.
PubMed
21) Horiguchi K, Murai H, Hasegawa Y, et al. Endoscopic endonasal skull base reconstruction using a nasal septal flap : surgical results and comparison with previous reconstructions. Neurosurg Rev 2010 ; 33 : 235-41.
PubMed
22) Ishii Y, Tahara S, Hattori Y, et al. Fascia patchwork closure for endoscopic endonasal skull base surgery.Neurosurg Rev 2015 ; 38 : 551-7.
PubMed
23) Shapiro B, Fig LM, Gross MD. Intracavitary therapy of craniopharyngiomas. Q J Nucl Med 2000 ; 43 : 367-74.
 
P.182 掲載の参考文献
1) Guidetti B, Gagliardi FM. Epidermoid and dermoid cysts. Clinical evaluation and late surgical results. J Neurosurg 1977 ; 47 : 12-8.
PubMed
2) Lunardi P, Missori P. Supratentorial dermoid cysts. J Neurosurg 1991 ; 75 : 262-6.
PubMed
3) Committee of Brain Tumor Registry of Japan. Report of Brain Tumor Registry of Japan (2001-2004). Neurol Med Chir (Tokyo) 2014 ; suppl (1).
 
4) Yamakawa K, et al. Clinical course and surgical prognosis of 33 cases of intracranial epidermoid tumors. Neurosurgery 1989 ; 24 : 568-73.
PubMed
5) Rubin G, et al. Craniocerebral epidermoids and dermoids. Acta Neurochir 1989 ; 97 : 1-16.
PubMed
6) Fujimaki T, et al. Dermoid cyst of the frontal bone away from the anterior fontanel. Childs Nerv Syst 1995 ; 11 : 424-7.
PubMed
7) Peter JC, Sinclair-Smith C, de Villiers JC. Midline dermal sinuses and cysts and their relationship to the central nervous system. Eur J Pediatr Surg 1991 ; 1 : 73-9.
 
8) Lunardi P, et al. Dermoid cysts of the posterior cranial fossa in children. Report of nine cases and review of the literature. Surg Neurol 1990 ; 34 : 39-42.
PubMed
9) Ahmad I, et al. Ruptured suprasellar dermoid associated with middle cerebral artery aneurysm : case report. Surg Neurol 1992 ; 38 : 341-6.
PubMed
10) Samii M, et al. Surgical treatment of epidermoid cysts of the cerebellopontine angle. J Neurosurg 1996 ; 84 : 14-9.
PubMed
11) Shen CC, et al. Microsurgical management of intracranial epidermoid cysts. Chung Hua I Hsueh Tsa Chih (Taipei) 1998 ; 61 : 313-23.
PubMed
12) Mori Y, et al. [A case report of epidermoid carcinoma in the cerebello-pontine angle]. No Shinkei Geka 1995 ; 23 : 905-9.
PubMed
13) Gi H, et al. [C-P angle epidermoid carcinoma : a case report]. No Shinkei Geka 1990 ; 18 : 1041-5.
 
14) Parikh S, et al. Recurrent intracranial epidermoid cyst treated with radiotherapy. J Neurooncol 1995 ; 24 : 293-7.
PubMed
15) Murase S, et al. Primary intracranial squamous cell carcinoma-case report. Neurol Med Chir (Tokyo) 1999 ; 39 : 49-54.
PubMed
16) Yasargil MG, Abernathey CD, Sarioglu AC. Microneurosurgical treatment of intracranial dermoid and epidermoid tumors. Neurosurgery 1989 ; 24 : 561-7.
PubMed
17) Altschuler EM, et al. Operative treatment of intracranial epidermoid cysts and cholesterol granulomas : report of 21 cases. Neurosurgery 1990 ; 26 : 606-13 ; discussion 614.
 
18) Gopalakrishnan CV, Ansari KA, Nair S, Menon G. Long term outcome in surgically treated posterior fossa epidermoids. Clin Neurol Neurosurg 2014 ; 117 : 93-9.
PubMed
19) deSouza CE, et al. Cerebellopontine angle epidermoid cysts : a report on 30 cases. J Neurol Neurosurg Psychiatry 1989 ; 52 : 986-90.
 
20) Zhou LF. Intracranial epidermoid tumours : thirty-seven years of diagnosis and treatment. Br J Neurosurg 1990 ; 4 : 211-6.
PubMed
21) Caldarelli M, Massimi L, Kondageski C, Di Rocco C. Intracranial midline dermoid and epidermoid cysts in children. J Neurosurg 2004 ; 100 (5 Suppl Pediatrics) : 473-80.
 
22) Mohanty A, et al. Experience with cerebellopontine angle epidermoids. Neurosurgery 1997 ; 40 : 24-30.
PubMed
23) Gormley WB, et al. Craniocerebral epidermoid and dermoid tumours : a review of 32 case. Acta Neurochir 1994 ; 128 : 114-21.
 
24) Berger MS, Wilson CB. Epidermoid cyst of the posterior fossa. J Neurosurg 1985 ; 62 : 214-9.
 
25) Ecker RD, Atkinson JL, Nichols DA. Delayed ischemic deficit after resection of a large intracranial dermoid : case report and review of the literature. Neurosurgery 2003 ; 52 : 706-10 ; discussion 709-10.
 
26) Nishio S, Takeshita I, Morioka T, Fukui M. Primary intracranial squamous cell carcinoma : report of two cases. Neurosurgery 1995 ; 37 : 329-32.
PubMed
P.188 掲載の参考文献
1) al-Mefty O, Borba LA. Skull base chordomas : a management challenge. J Neurosurg 1997 ; 86 : 182-9.
PubMed
2) Belza MG, Urich H. Chordoma and malignant fibrous histiocytoma. Evidence of transformation. Cancer 1986 ; 58 : 1082-7.
PubMed
3) Boari N, Gagliardi F, Cavalli A, et al. Skull base chordomas : clinical outcome in a consecutive series of 45 patients with long-term follow-up and evaluation of clinical and biological prognostic factors. J Neurosurg 2016 Jan 8 : 1-11 Epub
 
4) Casali PG, Messina A, Stracchiotti S, et al. Imatinib mesylate in chordoma. Cancer 2004 ; 101 : 2086-97.
PubMed
5) Colli B, Al-Mefty O. Chordomas of the cranio-cervical junction : follow-up review and prognostic factors. J Neurosurg 2001 ; 95 : 933-43.
 
6) Dassoulas K, Schlesinger D, et al. The role of Gamma Knife surgery in the treatment of skull base chordomas. J Neurooncol 2009 ; 94 : 243-8.
PubMed
7) Debus J, Hug EB, Liebsch NJ, et al. Brainstem tolerance to conformal radiotherapy of skull base tumors. Int J Radiat Oncol Biol Phys 1997 ; 39 : 967-75.
PubMed
8) Debus J, Schulz-Ertner D, Schad L, et al. Stereotactic fractionated radiotherapy for chordomas and chondrosarcomas of the skull base. Int R Radiat Oncol Biol Phys 2000 ; 47 : 591-6.
 
9) Favre A. Skull base chordomas, presentation of six cases and review of the literature. J Clinical Neuroscience 1994 ; 1 : 7-18.
 
10) Forsyth PA, Cascino TL, Shaw EG, et al. Intracranial chordomas : a clinicopathological and prognostic study of 51 cases. J Neurosurg 1993 ; 78 : 741-7.
 
11) Gay E, Sekhar LN, Rubinstein E, et al. Chordomas and chondrosarcomas of the cranial base : results and follow-up of 60 patients. Neurosurgery 1995 ; 36 : 887-97.
PubMed
12) Hasegawa T, Ishii D, et al. Gamma Knife surgery for skull base chordomas and chondrosarcomas. J Neurosurg 2007 ; 107 : 752-7.
PubMed
13) Heffelfinger MJ, Dahlin DC, MacCarty CS, et al. Chordomas and cartilaginous tumours at the skull base. Cancer 1973 ; 32 : 410-20.
PubMed
14) Hug EB, Loredo LN, Slater JD, et al. Proton radiation therapy for chordomas and chondrosarcomas of the skull base. J Neurosurg 1999 ; 91 : 432-9.
PubMed
15) Jahangiri A, Chin AT, Wagner JR, Kunwar S, et al. Factors predicting recurrence after resection of clival chordoma using variable surgical approaches and radiation modalities. Neurosurgery 2015 ; 76 : 179-85 ; discussion 185-6.
 
16) Kaneko Y, Sato Y, Iwaki T, et al. Chordoma in early childhood : a clinicopathological study. Neurosurgery 1991 ; 29 : 442-6.
PubMed
17) Le Charpentier Y, Bellefqih S, Boisnic S, et al. [Chordomas]. Ann Pathol 1988 ; 8 : 25-32.
PubMed
18) Maira G, Pallini R, Anile C, et al. Surgical treatment of clival chordomas : the transsphenoidal approach revisited. J Neurosurg 1996 ; 85 : 784-92.
PubMed
19) 松谷雅生. 脳腫瘍 第2版, 篠原出版, 1996.
 
20) McMaster ML, Goldstein AM, Bromley CM, et al. Chordoma : incidence and survival patterns in the United States, 1973-1995. Cancer Causes Control 2001 ; 12 : 1-11.
PubMed
21) Menezes AH, Gantz BJ, Traynelis VC, et al. Cranial base chodomas. Clin Neurosurg 1997 ; 44 : 491-509.
PubMed
22) Rubinsttein LJ. chordomas, 3d 5th ed, Edward Arnold, London, 1989.
 
23) Stippler M, Gardner PA, Snyderman CH, et al. Endoscopic endonasal approach for clival chordomas. Neurosurgery 2009 ; 64 : 268-78.
PubMed
24) Takahashi S, Kawase T, Yoshida K, et al. Skull base chordomas : efficacy of surgery followed by carbon ion radiotherapy. Acta Neurochir 2009 ; 151 : 759-69.
PubMed
25) Tomlinson FH, Scheithauer BW, Forsythe PA, et al. Sarcomatous transformation in cranial chordoma. Neurosurgery 1992 ; 31 : 13-8.
PubMed
26) Tzortzidis F, Elahi F, Wright D, et al. Patient outcome at longterm follow-up after aggressive microsurgical resection of cranial base chordomas. Neurosurgery 2006 ; 59 : 230-7.
 
27) 山家健一, 金沢敬介, 他. A case report of chordoma in the cranial basis頭蓋底に発生せる脊索腫の一例と本邦の文献的考察. 奈良医誌 1963 ; 14 : 241-8.
 
P.191 掲載の参考文献
1) 内藤春子. 神経線維腫症1型. 別冊日本臨床 領域別症候群シリーズ No28 神経症候群 III, 日本臨床社, 2000, p488-91.
 
2) Conference NIoHCD. Neurofibromatosis. Conference statement. Arch Neurol 1988 ; 45 : 575-8.
PubMed
3) von Deimling A, Perry A. Neurofibromatosis type 1. In ; Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, eds. WHO Classification of Tumours of the Central Nervous System, Lyon : IARCPress, 2007, p206-9.
 
4) Burger PC, Scheithauer BW, Paulus W, et al. Pilocytic astrocytoma. In ; Kleihause P, Kavenee WK, eds. Pathology and genetics of tumours of the nervous system. Lyon : IARCPress, 2000, p45-51.
 
5) 新村真人. Reckinghausen病. 日本臨床 50 (増刊号) ; 1992, p168-75.
 
6) 倉田清子. 神経線維腫症2型. 別冊日本臨床 領域別症候群シリーズ No28 神経症候群 III, 日本臨床社, 2000, p492-4.
 
7) Stemmer-Tachamimov AO, Wiestler OD, Loius DN. Neurofibromatosis type 2. In ; Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, eds. WHO Classification of Tumours of the Central Nervous System. Lyon : IARCPress, 2007, p210-4.
 
8) Ferner RE. Neurofibromatosis 1 and neurofibromatosis 2 : a twenty first century perspective. Lancet Neurol 2007 ; 6 : 340-51.
PubMed
9) Merker VL, Esparza S, Smith MJ, et al. Clinical features of schwannomatosis : a retrospective analysis of 87 patients. Oncologist 2012 ; 17 : 1317-22.
PubMed
10) Piotrowski A, Xie J, Liu YF, et al. Germline loss-of-function mutations in LZTR1 predispose to an inherited disorder of multiple schwannomas. Nat Genet 2014 ; 46 : 182-7.
 
11) Aoki S, Barkovich AJ, Nishimura K, et al. Neurofibromatosis types 1 and 2 : cranial MR findings. Radiology 1989 ; 172 : 527-34.
PubMed
12) DiPaolo DP, Zimmerman RA, Rorke LB, et al. Neurofibromatosis type 1 : pathologic substrate of high-signal-intensity foci in the brain. Radiology 1995 ; 195 : 721-4.
PubMed
13) Alkan A, Sigirci A, Kutlu R, et al. Neurofibromatosis type 1 : diffusion weighted imaging findings of brain. Eur J Radiol 2005 ; 56 : 229-34.
PubMed
14) Carella A, Medicamento N. Malignant evolution of presumed benign lesions in the brain in neurofibromatosis : case report. Neuroradiology 1997 ; 39 : 639-41.
PubMed
15) Bilaniuk LT, Molloy PT, Zimmerman RA, et al. Neurofibromatosis type 1 : brain stem tumours. Neuroradiology 1997 ; 39 : 642-53.
PubMed
16) Plotkin SR, Stemmer-Rachamimov AO, Barker FG 2nd, et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 2009 ; 361 : 358-67.
PubMed
17) Scoles DR. The merlin interacting proteins reveal multiple targets for NF2 therapy. Biochim Biophys Acta 2008 ; 1785 : 32-54.
PubMed
P.193 掲載の参考文献
1) Lonser RR, Glenn GM, Walther M, et al. von Hippel-Lindau disease. Lancet 2003 ; 361 : 2059-67.
PubMed
2) 「フォン・ヒッペルリンドウ病の病態調査と診断治療系確立の研究」班. フォン・ヒッペルリンドウ (VHL) 病診療ガイドライン, 2011.
 
3) Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel- Lindau disease tumor suppressor gene. Science 1993 ; 260 : 1317-20.
PubMed
4) Knudson AG Jr. Mutation and cancer : statistical study of retinoblastoma. Proc Natl Acad Sci U S A 1971 ; v68 : 820-3.
 
5) Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999 ; 399 : 271-5.
PubMed
6) Statement of the American Society of Clinical Oncology. genetic testing for cancer susceptibility, Adopted on February 20, 1996. J Clin Oncol 1996 ; 14 : 1730-6 ; discussion 7-40.
 
7) Choyke PL, Glenn GM, Walther MM, et al. von Hippel-Lindau disease : genetic, clinical, and imaging features. Radiology 1995 ; 194 : 629-42.
PubMed
P.196 掲載の参考文献
1) Northrup H, et al. Tuberous sclerosis complex diagnostic criteria update : recommendations of the 2012 Iinternational Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol 2013 ; 49 : 243-54.
PubMed
2) Roth J, et al. Subependymal giant cell astrocytoma : diagnosis, screening, and treatment. Recommendations from the International Tuberous Sclerosis Complex Consensus Conference 2012. Pediatr Neurol 2013 ; 49 : 439-44.
PubMed
3) de Ribaupierre S, et al. Subependymal giant-cell astrocytomas in pediatric tuberous sclerosis disease : when should we operate? Neurosurgery 2007 ; 60 : 83-9.
PubMed
4) Kotulska K, et al. Surgical treatment of subependymal giant cell astrocytoma in tuberous sclerosis complex patients. Pediatr Neurol 2014 ; 50 : 307-12.
PubMed
5) Park KJ, et al. Gamma Knife surgery for subependymal giant cell astrocytomas. Clinical article. J Neurosurg 2011 ; 114 : 808-13.
PubMed
6) Franz DN, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1) : a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2013 ; 381 : 125-32.
PubMed
7) Franz DN, et al. Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex : 2-year open-label extension of the randomised EXIST-1 study. Lancet Oncol 2014 ; 15 : 1513-20.
PubMed
P.207 掲載の参考文献
1) Garber JE, Offit K. Hereditary cancer predisposition syndromes. J
 
2) Schneider K, Zelley K, Nichols KE, et al. Li-Fraumeni Syndrome. In ; Pagon RA, Adam MP, Ardinger HH, et al. eds. GeneReviews? [Internet]. Seattle (WA), University of Washington, Seattle ; 1993-2015.
 
3) Ohgaki H, Oliver M, Hainaut P. Li-Fraumeni syndrome and TP53 germline mutations. In ; Louis DN, Ohgaki H, Wiestler OD, et al, eds. World Health Organization Classification of Tumours of the Central Nervous System, Lyon, IARC Press, 2007, p222-5.
 
4) Gonzalez KD, Buzin CH, Noltner KA, et al. High frequency of de novo mutations in Li-Fraumeni syndrome. J Med Genet 2009 ; 46 : 689-93.
 
5) Olivier M, Goldgar DE, Sodha N, et al. Li-Fraumeni and related syndromes : correlation between tumor type, family structure, and TP53 genotype. Cancer Res 2003 ; 63 : 6643-50.
PubMed
6) Kamihara J, Rana HQ, Garber JE. Germline TP53 mutations and the changing landscape of Li-Fraumeni syndrome. Hum Mutat 2014 ; 35 : 654-62.
PubMed
7) Ruijs MW, Verhoef S, Rookus MA, et al. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome : Mutation detection rate and relative frequency of cancers in different familial phenotypes. J Med Genet 2010 ; 47 : 421-8.
PubMed
8) Chompret A, Brugieres L, Ronsin M, et al. P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer 2000 ; 82 : 1932-7.
PubMed
9) Gonzalez KD, Noltner KA, Buzin CH, et al. Beyond Li Fraumeni Syndrome : clinical characteristics of families with p53 germline mutations. J Clin Oncol 2009 ; 27 : 1250-6.
PubMed
10) Lalloo F, Varley J, Ellis D, et al. Prediction of pathogenic mutations in patients with earlyonset breast cancer by family history. Lancet 2003 ; 361 : 1101-2.
 
11) Malkin D. Li-fraumeni syndrome. Genes Cancer 2011 ; 2 : 475-84.
PubMed
12) Li FP, Fraumeni JF Jr, Mulvihill JJ, et al. A cancer family syndrome in twenty-four kindreds. Cancer Res 1988 ; 48 : 5358-62.
PubMed
13) Tinat J, Bougeard G, Baert-Desurmont S, et al. 2009 Version of the Chompret criteria for Li Fraumeni syndrome. J Clin Oncol 2009 ; 27 : e108-9.
PubMed
14) Zhukova N, Ramaswamy V, Remke M, et al. Subgroupspecific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol 2013 ; 31 : 2927-35.
 
15) Evans DG, Birch JM, Ramsden RT, et al. Malignant transformation and new primary tumours after therapeutic radiation for benign disease : substantial risks in certain tumour prone syndromes. J Med Genet 2006 ; 43 : 289-94.
PubMed
16) Hisada M, Garber JE, Fung CY, et al. Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst 1998 ; 90 : 606-11.
PubMed
17) Kleinerman RA. Radiation-sensitive genetically susceptible pediatric sub-populations. Pediatr Radiol 2009 ; 39 Suppl 1 : S27-31.
PubMed
18) Felix CA, Hosler MR, Provisor D, et al. The p53 gene in pediatric therapy-related leukemia and myelodysplasia. Blood 1996 ; 87 : 4376-81.
PubMed
19) Lustbader ED, Williams WR, Bondy ML, et al. Segregation analysis of cancer in families of childhood soft tissue sarcoma patients. Am J Hum Genet 1992 ; 51 : 344-56.
PubMed
20) Varley JM, Evans DG, Birch JM. Li-Fraumeni syndrome : a molecular and cinical review. BR J Cancer 1997 ; 76 : 1-14.
 
21) Wu CC, Shete S, Amos CI, et al. Joint effects of germ-line p53 mutation and sex on cancer risk in Li-Fraumeni syndrome. Cancer Res 2006 ; 66 : 8287-92.
 
22) Eng C. PTEN Hamartoma Tumor Syndrome (PHTS). In ; Pagon RA, Adam MP, Ardinger HH et al. eds, GeneReviews? [Internet]. Seattle (WA), University of Washington, Seattle, 1993-2015.
 
23) Pilarski R, Burt R, Kohlman W, et al. Cowden syndrome and the PTEN hamartoma tumor syndrome : systematic review and revised diagnostic criteria. J Natl Cancer Inst 2013 ; 105 : 1607-16.
PubMed
24) Marsh DJ, Kum JB, Lunetta KL, et al. PTEN mutation spectrum and genotype-phenotype correlations in Bannayan- Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome. Hum Mol Genet 1999 ; 8 : 1461-72.
PubMed
25) Nelen MR, Kremer H, Konings IB, et al. Novel PTEN mutations in patients with Cowden disease : absence of clear genotype-phenotype correlations. Eur J Hum Genet 1999 ; 7 : 267-73.
PubMed
26) Eng C. Will the real Cowden syndrome please stand up : revised diagnostic criteria. J Med Genet 2000 ; 37 : 828-30.
PubMed
27) Bubien V, Bonnet F, Brouste V, et al. High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. J Med Genet 2013 ; 50 : 255-63.
PubMed
28) Tan MH, Mester JL, Ngeow J, et al. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res 2012 ; 18 : 400-7.
PubMed
29) Cavenee WK, Burger PC, Leunig SY, et al. Turcot syndrome ; In ; Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, eds. World Health Organization Classification of Tumours of the Central Nervous System, Lyon, IARC Press, 2007, p229-31.
 
30) Kohlmann W, Gruber SB. Lynch Syndrome. In ; Pagon RA, Adam MP, Ardinger HH, et al, eds. GeneReviews? [Internet]. Seattle (WA), University of Washington, Seattle, 1993-2015.
 
31) Jasperson KW, Burt RW. APC-Associated Polyposis Conditions. In ; Pagon RA, Adam MP, Ardinger et al, eds. GeneReviews? [Internet]. Seattle (WA), University of Washington, Seattle, 1993-2015.
 
32) Paraf F, Jothy S, Van Meir EG. Brain tumor-polyposis syndrome : two genetic diseases? J Clin Oncol 1997 ; 15 : 2744-58.
PubMed
33) 大腸癌研究会. 遺伝性大腸癌診療ガイドライン 2012年版, 金原出版, 東京, 2012.
 
34) Therkildsen C, Ladelund S, Rambech E, et al. Glioblastomas, astrocytomas and oligodendrogliomas linked to Lynch syndrome. Eur J Neurol 2015 ; 22 : 717-24.
PubMed
35) Attard TM, Giglio P, Koppula S, et al. Brain tumors in individuals with familial adenomatous polyposis : a cancer registry experience and pooled case report analysis. Cancer 2007 ; 109 : 761-6.
 
36) Barrow E, Robinson L, Alduaij W, et al. Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome : a report of 121 families with proven mutations. Clin Genet 2009 ; 75 : 141-9.
PubMed
37) Vasen HF, Moslein G, Alonso A, et al. Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet 2007 ; 44 : 353-62.
 
38) Van Meir EG. "Turcot's syndrome" : phenotype of brain tumors, survival and mode of inheritance. Int J Cancer 1998 ; 75 : 162-4.
 
39) Hamilton SR, Liu B, Parsons RE, et al. The molecular basis of Turcot's syndrome. N Engl J Med 1995 ; 332 : 839-47.
PubMed
40) Evans DG, Farndon PA. Nevoid Basal Cell Carcinoma Syndrome. In ; Pagon RA, Adam MP, Ardinger et al, eds. GeneReviews? [Internet]. Seattle (WA), University of Washington, Seattle, 1993-2015.
 
41) Eberhart CG, Cavenee WK, Pietsch T. Nevoid basal cell carcinoma syndrome. In ; Louis DN, Ohgaki H, Wiestler OD, et al, eds. World Health Organization Classification of Tumours of the Central Nervous System, Lyon, IARC Press, 2007, p232-3.
 
42) Evans DG, Ladusans EJ, Rimmer S, et al. Complications of the naevoid basal cell carcinoma syndrome : results of a population based study. J Med Genet 1993 ; 30 : 460-4.
PubMed
43) Cowan R, Hoban P, Kelsey A, et al. The gene for the naevoid basal cell carcinoma syndrome acts as a tumour-suppressor gene in medulloblastoma. Br J Cancer 1997 ; 76 : 141-5.
PubMed
44) Amlashi SF, Riffaud L, Brassier G, et al. Nevoid basal cell carcinoma syndrome : relation with desmoplastic medulloblastoma in infancy. A population-based study and review of the literature. Cancer 2003 ; 98 : 618-24.
PubMed
45) Kijima C, Miyashita T, Suzuki M, et al. Two cases of nevoid basal cell carcinoma syndrome associated with meningioma caused by a PTCH1 or SUFU germline mutation. Fam Cancer 2012 ; 11 : 565-70.
PubMed
46) Endo M, Fujii K, Sugita K, et al. Nationwide survey of nevoid basal cell carcinoma syndrome in Japan revealing the low frequency of basal cell carcinoma. Am J Med Genet A 2012 ; 158A : 351-7.
PubMed
47) Smith MJ, Beetz C, Williams SG, et al. Germline mutations in SUFU cause Gorlin syndrome-associated childhood medulloblastoma and redefine the risk associated with PTCH1 mutations. J Clin Oncol 2014 ; 32 : 4155-61.
PubMed
48) Evans DG, Farndon PA, Burnell LD, et al. The incidence of Gorlin syndrome in 173 consecutive cases of medulloblastoma. Br J Cancer 1991 ; 64 : 959-61.
PubMed
49) Kimonis VE, Goldstein AM, Pastakia B, et al. Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome. Am J Med Genet 1997 ; 69 : 299-308.
PubMed
50) Shanley S, Ratcliffe J, Hockey A, et al. Nevoid basal cell carcinoma syndrome : review of 118 affected individuals. Am J Med Genet 1994 ; 50 : 282-90.
PubMed
51) Evans DG, Howard E, Giblin C, et al. Birth incidence and prevalence of tumor-prone syndromes : estimates from a UK family genetic register service. Am J Med Genet A 2010 ; 152A : 327-32.
PubMed
52) Brugieres L, Remenieras A, Pierron G, et al. High frequency of germline SUFU mutations in children with desmoplastic/nodular medulloblastoma younger than 3 years of age. J Clin Oncol 2012 ; 30 : 2087-93.
 
53) Low JA, de Sauvage FJ. Clinical experience with Hedgehog pathway inhibitors. J Clin Oncol 2010 ; 28 : 5321-6.
PubMed
54) Wilding A, Ingham SL, Lalloo F, et al. Life expectancy in hereditary cancer predisposing diseases : an observational study. J Med Genet 2012 ; 49 : 264-9.
PubMed
55) Wesseling P, Biegel JA, Eberhart CG, et al. Rhabdoid Tumor Predisposition Syndrome. In ; Louis DN, Ohgaki H, Wiestler OD, et al, eds. World Health Organization Classification of Tumours of the Central Nervous System, Lyon, IARC Press, 2007, p234-5.
 
56) Sredni ST, Tomita T. Rhabdoid tumor predisposition syndrome. Pediatr Dev Pathol, 2015 ; 18 : 49-58.
PubMed
57) Sevenet N, Sheridan E, Amram D, et al. Constitutional mutations of the hSNF5/INI1 gene predispose to a variety of cancers. Am J Hum Genet 1999 ; 65 : 1342-8.
PubMed
58) Bourdeaut F, Lequin D, Brugieres L, et al. Frequent hSNF5/INI1 germline mutations in patients with rhabdoid tumor. Clin Cancer Res 2011 ; 17 : 31-8.
PubMed
59) Eaton KW, Tooke LS, Wainwright LM, et al. Spectrum of SMARCB1/INI1 mutations in familial and sporadic rhabdoid tumors. Pediatr Blood Cancer 2011 ; 56 : 7-15.
PubMed
60) Schneppenheim R, Fruhwald MC, Gesk S, et al. Germline nonsense mutation and somatic inactivation of SMARCA4/BRG1 in a family with rhabdoid tumor predisposition syndrome. Am J Hum Genet 2010 ; 86 : 279-84.
 
61) Schiffman JD, Geller JI, Mundt E,et al. Update on pediatric cancer predisposition syndromes. Pediatr Blood Cancer 2013 ; 60 : 1247-52.
PubMed
62) Hasselblatt M, Nagel I, Oyen F, et al. SMARCA4-mutated atypical teratoid/rhabdoid tumors are associated with inherited germline alterations and poor prognosis. Acta Neuropathol 2014 ; 128 : 453-6.
PubMed
63) Giusti F, Marini F, Brandi ML. Multiple Endocrine Neoplasia Type 1. In ; Pagon RA, Adam MP, Ardinger et al. eds, GeneReviews? [Internet]. Seattle (WA), University of Washington, Seattle, 1993-2015.
 
64) 多発性内分泌腫瘍症診療ガイドブック編集委員会. 多発性内分泌腫瘍症診療ガイドブック, 金原出版, 東京, 2013.
 
65) Asgharian B, Turner ML, Gibril F, et al. Cutaneous tumors in patients with multiple endocrine neoplasm type 1 (MEN1) and gastrinomas : prospective study of frequency and development of criteria with high sensitivity and specificity for MEN1. J Clin Endocrinol Metab 2004 ; 89 : 5328-36.
PubMed
66) Thakker RV, Newey PJ, Walls GV, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab 2012 ; 97 : 2990-3011.
PubMed
67) Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001 ; 86 : 5658-71.
PubMed
68) Guo SS, Sawicki MP. Molecular and genetic mechanisms of tumorigenesis in multiple endocrine neoplasia type-1. Mol Endocrinol 2001 ; 15 : 1653-64.
PubMed
69) Marini F, Falchetti A, Del Monte F, et al. Multiple endocrine neoplasia type 1. Orphanet J Rare Dis 2006 ; 1 : 38.
PubMed
70) Sakurai A, Suzuki S, Kosugi S, et al. Multiple endocrine neoplasia type 1 in Japan : establishment and analysis of a multicentre database. Clin Endocrinol (Oxf) 2012 ; 76 : 533-9.
PubMed
71) Verges B, Boureille F, Goudet P, et al. Pituitary disease in MEN type 1 (MEN1) : data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab 2002 ; 87 : 457-65.
PubMed
72) Pieterman CR, Vriens MR, Dreijerink KM, et al. Care for patients with multiple endocrine neoplasia type 1 : the current evidence base. Fam Cancer, 2011 ; 10 : 157-71.
PubMed
P.215 掲載の参考文献
1) Hojo S, Hirano A. Pathology of metastases affecting the central nervous system. In ; Takakura K, Sano K, Hojo S, and Hirano A, eds. Metastatic tumors of the central nervous system. Igaku-Shoin, Tokyo, 1982, p5-111.
 
2) Gavrilovic IT, Posner JB. Brain metastases : epidemiology and pathophysiology. J Neuro-Oncol 2005 ; 75 : 5-14.
 
3) The committee of brain tumor registry of Japan. Report of brain tumor registry of Japan (2001-2004). Neurol Med Chir (Tokyo) 2014 ; 54 Suppl 1 : 77-96.
 
4) Schouten LJ, Rutten J, Huveneers HA, et al. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 2002 ; 94 : 2698-705.
 
5) Baumert BG, Rutten I, Dhing-Oberue C, et al. A pathology-based substrate for target definition in radiosurgery of brain metastases. Int J Radiation Oncology Biol Phys 2006 ; 66 : 187-94.
 
6) Kamp MA, Grosser P, Felsberg J, et al. 5-Aminolevulinic acid (5-ALA) -induced fluorescence in intracerebral metastases : a retrospective study. Acta Neurochir 2012 ; 154 : 223-8.
PubMed
7) Schellinger PD, Meinck HM, Thron A. Diagnostic accuracy of MRI compared to CCT in patients with brain metastases. J Neuro-Oncol 1999 ; 44 : 275-81.
 
8) Minniti G, Clarke E, Lanzetta G, et al. Stereotactic radiosurgery for brain metastases : analysis of outcome and risk of brain radionecrosis. Radiat Oncol 2011 ; 6 : 48.
PubMed
9) Lin NU, Lee EQ, Aoyama H, et al. Response assessment criteria for brain metastases : proposal from the RANO group. Lancet Oncol 2015 ; 16 : e270-78.
PubMed
10) Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain. A randomized trial. JAMA 1998 ; 280 : 1485-9.
 
11) Kocher M, Soffietti R, Abacioglu U, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases : results of the EORTC 22952-26001 study. J Clin Oncol 2011 ; 29 : 134-41.
 
12) Yamamoto M, Serizawa T, Shuto T, et al. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901) : a multi-institutional prospective observational study. Lancet Oncol 2014 ; 15 : 387-95.
PubMed
13) Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases. A randomized controlled trial. JAMA 2006 ; 295 : 2483-91.
PubMed
14) Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases : phase III results of the RTOG 9508 randomized trial. Lancet 2004 ; 363 : 1665-72.
PubMed
15) Sperduto PW, Shanley R, Luo X, et al. Secondary analysis of RTOG 9508, a phase 3 randomized trial of whole-brain radiation therapy versus WBRT plus stereotactic radiosurgery in patients with 1-3 brain metastases ; poststratified by the Graded Prognostic Assessment (GPA). Int J Radiation Oncology Biol Phys 2014 ; 90 : 526-31.
 
16) Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997 ; 37 : 745-51.
PubMed
17) Nieder C, Mehta MP. Prognostic indices for brain metastases-usefulness and challenges. Radiat Oncol 2009 ; 4 : 10-21.
PubMed
18) Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990 ; 322 : 494-500.
 
19) Vecht CJ, Haaxma-Reiche H, Noordijk EM, et al. Treatment of single brain metastasis : radiotherapy alone or combined with neurosurgery? Ann Neurol 1993 ; 33 : 583-90.
 
20) Mintz AH, Kestle J, Rathbone MP, et al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer 1996 ; 78 : 1470-6.
PubMed
21) Hart MG, Grant R, Walker M, et al. Surgical resection and whole brain radiation therapy versus whole brain radiation therapy alone for single brain metastases. Cochrane Database Syst Rev 2005 : CD003292.
PubMed
22) Kondziolka D, Patel A, Lunsford LD, et al. Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiation Oncology Biol Phys 1999 ; 45 : 427-34.
 
23) Chang EL, Wefel JS, Hess KR, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation : a randomized controlled trial. Lancet Oncol 2009 ; 10 : 1037-44.
PubMed
24) Sperduto PW, Wang M, Robins HI, et al. A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for nonsmall cell lung cancer and 1 to 3 brain metastases ; Radiation Therapy Oncology Group 0320. Int J Radiation Oncology Biol Phys 2012 ; 85 : 1312-8.
PubMed
25) Lim SH, Lee JY, Lee MY, et al. A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral olio-metastases in non-small-cell lung cancer. Ann Oncol 2015 ; 26 : 762-68.
 
26) Lin X and DeAngelis LM. Treatment of Brain metastases. J Clin Oncol 2015 ; 33 : e-pub.
 
27) Soffietti R, Kocher M, Abacioglu UM, et al. A European Organization for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery : quality-of-life results. J Clin Oncol 2013 ; 31 : 65-72.
PubMed
28) DeAngelis LM, Delattre JY, Posner JB. Radiation-induced dementia in patients cured of brain metastases. Neurology 1989 ; 39 : 789-96.
PubMed
29) Aoyama H, Tago M, Kato N, et al. Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. Int J Radiation Oncology Biol Phys 2007 ; 68 : 1388-95.
PubMed
30) O'Neill BP, Iturria NJ, Link MJ, et al. A comparison of surgical resection and stereotactic radiosurgery in the treatment of solitary brain metastases. Int J Radiation Oncology Biol Phys 2003 ; 55 : 1169-76.
 
31) Gans JH, Raper DMS, Shah AH, et al. The role of radiosurgery to the tumor bed after resection of brain metastases. Neurosurgery 2013 ; 72 : 317-26.
 
32) Obermueller T, Schaeffner M, Gerhardt J, et al. Risks of postoperative paresis in motor eloquently and non-eloquently located brain metastases. BMC Cancer 2014 ; 14 : 21-30.
PubMed
33) Serizawa T, Higuchi Y, Ono J, et al. Gamma knife surgery for metastatic brain tumors without prophylactic whole-brain radiotherapy : results in 1000 consecutive cases. J Neurosurg 2006 ; 105 Suppl : 86-90.
 
34) 宮武伸一, 古瀬元雅, 野々口直助, 他. 症候性脳放射線壊死の核医学的診断とベバシズマブによる治療-先進医療Bからの薬事承認に向けて-. Jpn J Neurosurg (Tokyo) 2015 ; 24 : 399-406.
 
35) Kohno T, Nakaoku T, Tsuta K, et al. Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer. Transl Lung Cancer Res 2015 ; 4 : 156-64.
PubMed
36) Iuchi T, Shingyoji M, Sakaida T, et al. Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma. Lung Cancer 2013 ; 82 : 282-7.
PubMed
37) Khasraw M, Holodny A, Goldlust SA, et al. Intracranial hemorrhage in patients with cancer treated with bevacizumab : the Memorial Sloan-Kettering experience. Ann Oncol 2012 ; 23 : 458-63.
PubMed
38) Cameron D, Casey M, Press M, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trstuzumab : updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008 ; 112 : 533-43.
 
39) Heon S, Yeap BY Lindeman NI, et al. The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations. Clin Cancer Res 2012 ; 18 : 4406-14.
PubMed
40) Roos DE, Wirth A, Burmeister BH, et al. Whole brain irradiation following surgery or radiosurgery for solitary brain metastases : Mature results of a prematurely closed randomized Trans-Tasman Radiation Oncology Group trial (TROG 98.05). Radiotherapy Oncol 2006 ; 80 : 318-22.
PubMed
41) Muacevic A, Wowra B, Siefert A, et al. Microsurgery plus whole brain irradiation versus Gamma Knife surgery alone for treatment of single metastases to the brain : a randomized controlled multicentre phase III trial. J Neurooncol ; 2008 ; 87 : 299-307.
 
P.219 掲載の参考文献
1) Aho CJ, Liu C, Zelman V, et al. Surgical outcomes in 118 patients with Rathke cleft cysts. J Neurosurg 2005 ; 102 : 189-93.
PubMed
2) Amano K, Kubo O, Komori T, et al. Clinicopathological features of sellar region xanthogranuloma : correlation with Rathke's cleft cyst. Brain Tumor Pathol 2013 ; 30 : 233-41.
 
3) The Endocrine Society. Pituitary Incidentaloma : an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2011 ; 96 : 894-904.
PubMed
4) Fleseriu M, Yedinak C, Campbell C, et al. Significant headache improvement after transsphenoidal surgery in patients with small sellar lesions. J Neurosurg 2009 ; 110 : 354-8.
PubMed
5) Hama S, Arita K, Nishisaka T, et al. Changes in the epithelium of Rathke cleft cyst associated with inflammation. J Neurosurg 2002 ; 96 : 209-16.
PubMed
6) Kim JE, Kim JH, Kim OL, et al. Surgical treatment of symptomatic Rathke cleft cysts : clinical features and results with special attention to recurrence. J Neurosurg 2004 ; 100 : 33-40.
PubMed
7) Laws ER, Kanter AS. Editorial. Rathke cleft cysts. J Neurosurg 2004 ; 101 : 571-2.
PubMed
8) Maruyama H, Iwasaki Y, Tsugita M, et al. Rathke's cleft cyst with short-term size changes in response to glucocorticoid replacement. Endocr J 2008 ; 55 : 425-8.
 
9) Nishioka H, Haraoka J, Izawa H, et al. Headaches associated with Rathke's cleft cyst. Headache 2006 ; 46 : 1580-6.
 
10) Nishioka H, Haraoka J, Izawa H, et al. Magnetic resonance imaging, clinical manifestations, and management of Rathke's cleft cyst. Clin Endocrinol 2006 ; 64 : 184-8.
 
11) Ogawa Y, Watanabe M, Tominaga T. Prognostic factors of operated Rathke's cleft cysts with special reference to re-accumulation and recommended surgical strategy. Acta Neurochir (Wien) 2011 ; 153 : 2427-33.
 
12) Oyama K, Taguchi M, Takeshita A, et al. Transsphenoidal cyst cisternostomy with a keyhole dural opening for sellar arachnoid cysts : technical note. Neurosurg Rev 2014 ; 37 : 261-7.
PubMed
13) Schweizer L, Capper D, Holsken A, et al. BRAF V600E analysis for the differentiation of papillary craniopharyngiomas and Rathke's cleft cysts. Neuropathol Appl Neuobiol 2015 ; 41 : 733-42.
 
14) Trifanescu R, Ansorge O, Wass JA, et al. Rathke's cleft cysts. Clin Endocrinol 2012 ; 76 : 151-60.
 
15) Wolfe SQ, Heros RC. A Rathke cleft cyst to craniopharyngioma : is there a spectrum? J Neurosurg 2010 ; 112 : 1324-6.
 
P.221 掲載の参考文献
1) Yadav YR, Yadav N, Parihar V, et al. Management of colloid cyst of third ventricle. Turk Neurosurg 2014 ; 25 : 362-71.
 
2) Pollock BE, Schreiner SA, Huston J 3rd. A theory on the natural history of colloid cysts of the third ventricle. Neurosurgery 2000 ; 46 : 1077-81.
PubMed
3) Ho KL, Garcia JH. Colloid cysts of the third ventricle : ultrastructural features are compatible with endodermal derivation. Acta Neuropathol 1992 ; 83 : 605-12.
PubMed
4) Iacoangeli M, di Somma LGM, Di Rienzo A, et al. Combined endoscopic transforaminal-transchoroidal approach for the treatment of third ventricle colloid cysts. J Neurosurg 2014 ; 120 : 1471-6.
 
5) Humphries RL, Stone CK, Bowers RC. Colloid cyst : A case report and literature review of a rare but deadly condition. J Emerg Med 2011 ; 40 : e5-9.
PubMed
6) Armao D, Castillo M, Chen H, et al. Colloid cyst of the third ventricle : Imaging-pathologic correlation. AJNR Am J Neuroradiol 2000 ; 21 (September) : 1470-7.
 
7) El Khoury C, Brugieres P, Decq P, et al. Colloid cysts of the third ventricle : Are MR imaging patterns predictive of difficulty with percutaneous treatment? AJNR Am J Neuroradiol 2000 ; 21 (March) : 489-92.
 
8) Kapu R, Symss NP, Pande A, et al. Management of pediatric colloid cysts of anterior third ventricle : A review of five cases. J Pediatr Neurosci 2012 ; 7 : 90-5.
 
9) Sheikh AB, Mendelson ZS, Liu JK. Endoscopic versus microsurgical resection of colloid cysts : a systematic review and meta-analysis of 1,278 patients. World Neurosurg 2014 ; 82 : 1187-97.
PubMed
10) Pollock BE, Huston J. Natural history of asymptomatic colloid cysts of the third ventricle. J Neurosurg 1999 ; 91 : 364-9.
PubMed
P.223 掲載の参考文献
1) Al-Holou WN, Garton HJ, Muraszko KM, et al. Prevalence of pineal cysts in children and young adults. Clinical article. J Neurosurg Pediatr 2009 ; 4 : 230-6.
 
2) Al-Holou WN, Maher CO, Muraszko KM, et al. The natural history of pineal cysts in children and young adults. J Neurosurg Pediatr. 2010 ; 5 : 162-6.
 
3) Al-Holou WN, Terman SW, Kilburg C, et al. Prevalence and natural history of pineal cysts in adults. J Neurosurg 2011 ; 115 : 1106-14.
PubMed
4) Berhouma M, Ni H, Delabar V, et al. Update on the management of pineal cysts : Case series and a review of the literature. Neurochirurgie 2015 ; 61 : 201-7.
 
5) Bosnjak J, Budisic M, Azman D, et al. Pineal gland cysts-an overview. Acta Clin Croat 2009 ; 48 : 355-8.
PubMed
6) Fain JS, Tomlinson FH, Scheithauer BW,et al. Symptomatic glial cysts of the pineal gland. J Neurosurg 1994 ; 80 : 454-60.
PubMed
7) Fakhran S, Escott EJ. Pineocytoma mimicking a pineal cyst on imaging : true diagnostic dilemma or a case of incomplete imaging? AJNR Am J Neuroradiol 2008 ; 29 : 159-63.
PubMed
8) Fleege MA, Miller GM, Fletcher GP, et al. Benign glial cysts of the pineal gland : unusual imaging characteristics with histologic correlation. AJNR Am J Neuroradiol 1994 ; 15 : 161-6.
PubMed
9) Gur RE, Kaltman D, Melhem ER, et al. Incidental findings in youths volunteering for brain MRI research. AJNR Am J Neuroradiol 2013 ; 34 : 2021-5.
PubMed
10) Kalani MY, Wilson DA, Koechlin NO, et al. Pineal cyst resection in the absence of ventriculomegaly or Parinaud's syndrome : clinical outcomes and implications for patient selection. J Neurosurg 2015 ; 123 : 352-6.
PubMed
11) Kulkarni AV. Pineal cyst resection. J Neurosurg 2015 ; 123 : 350.
PubMed
12) Mandera M, Marcol W, Bierzynska-Macyszyn G, et al. Pineal cysts in childhood. Childs Nerv Syst 2003 ; 19 : 750-5.
 
13) Marquez J, Rivero M. Pineal cysts. J Neurosurg Pediatr 2011 ; 8 : 422.
PubMed
14) Michielsen G, Benoit Y, Baert E, et al. Symptomatic pineal cysts : clinical manifestations and management. Acta Neurochir (Wien). 2002 ; 144 : 233-42 ; discussion 242.
 
15) Milroy CM, Smith CL. Sudden death due to a glial cyst of the pineal gland. J Clin Pathol 1996 ; 49 : 267-9.
PubMed
16) Morgan JT, Scumpia AJ, Webster TM, et al. Resting tremor secondary to a pineal cyst : case report and review of the literature. Pediatr Neurosurg 2008 ; 44 : 234-8.
PubMed
17) Sarikaya-Seiwert S, Turowski B, Hanggi D, et al. Symptomatic intracystic hemorrhage in pineal cysts. Report of 3 cases. J Neurosurg Pediatr 2009 ; 4 : 130-6.
 
18) Smith AB, Rushing EJ, Smirniotopoulos JG. From the archives of the AFIP : lesions of the pineal region : radiologic-pathologic correlation. Radiographics 2010 ; 30 : 2001-20.
PubMed
19) Tamura Y, Yamada Y, Tucker A, et al. Endoscopic surgery for hemorrhagic pineal cyst following antiplatelet therapy : case report. Neurol Med Chir (Tokyo) 2013 ; 53 : 625-9.
PubMed
20) Taraszewska A, Matyja E, Koszewski W, et al. Asymptomatic and symptomatic glial cysts of the pineal gland. Folia Neuropathol 2008 ; 46 : 186-95.
PubMed
P.227 掲載の参考文献
1) Shields JA, Shields CL, Scartozzi R. Survey of 1264 patients with orbital tumors and simulating lesions : The 2002 Montgomery Lecture, part 1. Ophthalmology 2004 ; 111 : 997-1008.
PubMed
2) Tailor TD, Gupta D, Dalley RW, et al. Orbital neoplasms in adults : clinical, radiologic, and pathologic review. Radiographics 2013 ; 33 : 1739-58.
PubMed
3) Shinder R, Al-Zubidi N, Esmaeli B. Survey of orbital tumors at a comprehensive cancer center in the United States. Head Neck 2011 ; 33 : 610-4.
 
4) Lindfield D, Attfield K, McElvanney A. Systemic immunoglobulin G4 (IgG4) disease and idiopathic orbital inflammation ; removing 'idiopathic' from the nomenclature? Eye (Lond) 2012 ; 26 : 623-9.
PubMed
5) Wallace ZS, Khosroshahi A, Jakobiec FA, et al. IgG4-related systemic disease as a cause of "idiopathic" orbital inflammation, including orbital myositis, and trigeminal nerve involvement. Surv Ophthalmol 2012 ; 57 : 26-33.
PubMed
6) Andrew N, Kearney D, Selva D. IgG4-related orbital disease : a meta-analysis and review. Acta Ophthalmol 2013 ; 91 : 694-700.
PubMed
7) Glass LR, Freitag SK. Management of orbital IgG4-related disease. Curr Opin Ophthalmol 2015 ; 26 : 491-7.
PubMed
8) Chung EM, Specht CS, Schroeder JW. From the archives of the AFIP : Pediatric orbit tumors and tumorlike lesions : neuroepithelial lesions of the ocular globe and optic nerve. Radiographics 2007 ; 27 : 1159-86.
PubMed
9) Rao AA, Naheedy JH, Chen JY, et al. A clinical update and radiologic review of pediatric orbital and ocular tumors. J Oncol 2013 ; 2013 : 975908.
PubMed
10) Jaspers H, Blaisse R, Maessen-Visch B, et al. Bilateral swollen eyelids occurring during adjuvant treatment with tamoxifen for early breast cancer. Neth J Med 2009 ; 67 : 245-6.
PubMed
11) Saffra, N, Rakhamimov A, Wrzolek MA, et al. Orbital metastasis as the initial presentation in bilateral lobular invasive carcinoma of the breast. Ophthal Plast Reconstr Surg 2014 ; 30 : e30-2.
PubMed
12) Muci-Mendoza R, Arevalo JF, Ramella M, et al. Optociliary veins in optic nerve sheath meningioma. Indocyanine green videoangiography findings. Ophthalmology 1999 ; 106 : 311-8.
PubMed
13) Tanaka, A, Mihara F, Yoshiura T, et al. Differentiation of cavernous hemangioma from schwannoma of the orbit : a dynamic MRI study. AJR Am J Roentgenol 2004 ; 183 : 1799-804.
PubMed
14) Xian, J, Zhang Z, Wang Z, et al. Evaluation of MR imaging findings differentiating cavernous haemangiomas from schwannomas in the orbit. Eur Radiol 2010 ; 20 : 2221-8.
PubMed
15) Hatton MP, Remulla HD, Tolentino MJ, et al. Clinical applications of color Doppler imaging in the management of orbital lesions. Ophthal Plast Reconstr Surg 2002 ; 18 : 462-5.
PubMed
16) Parikh RR, Moskowitz BK, Maher E, et al. Long-term outcomes and patterns of failure in orbital lymphoma treated with primary radiotherapy. Leuk Lymphoma 2015 ; 56 : 1266-70.
PubMed
17) Fung CY, Tarbell NJ, Lucarelli MJ, et al. Ocular adnexal lymphoma : clinical behavior of distinct World Health Organization classification subtypes. Int J Radiat Oncol Biol Phys 2003 ; 57 : 1382-91.
PubMed
18) Stafford SL, Kozelsky TF, Garrity JA, et al. Orbital lymphoma : radiotherapy outcome and complications. Radiother Oncol 2001 ; 59 : 139-44.
PubMed
19) Hasegawa, M, Kojima M, Shioya M, et al. Treatment results of radiotherapy for malignant lymphoma of the orbit and histopathologic review according to the WHO classification. Int J Radiat Oncol Biol Phys 2003 ; 57 : 172-6.
 
20) Tran KH, Campbell BA, Fua T, et al. Efficacy of low dose radiotherapy for primary orbital marginal zone lymphoma. Leuk Lymphoma 2013 ; 54 : 491-6.
PubMed
21) Auran J, Jakobiec FA, Krebs W. Benign mixed tumor of the palpebral lobe of the lacrimal gland. Clinical diagnosis and appropriate surgical management. Ophthalmology 1988 ; 95 : 90-9.
PubMed
22) Lai T, Prabhakaran VC, Malhotra R, et al. Pleomorphic adenoma of the lacrimal gland : is there a role for biopsy? Eye (Lond) 2009 ; 23 : 2-6.
 
23) Turbin RE, Thompson CR, Kennerdell JS, et al. A long-term visual outcome comparison in patients with optic nerve sheath meningioma managed with observation, surgery, radiotherapy, or surgery and radiotherapy. Ophthalmology 2002 ; 109 : 890-9 ; discussion 899-900.
PubMed
24) Adams G, Roos DE, Crompton JL. Radiotherapy for optic nerve sheath meningioma : a case for earlier intervention? Clin Oncol (R Coll Radiol) 2013 ; 25 : 356-61.
PubMed
25) Schick U, Dott U, Hassler W. Surgical management of meningiomas involving the optic nerve sheath. J Neurosurg 2004 ; 101 : 951-9.
 
26) Thomas RP, Gibbs IC, Xu LW, et al. Treatment options for optic pathway gliomas. Curr Treat Options Neurol 2015 ; 17 : 333.
PubMed
27) Shapey, J, Danesh-Meyer HV, Kaye AH. Diagnosis and management of optic nerve glioma. J Clin Neurosci 2011 ; 18 : 1585-91.
PubMed
28) Berger M, Char DH. Interactive image guidance for surgical localization of orbital apical tumors. Orbit 2002 ; 21 : 199-203.
PubMed
29) Arai, H, Sato K, Katsuta T, et al. Lateral approach to intraorbital lesions : anatomic and surgical considerations. Neurosurgery 1996 ; 39 : 1157-62 ; discussion 1162-3.
 
30) Margalit N, Ezer H, Fliss DM, et al. Orbital tumors treated using transcranial approaches : surgical technique and neuroophthalmogical results in 41 patients. Neurosurg Focus 2007 ; 23 : E11.
PubMed
31) Norris JL, Cleasby GW. Endoscopic orbital surgery. Am J Ophthalmol 1981 ; 91 : 249-52.
PubMed
32) Signorelli F, Anile C, Rigante M, et al. Endoscopic treatment of orbital tumors. World J Clin Cases 2015 ; 3 : 270-4.
PubMed
33) Rivkin MA, Turtz AR, Morgenstern KE. Transorbital endoscopic removal of posterior lateral orbital mass. Laryngoscope 2013 ; 123 : 3001-4.
PubMed
34) Umehara H, Okazaki K, Masaki Y, et al. A novel clinical entity, IgG4-related disease (IgG4RD) : general concept and details. Mod Rheumatol 2012 ; 22 : 1-14.
PubMed
35) Umehara H, Okazaki K, Masaki Y, et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol 2012 ; 22 : 21-30.
PubMed
36) Masaki Y, Sugai S, Umehara H. IgG4-related diseases including Mikulicz's disease and sclerosing pancreatitis : diagnostic insights. J Rheumatol 2010 ; 37 : 1380-5.
PubMed
37) Eddleman CS, Liu JK. Optic nerve sheath meningioma : current diagnosis and treatment. Neurosurg Focus 2007 ; 23 : E4.
PubMed
38) Carrasco JR, Penne RB. Optic nerve sheath meningiomas and advanced treatment options. Curr Opin Ophthalmol 2004 ; 15 : 406-10.
PubMed
39) Liu JK, Forman S, Moorthy CR, et al. Update on treatment modalities for optic nerve sheath meningiomas. Neurosurg Focus 2003 ; 14 : e7.
PubMed
40) Kim JW, Rizzo JF, Lessell S. Controversies in the management of optic nerve sheath meningiomas. Int Ophthalmol Clin 2005 ; 45 : 15-23.
PubMed
41) Shapey J, Sabin HI, Danesh-Meyer HV, et al. Diagnosis and management of optic nerve sheath meningiomas. J Clin Neurosci 2013 ; 20 : 1045-56.
PubMed
42) Woo KI, Yeom A, Esmaeli B. Management of Lacrimal Gland Carcinoma : Lessons From the Literature in the Past 40 Years. Ophthal Plast Reconstr Surg 2016 ; 32 : 1-10.
PubMed
43) Font RL, Smith SL, Bryan RG. Malignant epithelial tumors of the lacrimal gland : a clinicopathologic study of 21 cases. Arch Ophthalmol 1998 ; 116 : 613-6.
PubMed
44) Wright JE, Rose GE, Garner A. Primary malignant neoplasms of the lacrimal gland. Br J Ophthalmol 1992 ; 76 : 401-7.
PubMed
45) Henderson JW, Neault RW. En bloc removal of intrinsic neoplasms of the lacrimal gland. Am J Ophthalmol 1976 ; 82 : 905-9.
PubMed
46) Riedel, K.G, Markl A, Hasenfratz G, et al. Epithelial tumors of the lacrimal gland : clinico-pathologic correlation and management. Neurosurg Rev 1990 ; 13 : 289-98.
PubMed
47) Ahmad SM, Esmaeli B, Williams M, et al. American Joint Committee on Cancer classification predicts outcome of patients with lacrimal gland adenoid cystic carcinoma. Ophthalmology 2009 ; 116 : 1210-5.
PubMed
P.232 掲載の参考文献
1) Alleyne CH Jr, Theodore N, Spetzler RF, et al. Osteosarcoma of the temporal fossa with hemorrhagic presentation : case report. Neurosurgery 2000 ; 47 : 447-50.
PubMed
2) Aoki A, Mori K, Taima A, et al. Sellar chondroma : Case report. Neurol Med Chir (Tokyo) 1999 ; 39 : 870-4.
 
3) 青木悟, 本道洋昭, 河野充夫, 他. Orbital osteomaの1手術例-本邦報告42例のまとめおよびmicrosurgical drillingの有用性について. No Shinkei Geka 2002 ; 30 : 509-14.
 
4) Avrahami E, Even I. Osteoma of the inner table of the skull-CT diagnosis. Clin Radiol 2000 ; 55 : 435-8.
PubMed
5) Bose B. Primary osteogenic sarcoma of the skull. Surg Neurol 2002 ; 58 : 234-9.
PubMed
6) Ceylan S, Koc K, Anik I. Extended enodscopic approaches for midline skull base lesions. Neurosurg Rev 2009 ; 32 : 309-19.
 
7) Chennupati SK, Norris R, Dunham B, et al. Osteosarcoma of the skull base : case report and review of literature. Int J Pediat Otorhinolaryngol 2008 ; 72 : 115-9.
 
8) Chou EK, Chang CS, Chen PK, et al. Long term management of craniofacial osteosarcoma. J Craniofac Surg 2009 ; 20 : 406-9.
PubMed
9) Dahlin DC, Unni KK. Bone Tumors, 4th ed, Thomas CC, Spring field, 1986.
 
10) Di Maio S, Yip S, Al Zhrani GA, et al. Novel targeted therapies in chordoma : an update. Ther Clin Risk Manag 2015 ; 11 : 873-83.
PubMed
11) 石岡薫, 神崎仁, 原田竜彦, 他. 中頭蓋窩法で摘除した側頭骨に発生した軟骨芽細胞腫. 日耳鼻 2015 ; 118 : 213-8.
 
12) Fletcher CDM, Unni KK. Pathology and Genetics of Tumours of Soft Tissue and Bone. In ; Kleihues P, Sobin LH, eds. World Health Organization Classification of Tumours. IARC Press, Lyon, 2002, p225-67.
 
13) Fletcher CDM, Bridge JA, Hogendoorn PCW (eds). WHO Classification of Tumours of Soft Tissue and Bone. IARC Press, Lyon, 2013.
 
14) Ferrer AI, Lambea SL, Vidal LMJ, et al. Skull base chondrosarcoma : a case treated by the Cyberknife system. Clin Transl Oncol 2008 ; 10 : 670-2.
 
15) Haddad H, Benchakroun N, Sahraoul S, et al. Osteosarcoma of the skull base : a case report. Neurochirurgie 2007 ; 53 : 483-5.
 
16) Hayashi T, Kuroshima Y, Yoshida K, et al. Primary osteosarcoma of the sphenoid bone with extensive periosteal extension-case report. Neurol Med Chir (Tokyo) 2000 ; 40 : 419-22.
PubMed
17) 東田哲博, 坂田勝巳, 菅野洋, 他. 頭蓋底軟骨腫の2例-画像上での鑑別診断を中心に. No Shinkei Geka 2007 ; 35 : 495-501.
 
18) 日高浩史, 山内大輔, 野村和弘. First Bite syndromeを契機として発見された側頭骨osteoid osteomaの一例. Otol Jpn 2014 ; 24 : 554.
 
19) Hong P, Taylor SM, Trites JR, et al. Chondrosarcoma of the head and neck : report of 11cases and literature review. J Otolaryngol Head Neck Surg 2009 ; 38 : 279-85.
 
20) 戎谷昭吾, 最所裕司, 森田未沙子, 他. 右頬骨に生じた骨腫の1例. 臨皮 2015 ; 69 : 297-301.
 
21) 河本圭司, 笠井治文, 吉村晋一, 他. 頭蓋骨腫瘍分類・軟骨腫・良性軟骨芽細胞腫・軟骨肉腫. No Shinkei Geka 2004 ; 32 : 427-35.
 
22) 河本圭司, 稲垣隆介, 塚崎裕司, 他. 骨腫・良性骨芽細胞腫・骨肉腫. No Shinkei Geka 2004 ; 32 : 549-56.
 
23) 河本圭司, 中嶋安彬. 原発性頭蓋骨腫瘍. Clinical Neuroscience 2005 ; 23 : 556-61.
 
24) 河本圭司, 中嶋安彬. 骨肉腫. 脳神経外科学大系 7 脳腫瘍 III, 中山書店, 2004, pp216-218.
 
25) 河本圭司, 頭蓋骨腫瘍. EBMに基づく脳神経疾患の基本治療指針 第3版 (田村晃, 松谷雅生, 清水輝夫, 編), メジカルビュー社, 2010, p195-9.
 
26) Kromer JH, Ludwig K, Burger H, et al. Chondrosarcoma of the sphenoethmoid complex. Laryngorhinootologie 2002 ; 81 : 702-5.
PubMed
27) Louis DN, Ohgaki H, WiestlerOD, et al. WHO classification of tumours of the central nervous system, IARC, Lton, 2007.
 
28) Meningaud JP, ToureG, Lantieri L. Endoscopic resection of osteoma ot the forehead. Scand J Plast Rceconstr Surg Hand Surg 2008 ; 42 : 286-9.
 
29) 宮田倫明, 富田雅人, 松尾洋昭, 他. 当科におけるSolitary fibrous tumor (SFT) の予後調査. 整形外科と災害外科 2014 ; 63 : 685-7.
Medical*Online
30) Nakayama M, Nagayama T, Hirano H, et al. Giant chondroma arising from the dura mater of the convexity. Case report and review of the literature. J Neurosurg 2001 ; 94 : 331-4.
PubMed
31) 西本博, 四條克倫, 栗原淳. 小児における原発性頭皮・頭蓋骨腫瘍の臨床的特徴. 小児の脳神経 2013 ; 38 : 211-9.
Medical*Online
32) 野村敬清, 丹羽徹, 岡崎隆.年齢, 骨内発生部位, 解剖学的好発部位による小児骨腫瘍の鑑別. 臨床放射線 2015 ; 60 : 266-76
 
33) Masahiro S, Kondo K, Saito N. Neuroendoscopic transnasal surgery for skull base tumors : basic approaches, avoidance of pitfalls, and recent innovations. Neurol Med Chir (Tokyo) 2012 ; 52 : 697-703.
 
34) 物部寛子. 側頭骨病変鑑別におけるDiffuson weighted image (DWI)について. Otol Jpn 2012 ; 22 : 691.
 
35) 大重英行, 櫻井靖夫, 岩田亮一, 他. 稀な頭蓋骨形質細胞腫の2例. Neuro-Oncol進歩 2013 ; 20 : 54-7.
 
36) 小田義直. 骨軟部腫瘍・2013年新WHO分類. 病理と臨床 2013 ; 31 : 今月の話題から.
 
37) Samii A, Gerganov V, Herold C, et al. Surgical treatment of skull base chondrosarcoma. Neurosurg Rev 2009 ; 32 : 67-75.
PubMed
38) Sekhar LN. Intarcranial extension of cranial bone tumors and combined resection, Churchill Livingstone, 1991.
 
39) Tamura R, Miwa T, Shimizu K, et al. Giant Cell Tumor of the Skull : Review of the Literature. J Neurol Surg A Cent Eur Neurosurg. 2015.
PubMed
40) Tashiro R, Kanamori M, Suzuki H,et al. Diffuse large B cell lymphoma of the cranial vault : two case reports. Brain Tumor Pathol 2015 ; 83-8520
 
41) Yamasaki F, Takayasu T, Nosaka R,et al. Benign fibrous histiocytoma arising at the temporal bone of an infant-case report and review of the literature.Childs Nerv Syst 2015 ; 734-8551.
 
P.237 掲載の参考文献
1) Committee_of_Brain_Tumor_Registry_of_Japan. Report of Brain Tumor Registry of Japan (2001-2004) vol.13. Neurol Med Chir (Tokyo). 2014 ; 54 (Suppl) : 1-102.
 
2) 吉村泰典. 生殖補助医療と法 (櫻田嘉章編), 公益財団法人 日本学術協力財団, 東京, 2012, p145.
 
3) 日本産科婦人科学会. 倫理に関する見解. 2015. Available from : http://www.jsog.or.jp/ethic/index.html.
 
4) 己斐秀樹.【がん・生殖医療の現状と展望】がん・生殖医療における倫理的配慮. 産科と婦人科 2014 ; 81 : 1189-96.
 
5) Loren AW, Mangu PB, Beck LN, et al. Fertility preservation for patients with cancer : American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013 ; 31 : 2500-10. Epub 2013/05/30.
 
6) 日本がん・生殖医療研究会. 乳がん患者における妊孕性保持支援のための治療選択および患者支援プログラム・関係ガイドラインの開発. 乳がん患者の妊娠出産と生殖医療に関する診療の手引き 2014年版, 金原出版, 東京, 2014.
 
7) 日本がん・生殖医療学会. がん治療と妊娠～がん治療後の将来を見据えて～. 東京, 2015 [cited 2015] ; Available from : http://www.j-sfp.org/index.html.
 
8) Dalberg K, Eriksson J, Holmberg L. Birth outcome in women with previously treated breast cancer--a population-based cohort study from Sweden. PLoS Med 2006 ; 3 : e336. Epub 2006/09/14.
 
9) Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996 ; 14 : 1718-29. Epub 1996/05/01.
 
10) Tham YL, Sexton K, Weiss H, et al. The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane. Am J Clin Oncol. 2007 ; 30 : 126-32. Epub 2007/04/07.
 
11) Ben-Aharon I, Shalgi R. What lies behind chemotherapy-induced ovarian toxicity? Reproduction. 2012 ; 144 : 153-63. Epub 2012/06/02.
 
12) Meirow D. Reproduction post-chemotherapy in young cancer patients. Mol Cell Endocrinol. 2000 ; 169 : 123-31. Epub 2001/01/13.
 
13) Bar-Joseph H, Ben-Aharon I, Rizel S, et al. Doxorubicin-induced apoptosis in germinal vesicle (GV) oocytes. Reprod Toxicol. 2010 ; 30 : 566-72. Epub 2010/07/27.
 
14) Oktem O, Oktay K. Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function. Cancer 2007 ; 110 : 2222-9. Epub 2007/10/13.
 
15) Devine PJ, Perreault SD, Luderer U. Roles of reactive oxygen species and antioxidants in ovarian toxicity. Biol Reprod 2012 ; 86 : 27. Epub 2011/10/29.
 
16) Lee SJ, Schover LR, Partridge AH, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006 ; 24 : 2917-31. Epub 2006/05/03.
 
17) Wallace WH, Anderson RA, Irvine DS. Fertility preservation for young patients with cancer : who is at risk and what can be offered? Lancet Oncol 2005 ; 6 : 209-18. Epub 2005/04/07.
 
18) Behringer K, Mueller H, Goergen H, et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. J Clin Oncol 2013 ; 31 : 231-9. Epub 2012/11/15.
 
19) Meistrich ML. Effects of chemotherapy and radiotherapy on spermatogenesis in humans. Fertil Steril. 2013 ; 100 : 1180-6. Epub 2013/09/10.
 
20) Blumenthal DT, Parreno MG, Batten J, et al. Management of malignant gliomas during pregnancy : a case series. Cancer 2008 ; 113 : 3349-54.
PubMed
21) Zwinkels H, Dorr J, Kloet F, et al. Pregnancy in women with gliomas : a case-series and review of the literature. J Neurooncol 2013 ; 115 : 293-301.
PubMed
22) Yust-Katz S, de Groot JF, Liu D, et al. Pregnancy and glial brain tumors. Neuro Oncol 2014 ; 16 : 1289-94.
PubMed
23) Sitbon Sitruk L, Sanson M, Prades M, et al. [Unknown gonadotoxicity chemotherapy and preservation of fertility : example of Temozolomide]. Gynecol Obstet Fertil 2010 ; 38 : 660-2. Epub 2010/10/30. Chimiotherapie a gonadotoxicite inconnue et preservation de la fertilite : exemple du temozolomide.
 
24) Strowd RE, Blackwood R, Brown M, et al. Impact of temozolomide on gonadal function in patients with primary malignant brain tumors. J Oncol Pharm Pract 2013 ; 19 : 321-7. Epub 2013/01/08.
 
25) 国立医薬品食品衛生研究所安全情報部. Bevacizumab ['Avastin'] : 早発卵巣機能不全に関する注意喚起. 医薬品安全性情報 2011 ; 9 : 12.
 
26) Sabanegh ES Jr, Ragheb AM. Male fertility after cancer. Urology 2009 ; 73 : 225-31. Epub 2008/11/28.
 
27) Koustenis E, Pfitzer C, Balcerek M, et al. Impact of cranial irradiation and brain tumor location on fertility : a survey. Klin Padiatr 2013 ; 225 : 320-4. Epub 2013/10/26.
 
28) van Casteren NJ, Pieters R, Dohle GR, et al. Cranial irradiation does not result in pituitary-gonadal axis dysfunction in very long-term male survivors of childhood acute lymphoblastic leukemia. Leukemia 2009 ; 23 : 2310-3. Epub 2009/09/04.
PubMed
29) Pallud J, Mandonnet E, Deroulers C, et al. Pregnancy increases the growth rates of World Health Organization grade II gliomas. Ann Neurol 2010 ; 67 : 398-404.
PubMed
30) Sneed PK, Albright NW, Wara WM, et al. Fetal dose estimates for radiotherapy of brain tumors during pregnancy. Int J Radiat Oncol Bio Phys 1995 ; 32 : 823-30.
 
31) Horowitz DP, Wang TJ, Wuu CS, et al. Fetal radiation monitoring and dose minimization during intensity modulated radiation therapy for glioblastoma in pregnancy. J Neurooncol 2014 ; 120 : 405-9.
PubMed
32) Lynch JC, Gouvea F, Emmerich JC, et al. Management strategy for brain tumour diagnosed during pregnancy. Brit J Neurosurg 2011 ; 25 : 225-30.
 

第3章 頭部外傷

P.248 掲載の参考文献
1) http://www.jtcr-jatec.org/traumabank/dataroom/data/JTDB2014rev.pdf
 
2) Maas AI, Stocchetti N, Bullock R. Moderate and severe traumatic brain injury in adults. Lancet Neurol 2008 ; 7 : 728-41.
PubMed
3) 亀山元信, 刈部博, 川瀬誠, 他. 頭部外傷の年齢構成はどのように変化してきたか? : 頭部外傷データバンク【プロジェクト1998, 2004, 2009】の推移. 神経外傷 2013 ; 10-6.
 
4) Cooper DJ, Rosenfeld JV, Murray L, et al. Decompressive craniectomy in diffuse traumatic brain injury. N Engl J Med 2011 ; 364 : 1493-502.
PubMed
5) Honeybul S, Janzen C, Kruger K, et al. Decompressive craniectomy for severe traumatic brain injury : is life worth living? J Neurosurg 2013 ; 119 : 1566-75.
PubMed
6) Bor-Seng-Shu E, Figueiredo EG, Amorim RL, et al. Decompressive craniectomy : a meta-analysis of influences on intracranial pressure and cerebral perfusion pressure in the treatment of traumatic brain injury. J Neurosurg 2012 ; 117 : 589-96.
PubMed
7) Nambiar M, MacIsaac C, Grabinski R, et al. Outcomes of decompressive craniectomy in patients after traumatic brain injury. Crit Care Resusc 2015 ; 17 : 67-72.
PubMed
8) Mendelow AD, Gregson BA, Rowan EN, et al. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial lobar intracerebral haematomas (STICH II) : a randomised trial. Lancet 2013 ; 382 : 397-408.
 
9) Gregson BA, Rowan EN, Mitchell PM, et al. Surgical trial in traumatic intracerebral hemorrhage (STITCH (Trauma)) : study protocol for a randomized controlled trial. Trials 2012 ; 13 : 193.
PubMed
10) Mendelow AD, Gregson BA, Rowan EN, et al. Early Surgery versus Initial Conservative Treatment in Patients with Traumatic Intracerebral Hemorrhage (STITCH [Trauma]) : The First Randomized Trial. J Neurotrauma 2015 ; 32 : 1312-23.
 
11) Chesnut RM, Temkin N, Carney N, et al. A trial of intracranial-pressure monitoring in traumatic brain injury. N Engl J Med 2012 ; 367 : 2471-81.
 
12) Chesnut R, Bleck T, Citerio G, et al. A Consensus-based Interpretation of the BEST TRIP ICP Trial. J Neurotrauma 2015 ; 32 : 1722-4.
 
13) Farahvar A, Gerber LM, Chiu YL, et al. Increased mortality in patients with severe traumatic brain injury treated without intracranial pressure monitoring. J Neurosurg 2012 ; 117 : 729-34.
PubMed
14) Alali AS, Fowler RA, Mainprize TG, et al. Intracranial Pressure Monitoring in Severe Traumatic Brain Injury : Results from the American College of Surgeons Trauma Quality Improvement Program. J Neurotrauma 2013 ; 30 : 1737-46.
 
15) Stocchetti N, Picetti E, Berardino M, et al. Clinical applications of intracranial pressure monitoring in traumatic brain injury : report of the Milan consensus conference. Acta Neurochir (Wien) 2014 ; 156 : 1615-22.
PubMed
16) Le Roux P. Intracranial pressure after the BEST TRIP trial : a call for more monitoring. Curr Opin Crit Care 2014 ; 20 : 141-7.
 
17) Green JA, Pellegrini DC, Vanderkolk WE, et al. Goal directed brain tissue oxygen monitoring versus conventional management in traumatic brain injury : an analysis of in hospital recovery. Neurocrit Care 2013 ; 18 : 20-5.
PubMed
18) Lazaridis C, Andrews CM. Brain tissue oxygenation, lactate-pyruvate ratio, and cerebrovascular pressure reactivity monitoring in severe traumatic brain injury : systematic review and viewpoint. Neurocrit Care 2014 ; 21 : 345-55.
PubMed
19) Le Roux P, Menon DK, Citerio G, et al. The International Multidisciplinary Consensus Conference on Multimodality Monitoring in Neurocritical Care : a list of recommendations and additional conclusions : a statement for healthcare professionals from the Neurocritical Care Society and the European Society of Intensive Care Medicine. Neurocrit Care 2014 ; 21 Suppl 2 : S282-96.
 
20) Clifton GL, Valadka A, Zygun D, et al. Very early hypothermia induction in patients with severe brain injury (the National Acute Brain Injury Study : Hypothermia II) : a randomised trial. Lancet Neurol 2011 ; 10 : 131-9.
 
21) Maekawa T, Yamashita S, Nagao S, et al. Prolonged mild therapeutic hypothermia versus fever control with tight hemodynamic monitoring and slow rewarming in patients with severe traumatic brain injury : a randomized controlled trial. J Neurotrauma 2015 ; 32 : 422-9.
PubMed
22) Suehiro E, Koizumi H, Fujisawa H, et al. Diverse effects of hypothermia therapy in patients with severe traumatic brain injury based on the computed tomography classification of the traumatic coma data bank. J Neurotrauma 2015 ; 32 : 353-8.
 
23) Andrews PJ, Sinclair HL, et al. Hypothermia for Intracranial Hypertension after Traumatic Brain Injury. N Engl J Med 2015 ; 373 : 2403-12.
PubMed
24) Shakur H, Roberts I, Bautista R, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2) : a randomised, placebo-controlled trial. Lancet 2010 ; 376 : 23-32.
PubMed
25) Ker K, Roberts I, Shakur H, et al. Antifibrinolytic drugs for acute traumatic injury. Cochrane Database Syst Rev 2015 ; 5 : CD004896.
PubMed
26) Yutthakasemsunt S, Kittiwatanagul W, Piyavechvirat P, et al. Tranexamic acid for patients with traumatic brain injury : a randomized, double-blinded, placebo-controlled trial. BMC Emerg Med 2013 ; 13 : 20.
PubMed
27) Dewan Y, Komolafe EO, Mejia-Mantilla JH, et al. CRASH-3-tranexamic acid for the treatment of significant traumatic brain injury : study protocol for an international randomized, double-blind, placebo-controlled trial. Trials 2012 ; 13 : 87.
PubMed
28) Wright DW, Yeatts SD, Silbergleit R, et al. Veryearly administration of progesterone for acute traumatic brain injury. N Engl J Med 2014 ; 371 : 2457-66.
PubMed
29) Skolnick BE, Maas AI, Narayan RK, et al. A clinical trial of progesterone for severe traumatic brain injury. N Engl J Med 2014 ; 371 : 2467-76.
PubMed
30) 重症頭部外傷治療管理のガイドライン作成委員会. 重症頭部外傷治療・管理のガイドライン. 医学書院, 東京, 2103.
 
31) Bullock MR, Chesnut R, Ghajar J, et al. Surgical management of acute epidural hematomas. Neurosurgery 2006 ; 58 (3 Suppl) : S7-15.
 
32) Andrews BT, Chiles BW 3rd, Olsen WL, et al. The effect of intracerebral hematoma location on the risk of brain-stem compression and on clinical outcome. J Neurosurg 1988 ; 69 : 518-22.
PubMed
33) Bullock MR, Chesnut R, Ghajar J, et al. Surgical management of acute subdural hematomas. Neurosurgery 2006 ; 58 (3 Suppl) : S16-24.
 
34) Guidelines for the management of severe traumatic brain injury. J Neurotrauma 2007 ; 24 Suppl 1 : S1-106.
 
35) Bullock MR, Chesnut R, Ghajar J, et al. Surgical management of traumatic parenchymal lesions. Neurosurgery 2006 ; 58 (3 Suppl) : S25-46.
 
36) Bullock MR, Povlishock JT. Guidelines for the management of severe traumatic brain injury. Editor's Commentary. J Neurotrauma 2007 ; 24 Suppl 1 : 2 p preceding S1.
 
P.254 掲載の参考文献
1) Langlois J, Rutland-Brown W, Thomas K. Traumatic Brain Injury in the United States : Emergency Department Visits, Hospitalizations, and Deaths. Atlanta, Centers for Disease Control and Prevention, National Center for Injury Prevention and Control, 2004.
 
2) Keenan HT, Runyan DK, Marshall SW, et al. A population-based study of inflicted traumatic brain injury in young children. JAMA 2003 ; 290 : 621-6.
PubMed
3) Injury Prevention and Control : Traumatic Brain Injury, Centers for Disease Control and Prevention. http://www.cdc.gov/traumaticbraininjury/data/dist_hosp.html access 2015.9.22
 
4) Injury Prevention and Control : Traumatic Brain Injury, Centers for Disease Control and Prevention. http://www.cdc.gov/traumaticbraininjury/data/dist_death.html access.2015.9.22
 
5) Agran PF, Anderson CL, Winn DG. Factors associated with restraint use of children in fatal crashes. Pediatrics 1998 ; 102 : E39.
PubMed
6) Silen ML, Kokoska ER, Fendya DG, et al. Rollover injuries in residential driveways : age-related patterns of injury. Pediatrics 1999 ; 104 : e7.
PubMed
7) Centers for Disease Control and Prevention. WISCARS. Leading Causes of Death Reports, National and Regional, 1999-2013, 2015. http://webappa.cdc.gov/cgi-bin/broker.exe Access 2015.9.22
 
8) Thompson D, Rivara F, Thompson R. Helmets for prevention head and facial injuries in bicyclists. Cochrane Database Syst Rev 2000 ; 2 : CD001855. CD001855. http://www.update-software.com/Abstracts/ab001855.htm.
 
9) Agran PF, Winn D, Anderson C, et al. Rates of pediatric and adolescents injuries by year of age. Pediatrics 2001 ; 108 : E45.
PubMed
10) Haydel MJ, Preston CA, Mills TJ, et al. Indications for computed tomography in patients with minor head injury. N Engl J Med 2000 ; 343 : 100-5.
PubMed
11) Stiell IG, Wells GA, Vandemheen K, et al. The Canadian CT Head Rule for patients with minor head injury. Lancet 2001 ; 357 : 1391-6.
PubMed
12) Stiell IG, Clement CM, Rowe BH, et al. Comparison of the Canadian CT Head Rule and the New Orleans Criteria in patients with minor head injury. JAMA 2005 ; 294 : 1511-8.
PubMed
13) Osmond MH, Klassen TP, Wells GA, et al. Pediatric Emergency Research Canada (PERC) Head Injury Study Group. CATCH : a clinical decision rule for the use of computed tomography in children with minor head injury. CMAJ 2010 ; 182 : 341-8.
 
14) Dunning J, Daly JP, Malhotra R, et al. Children's Head injury Algorithm for the Identification of significant Clinical Events Study (CHALICE Study). The implications of NICE guidelines on the management of children presenting with head injury. Arch Dis Child 2004 ; 89 : 763-7.
 
15) Kuppermann N, Holmes JF, Dayan PS,et al. Identification of children at very low risk of clinically-important brain injuries after head trauma : a prospective cohort study. Lancet 2009 ; 374 : 1160-70.
PubMed
16) Easter JS, Bakes K, Dhaliwal J, et al. Comparison of PECARN, CATCH, and CHALICE rules for children with minor head injury : a prospective cohort study. Ann Emerg Med 2014 ; 2 : 145-52.
PubMed
17) Hunter JV, Wilde EA, Tong KA, et al. Emerging imaging tools for use with traumatic brain injury research. J Neurotrauma 2012 ; 29 : 654-71.
 
18) 永廣信治, 谷諭, 荻野雅弘, 他. スポーツ頭部外傷における脳神経外科医の対応. 神経外傷 2013 ; 36 : 119-28.
 
19) 日本脳神経外科学会・日本脳神経外傷学会監修. 重症頭部外傷治療・管理のガイドライン 第3版, 医学書院, 東京, 2013.
 
20) Riyaz M, Waqas M, Ujjan BU, et al. Decompressive craniectomy for infants : a case series of five patients. Childs Nerv Syst 2015 Jul 5. [Epub ahead of print]
 
21) Polin RS, Shaffrey ME, Bogaev CA, et al. Decompressive bifrontal craniectomy in the treatment of severe refractory posttraumatic cerebral edema. Neurosurgery 1997 ; 41 : 84-92.
PubMed
22) Pechmann A, Anastasopoulos C, Korinthenberg R, et al. Decompressive craniectomy after severe traumatic brain injury in children : complications and outcome. Neuropediatrics 2015 ; 46 : 5-12.
PubMed
23) Oluigbo CO, Wilkinson CC, Stence NV, et al. Comparison of outcomes following decompressive craniectomy in children with accidental and nonaccidental blunt cranial trauma. J Neurosurg Pediatr 2012 ; 9 : 125-32.
PubMed
24) Liesemer K, Bratton SL, Zebrack CM, et al. Early post-traumatic seizures in moderate to severe pediatric traumatic brain injury : rates, risk factors, and clinical features. J Neurotrauma 2011 ; 28 : 755-62.
PubMed
25) Alali AS, Gomez D, Sathya C, et al. Intracranial pressure monitoring among children with severe traumatic brain injury. J Neurosurg Pediatr 2015 ; 14 : 1-10.
 
26) 栗原まな, 宍戸淳, 吉橋学, 他. 小児外傷後てんかんの検討. てんかん研究 2012 ; 29 : 460-9.
 
27) 栗原まな, 荒木尚, 編著. 小児頭部外傷-急性期からリハビリテーションまで-, 医歯薬出版, 東京, 2013.
 
28) Hristeva L, Booy R, Bowler I, et al. Prospective surveillance of neonatal meningitis. Arch Dis Child 1993 ; 69 : 14-8.
PubMed
29) Christian CW, Block R. Abusive head trauma in infants and children. Pediatrics 2009 ; 123 : 1409-11.
PubMed
30) Talvik I, Metsvaht T, Leito K, et al. Inflicted traumatic brain injury (ITBI) or shaken baby syndrome (SBS) in Estonia. Acta Paediatr 2006 ; 95 : 799-804.
PubMed
31) Fanconi M, Lips U. Shaken baby syndrome in Switzerland : results of a prospective follow-up study, 2002-2007. Eur J Pediatr 2010 ; 169 : 1023-8.
PubMed
32) Brennan LK, Rubin D, Christian CW, et al. Neck injuries in young pediatric homicide victims. J Neurosurg Pediatr 2009 ; 3 : 232-9.
PubMed
33) Duhaime AC, Gennarelli TA, Thibault LE, et al. The shaken baby syndrome. A clinical, pathological, and biomechanical study. J Neurosurg 1987 ; 66 : 409-15.
PubMed
34) Maguire S, Pickerd N, Farewell D, et al. Which clinical features distinguish inflicted from non-inflicted brain injury? A systematic review. Arch Dis Child 2009 ; 94 : 860-7.
PubMed
35) Bhardwaj G, Chowdhury V, Jacobs MB, et al. A systematic review of the diagnostic accuracy of ocular signs in pediatric abusive head trauma. Ophtalmology 2010 ; 117 : 983-92.
 
36) McCrory P, Meeuwisse WH, Aubry M, et al. Consensus statement on concussion in sport : the 4th International Conference on Concussion in Sport held in Zurich, November 2012. Br J Sports Med 2013 ; 47 : 250-8.
PubMed
37) Orr CA, Albaugh M, Watts R, et al. Neuroimaging biomarkers of a history of concussion observed in asymptomatic young athletes. J Neurotrauma 2015 Sep 28. [Epub ahead of print]
 
38) Fidan E, Lewis J, Kline AE, et al. Repetitive mild traumatic brain injury in the developing brain : effects on long-term functional outcome and neuropathology. J Neurotrauma 2015 Jul 27. [Epub ahead of print]
 
39) Steinbok P, Flodmark O, Martens D, et al. Management of simple depressed skull fractures in children. J Neurosurg 1987 ; 66 : 506-10.
 
40) Ersahin Y, Mutluer S, Mirzai H, et al. Pediatric depressed skull fractures : analysis of 530 cases. Childs Nerv Syst 1996 ; 12 : 323-31.
PubMed
41) 外傷性てんかん調査会. 外傷性てんかんのリスクファクター 多施設共同研究. 脳外誌 1991 ; 19 : 1151-9.
 
42) Donovan DJ. Simple depressed skull fracture causing sagittal sinus stenosis and increased intracranial pressure : case report and review of the literature. Surg Neurol 2005 ; 63 : 380-3.
PubMed
43) Tamimi A, Abu-Elrub M, Shudifat A, et al. Superior sagittal sinus thrombosis associated with raised intracranial pressure in closed head injury with depressed skull fracture. Pediatr Neurosurg 2005 ; 41 : 237-40.
PubMed
44) Morota N, Sakamoto K, Kobayashi N, et al. Infantile subdural fluid collection : diagnosis and postoperative course. Childs Nerv Syst 1995 ; 11 : 459-66.
PubMed
45) Aoki N. Chronic subdural hematoma in infancy. Clinical analysis of 30 cases in the CT era. J Neurosurg 1990 ; 73 : 201-5.
PubMed
46) Prasad GL, Gupta DK, Mahapatra AK, et al. Surgical results of growing skull fractures in children : a single centre study of 43 cases. Childs Nerv Syst 2015 ; 31 : 269-77.
PubMed
P.259 掲載の参考文献
1) 谷諭, 川又達朗, 荻野雅宏, 他. スポーツにおける頭部外傷 (頻度, 分類, 特殊性など). 臨床スポーツ医学 2008 ; 25 : 309-31.
Medical*Online
2) Forbes JA, Zuckerman S, Abla AA, et al. Biomechanics of subdural hemorrhage in American football : review of the literature in response to rise in incidence. Childs Nerv Syst 2014 ; 30 : 197-203.
PubMed
3) Mueller FO. Catastrophic head injuries in high school and collegiate sports. J Athl Train 2001 ; 36 : 312-5.
PubMed
4) 永廣信治, 谷諭, 荻野雅宏, 他. スポーツ頭部外傷における脳神経外科医の対応 ガイドライン作成に向けた中間提言. 神経外傷 2013 ; 36 : 119-28.
 
5) 永廣信治. 柔道と頭部外傷. 日医師会誌 2014 ; 142 : 2464-6.
 
6) 永廣信治, 溝渕佳史. スポーツ頭部外傷を可視化する. 脳外誌 2014 ; 23 : 957-64.
 
7) 永廣信治, 溝渕佳史, 本藤秀樹, 他. 柔道における重症頭部外傷. No Shinkei Geka 2011 ; 39 : 1139-47.
 
8) Alexandrino GM, Damasio J, Canhao P, et al. Stroke in sports : a case series J Neurol. 2014 ; 261 : 1570-4.
 
9) Arnold M, Fischer U, Nedeltchev K. Carotid artery dissection and sports. Kardiovaskulare Medizin 2009 ; 12 : 209-13.
 
10) Suzuki R, Osaki M, Endo K, et al. Common carotid artery dissection caused by a frontal thrust in Kendo (Japanese swordsmanship). Circulation 2012 ; 125 : e617-9.
PubMed
11) Fridley J, Mackey J, Hampton C, et al. Internal carotid artery dissection and stroke associated with wakeboarding. J Clin Neurosci 2011 ; 18 : 1258-60.
PubMed
12) Hafner F, Gary T, Harald F, et al. Dissection of the internal carotid artery after SCUBA-diving : a case report and review of the literature. Neurologist 2011 ; 17 : 79-82.
 
13) Bartsch T, Palaschewski M, Thilo B, et al. Internal carotid artery dissection and stroke after SCUBA diving : a case report and review of the literature. J Neurol 2009 ; 256 : 1916-9.
 
14) Fukuoka T, Kato Y, Ohe Y, et al. A case of anterior Cerebral Artery Dissection Caused by Scuba Diving.. J Stroke Cerebrovasc Dis 2014 ; 23 : 1982-4.
PubMed
15) Kalantzis G, Georgalas I, Chang BY, al. An Unusual Case of Traumatic Internal Carotid Artery Dissection during Snowboarding. J Sports Sci Med 2014 ; 13 : 451-3.
 
16) 徳元一樹, 上田進彦. ごるふによる一側椎骨動脈解離が原因となった頸髄梗塞の1例. 臨床神経 2014 ; 54 : 151-7.
 
17) Choi MH, Hong JM, Lee JS, et al. Preferential location for arterial dissection presenting as golf-related stroke. AJNR Am J Neuroradiol 2014 ; 35 : 323-6.
PubMed
18) Vertinsky AT, Schwartz NE, Fischbein NJ, et al. Comparison of multidetector CT angiography and MR imaging of cervical artery dissection. AJNR Am J Neuroradiol 2008 ; 29 : 1753-60.
 
19) Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack : a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014 ; 45 : 2160-236.
PubMed
20) Smith WS, Johnston SC, Skalabrin EJ, et al. Spinal manipulative therapy is an independent risk factor for vertebral artery dissection. Neurology 2003 ; 60 : 1424-8.
PubMed
21) Giza CC, Kutcher JS, Ashwal S, et al. Summary of evidence-based guideline update : evaluation and management of concussion in sports : report of the Guideline Development Subcommittee of the American Academy of Neurology, Neurology 2013 ; 80 : 2250-7.
PubMed
22) Guskiewicz KM, McCrea M, Marshall SW, et al : Cumulative effects associated with recurrent concussion in collegiate football players : the NCAA Concussion Study. JAMA 2003 ; 290 : 2549-55.
PubMed
23) Guskiewicz KM, Weaver NL, Padua DA, et al. Epidemiology of concussion in collegiate and high school football players. Am J Sports Med 2000 ; 28 : 643-50.
PubMed
24) Harmon KG, Drezner JA, Gammons M, et al. American Medical Society for Sports Medicine position statement : concussion in sport. Br J Sports Med 2013 ; 47 : 15-26.
PubMed
25) Jordan BD. The clinical spectrum of sport-related traumatic brain injury. Nat Rev Neurol 2013 ; 9 : 222-30.
PubMed
26) 平川公義. スポーツによる脳振盪-脳振盪と硬膜下血腫-. 臨床スポーツ医学 1991 ; 8 : 147-52.
 
27) 川原貴. アメリカンフットボールにおける重大事故の統計的観察. 臨床スポーツ医学 1995 ; 12 : 1-3.
 
28) 川原貴. アメリカンフットボールにおける重大事故の統計的観察. 臨床スポーツ医学 1995 ; 12 : 1-3.
 
29) Cantu RC. Second-impact syndrome. Clin Sports Med 1998 ; 17 : 37-44.
PubMed
30) Cantu RC, Gean AD. Second-impact syndrome and a small subdural hematoma : an uncommon catastrophic result of repetitive head injury with a characteristic imaging appearance. J Neurotrauma 2010 ; 27 : 1557-64.
 
31) Mori T, Katayama Y, Kawamata T. Acute hemispheric swelling associated with thin subdural hematomas : pathophysiology of repetitive head injury in sports. Acta Neurochir 2006 ; Suppl 96 : 40-3.
PubMed
32) McCrory P, Meeuwisse WH, Aubry M, et al. Consensus statement on concussion in sport : the 4th International Conference on Concussion in Sport held in Zurich, November 2012. J Athletic Training 2013 ; 48 : 554-75.
 
33) McCrea M, Guskiewicz K, Randolph C. Effects of a symptom-free waiting period on clinical outcome and risk of reinjury after sport-related concussion, Neurosurgery 2009 ; 65 : 876.
PubMed
34) Putukian M. The acute symptoms of sport-related concussion : diagnosis and on-field management. Clin Sports Med 2011 ; 30 : 49-61, viii.
 
35) Lishman WA : Physiogenesis and psychogenesis in the 'post-concussional syndrome'. Br J Psychiatry 1988 ; 153 : 460-9.
PubMed
36) Ommaya AK, Gennarelli TA : Cerebral concussion and traumatic unconsciousness. Correlation of experimental and clinical observations of blunt head injuries. Brain 1974 ; 97 : 633-54.
PubMed
37) 前原健寿, 大野喜久郎, 富永勉, 他. スポーツによる頭蓋内出血 警戒症状としての頭痛. 臨床スポーツ医学 1993 ; 10 : 311-4.
 
38) 前原健寿, 成相直, 鈴木竜太, 他. スポーツによる脳振盪の急性期画像診断 脳損傷患者2例の画像診断より. 臨床スポーツ医学 1994 ; 11 : 845-50.
 
39) 川又達朗, 片山容一. 脳振盪を繰り返すとどうなるのか-いつ復帰できるか-. 臨床スポーツ医学 2002 ; 19 : 637-43.
Medical*Online
40) Cantu RC. Second-impact syndrome. Clin Sports Med 1998 ; 37-44. Review.
PubMed
41) McCrory P, Davis G, Makdissi M. Second impact syndrome or cerebral swelling after sporting head injury. Curr Sports Med Rep. 2012 ; 11 : 21-3.
PubMed
42) Wetjen NM, Pichelmann MA, Atkinson JL. Second impact syndrome : concussion and second injury brain complications. J Am Coll Surg 2010 ; 211 : 553-7.
PubMed
43) Weinstein E, Turner M, Kuzma BB, et al. Second impact syndrome in football : new imaging and insights into a rare and devastating condition. J Neurosurg Pediatr 2013 ; 11 : 331-4
 
44) McKee AC, Cantu RC, Nowinski CJ, et al. Chronic traumatic encephalopathy in athletes : progressive tauopathy after repetitive head injury. J Neuropathol Exp Neurol 2009 ; 68 : 709-35.
PubMed
45) Baugh CM, Stamm JM, Riley DO, et al. Chronic traumatic encephalopathy : neurodegeneration following repetitive concussive and subconcussive brain trauma. Brain Imaging Behav 2012 ; 6 : 244-54.
PubMed
46) McCrory P, Meeuwisse WH, Kutcher JS, et, al. What is the evidence for chronic concussion-related changes in retired athletes : behavioural, pathological and clinical outcomes? Br J Sports Med 2013 ; 47 : 327-30.
PubMed
47) Tator CH. Chronic traumatic encephalopathy : how serious a sports problem is it? Br J Sports Med 2014 ; 48 : 81-3.
PubMed

第4章 小児・先天奇形

P.264 掲載の参考文献
1) Amacher AL, Wellington J. Infantile hydrocephalus : Long-term results of surgical therapy. Child's Brain 1984 ; 11 : 217-29.
PubMed
2) Anwar M, Doyle AJ, Kadam S, et al. Management of posthemorrhagic hydrocephalus in the preterm infant. J Pediatr Surg 1986 ; 21 : 334-7.
PubMed
3) Blomquist HK, Sundin S, Eksted J. Cerebrospinal fluid hydrodynamic studies in children. J Neurol Neurosurg Psychiatry 1986 ; 49 : 536-48.
 
4) Bourgeois M, Sainte-Rose C, Cinalli G, et al. Epilepsy in children with shunted hydrocephalus. J Neurosurg 1999 ; 90 : 274-81.
PubMed
5) Casey AT, Kimmings EJ, Kleinlugtebeld AD, et al. The long-term outlook for hydrocephalus in study of 155 patients. Pediatr Neurosurg 1997 ; 27 : 63-70.
 
6) Chumas P, Tyagi A, Livingston J. Hydrocephalus? what's new? Arch Dis Child Fetal Neonatal Ed 2001 ; 85 : F149-54.
 
7) Cohen AR. Ventriculoscopic surgery. Clin Neurosurg 1991 ; 41 : 546-62.
 
8) Dincer A, Ozek MM. Radiologic evaluation of pediatric hydrocephalus. Childs Nerv Syst 2011 ; 27 : 1543-62.
PubMed
9) Drake JM, Kestle JR, Milner R, et al. Randomized trial of cerebrospinal fluid shunt valve design in pediatric hydrocephalus. Neurosurgery 1998 ; 43 : 294-305.
PubMed
10) Drake JM, Kestle JR, Tuli S. CSF shunts 50 years on-past, present and future. Child's Nerv Syst 2000 ; 16 : 800-4.
 
11) Drake JM, Canadian Pediatric Neurosurgery Study Group. Endoscopic third ventriculostomy in pediatric patients : The Canadian experience. Neurosurgery 2007 ; 60 : 881-6.
 
12) Edsbagge M, Tisell M, Jacobsson L, et al. Spinal CSF absorption in healthy individuals. J Physiol Regul Integr Comp Physiol 2004 ; 287 : R1450-5.
 
13) Gurtner P, Bass T, Gudeman SK, et al. Surgical management of posthemorrhagic hydroephalus in 22 low-birth-weight infants. Childs Nerv Syst 1992 ; 8 : 198-202.
 
14) Hirsch JF. Consensus : long-term outcome in hydrocephalus. Child's Nerv Syst 1994 ; 10 : 64-9.
 
15) Hopf NJ, Grunert P, Fries G, et al. Endoscopic third ventriculostomy : Outcome analysis of 100 consecutive procedures. Neurosurgery 1999 ; 44 : 795-806.
PubMed
16) Jeng S, Gupta N, Wrensch M, et al. Prevalence of congenital hydrocephalus in California, 1991-2000. Pediatric Neurology 2011 ; 45 : 67-71.
PubMed
17) Klimo P Jr, Van Poppel M, Thompson CJ, et al. Pediatric hydrocephalus : systematic literature review and evidence-based guideline. Part 6 : Preoperative antibiotics for shunt surgery in children with hydrocephalus : a systematic review and meta-analysis. J Neurosurg Pediatrics 2014 ; (Suppl) 14 : 44-52.
 
18) Laurence KM, Coates S. The natural history of hydrocephalus ; Detailed analysis of 182 unoperated cases. Arch Dis Child 1962 ; 37 : 345-362.
PubMed
19) Limbrick DD Jr, Baird LC, Klimo P Jr, et al. Pediatric hydrocephalus : systematic literature review and evidence-based guideline. Part 4 : Cerebrospinal fluid shunt or endoscopic third ventriculostomy for the treatment of hydrocephalus in children. J Neurosurg Pediatrics 2014 ; (Suppl) 14 : 30-4.
PubMed
20) Lorenzo AV, Page LK, Galichich J, et al. Formation and absorption of cerebrospinal fluid in man. Brain 1970 ; 91 : 707-20.
 
21) Lumenta CB, Skotarczak U. Long-term follow-up in 233 patients with congenital hydrocephalus. Child's Nerv Syst 1995 ; 11 : 173-5.
 
22) Oi S, Honda Y, Hidaka M, et al. Intrauterine high-resolution magnetic resonance imaging in fetal hydrocephalus and prenatal estimation of post natal outcomes with "perspective classification". J Neurosurg 1998 ; 77 : 551-5.
 
23) Oreskovic D, Klarica M. The formation of cerebrospinal fluid : nearly a hundred years of interpretations and misinterpretations. Brain Res Rev 2010 ; 64 : 241-62.
PubMed
24) Pilu G, Falco P, Gabrielli S, et al. The clinical significance of fetal isolated cerebral borderline ventriculomegaly : report of 31 cases and review of the literature. Ultrasound Obstet Gynecol 1999 ; 14 : 320-6.
PubMed
25) Prusseit J, Simon M, von der Brelie C, et al. Epidemiology, prevention and management of VP shunt infections in children. Pediatr Neurosurg 2009 ; 45 : 325-36.
 
26) Ransohoff J, Schulman K, Fishman RA. Hydrocephalus : A review of etiology and treatment. J Pediatr 1960 ; 56 : 499-511.
 
27) Rekate HL. A contemporary definition and classification of hydrocephalus. Semin Pediatr Neurol 2009 ; 16 : 9-15.
PubMed
28) Tuli S, O'Hayon B, Drake J, et al. Change in ventricular size and effect of ventricular catheter placement in pediatric patients with shunted hydrocephalus. Neurosurgery 1999 ; 45 : 1329-35.
 
29) 胎児期水頭症ガイドライン編集委員会編. 胎児期水頭症 診断と治療ガイドライン, 金芳堂, 京都, 2005, p167-73.
 
30) Whitelaw A. Repeated lumbar or ventricular punctures in newborns with intraventricular hemorrhage. Cochrane Database Syst Rev 2001 ; (1) : CD000216.
 
31) Whitelaw A, Kennedy CR, Brion LP. Diuretic therapy for newborn infants with posthemorrhagic ventricular dilatation. Cochrane Database Syst Rev 2001 ; (2) : CD002270.
PubMed
32) Whitelaw A, Odd DE. Intraventricular streptokinase after intraventricular hemorrhage in newborn infants. Cochrane Database Syst Rev 2007 ; (4) : CD000498.
PubMed
33) 横浜市立大学 先天異常モニタリングセンター 先天異常データベース, 2010年. http://www.icbdsrj.jp/2010data.html
 
P.268 掲載の参考文献
1) 秋月種高, 大森喜太郎. 当科におけるcraniofacial surgeryの長期follow-up. 形成外科 1997 ; 40 : 451-62.
 
2) Cinalli G, Chumas P, Arnaud E, et al. Occipital remodeling and suboccipital decompression in severe craniosynostosis associated with tonsillar herniation. Neurosurgery 1998 ; 42 : 66-73.
PubMed
3) Christian EA, Lmahiyerobo TA, Nallapa S, et al. Intracranial hypertension after surgical correction for craniosynostosis : a systematic review. Neurosurg Focus 2015 ; 38 : E6.
 
4) Cohen MM. Epidermiology of craniosynostosis. In ; Choen MM, Maclean RE, eds. Craniosynostosis, 2nd ed, Oxford University Press, 2000, p112-8.
 
5) Cohen SR, Cho DC, Nichols SL, et al. American society of maxillofacial surgeons outcome study ; preoperative and postoperative neurodevelopmental findings in single-suture craniofacial synostosis. Plast Reconst Surg 2004 ; 15 : 841-7.
PubMed
6) Diaz JH, Lockhart CH. Hypotensive anesthesia for craniectomy in infancy. British J Anaesthesia 1979 ; 51 : 233-5.
 
7) Fearon JA, Weinthal J. The use of recombinant erythropoietin in the reduction of blood transfusion rates in craniosynostosis repair in infants and children. Plast Reconstr Surg 2002 ; 109 : 2190-6.
PubMed
8) 今井啓介, 辻口幸之助, 成耆徹, 他. Craniosynostosisの術後の頭蓋顔面の長期follow-up. 形成外科 1997 ; 40 : 463-9.
 
9) Hirabayashi S, Sugawara Y, Sakurai A, et al. Frontoorbital advancement by gradual distraction. Technical note. J Neurosurg 1998 ; 89 : 1058-61.
PubMed
10) Imai K, Komune H, Toda C, et al. Cranial remodeling to treat craniosynostosis by gradual diatraction using a new device. J Neurosurg 2002 ; 96 : 654-9.
 
11) 今井啓介, 山田朗, 坂本博昭, 他. 頭蓋骨延長術における中期経過での評価とその適応. 形成外科 2006 ; 49 : 269-79.
 
12) Jimenez DF, Barone CM. Endoscopic technique for sagittal synostosis. Childs Nerv Syst 2012 ; 28 : 1333-9.
PubMed
13) Kapp-Simon KA, Figueroa A, Jocher CA, et al. Longitudinal assessment of mental development in infants with nonsyndromic craniosynostosis with and without cranial release and reconstruction. Plast Recontr Surg 1993 ; 92 : 831-9.
PubMed
14) Marchac D, Renier D, Broumand S. Timing of treatment for craniosynostosis and faciocraniosynostosis : a 20-year experience. Brit J Plast Surg 1994 ; 47 : 211-22.
 
15) MacCarthy JG, Gasberg SB, Cutting CB, et al. Twenty-year experience with early surgery for craniosynostosis : I. Isolated craniofacial synostosis-results and unsolved problems. Plast Reconstr Surg 1995 ; 96 : 272-83.
 
16) MacCarthy JG, Gasberg SB, Cutting CB, et al. Twenty-year experience with early surgery for craniosynostosis : II. The craniofacial synostosis syndromes and pansynostosis-results and unsolved problems. Plast Reconstr Surg 1995 ; 96 : 284-98.
 
17) Matsumoto K, Nakanishi H, Seike T, et al. Application of the distracion technique to scaphocephaly. J Craniofac Surg 2000 ; 11 : 172-6.
PubMed
18) 中嶋英雄. Craniosynostosisの手術. 手術 1987 ; 36 : 1049-62.
 
19) 西本博, 牧山康秀, 西村二郎, 他. Craniosynostosisの長期治療成績と治療上の今後の課題. Jpn J Neurosurg 2001 ; 10 : 92-8.
 
20) 西本博, 栗原淳. 頭蓋骨縫合早期癒合術に伴うchronic tonsillar herniation (後天性Chiari I型奇形). 小児の脳神経 2013 ; 38 : 463-71.
 
21) 西本博, 栗原淳. 頭蓋骨縫合早期癒合症の手術方法と長期治療成績. Jpn J Neurosurg 2014 ; 23 : 401-8.
 
22) Prevot M, Renier D, Marchac D. Lack of ossification after cranioplasty for craniosynostosis : A review of relevant factors in 592 consecutive patients. J Craniofacial Surg 1993 ; 4 : 247-54.
 
23) Renier D, Lajeunie E, Arnaud E, et al. Management of craniosynostosis. Child's Nerv Syst 2000 ; 16 : 645-58.
 
24) Sun PP, Persing JA. Craniosynostosis. In ; Albright AL, Pollack IF, Adelson PD, eds. Principles and practice of pediatric neurosurgery, Thieme, 1999, p219-42.
 
25) Tessier P. Craniofacial surgery in syndromic craniosynostosis. In ; Choen MM, MacleanRE, eds. Craniosynostosis, 2nd ed, Oxford University Press, 2000, p228-68.
 
26) Whitaker LA, Munro IR, Salyer KE, et al. Combined report of problems and complications in 793 craniofacial operations. Plast Reconstr Surg 1979 ; 64 : 198-203.
PubMed
27) Whitaker LA, Bartlett S, Schut L, et al. Craniosynostosis : An analysis of the timing, treatment and complications in 164 consecutive patients. Plast Reconstr Surg 1987 ; 80 : 195-212.
PubMed
28) Wall SA, Goldin JH, Hockley AD, et al. Fronto-orbital re-operation in craniosynostosis. British J Plast Surg 1994 ; 47 : 180-4.
 
29) Wagner JD, Cohen SR, Maher H, at al. Critical analysis of results of craniofacial surgery for nonsyndromic bicoronal synostosis. J Craniofacial Surg 1995 ; 6 : 32-7.
 
30) Williams JK, Cohen SR, Fernando D, et al. A longitudinal, statistical study of reoperation rates in craniosynostosis. Plast Reconstr Surg 1997 ; 100 : 305-10.
 
31) Wong GB, Kakulis EG, Mulliken JB. Analysis of fronto-orbital advancement for Apert, Crouzon, Pfeiffer, and Saethre-Chotzen syndromes. Plast Reconstr Surg 2000 ; 105 : 2314-23.
PubMed
32) 山口和郎, 関戸謙一. 狭頭症の治療とその限界. 小児の脳神経 1993 ; 18 : 479-85.
 
P.275 掲載の参考文献
1) Berry RJ, Li Z, Erickson JD, et al. Prevention of neural-tube defects with folic acid in China. China-U.S. Collaborative Project for Neural Tube Defect Prevention. N Engl J Med 1999 ; 341 : 1485-90.
PubMed
2) 国際先天異常調査研究機構日本支部ICBDSR (International Clearinghouse for Birth Defects Surveillance and Research)
 
3) 山崎麻美, 胎児期水頭症ガイドライン編集委員会. 胎児期水頭症診断と治療ガイドライン 改訂2版, 金芳堂, 京都, 2010.
 
4) Adzick NS, Thom EA, Spong CY, et al. MOMS Investigators : A randomized trial of prenatal versus postnatal repair of myelomeningocele. N Engl J Med 2011 ; 364 : 993-1004.
PubMed
5) Majed M1, Nejat F, Khashab ME, et al. Risk factors for latex sensitization in young children with myelomeningocele. Clinical article. J Neurosurg Pediatr 2009 ; 4 : 285-8.
 
6) McLone DG. Care of the neonate with a myelomeningocele. Neurosurg Clin N Am 1998 ; 9 : 111-20.
PubMed
7) Radmanesh F, Nejat F, El Khashab M, et al. Shunt complications in children with myelomeningocele : effect of timing of shunt placement. Clinical article. J Neurosurg Pediatr 2009 ; 3 : 516-20.
PubMed
8) Naftel RP, Reed GT, Kulkarni AV, et al. Evaluating the Children's Hospital of Alabama endoscopic third ventriculostomy experience using the Endoscopic Third Ventriculostomy Success Score : an external validation study. J Neurosurg Pediatr 2011 ; 8 : 494-501.
 
9) Talamonti G, D'Aliberti G, Collice M. Myelomeningocele : long-term neurosurgical treatment and follow-up in 202 patients. J Neurosurg 2007 ; (5 Suppl) 107 : 368-86.
 
10) Oakeshott P, Hunt GM, Poulton A, et al. Expectation of life and unexpected death in open spina bifida : a 40-year complete, non-selective, longitudinal cohort study. Dev Med Child Neurol 2010 ; 52 : 749-53.
PubMed
11) Hampton LE, Fletcher JM, Cirino PT, et al. Hydrocephalus status in spina bifida : an evaluation of variations in neuropsychological outcomes. J Neurosurg Pediatr 2011 ; 8 : 289-98.
PubMed
12) Pierre-Kahn A, Zerah M, Renier D, et al. Congenital lumbosacral lipomas. Childs Nerv Syst 1997 ; 13 : 298-334.
PubMed
13) Wykes V, Desai D, Thompson DN. Asymptomatic lumbosacral lipomas-a natural history study. Childs Nerv Syst 2012 ; 28 : 1731-9.
PubMed
14) Oi S, Nomura S, Nagasaka M, et al. Embryopathogenetic surgicoanatomical classification of dysraphism and surgical outcome of spinal lipoma : a nationwide multicenter cooperative study in Japan. J Neurosurg Pediatr 2009 ; 3 : 412-9.
PubMed
15) Caldarelli M, Boscarelli A, Massimi L. Recurrent tethered cord : radiological investigation and management. Childs Nerv Syst 2013 ; 29 : 1601-9.
PubMed
16) Ackerman LL, Menezes AH. Spinal congenital dermal sinuses : a 30-year experience. Pediatrics 2003 ; 112 : 641-7.
PubMed
17) Pang D, Zovickian J, Oviedo A, et al. Limited dorsal myeloschisis : a distinctive clinicopathological entity. Neurosurgery 2010 ; 67 : 1555-79.
PubMed
18) Vinchon M, Soto-Ares G, Assaker R, et al. Occipital dermal sinuses : report of nine pediatric cases and review of the literature. Pediatr Neurosurg 2001 ; 34 : 255-63.
PubMed
19) Bui CJ, Tubbs RS, Shannon CN, et al. Institutional experience with cranial vault encephaloceles. J Neurosurg 2007 ; (1 Suppl) 107 : 22-5.
 
20) Lo BW, Kulkarni AV, Rutka JT, et al. Clinical predictors of developmental outcome in patients with cephaloceles. J Neurosurg Pediatr 2008 ; 2 : 254-7.
PubMed
P.279 掲載の参考文献
1) 阿部俊昭. 脊髄空洞症の発生機序と外科的治療. No Shinkei Geka 1995 ; 23 : 759-66.
 
2) Adzick NS. Fetal myelomeningocele : Natural history, pathophysiology, and in-utero intervention. Seminar Fetal Naeonatal Med 2010 ; 15 : 9-14.
 
3) Adzick NS, Thom EA, Spong CY, et al. A randomized trial of prenatal versus postnatal repair of myelomeningocele. N Engl J Med 2011 ; 364 : 993-1004.
PubMed
4) Aghakhani N, Parker F, DavidP, et al. Long-term follow-up of Chiari-related syringomyelia in adults : Analysis of 157 surgically treated cases. Neurosurgery 2009 ; 64 : 308-15.
 
5) Badie B, Mendoza D, Batzdorf U. Posterior fossa volumes and response to suboccipital decompression in patients with Chiari I malformation. Neurosurgery 1995 ; 37 : 214-8.
 
6) Barkovich AJ, Wipoold FJ, Sherman JL, et al. Significance of cerebellar tonsillar position on MR. AJNR Am J Neuroradiol 1986 ; 7 : 795-9.
 
7) Batzorf U, McArthur DL. Surgical treatment of Chiari malformation with and without syringomyelia : experience with 177 adult patients. J Neurosurg 2013 ; 118 : 232-42.
 
8) Chaney EB, Rokes LB, Sutton LN. Management of Chiari II complications in infants with myelomeningocele. J Pediatrics 1987 ; 111 : 364-71.
 
9) Chern JJ, Gordon AJ, Mortazavi MM, et al. Pediatric Chiari malformation type 0 : a 12-year institutional experience. J Neurosurg Pediatics 2011 ; 8 : 1-5.
 
10) Depreitere B, Calen bergh FV, Loon JV, et al. Posterior fossa decompression in syringomyelia associated with a Chiari malformation : A retrospective analysis of 22 patients. Clin Neurol Neurosurg 2000 ; 102 : 91-6.
 
11) Dyste GN, Menezes AH, Vangilder JC. Symptomatic Chiari malformations. J Neurosurg 1989 ; 71 : 159-68.
PubMed
12) Durham SR, Fjeld-Olenec K. Comparison of posterior fossa decompression with and without duraplasty for the surgical treatment of Chiari malformation Type I in pediatric patients : a meta-analysis. J Neurosurg Pediatrics 2008 ; 2 : 42-9.
 
13) Genitori L, Pretta P, Nurisso C, et al. Chiari type I anomalies in children and adolescents : minimally invasive management in a series of 53 cases. Child's Nerv Syst 2000 ; 16 : 707-18.
 
14) Guyotat J, Jouanneau E, Ricci AC, et al. Syringomyelia associated with type I Chiari malformation. A 21-year retrospective study on 75 cases treated by foramen magnum decompression with a special emphasis on the value of tonsils resection. Acta Neurochir (wien) 1998 ; 140 : 745-54.
PubMed
15) Hains S, Berger M. Current treatment of Chiari malformations type I and II : A survey of the pediatric section of the American Association of Neurological Surgeons. Neurosurgery 1991 ; 28 : 353-7.
 
16) Haroun RI, Guarnieri M, Meadow JJ, et al. Current opinions for the treatment of syringomyelia and Chiari malformations : Survey of the pediatric section of the American Association of Neurological Surgeons. Pediatric Neurosurg 2000 ; 33 : 311-7.
 
17) Hida K, Iwasaki Y, Koyanagi I, et al. Surgical indication and results of foramen magnum decompression versus syringosubarachnoid shunting for syringomyelia associated with Chiari I malformation. Neurosurg 1995 ; 37 : 673-9.
 
18) Heiss JD, Suffredini G, Bakhtian KD, et al. Normalization of hindbrain morphology after decompression of Chiari malformation Type I. J Neurosurg 2012 ; 117 : 942-6.
PubMed
19) Hida K, Iwasaki Y, Koyanagi I, et al. Pediatric syringomyelia with Chiari malformation : Its clinical characteristics and surgical outcomes. Surg Neurol 1999 ; 51 : 383-91.
PubMed
20) 国際頭痛学会・頭痛分類委員会, 編. 7. 非血管性頭蓋内疾患による頭痛 7.7キアリ奇形I型 (CM1)による頭痛. 国際頭痛分類 第3版 beta版 (ICHD-3β) 日本語版 日本頭痛学会・国際頭痛分類普及委員会訳, 医学書院, 2014, p94.
 
21) Klekamp J, Batzdorf U, Samii M, et al. The surgical treatment of Chiari I malformation. Acta Neurochir (Wien) 1996 ; 138 : 788-801.
PubMed
22) Klekamp J : Neurological deterioration after foramen magnum decompression for Chiari malformation Type I : old or new pathology? Clinical article. J Neurosurg Pediatrics 2012 ; 10 : 538-47.
PubMed
23) Krieger MD, McComb JG, Levy ML. Toward a simpler surgical management of Chiari I malformation in a pediatric population. Pediatric Neurosurg 1999 ; 30 : 113-21.
 
24) Kennedy BC, Kelly KM, Phan MQ, et al. Outcomes after suboccipital decompression without dural opening in children with Chiari malformation Type I. J Neurosurg Pediatr 2015 ; online May 1,E1-9.
 
25) Levy WJ, Mason L, Hahn JF. Chiari malformation presenting in adults : a surgical experience in 127 cases. Neurosurg 1983 ; 12 : 377-90.
 
26) Menezes AH. Chiari I malformations and hydromyelia-Complications. Pediatr Neurosurg 1991-1992 ; 17 : 146-54.
 
27) McLone DG. Myelomeningocele. In ; Youman JR ed. Youman's Neurological Surgery, 4th ed,, Philadelphia, WB Saunders, 1996, pp843-59.
 
28) Nishikawa M, Sakamoto H, Hakuba A, et al. Pathogenesis of Chiari malformation : a morphometric study of the posterior cranial fossa. J Neurosurg 1997 ; 86 : 40-7.
PubMed
29) 長坂昌登. Chiari II型奇形-ミニレクチャー. 小児の脳神経 2000 ; 25 : 121-6.
 
30) Noudel R, Gomis P, Sotoares G, at al. Posterior fossa volume increase after surgery for Chiari malformation Type I : a quantitive assessment using magnetic resonance imaging and correlations with the treatment response. J Neurosurg 2011 ; 115 : 647-58.
 
31) Park TS, Hoffman HJ, Hendrick B, et al. Experience with surgical decompression of the Arnold-Chiari malformation in young infants with myelomeningocele. Neurosurg 1983 ; 13 : 147-52.
 
32) Paul K, Lye R, Strang FA, et al. Arnold-Chiari malformation. Review of 71 cases. J Neurosurg 1983 ; 58 : 183-7.
 
33) Pillay PK, Awad IA, Little JR, et al. Symptomatic Chiari malformation in adults : a new classification based on magnetic resonance imaging with clinical and prognostic significance. Neurosurgery 1991 ; 28 : 639-45.
PubMed
34) Goel A, Desai K. Surgery for syringomyelia : An analysis based on 163 surgical cases. Acta Neurochir (Wien) 2000 ; 142 : 293-302.
PubMed
35) Pollack IF, Pang D, Albright AL, et al. Outcome following hindbrain decompression of symptomatic Chiari malformations in 240 children previously treated with myelomeningocele closure and shunts. J Neurosurg 1992 ; 77 : 881-8.
 
36) Pollack IF, Kinnunen D, Albright AL. The effect of early craniocervical decompression on functional outcome in neonates and young infants with myelodysplasia and symptomatic Chiari II malformations : results from a prospective series. Neurosurg 1996 ; 38 : 703-10.
 
37) Saez R, Onofrio BM, Yanagihara T. Experience with Arnold-Chairi malformation, 1960 to 1970. J Neurosurg 1976 ; 45 : 416-22.
 
38) Sahuquilo J, Rubio E, Poca MA, et al. Posterior fossa reconstruction : surgical technique for the treatment of Chiari I malformation and Chiari I/syringomyelia complex-Preliminary results and magnetic resonance imaging quantitative assessment of hindbrain migration. Neurosurg 1994 ; 35 : 874-85.
 
39) Sgouros S, Williams B. A critical appraisal of drainage in syringomyelia. J Neurosurg 1995 ; 82 : 1-10.
 
40) Sindou M, Gimbert E. Decompression for Chiari type I-malformation (with or without syringomyelia) by extreme lateral foramen magnum opening and expansile duraplasty with arachnoid preservation : comparison with other technical modalities (Lierature review). Adv Tech Stand Neurosurg 2009 ; 34 : 85-110.
PubMed
41) Tubbs RS, Iskandar BJI, Bartolucci AA, et al. A critical analysis of the Chiari 1.5 malformation. J Neurosurg (Pediatrics 2) 2004 ; 101 : 179-83.
 
42) Tubbs RS, Oakes WJ. Treatment and management of the Chiari II malformation : an evidence-based review of the literature. Childs Nerv Syst 2004 ; 20 : 375-81.
PubMed
43) Tubbs RS, Lyer ly MJ, Loukas LM, et al. The pediatric Chiari I malformation : a review. Childs Nerv Syst 2007 ; 23 : 1239-50.
 
44) Tubbs RS, Beckman J, Naftel RP et al. Institutinal experience with 500 Cases of surgically treated pediatric Chiari malformation Type I. Clinical article. J Neurosurg Pediatics 2011 ; 7 : 248-56.
 
45) Venes J, Black KI, latack J. Preoperative evaluation and surgical management of the Arnold-Chiari II malformation. J Neurosurg 1986 ; 64 : 363-70.
 
46) Weprin BE, Oakes WJ. The Chiari malformations and associated syringohydromyelia. In ; McLone DG, ed. Pediatric Neurosurgery, 4th ed, Philadelphia, WB Saunders, 2000, p214-35.
 
P.283 掲載の参考文献
1) Arnautovic A, Splavski B, Boop FA, et al. Pediatric and adult Chiari malformation Type I surgical series 1965-2013 : a review of demographics, operative treatment, and outcomes J Neurosurg Pediatr 2015 ; 15 : 161-77.
 
2) Bixenmann BJ, Kline-Fath BM, Bierbrauer KS, et al. Prenatal and postnatal evaluation for syringomyelia in patients with spinal dysraphism. J Neurosurg Pediatrics 2014 ; 14 : 316-21.
 
3) Bogdanov EI, Heiss JD, Mendelevich EG. The post-syrinx syndrome : stable central myelopathy and collapsed or absent syrinx. J Neurol 2006 ; 253 : 707-13.
PubMed
4) Durham SR, Fjeld-Olenec K. Comparison of posterior fossa decompression with and without duraplasty for the surgical treatment of Chiari malformation Type I in pediatric patients : a meta-analysis. J Neurosurg Pediatr 2008 ; 2 : 42-9.
PubMed
5) Gardner WJ. Hydrodymanic mechanism of syringomyelia, its relationship to myelocele. J Neurol Neurosurg Psychatrry 1965 ; 28 : 247-59.
 
6) Godzik J, Kelly MP, Radmanesh A, et al. Relationship of syrinx size and tonsillar descent to spinal deformity in Chiari malformation Type I with associated syringomyelia. J Neurosurg Pediatr 2014 ; 13 : 368-74.
PubMed
7) Hayashi T, Ueta T, Kubo M, et al. Subarachnoid-subarachnoid bypass : a new surgical technique for posttraumatic syringomyelia. J Neurosurg Spine 2013 ; 18 : 382-7.
PubMed
8) Heiss JD, Snyder K, Peterson MM, et al. Pathophysiology of primary spinal syringomyelia. J Neurosurg Spine 2012 ; 17 : 367-80.
PubMed
9) Isu T, Sasaki H, Takamura H, et al. Foramen magnum decompression with removal of the outer layer of the dura as treatment for syringomyelia occurring with Chiari I malformation. Neurosurgery 1993 ; 33 : 844-50.
 
10) Krieger MD, Falkinstein Y, Bowen IE, et al. Scoliosis and Chiari malformation Type I in children. J Neurosurg Pediatr 2011 ; 7 : 25-29.
 
11) Klekamp J. Treatment of posttraumatic syringomyelia. J Neurosurg Spine 2012 ; 17 : 199-211.
PubMed
12) Klekamp J. Treatment of syringomyelia related to nontraumatic arachnoid pathologies of the spinal canal. Neurosurgery 2013 ; 72 : 376-89.
PubMed
13) Lee JY, Phi JH, Cheon JE, et al. Preuntethering and postuntethering courses of syringomyelia associated with tethered spinal cord. Neurosurgery 2012 ; 71 : 23-9.
PubMed
14) Milhorat TH, Johnson WD, Miller JI, et al. Surgical treatment of syringomyelia based on magnetic resonance imaging criteria. Neurosurgery 1992 ; 31 : 231-45.
PubMed
15) Nakamura M, Chiba K, Nishizawa T, et al. Retrospective study of surgery-related outcomes in patients with syringomyelia associated with Chiari I malformation : clinical significance of changes in the size and localization of syrinx on pain relief. J Neurosurg Spine 2004 ; 100 : 241-4.
 
16) Oi S, Kudo H, Yamada H, et al. Hydromyelic hydrocephalus. Correlation of hydromyelia with various stages of hydrocephalus in postshunt isolated compartments. J Neurosurg 1991 ; 74 : 371-9.
PubMed
17) Piatt JH Jr : Syringomyelia complicating myelomeningocele : review of the evidence. J Neurosurg Spine 2004 ; 100 : 101-9.
 
18) Rodriguez A, Kuhn EN, Somasundaram A, et al. Management of idiopathic pediatric syringohydromyelia. J Neurosurg Pediatr 2015 ; 24 : 1-6.
 
19) Sakushima K, Tsuboi S, Yabe I, et al. Nationwide survey on the epidemiology of syringomyelia in Japan. J Neurol Sci 2012 ; 313 : 147-52.
PubMed
20) Sgouros S, Williams B. A critical appraisal of drainage in syringomyelia. J Neurosurg 1995 ; 82 : 1-10.
 
21) Strahle J, Muraszko KM, Kapurch J, et al. Natural history of Chiari malformation Type I following decision for conservative treatment. J Neurosurg Pediatr 2011 ; 8 : 214-21.
PubMed
22) Strahle J, Smith BW, Martinez M, et al. The association between Chiari malformation Type I, spinal syrinx, and scoliosis. Neurosurg Pediatr 2015 ; 15 : 607-11.
PubMed
23) Tsitouras V, Sgouros S. Syringomyelia and tethered cord in children. Childs Nerv Syst 2013 ; 29 : 1625-34.
PubMed
24) Williams B. The distending force in the production of communicating syringomyelia. Lancet 1970 ; 2 : 41-2.
PubMed
P.285 掲載の参考文献
1) Arponen H, Vuorimies I, Haukka J, et al. Cranial base pathology in pediatric osteogenesis imperfecta patients treated with bisphosphonates. J Neurosurg Pediatr 2015 ; 15 : 313-20.
PubMed
2) Bollo RJ, Riva-Cambrin J, Brockmeyer MM, et al. Complex Chiari malformations in children : an analysis of preoperative risk factors for occipitocervical fusion. J Neurosurg Pediatr 2012 ; 10 : 134-41.
PubMed
3) Chivukula S, Koutourousiou M, Snyderman CH, et al. Endoscopic endonasal skull base surgery in the pediatric population. J Neurosurg Pediatr 2013 ; 11 : 227-41.
PubMed
4) Dahdaleh NS, Dlouhy BJ, Menezes AH. Application of neuromuscular blockade and intraoperative 3D imaging in the reduction of basilar invagination. J Neurosurg Pediatr 2012 ; 9 : 119-24.
PubMed
5) Goel A, Bhatjiwale M, Desai K. Basilar invagination : a study based on 190 surgically treated patients. J Neurosurg 1998 ; 88 : 962-8.
PubMed
6) Ibrahim AG, Crockard HA. Basilar impression and osteogenesis imperfecta : a 21-year retrospective review of outcomes in 20 patients. J Neurosurg Spine 2007 ; 7 : 594-600.
PubMed
7) Kosnik-Infinger L, Glazier SS, Frankel BM. Occipital condyle to cervical spine fixation in the pediatric population. J Neurosurg Pediatr 2014 ; 13 : 45-53.
PubMed
8) Kovero O, Pynnonen S, Kuurila-Svahn K, et al. Skull base abnormalities in osteogenesis imperfecta : a cephalometric evaluation of 54 patients and 108 control volunteers. J Neurosurg 2006 ; 105 : 361-70.
PubMed
9) Pang D, Thompson DNP. Embryology and bony malformations of the craniovertebral junction : Childs Nerv Syst 2011 ; 27 : 523-64.
 
10) Smith JS, Shaffrey CI, Abel MF, et al. Basilar invagination. Neurosurgery 2010 ; 66 (3 Suppl) : 39-47.
 
11) Smoker WR, Khanna G. Imaging the craniocervical junction. Childs Nerv Syst 2008 ; 24 : 1123-45.
PubMed
12) Swain PD, Menezes AH. Basilar invagination in osteogenesis imperfecta and related osteochondrodysplasia. medical and surgical management. J Neurosurg 1997 ; 86 : 950-60.
 
P.290 掲載の参考文献
1) Al-Holou WN, Yew AY, Boomsaad ZE et al. Prevalence and natural history of arachnoid cysts in children. J Neurosurg Pediatr 2010 ; 5 : 578-85.
 
2) Al-Holou WN, Terman S, Kilburg C, et al. Prevalence and natural history of arachnoid cysts in adults. J Neurosurg 2013 ; 118 : 222-31.
PubMed
3) Ali M, Bennardo M, Almenawer SA, et al. Exploring predictors of surgery and comparing operative treatment approaches for pediatric intracranial arachnoid cysts : a case series of 83 patients. J Neurosurg Pediatr 2015 ; 16 : 275-82.
PubMed
4) Cinalli G, Spennato P, Columbano L, et al. Neuroendoscopic treatment of arachnoid cysts of the quadrigeminal cistern : a series of 14 cases. J Neurosurg Pediatr 2010 ; 6 : 489-97.
 
5) El-Ghandour NM. Endoscopic treatment of middle cranial fossa arachnoid cysts in children. J Neurosurg Pediatr 2012 ; 9 : 231-8.
 
6) El-Ghandour NM. Endoscopic treatment of quadrigeminal arachnoid cysts in children. J Neurosurg Pediatr 2013 ; 12 : 521-8.
 
7) Galassi E, Tognetti F, Gaist G, et al. CT scan and metrizamide CT cisternography in arachnoid cysts of the middle cranial fossa : classification and pathophysiological aspects. Surg Neurol 1982 ; 17 : 363-9.
PubMed
8) Gangemi M, Seneca V, Colella G, et al. Endoscopy versus microsurgical cyst excision and shunting for treating intracranial arachnoid cysts. J Neurosurg Pediatr 2011 ; 8 : 158-64.
PubMed
9) Kimiwada T, Hayashi T, Narisawa A, et al. Shunt placement after cyst fenestration for middle cranial fossa arachnoid cysts in children. J Neurosurg Pediatr 2015 ; 31 : 1-7.
 
10) 栗原淳, 西本博. 小児くも膜嚢胞の自然歴. 小児の脳神経 2012 ; 37 : 409-15.
 
11) Lee JY, Kim JW, Phi JH, et al. Enlarging arachnoid cyst : a false alarm for infants. Childs Nerv Syst 2012 ; 28 : 1203-11.
PubMed
12) Maher CO, Goumnerova L. The effectiveness of ventriculocystocisternostomy for suprasellar arachnoid cysts. J Neurosurg Pediatr 2011 ; 7 : 64-72.
PubMed
13) Marin-Sanabria EA, Yamamoto H, Nagashima T, et al. Evaluation of the management of arachnoid cyst of the posterior fossa in pediatric population : experience over 27 years. Childs Nerv Syst 2007 ; 23 : 535-42.
PubMed
14) Oertel JM, Wagner W, Mondorf Y, et al. Endoscopic treatment of arachnoid cysts : a detailed account of surgical techniques and results. Neurosurgery 2010 ; 67 : 824-36.
PubMed
15) Parsch CS, Krauss J, Hofmann E, et al. Arachnoid cysts associated with subdural hematomas and hygromas : analysis of 16 cases, long-term follow-up, and review of the literature. Neurosurgery 1997 ; 40 : 483-90.
PubMed
16) Spacca B, Kandasamy J, Mallucci CL, et al. Endoscopic treatment of middle fossa arachnoid cysts : a series of 40 patients treated endoscopically in two centres. Childs Nerv Syst 2010 ; 26 : 163-72.
PubMed
17) Tamburrini G, Caldarelli M, Massimi L, et al. Subdural hygroma : an unwanted result of Sylvian arachnoid cyst marsupialization. Childs Nerv Syst 2003 ; 19 : 159-65.
 
18) Wester K, Helland CA. How often do chronic extra-cerebral haematomas occur in patients with intracranial arachnoid cysts? J Neurol Neurosurg Psychiatry 2008 ; 79 : 72-5.
PubMed
19) Wester K. Intracranial arachnoid cysts-do they impair mental functions? J Neurol 2008 ; 255 : 1113-20.
PubMed
20) 吉岡進. 5章 先天性疾患 §5 くも膜嚢胞・頭蓋内嚢胞性疾患. In ; 山崎麻美, 坂本博昭 編集. 小児脳神経外科学, 金芳堂, 京都, 2015, p346-79.
 
P.294 掲載の参考文献
1) Robinson S. Neonatal posthemorrhagic hydrocephalus from Neurosurg Pediatr 2012 ; 9 : 242-58.
PubMed
2) Kusuda S, Fujimura M, Sakuma I, et al. Neonatal Research Network, Japan : Morbidity and mortality of infants with very low birth weight in Japan : center variation. Pediatrics 2006 ; 118 : e1130-8.
 
3) Mazzola CA, Choudhri AF, Auguste KI, et al. Pediatric Hydrocephalus Systematic Review and Evidence-Based Guidelines Task Force. Pediatric hydrocephalus : systematic literature review and evidence-based guidelines. Part 2 : Management of posthemorrhagic hydrocephalus in premature infants. J Neurosurg Pediatr 2014 ; Suppl 1 : 8-23.
 
4) Wang JY, Amin AG, Jallo GI, et al. Ventricular reservoir versus ventriculosubgaleal shunt for posthemorrhagic hydrocephalus in preterm infants : infection risks and ventriculoperitoneal shunt rate. J Neurosurg Pediatr 2014 ; 14 : 447-54.
 
5) 宮嶋雅一, 木村孝興, 近藤聡英, 他. 未熟児脳室内出血と出血後水頭症の周術期管理. 脳外誌 2013 ; 22 : 276-82.
 
6) Badhiwala JH, Hong CJ, Nassiri F, et al. Treatment of posthemorrhagic ventricular dilation in preterm infants : a systematic review and meta-analysis of outcomes and complications. J Neurosurg Pediatr 2015 ; 16 : 1-11.
PubMed
7) Chamiraju P, Bhatia S, Sandberg DI, et al. Endoscopic third ventriculostomy and choroid plexus cauterization in posthemorrhagic hydrocephalus of prematurity. J Neurosurg Pediatr 2014 ; 13 : 433-9.
PubMed
8) Schulz M, Buhrer C, Pohl-Schickinger A, et al. Neuroendoscopic lavage for the treatment of intraventricular hemorrhage and hydrocephalus in neonates. J Neurosurg Pediatr 2014 ; 13 : 625-35.
 
9) Radic JA, Vincer M, McNeely PD. Outcomes of intraventricular hemorrhage and posthemorrhagic hydrocephalus in a population-based cohort of very preterm infants born to residents of Nova Scotia from 1993 to 2010. J Neurosurg Pediatr 2015 ; 15 : 580-8.
 
10) 山崎麻美, 胎児期水頭症ガイドライン編集委員会. 胎児期水頭症, 診断と治療ガイドライン 改訂2版, 金芳堂, 京都, 2010.
 
11) Bolisetty S, Dhawan A, Abdel-Latif M, et al. Intraventricular hemorrhage and neurodevelopmental outcomes in extreme preterm infants. Pediatrics 2014 ; 133 : 55-62.
PubMed
12) Whitby EH, Griffiths PD, Rutter S, et al. Frequency and natural history of subdural haemorrhaes in babies and relation to obstetric factors. Lancet 2004 ; 363 : 846-51.
PubMed
13) Huang AH, Robertson RL. Spontaneous superficial parenchymal and leptomeningial hemorrhage in term neonates. AJNR Am J Neuroradiol 2004 ; 25 : 469-75.
 
14) Alatas FS, Hayashida M, Matsuura T, et al. Intracranial hemorrhage associated with vitamin K-deficiency bleeding in patients with biliary atresia : focus on long-term outcomes. J Pediatr Gastroenterol Nutr 2012 ; 54 : 552-7.
PubMed
15) Richards M, Lavigne Lissalde G, et al. Europian Haemophilia Treatment and Standardization Board. Neonatal bleeding in haemophilia : a European cohort study. Br J Haematol 2012 ; 156 : 374-82.
 
16) Curtis BR. Recent progress in understanding the pathogenesis of fetal and neonatal alloimmune thrombocytopenia. Br J Haematol 2015 ; 171 : 671-82.
PubMed
17) Coutinho J, de Bruijn SF, Deveber G, et al. Anticoagulation for cerebral venous sinus thrombosis. Cochrane Database Syst Rev 2011 ; 8, Art. No. : CD002005.
 
18) 塩谷隆信 編集. 遺伝性出血性末梢血管拡張症 (オスラー病 : HHT) の診療マニュアル 増補版, 中外医学社, 東京, 2015.
 
19) Van Raay Y, Darteyre S, Di Rocco F, et al. Neonatal ruptured intracranial aneurysms : case report and literature review. Childs Nerv Syst 2009 ; 25 : 1025-33.
PubMed
20) Lerner A, Gilboa Y, Gerad L, et al. Sonographic detection of fetal cerebellar cavernous hemangioma with in-utero hemorrhage leading to cerebellar hemihypoplasia. Ultrasound Obstet Gynecol 2006 ; 28 : 968-71.
PubMed
P.299 掲載の参考文献
1) Amacher AL, Shillto J Jr. The syndrome and surgical treatment of aneurysm of the great vein of Galen. J Neurosurg 1973 ; 39 : 89-98.
 
2) Andeweg J. Intracranial venous pressure hydrocephalus and effects of cerebrospinal fliud shunt. Childs Nerv Syst 1989 ; 5 : 318-23.
 
3) 新井一, 佐藤潔, 飯塚有応, 他. ガレン大静脈瘤の診断と治療. 脳外誌 2002 ; 11 : 379-88.
 
4) 新井一, 宮嶋雅一, 屋田修, 他. 小児脳神経外科領域におけるminimally invasive neurosurgery. 脳外誌 1999 ; 8 : 315-24.
 
5) Askenasy HM, Herzberger EE, Wijsenbeek HS. Hydrocephalus with vascular malformations of the brain. : A primary report. Neurology 1953 ; 3 : 213-20.
 
6) Alvarez H, Garcia Monaco R, Rodesch G, et al. Vein of galen aneurysmal malformations. Neuroimaging Clin N Am 2007 ; 17 : 189-206.
PubMed
7) Beltremello A, Preini S, Mazza C. Spontaneously healed vein of Galen aneurysm. Childs Nerv Sys 1991 ; 7 : 129-34.
 
8) Berenstein A, Lasjaunias P. Arteriovenous fistulas of the brain. In ; Surgical neuroangiography 4 : endovascular treatment of the cerebral lesions. Heiderberg, Springer Verlag, 1992, p267-317.
 
9) Berenstein A, Niimi Y. Vein of Galen aneurysmal malformation, in Winn HR (ed) : Youmans Neurological Surgery, ed 6. Philadelphia : Elsevier/Saunders, 2011, Vol 2, pp 2150-65.
 
10) Casasco A, Lylyk P, Hodes JE, et al. Percutaneous transvenous catheterization and embolization of vein of galen aneurysms. Neurosurgery 1991 ; 28 : 260-6.
PubMed
11) Charafeddine L, Numaguchi Y, Sinkin RA. Disseminatedcoagulopathy associated with transtorcular embolization of vein of Galen aneurysm in a neonate. J Perinatol 1999 ; 19 : 61-3.
 
12) Chevret L, Durand P, Alvarez H, et al. Severe cardiac failure in newborns withVGAM. Prognosis significance of hemodynamic parameters in neonates presenting with severe heart failure owing to vein of Galen arteriovenous malformation. Intensive Care Med 2002 ; 28 : 1126-30.
PubMed
13) Chow ML, Cooke DL, Fullerton HJ, et al. Radiological and clinical features of vein of Galen malformations. J Neurointerv Surg 2015 ; 7 : 443-8.
PubMed
14) Ciricillo SF, Edwards MS, Schmidt KG, et al. Interventional neuroradiological management of vein of Galen malformations in the neonate. Neurosurgery 1990 ; 27 : 22-7.
PubMed
15) De Lange SA, De Vliger M. Hydrocephalus associated with raised venous pressure. Dev Med Child Neurol 1970 ; 12 (Suppl 22) : 28-9.
 
16) De Morais JV, Lemos S. Calcified aneurysm of the vein of Galen. : Successful removal. Surg Neurol 1982 ; 174 : 304-6.
 
17) Dowd CF, Halbach VV, Barnwell SL, et al. Transfemoral venous embolization of vein of Galen malformations. AJNR Am J Neuroradiol 1990 ; 11 : 643-8.
PubMed
18) Drake CG. Cerebral arteriovenous malformations : considerations for and experience with surgical treatment in 166 cases. Clin Neurosurg 1979 ; 26 : 145-208.
PubMed
19) Garcia-Monaco R, De Victor D, Mann C, et al. Congestive cardiac manifestations from cerebrocranial arteriovenous shunts. Endovascular management in 30 children. Childs Nerv Syst 1991 ; 7 : 48-52.
PubMed
20) Garcia-Monaco R. The management of vein of Galen aneurysmal malformations. Neurosurgery 2006 ; 59 (5 Suppl 3) : S184-94 (Erratum in Neurosurgery 2007 ; 60 [4 Suppl) : 393).
 
21) Gold A, Ransohoff JR, Carter S. Vein of Galen malformation. Acta Neurol Scand 1964 ; 40 (Suppl 11) : 1-31.
 
22) Halbach VV, Dowd CF, Higashida RT, et al. Endovascular treatment of mural-type vein of Galen malformations. J Neurosurg 1998 ; 89 : 74-80.
PubMed
23) Harrigan MR, Deveiks JP. Appendix : Vein of Galen malformations. In ; Handbook of Cerebrovascular Disease and NeurointerventionalTechnique, 2nd ed. New York, Humana Press, 2009, p527-31.
 
24) Hoffman HJ, Chuang S, Hendrick EB, Humphreys RP. Aneurysms of the vein of Galen : Experience at the hospital for Sick Children, Toronto. J Neurosurg 1982 ; 57 : 316-22.
PubMed
25) 飯塚有応, 阿部通, 新島新一, 他. ガレン大静脈瘤に対する血管内治療-自験6例の臨床的検討. 小児の脳神経 1997 ; 22 : 248-57.
 
26) Johnston IH, Whittle IR, Besser M, et al. Vein of Galen malformation : diagnosis and management. Neurosurgery 1987 ; 20 : 747-58.
PubMed
27) Lasjaunias P, Garcia-Monaco R, Rodesch G, et al. Vein of Galen malformation. Endovascular management of 43 cases. Childs Nerv Syst 1991 ; 7 : 360-7.
PubMed
28) Lasjaunias P, Ter Brugge K, Berenstein A. Vein of Galen aneurysmal malformation. In ; Surgical Neuroangiography 3. Clinical and Interventional Aspects in Children, 2nd ed 2. Berlin, Springer, Vol 3, 2006, p105-226.
 
29) Lasjaunias P. Vascular Diseases in Neonates, Infants and Children : Interventional Neuroradiology Management. Berlin, Springer, 1997, p49.
 
30) Las jaunias P, Alvarez H, Rodesch G, et al. Aneurysmal Malformations of the Vein of Galen. Follow-up of 120 Children Treated between 1984 and 1994. Interv Neuroradiol 1996 ; 2 : 15-26.
 
31) Lasjaunias P. Vein of Galen aneurysmal malformation. In ; Vasucular disease in neonates. Infants and children. Springer-Verlag, Berlin/Heidelberg, 1997, p67-202.
 
32) Locksley HB. Natural history of subarachnoid hemorrhage, intracranial aneurysms and arteriovenous malformations. J Neurosurg 1966 ; 25 : 321-68.
PubMed
33) Locksley HB, Sahs AL, Knowler L. Report on the cooperative study of intracranial aneurysms and subarachnoid hemorrhage. Section II. General survey of cases in the central registry and characteristics of the sample population. J Neurosurg 1966 ; 24 : 922-32.
PubMed
34) Lylyk P, Vinuela F, Dion JE, et al. Therapeutic alternatives for vein of Galen vascular malformations. J Neurosurg 1993 ; 78 : 438-45.
PubMed
35) Mickle JP, Mericle RA, Burry MV, et al. Vein of Galen malformations. In ; Winn HR, ed. Youmans Neurological Surgery, 5th ed. Philadelphia, Saunders, 2004, p3433-46.
 
36) Mickle JP, Quisling RG. The transtorcular embolization of vein of Galen aneurysms. J Neurosurg 1986 ; 64 : 731-5.
PubMed
37) Mortazavi MM, Griessenauer CJ, Foreman P, et al. Vein of Galen aneurysmal malformations : critical analysis of the literature with proposal of a new classification system. J Neurosurg Pediatr 2013 ; 12 : 293-306.
PubMed
38) Payne BR, Prasad D, Steiner M, et al. Gamma surgery for vein of Galen malformations. J Neurosurg 2000 ; 93 : 229-36.
PubMed
39) Raybaud C, Strother CM, Hald JK. Aneurysms of the vein of Galen : Embryonic considerations and anatomical features relating to the pathogensis of the malformation. Neuroradiology1989 ; 31 : 109-28.
 
40) Rodesch G, Hui F, Alvarez H, et al. Prognosis of antenatally diagnosed vein of Galen aneurysmal malformations. Childs Nerv Syst 1994 ; 10 : 79-83.
PubMed
41) Sahs AL, Perret G, Locksley HB, et al. Preliminary remarks on subarachnoid hemorrhage. J Neurosurg 1966 ; 24 : 782-8.
PubMed
42) Sainte-Rose C, LaCombe J, Pierre-Kahn A, et al. Intracranial venous sinus hypertention : Cause or consequence of hydrocephalus in infants? J Neurosurg 1984 ; 60 : 727-36.
PubMed
43) Spetzler RF, Martin NA. A proposed grading system for arteriovenous malformations. J Neurosurg 1986 ; 65 : 476-83.
PubMed
44) 竹本理, 森本良一, 若山暁, 他. 心不全で発症した新生児ガレン大静脈瘤に対する外科治療-多期的直達手術の経験. 脳と神経 1999 ; 51 : 339-44.
 
45) Watban JA, Rodesch G, Alvarez H, et al. Transarterial embolization of vein of Galen aneurysmal malformation after unsuccessful stereotactic radiosurgery. Report of three cases. Childs Nerv Syst 1995 ; 11 : 406-8.
PubMed
46) Wisoff JH, Berebstein A, Choi IS et al. Management of vein of Galen malformations. Concepts Ped. Neurosurg 1990 ; 10 : 137-55.
 
47) Yan J, Wen J, Gopaul R, et al. Outcome and complications of endovascular embolization for vein of Galen malformations : a systematic review and meta-analysis. J Neurosurg 2015 ; 123 : 872-90.
PubMed
48) Yasargil MG. Children with AVm. In Microneurosurgery III B, New York, George Thime Verlag Stuttgart, 1988, p323-96.
 
49) Zerah M, Garcia-Monaco R, Rodesch G, et al. Hydrodynamics in vein of Galen malformations. Childs Nerv Syst 1992 ; 8 : 111-7.
PubMed

第5章 脊椎・脊髄疾患

P.304 掲載の参考文献
1) Berenson J, Pflugmacher R, Jarzem P, et al. Cancer Patient Fracture Evaluation (CAFE) Investigators. Balloon kyphoplasty versus non-surgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer : a multicentre, randomised controlled trial. Investigators. Lancet Oncol 2011 ; 12 : 225-35.
 
2) Chamberlain MC. Temozolomide for recurrent low-grade spinal gliomas in adults. Cancer 2008 ; 113 : 1019-24.
PubMed
3) Constantini S, Miller DC, Allen JC, et al. Radical excision of intramedullary spinal cord tumors : surgical morbidity and longterm follow-up evaluation in 164 children and young adults. J Neurosurg 2000 ; 93 (2 Suppl) : 183-93.
 
4) Cristante L, Herrmann HD. Surgical management of intramedullary spinal cord tumors : Functional outcome and sources of morbidity. Neurosurgery 1994 ; 3 : 69-76.
 
5) Epstein FJ, Farmer JP, Freed D. Adult intramedullary astrocytomas of the spinal cord. J Neurosurg 1992 ; 77 : 355-9.
PubMed
6) Epstein FJ, Farmer JP, Freed D. Adult intramedullary spinal cord ependynlomas : The result of surgery in 38 patients. J Neurosurg 1993 ; 79 : 204-9.
PubMed
7) Fischer G, Brotchi J. Intramedullary spinal cord tumors. Thieme, Stuttgart, New York, 1996.
 
8) Guidetti B, Mercuri S, Vagnozzi R. Long-term results of the surgical treatment of 129 intramedullary spinal glioma. J Neurosurg 1981 ; 54 : 323-30.
PubMed
9) 花北順哉. 硬膜内髄外腫瘍の外科. 日獨医報 1999 ; 44 : 66-78.
 
10) 橋本順. 転移性脊椎・脊髄腫瘍に対する画像所見. 核医学検査での診断所見. 脊椎脊髄 2008 ; 21 : 738-46.
 
11) 長谷川光広, 藤沢弘範, 山下純宏. 脊髄腫瘍の疫学. 脊椎脊髄 2003 ; 16 : 640-45.
 
12) Kondziella D, Broderson P, Laursen H, et al. Cavernous hemangioma of the spinal cord-conservative or operative management? Acta Neirol Scand 2006 ; 114 : 287-90.
PubMed
13) 小山素麿. 良性髄外腫瘍への手術療法での問題点. Spine Frontier 1995 ; 2 : 11-7.
 
14) 小山素麿. 硬膜内髄外腫瘍 (砂時計型腫瘍を含む) の診断と外科治療. 脳外速報 2004 ; 14 : 629-41.
 
15) Kim MS, Chung CK, Choe G, et al. intramedullary spinal cord astrocytoma in adults : postoperative outcome. J Neurooncol 2001 ; 52 : 85-94.
PubMed
16) Linstadt DE, Wara WM, Leibel SA, et al. Postoperative radiotherapy of primary spinal cord tumors. lnt J Radiation Oncology Biol Phys 1989 ; 16 : 1397-403.
 
17) Louis DN, Ohgaki H, Wiestler OD, et al eds. WHO classification of tumors of the central nervous system. IARC, Lyon, 2007.
 
18) Malis LI. Intramedullary spinal cord tumors. Clinical Neurosurgery 1978 ; 25 : 512-39.
PubMed
19) 三島一彦, 廣瀬隆則, 松谷雅生. WHOの腫瘍分類. 最新知識の整理. 脊椎脊髄 2009 ; 22 : 12-28.
 
20) Nagib MG, O'Fallon MT. Intramedurally cavernous angiomas of the spinal cord in the pediatric age group : a pediatric series. Pediatr Neurosurg 2002 ; 36 : 57-63.
 
21) Nakamura M, Ishii K, Wantanabe K, et al. Surgical treatment of intramedurally spinal cord tumors : prognosis and complications. Spinal Cord 2008 ; 46 : 282-6.
 
22) Nitter K. Spinal meningiomas, neurinomas and hour-glass tumors. In ; Vinken PJ, Bruyn GW, eds. Handbook of Clinical Neurology 20 North Holland, Amsterdam, p177-322, 1976.
 
23) 小野寺俊輔, 青山英史. 脊髄腫瘍に対する放射線治療の役割. 脊椎脊髄 2009 ; 22 : 85-91.
 
24) Reimer R, Onofrio BM. Astrocytomas of the spinal cord in children and adolescents. J Neurosurg 1985 ; 63 : 669-75.
PubMed
25) Samii M, Klekamp J, Carvalho G. Surgical results for meningiomas of the craniovertebral junction. Neurosurgery 1996 ; 39 : 1086-95.
 
26) Sandler HM, Papadopoulous SM, Thomton AF, et al. Spinal cord astrocytomas : Results of therapy. Neurosurgery 1992 ; 30 : 490-3.
 
27) Sen CN, Sekhar LN. An extreme lateral approach to intradural lesions of the cervical spine and foramen magnum. Neurosurgery 1990 ; 27 : 197-204.
PubMed
28) Seppala MT, Haltia MJ, Sankila RJ, et al. Long-term outcome after removal of spinal schwannoma : a clinicopathological study of 187 cases. J Neurosurg 1995 ; 83 : 621-6.
 
29) Shirato H, Kamada T, Hida K, et al. The role of radiotherapy in the management of spinal cord glioma. Int J Radiat Oncol Biol Phys 1995 ; 33 : 323-8.
PubMed
30) 白土溥樹, 鬼丸力也, 青山英史, 他. 脊髄・脊椎腫瘍への放射線 治療戦略. 脊椎脊髄 2003 ; 16 : 681-7.
 
31) Solero CL, Fornari M, Giombini S. Spinal meningiomas : Review of 174 cases. Neurosurgery 1989 ; 25 : 153-60.
PubMed
32) Stein BM. Intramedullary spinal cord tumors. Clin Neurosurg 1983 ; 30 : 717-41.
PubMed
33) 戸川大輔. Balloon Kyphoplasty 日本の臨床治験と今後の課題. 脊椎脊髄 2009 ; 22 : 267-73.
 
34) Tokuhashi Y, Ajiro Y, Umezawa N. Outcome of treatment for spinal metastases using scoring system for preoperative evaluation of prognosis. Spine 2009 ; 34 : 69-73.
PubMed
35) Vishteh AG, Sankhla S, Anson JA. Surgical resection of intramedullary spinal cord cavernous malformations : Delayed complications, long-term outcomes and association with cryptic venous malformations. Neurosurgery 1997 ; 41 : 1094-101.
PubMed
36) Wardlaw D, Cummings SR, Van Meirhaeghe J, et al. Efficacy and safety of balloon kyphoplasty compared with non-surgical care for vertebral compression fracture (FREE) : a randomised controlled trial. Lancet 2009 ; 373 : 1016-24.
 
37) Waldron JN, Laperriere NJ, Jaakkimainen L, et al. Spinal cord ependymomas : A retrospective analysis of 59 cases. Int J Radiat Oncol Biol Phys 1993 ; 27 : 223-9.
PubMed
38) Wanebo JE, Lonser RR, Glenn GM, et al. The natural history of hemangioblastomas of the central nervous system in patients with von Hippe-Lindau disease. J Neurosurg 2003 ; 98 : 82-94.
 
39) 柳下章, 編. エキスパートのための脊椎・脊髄疾患のMRI, 三輪書店, 2004.
 
P.308 掲載の参考文献
1) van den Berg ME, Castellote JM, Mahillo-Fernandez I, et al. Incidence of nontraumatic spinal cord injury : a Spanish cohort study (1972-2008). Arch Phys Med Rehabil 2012 ; 93 : 325-31.
PubMed
2) Kim LJ, Spetzler RF. Classification and surgical management of spinal arteriovenous lesions : arteriovenous fistulae and arteriovenous malformations. Neurosurgery 2006 ; 59 (5 Suppl 3) : S195-201 ; discussion S3-13.
 
3) Miyasaka K, Asano T, Ushikoshi S, et al. Vascular anatomy of the spinal cord and classification of spinal arteriovenous malformations. Interv Neuroradiol 2000 ; 6 Suppl 1 : 195-8.
 
4) Rodesch G, Hurth M, Alvarez H, et al. Classification of spinal cord arteriovenous shunts : proposal for a reappraisal-the Bicetre experience with 155 consecutive patients treated between 1981 and 1999. Neurosurgery 2002 ; 51 : 374-9 ; discussion 9-80.
 
5) Takai K, Taniguchi M. Comparative analysis of spinal extradural arteriovenous fistulas with or without intradural venous drainage : a systematic literature review. Neurosurg Focus 2012 ; 32 : E8.
PubMed
6) Rangel-Castilla L, Holman PJ, Krishna C, et al. Spinal extradural arteriovenous fistulas : a clinical and radiological description of different types and their novel treatment with Onyx. J Neurosurg Spine 2011 ; 15 : 541-9.
 
7) Jellema K, Canta LR, Tijssen CC, et al. Spinal dural arteriovenous fistulas : clinical features in 80 patients. J Neurol Neurosurg Psychiatry 2003 ; 74 : 1438-40.
PubMed
8) Narvid J, Hetts SW, Larsen D, et al. Spinal dural arteriovenous fistulae : clinical features and long-term results. Neurosurgery 2008 ; 62 : 159-66 ; discussion 66-7.
 
9) Rosenblum B, Oldfield EH, Doppman JL, et al. Spinal arteriovenous malformations : a comparison of dural arteriovenous fistulas and intradural AVM's in 81 patients. J Neurosurg 1987 ; 67 : 795-802.
 
10) Mull M, Nijenhuis RJ, Backes WH, et al. Value and limitations of contrast-enhanced MR angiography in spinal arteriovenous malformations and dural arteriovenous fistulas. AJNR Am J Neuroradiol 2007 ; 28 : 1249-58.
PubMed
11) Sharma AK, Westesson PL. Preoperative evaluation of spinal vascular malformation by MR angiography : how reliable is the technique : case report and review of literature. Clin Neurol Neurosurg 2008 ; 110 : 521-4.
PubMed
12) Willinsky RA, terBrugge K, Montanera W, et al. Posttreatment MR findings in spinal dural arteriovenous malformations. AJNR Am J Neuroradiol 1995 ; 16 : 2063-71.
PubMed
13) Criscuolo GR, Oldfield EH, Doppman JL. Reversible acute and subacute myelopathy in patients with dural arteriovenous fistulas. Foix-Alajouanine syndrome reconsidered. J Neurosurg 1989 ; 70 : 354-9.
PubMed
14) Ferrell AS, Tubbs RS, Acakpo-Satchivi L, et al. Legacy and current understanding of the often-misunderstood Foix-Alajouanine syndrome. Historical vignette. J Neurosurg 2009 ; 111 : 902-6.
 
15) Aadland TD, Thielen KR, Kaufmann TJ, et al. 3D C-arm conebeam CT angiography as an adjunct in the precise anatomic characterization of spinal dural arteriovenous fistulas. AJNR Am J Neuroradiol 2010 ; 31 : 476-80.
 
16) Sakai Y, Matsuyama Y, Imagama S, et al. Clinical utility of multidetector row computed tomography for diagnosing spinal dural arteriovenous fistulas undiagnosed by magnetic resonance imaging. Geriatr Gerontol Int 2010 ; 10 : 255-63.
PubMed
17) Steinmetz MP, Chow MM, Krishnaney AA, et al. Outcome after the treatment of spinal dural arteriovenous fistulae : a contemporary single-institution series and meta-analysis. Neurosurgery. 2004 ; 55 : 77-87 ; discussion-8.
 
18) Tsuruta W, Matsumaru Y, Miyachi S, et al. Endovascular treatment of spinal vascular lesion in Japan : Japanese Registry of Neuroendovascular Therapy (JR-NET) and JR-NET2. Neurol Med Chir (Tokyo). 2014 ; 54 (1) : 72-8.
 
19) Gemmete JJ, Chaudhary N, Elias AE, et al. Spinal dural arteriovenous fistulas : clinical experience with endovascular treatment as a primary therapy at 2 academic referral centers. AJNR Am J Neuroradiol 2013 ; 34 : 1974-9.
PubMed
20) Van Dijk JM, TerBrugge KG, Willinsky RA, et al. Multidisciplinary management of spinal dural arteriovenous fistulas : clinical presentation and long-term follow-up in 49 patients. Stroke 2002 ; 33 : 1578-83.
PubMed
21) Bakker NA, Uyttenboogaart M, Luijckx GJ, et al. Recurrence Rates After Surgical or Endovascular Treatment of Spinal Dural Arteriovenous Fistulas : A Meta-analysis. Neurosurgery 2015 ; 77 : 137-44 ; discussion 44.
PubMed
22) Nogueira RG, Dabus G, Rabinov JD, et al. Preliminary experience with onyx embolization for the treatment of intracranial dural arteriovenous fistulas. AJNR Am J Neuroradiol 2008 ; 29 : 91-7.
PubMed
23) Ambekar S, Gaynor BG, Peterson EC, et al. Long-term angiographic results of endovascularly "cured" intracranial dural arteriovenous fistulas. J Neurosurg 2015 ; 25 : 1-5.
 
24) Blackburn SL, Kadkhodayan Y, Ray WZ, et al. Onyx is associated with poor venous penetration in the treatment of spinal dural arteriovenous fistulas. J Neurointerv Surg 2014 ; 6 : 536-40.
PubMed
25) Gokhale S, Khan SA, McDonagh DL, et al. Comparison of surgical and endovascular approach in management of spinal dural arteriovenous fistulas : A single center experience of 27 patients. Surg Neurol Int 2014 ; 5 : 7.
PubMed
26) Endo T, Shimizu H, Sato K, et al. Cervical perimedullary arteriovenous shunts : a study of 22 consecutive cases with a focus on angioarchitecture and surgical approaches. Neurosurgery 2014 ; 75 : 238-49 ; discussion 49.
 
27) Antonietti L, Sheth SA, Halbach VV, et al. Long-term outcome in the repair of spinal cord perimedullary arteriovenous fistulas. AJNR Am J Neuroradiol 2010 ; 31 : 1824-30.
PubMed
28) Bostrom A, Krings T, Hans FJ, et al. Spinal glomus-type arteriovenous malformations : microsurgical treatment in 20 cases. J Neurosurg Spine 2009 ; 10 : 423-9.
 
29) Velat GJ, Chang SW, Abla AA, et al. Microsurgical management of glomus spinal arteriovenous malformations : pial resection technique : Clinical article. J Neurosurg Spine 2012 ; 16 : 523-31.
PubMed
30) Corkill RA, Mitsos AP, Molyneux AJ. Embolization of spinal intramedullary arteriovenous malformations using the liquid embolic agent, Onyx : a single-center experience in a series of 17 patients. J Neurosurg Spine 2007 ; 7 : 478-85.
 
31) Ghobrial GM, Maulucci CM, Dalyai RT, et al. Radiosurgery for Spinal Intramedullary Arteriovenous Malformations : A Literature Review. J Neurol Surg A Cent Eur Neurosurg 2015 ; 76 : 392-8.
PubMed
32) Potharaju M, John R, Venkataraman M, et al. Stereotactic radiosurgery results in three cases of intramedullary spinal cord arteriovenous malformations. Spine J 2014 ; 14 : 2582-8.
PubMed
33) Mourier KL, Gobin YP, George B, et al. Intradural perimedullary arteriovenous fistulae : results of surgical and endovascular treatment in a series of 35 cases. Neurosurgery 1993 ; 32 : 885-91 ; discussion 91.
 
34) Wilson DA, Abla AA, Uschold TD, et al. Multimodality treatment of conus medullaris arteriovenous malformations : 2 decades of experience with combined endovascular and microsurgical treatments. Neurosurgery 2012 ; 71 : 100-8.
PubMed
35) Aminoff MJ, Logue V. The prognosis of patients with spinal vascular malformations. Brain 1974 ; 97 : 211-8.
PubMed
36) Song JK, Vinuela F, Gobin YP, et al. Surgical and endovascular treatment of spinal dural arteriovenous fistulas : long-term disability assessment and prognostic factors. J Nurosurg 2001 ; 94 (2 Suppl) : 199-204.
 
37) Lee YJ, Terbrugge KG, Saliou G, et al. Clinical features and outcomes of spinal cord arteriovenous malformations : comparison between nidus and fistulous types. Stroke 2014 ; 45 : 2606-12.
PubMed
P.320 掲載の参考文献
1) 新宮彦助. 日本における脊損発生の疫学調査. 日本パラプレジア医会誌 1993 ; 6 : 24-5.
 
2) Tator CH, Fehling MG, Thorpe K, Current use and timing of spinal surgery for management of acute spinal cord injury in North America ; results of a retrospective multicenter study. J Neurosurg 1999 ; 91 : 12-8.
 
3) Walters BC, Hadley MN, Hurbert RJ, et al : Guidelines for the Management of Acute Cervical Spine and Spinal Cord Injuries : 2013 Update. Clinical Neurosurg 2013 ; 60 : 82-91.
 
4) 脊椎脊髄損傷治療・管理のガイドライン. 脊髄外科 2005 ; 19 supple 1 : 1-41.
 
5) Kilburn MPB, Hadley MN. Contemporary treatment paradigms in spinal injury. Clin Neurosurg 2000 ; 46 : 153-69.
 
6) Maynard FM Jr, Bracken MB, Creasey G, et al. International Standards for Neurological and Functional classification of spinal cord injury. Americal Spinal Cord Injury Association. Spinal Cord 1997 ; 35 : 266-74.
 
7) Schaefer DM, Flanders AE, Osterholm JL, et al. Prognostic significance of magnetic resonance imaging in the acute phase of cervical spine injury. J Neurosurg 1992 ; 76 : 218-23.
PubMed
8) Flanders AE, Spettell CM, Friedman DP, et al. The relationship between functional abilities ofpatients with cervical spinal cord injury and the severity of damage revealed by MR imaging. AJNR Am J Neuroradiol 1999 ; 20 : 926-34.
 
9) Vale FL, Jackson AB, Hadley MN. Combined medical and surgical treatment after acute spinal cord injury ; results of a prospective pilot study to assess the merits of aggressive medical resuscitation and blod pressure management. J Neurosurg 1997 ; 87 : 239-46.
 
10) Harrop JS, Sharan AD, Vaccaro AR, et al. The cause of neurologic deterioration after acute cervical spinal cord injury. Spine 2001 ; 26 : 340-6.
PubMed
11) Bracken MB, Shepard MJ, Collins WF, et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury : Results of the second National Acute Spinal Cord Injury Study. N Engl J Med 1990 ; 322 : 1405-11.
 
12) 大谷清, 阿部弘, 角家暁, 他. 急性期脊髄損傷に対するコハク酸メチルプレドニゾロンナトリウムの臨床成績. 脊椎脊髄 1994 ; 7 : 633-47.
 
13) Bracken MB, Shepard MJ, Collins WF, et al. Methylprednisolone or naloxone treatment after acute spinal cord injury : 1-year follow-up data. Results of the second National Acute Spinal Cord Injury Study. J Neurosurg 1992 ; 76 : 23-31.
 
14) Bracken MB, Shepard MJ, Holford TR, et al. Methylprednisolone or tirilazad mesylate administration after acute spinal cord injury : 1-year follow-up. Results of the third National Acute Spinal Cord Injury randomized controled trial. J Neurosurg 1998 ; 89 : 699-706.
 
15) Vieweg U, Schltheiss R. A review of halo vest treatment of upper cervical spine injuries. Arch Orthop Trauma Surg 2001 ; 121 : 50-5.
 
16) Dickman CA, Greene KA, Sonntag VKH : Injuries invoving the transverse atlantal ligament ; Classification and treatment guidelines based upon experience with 39 injuries. Neurosurgery 1996 ; 38 : 44-50.
 
17) Traynelis VC, Kaufman HH. Atlanto-occipital dislocation. In ; Wilkins RH, Rengachary SS, eds. Neurosurgery Update II, McGraw-Hill, New York, 1991, p218-21.
 
18) Sonntag VKH, Hadley MN. Management of upper cervical spinal instability. In ; Wilkins RH, Rengachary SS, eds. Neurosurgery Update II, McGraw-Hill, New York, 1991, p222-33.
 
19) Hadley MN, Dickman CA, Browner CM, et al. Acute traumatic atlas fractures ; Management and long term outcome. Neurosurgery 1988 ; 23 : 31-5.
PubMed
20) Dickman CA, Hadley MN, Browner C, et al. Neurosurgical management of acute atlas-axis combination fractures. A review of 25 cases. J Neurosurg 1989 ; 70 : 45-9.
 
21) Hadley MN, Dickman CA, Browner CM, et al. Acute axis fractures : a review of 229 cases. J Neurosurg 1989 ; 71 : 642-7.
 
22) Seybold EA, Bayley JC : Functional outcome of surgically and conservatively managed dens fractures. Spine 1998 ; 23 : 1837-45.
PubMed
23) Lennarson PJ, Mostafavi H, Traynelis VC, et al. Management of type II dens fractures ; a case-control study. Spine 2000 ; 15 : 1234-7.
 
24) Chiba K, Fujimura Y, Toyama Y, et al. Treatment protocol for fracture of the odontoid process. J Spinal Disord 1996 ; 9 : 267-76.
PubMed
25) 中西忠行, 佐々木孝, 高畑武司, 他. 軸椎歯突起骨折に対する螺子固定. 整・災外 1980 ; 23 : 399-406.
 
26) Dickman CA, Mamourian A, Sonntag VKH, et al. Magnetic resonance imaging of the transverse atlantal ligament for the evaluation of atlantoaxial instability. J Neurosurg 1991 ; 75 : 221-7.
 
27) Levine AM, Edwards CC. The management of traumatic spondylolisthesis of the axis. J Bone Joint Surg 1985 ; 67A : 217-26.
 
28) Tuite GF, Papadopoulos SM, Sonntag VKH. Caspar plate fixation for the treatment of complex hangman's fractures. Neurosurgery 1992 ; 30 : 761-5.
 
29) Fehlings M, Tator CH. Anevidence-based review of decompressive surgery in acute spinal cord injury : rationale, indications, and timing based on experimental and clinical studies. J Neurosurg 1999 ; 91 (Spine 1) : 1-11.
 
30) Vaccaro AR, Daugherty RJ, Sheehan TP, et al. Neurologic outcome of early versus late surgery for cervical spinal cord injury. Spine 1997 ; 22 : 2609-13.
PubMed
31) Levi L, Wolf A, Rigamonti D, et al. Anterior decompression in cervical spine trauma : Does the timing of surgery affect the outcome? Neurosurgery 1991 ; 29 : 216-22.
PubMed
32) Asazuma T, Satomi K, Suzuki N, et al. Management of patients with an incomplete cervical spinal cord injury. Spinal Cord 1996 ; 34 : 620-5.
PubMed
33) Katoh S, El Masry WS, Jaffray D, et al. Neurologic outcome in coservatively treated patients with incomplete closed traumatic cervical spinal cord injuries. Spine 1996 ; 21 : 2345-51.
PubMed
34) Koyanagi I, Iwasaki Y, Hida K, et al. Acute cervical cord injury without fracture or dislocation of the spinal column. J Neurosurg 2000 ; 93 (Suppl 1) : 15-20.
PubMed
35) Grant GA, Mirza SK, Chapman JR, et al. Risk of closed reduction in cervical spine subluxation injuries. J Neurosurg 1999 ; 9 : 13-8.
PubMed
36) Vaccaro AR, Falatyn SP, Flanders AE, et al. Magnetic resonance evaluation of the intervertebral disc, spinal ligaments, and spinal cord before and after closed traction reduction of cervical spine dislocations. Spine 1999 ; 24 : 1210-7.
PubMed
37) Xiong XH, Bean A, Anthony A, et al. Manipulation for cervical spinal dislocatopn under general anaesthesia ; serial review for 4 years. Spinal Cord 1998 ; 36 : 21-4.
PubMed
38) Bucholz RD, Cheung KC : Halo vest versus spinal fusion for cervical injury ; evidence from an outcome study. J Neurosurg 1989 ; 70 : 884-92.
PubMed
39) 藤村祥一, 平林冽, 大谷清. 脊椎損傷各論. In ; 片岡治, 蓮江光男, 編. 胸椎. 脊椎損傷ハンドブック, 南江堂, 東京, 1981, p134-54.
 
40) 金田清志, 橋本友幸. 胸・腰椎損傷の手術療法. 脊椎脊髄 1989 ; 2 : 199-208.
 
41) Kaneda K, Taneichi H, Abumi K, et al. Anterior decompression and stabilization with Kaneda device for thracolumbar burst fractures associated with neurologic deficits. J Bone Joint Surg 1997 ; 9 : 69-83.
 
42) Esses SI, Botsford DJ, Kostuik JP. Evaluation of surgical treatment for burst fractures. Spine 1990 ; 15 : 667-73.
PubMed
P.324 掲載の参考文献
1) Ahn UM, Ahn NU, Buchowski JM, et al. Cauda equine syndrome secondary to lumbar disc herniation : a meta-analysis of surgical outcomes. Spine 2000 ; 25 : 1515-22.
 
2) Benoist M. The natural history of lumbar disc herniation and radiculopathy. Joint Bone Spine 2002 ; 69 : 155-60.
PubMed
3) Bono CM, Lee CK. Critical analysis of trends in fusion for degenerative disc disease over past 20 years : influence of technique on fusion and clinical outcome. Spine 2004 ; 29 : 455-63.
PubMed
4) Carey TS. Randomized controlled trials in surgery : an essential component of scientific progress. Spine 1999 ; 24 : 2553-5.
 
5) Davis RA. A long-term outcome analysis of 984 surgically treated herniated lumbar discs. J Neurosurg 1994 ; 80 : 415-21.
PubMed
6) Edwards CC, Heller JG, Murakami H. Corpectomy versus laminoplasty for multilevel cervical myelopathy : an independent matched-cohort analysis. Spine 2002 ; 27 : 1168-75.
PubMed
7) Fischgrund JS, Mackay M, Herkowitz HN, et al. 1997 Volvo Award winner spondylolisthesis with spinal stenosis : a prospective randomized study comparing decompressive laminectomy and arthrodesis with and without spinal instrumentation. Spine 1997 ; 22 : 2807-12.
PubMed
8) Fouyas IP, Statham PF, Sandercock PA. Cochrane review on the role of surgery in cervical spondylotic radiculopathy. Spine 2002 ; 27 : 736-47.
PubMed
9) France JC, Yasemski MJ, Lauermann WC, et al. A randomized prospective study of posterolateral lumbar fusion. Outcomes with and without pedicle screw instrumentation. Spine 1999 ; 24 : 553-60.
 
10) Gibson JNA, Grant IC, Waddell G. Surgery for lumbar disc prolapsed (Cochrane Review). The Cochrane Library. Issue 3, 2000. Oxford : Update Software.
 
11) Hacker RJ, Cauthen JC, Gillbert TJ, et al. A prospective randomized multicenter clinical evaluation of an anterior cervical fusion cage. Spine 2000 ; 25 : 2646-55.
 
12) Hayashi H, Okada K, Hashimoto J, et al. Cervical spondylotic myelopathy in the aged patient. A radiographic evaluation of the aging changes in the cervical spine and etiologic factors of myelopathy. Spine 1988 ; 13 : 618-25.
 
13) Heliovaara M. Occupation and risk of herniated lumbar intervertebral disc or sciatica leading to hospitalization. J Chronic Dis 1987 ; 40 : 259-64.
 
14) Javid MJ. A 1-to 4-year follow-up review of treatment of sciatica using chemonucleosis or laminectomy. J Neurosurg 1992 ; 76 : 184-90.
PubMed
15) Kadanka Z, Bednarik J, Vohanka, et al. Conservative treatment versus surgery in spondylotic cervical myelopathy : a prospective randomized study. Eur Spine J 2000 ; 9 : 538-44.
PubMed
16) Kelsey JL, Githens PB, O'Conner T, et al. Acute prolapsed lumbar intervertebral disc. An epidemiologic study with special reference to driving automobiles and cigarette smoking. Spine 1984 ; 9 : 608-13.
 
17) Komori H, Shinomiya K, Nakai O, et al. The natural history of herniated nucleus pulposus with radiculopathy. Spine 1996 ; 21 : 225-9.
PubMed
18) Korovessis P, Papazisis Z, Koureas G, et al. Rigid, semirigid versus dynamic instrumentation for degenerative lumbar spinal stenosis : a correlative radiological and clinical analysis of shortterm results. Spine 2004 ; 29 : 735-42.
 
19) Kraemer J. Natural course and prognosis of intervertebral disc diseases. International Society for the Study of the lumbar Spine Seattle. Washington, June 1994. Spine 1995 ; 20 : 635-9.
 
20) Lees F, Turner JW. Natural history and prognosis of cervical spondylosis. Br Med J 1963 ; 2 : 1607-10.
PubMed
21) Moller H, Hedlund R. Instrumented and noninstrumented posterolateral fusion in adult spondylolisthesis. A prospective randomized study : part 2. Spine 2000 ; 25 : 1716-21.
PubMed
22) 西山隆之, 鷲見正敏, 片岡治, 他. 頸部脊髄症軽症例の手術治療成績. 保存療法による成績との比較研究. 整形外科 1999 ; 50 : 133-6.
 
23) Pappas CTE, Harrington T, Sonntag VKH. Outcome analysis of 654 surgically treated lumbar disc herniations. Neurosurgery 1992 ; 30 : 862-6.
 
24) Revel M, Payan C, Vallee C, et al. Automated percutaneous lumbar discectomy versus chemonucleolysis in the treatment of sciatica : A randomized multicenter trial. Spine 1993 ; 18 : 1-7.
PubMed
25) Riley LH III. Review of spinal instrumentation. Neurosurgery Quarterly 1992 ; 2 : 243-58.
 
26) Saal JA, Saal JS. The nonoperative treatment of herniated nucleus pulposus with radiculopathy : an outcome study. Spine 1989 ; 14 : 431-7.
PubMed
27) Saal JA, Saal JS, Herzog RJ. The natural history of lumbar intervertebral disc extrusions treated nonoperatively. Spine 1990 ; 15 : 683-6.
PubMed
28) Sampath P, Bendebba M, Davis JD, et al. Outcome of patients treated for cervical myelopathy. A prospective, multicenterstudy with independent clinical review. Spine 2000 ; 25 : 670-6.
 
29) Silvers HR, Lewis PJ, Asch HL. Decompressive lumbar laminectomy for spinal stenosis. J Neurosurg 1993 ; 78 : 695-701.
PubMed
30) Suk SL, Lee CK, Kin WJ, et al. Adding posterior lumbar interbody fusion to pedicle screw fixation and posterolateral fusion after decompression in spondylolytic spondylolisthesis. Spine 1997 ; 22 : 210-20.
 
31) Takada E, Takahashi M, Shimada K. Natural history of lumbar disc hernia with radicular pain : Spontaneous MRI changes of the herniated mass and correlation with clinical outcome. J Orthop Surg (Hong Kong) 2001 ; 9 : 1-7.
PubMed
32) Thomsen K, Christensen FB, Eiskjaer SP, et al. 1997 Volvo Award winner in clinical studies. The effect of pedicle screw instrumentation of functional outcome and fusion rates in posterolateral lumbar spinal fusion : a prospective, randomized clinical study. Spine 1997 ; 22 : 2813-22.
PubMed
33) Wada E, Suzuki S, Kanazawa A, et al. Subtotal corpectomy versus laminoplasty for multilevel cervical spondylotic myelopathy : along-term follow-up study over 10 years. Spine 2001 ; 26 : 1143-7.
 
34) Weber H. Lumbar disc herniation : a comtrolled prospective study with ten years of observation. Spine 1983 ; 8 : 131-40.
 
35) Weber H. The natural history of disc herniation and the influence of intervention. Spine 1994 ; 19 : 2234-8.
 
36) Weinstein JN, Lurie JD, Tosteson TD, et al. Surgical versus nonoperative treatment for lumbar disc herniation : four-year results for the Spine Patient Outcomes Research Trial (SPORT). Spine 2008 ; 33 : 2789-800.
PubMed
37) Winter RB. The prospective, randomized, controlled clinical trial in spine surgery : fact or fiction? Spine 1999 ; 24 : 2550-2.
PubMed
38) Yonenobu K, Hosono N, Iwasaki M, et al. Laminoplasty versus subtotal corpectomy. A comparative study of results in multisegmental cervical spondylotic myelopathy. Spine 1992 ; 17 : 1281-4.
PubMed
P.328 掲載の参考文献
1) Abe T, Nakamura N, Watanabe R, et al. Magnetic resonance cineflow imaging of cerebrospinal fluid in syringomyelia. Neuroradiology 1991 ; 33 (suppl) : 173-5.
 
2) 阿部俊昭, 田渋公一, 尾上尚志, 他. 脊髄空洞症の症状推移と神経症状発現機序についての考察. 臨床神経 1992 ; 32 : 979-83.
 
3) Abe T, Okuda Y, Hida T, et al. Diagnosis and treatment of syringomyelia our experience with 164 cases, In ; Tamaki N, Batzdorfu U, Nagashima T, eds. Syringomyelia. Current concepts in pathigenesis and management. Tokyo, Springer-Verlag, 2001, p154-8.
 
4) Aboulker J. La syringomyelia et les loquides intrarachidiens. Neuroschirurgie 1979 ; (Sulppl 1) 25 : 1-144.
 
5) Ball MJ, Dayan AD. Pathogenesis of syringomyelia. Lancet 1972 ; 2 : 799-801.
PubMed
6) Batzdorf U. Classification of syringomyelia. In ; Batzdorf U, ed. Syringomymelia : Current concepts in diagnosis and treatment. Baltimore, Williams & Wilkins, 1991, p11-2.
 
7) Foster JB, Hudgson P. Traditional concepts of syringomyelia. In ; Barnett HJM, Foster JB, Hudgson P, eds. Syringomyelia, Major Problems in Neurology Vol. 1, London, WB Sunders, 1973, p11-5.
 
8) Gardner WJ, Abdullah AF, McCormack LJ. The varying expressions of embryonal atresia of the fourth ventricle in adults. Arnold-Chiari malformation, Dandy-Walker syndrome, "Arachnoid" cyst of the cerebellum, and syringomyelia. J Neurosurg 1957 ; 14 : 591-607.
PubMed
9) Greenfield JG. Syringomyelia and syringobulbia, In ; Blookwood W, McMenemey WH, Meyer A, et al, eds. Greenfield's Neuropathology, 2nd edition, London, Arnold, 1963, p331-7.
 
10) Hida K, Iwasaki Y, Koyanagi I, et al. Surgical indication and results of foramen magnum decompression versus syringosubarachnoid shunting for syringomyelia associated with Chiari I malformation. Neurosurgery 1995 ; 37 : 673-9.
PubMed
11) Hoffman H. Syringomyelia in childhood. In ; Batzdorf U, ed. Syringomyelia : Current concepts in diagnosis and treatment. Baltimore, Williams & Wilkins, 1991, p151-62.
 
12) 北原宏, 南昌平, 荒井貞男, 他. 脊柱変形と脊髄空洞症-その自然経過と治療-. 日獨医報 1991 ; 36 : 24-38.
 
13) Milhorat TH, Johnson WD, Miller JI, et al. Surgical Treatment of Syringomyelia Based on Magnetic Resonance Imaging Criteria. Neurosurgery 1992 ; 31 : 231-45.
PubMed
14) 南昌平, 徳永誠. 脊柱側彎症を伴う脊髄空洞症の病態. 難治性の脊髄空洞症に伴う脊髄機能障害の治療と予防に関する研究 (班長 玉木紀彦), 平成9年度研究報告書, 1998, p61-7.
 
15) Nightingale S, Wiiliams B. Hindbrain hernahead-ache. Lancet 1987 ; 1 : 731-4.
 
16) Oldfield EH, Muraszko K, Shawker TH, et al. Pathophysiology of syringomyelia associated with Chiari I malformation of the cerebellar tonsils Implications for diagnosis and treatment. J Neurosurg 1994 ; 80 : 3-15.
PubMed
17) 田代邦雄, 森若文雄, 須藤和昌. 脊髄空洞症全国二次調査. 脊髄空洞症とその関連疾患の病態と治療に関する研究. 平成4年度研究報告書, 1993, p9-12.
 
18) Taylor AR, Byrnes DP. Foramen magnum and High cervical cord compression. Brain 1974 ; 97 : 473-80.
PubMed
19) Vinters HV. Neuropathology of syringomyelia. In ; Batzdorf U, ed. Syringomyelia Current concepts in diagnosis and treatment. Baltimore, Williams & Wilkins, 1991, p35-58.
 
20) Welch K, Shillito J, Strand R, et al. Chiari I "malformations" : an acquired disorder? J Neurosurg 1981 ; 55 : 604-60.
 
21) Williams B. The distending force in the production of "communicating syringomyelia". Lancet 1969 ; 2 : 189-93.
PubMed
P.332 掲載の参考文献
1) 日本整形外科学会診療ガイドライン委員会 頚椎後縦靱帯骨化症ガイドライン策定委員会, 厚生労働省特定疾患対策研究事業「脊柱靱帯骨化症に関する研究」班. 頚椎後縦靱帯骨化症診療ガイドライン 第2版, 南江堂, 東京, 2011.
 
2) Tsukimoto H. A case report : Autopsy of syndrome of compression of the spinal cord owing to ossification within the cervical spinal canal. Arch Jpn Chir 1960 ; 29 : 1003-7.
 
3) Shingyouchi Y, Nagahama A, Niida M. Ligamentous ossification of the cervical spine in the late middle-aged Japanese men. Its relation to body mass index and glucose metabolism. Spine 1996 ; 21 : 2474-8.
PubMed
4) 山内裕雄. 千葉県鴨川地区と山梨県甲府地区のX線写真検査におけるOPLLの発現率の比較, およびOPLL患者の毛髪中重金属含有量に関する研究. 厚生省特定疾患 脊柱靱帯骨化症調査研究班, 昭和56年度研究報告書 1982 : 15-9.
 
5) 寺山和雄, 大塚訓喜. 後縦靱帯骨化症の疫学. 神研の進歩 1989 ; 33 : 823-30.
 
6) 和田光司, 寺山和雄, 大塚訓喜, 他.〔脊柱管内靱帯骨化の病態と治療〕頸椎後縦靱帯骨化症患者における全身靱帯骨化所見のX線学的検討. 臨整外 1988 ; 23 : 489-94.
 
7) 松永俊二, 酒匂崇, 武富栄二. 脊柱靱帯骨化症の臨床経過と骨化巣の進展 頸椎後縦靱帯骨化症における臨床症状の自然経過について. 整形外科 1993 ; 44 : 1127-31.
 
8) Ohtsuka K, Terayama K, Yanagihara M, et al. A radiological population study on the ossification of the posterior longitudinal ligament in the spine. Arch Orthop Trauma Surg 1987 ; 106 : 89-93.
 
9) 佐々木隆一郎, 青木国雄, 水野正一, 他. 脊柱靱帯骨化症の全国疫学調査-全国有患者数. 厚生省特定疾患/脊柱靱帯骨化症調査研究班 昭和60年度研究報告書 1986 : 43-8.
 
10) Matsunaga S, Sakou T. Epidemiology of ossification of the posterior longitudinal ligament. In ; Yonenobu K, Sakou T, Ono K, eds. OPLL : Ossification of The Posterior Longitudinal Ligament, Springer-Verlag, Tokyo, 1997, p11-35.
 
11) 大塚訓喜, 柳原光圀. 脊柱靱帯骨化症の疫学と統計. 整形外科 MOOK, 金原出版, 東京, 1987, p242-59.
 
12) 岡野智裕, 酒匂崇, 武富栄二, 他. 頸椎後縦靱帯骨化症の自然経過. 西日脊椎研会誌 1994 ; 20 : 83-6.
 
13) 三原圭司, 鳥越雄喜, 小西宏昭, 他. 頸椎後縦靱帯骨化を伴った頸髄損傷. 整外と災外 1991 ; 40 : 763-5.
 
14) 松永俊二, 神囿純一, 石堂康弘, 他. QOLと機能評価 頸椎後縦靱帯骨化症患者の脊髄症状出現に関する外傷の関与. 厚生労働省特定疾患対策研究/脊柱靱帯骨化症に関する調査研究 平成12年度研究報告書 2001 : 138-40.
 
15) 梶浦清司, 井形高明, 加藤真介, 他. 頸椎後縦靱帯骨化の進展 10年以上経過観察症例による検討. 厚生省特定疾患研究・骨・関節系疾患調査研究班 平成10年度研究報告書 1998 : 146-8.
 
16) Taketomi E. Progression of ossification of the posterior longitudinal ligament in the cervical spine. 日脊椎外会誌 1997 ; 8 : 359-66.
 
17) Terayama K. Genetic studies on ossification of the posterior longitudinal ligament of the spine. Spine 1989 ; 14 : 1184-91.
PubMed
18) 三浦幸雄, 河合清. 脊柱靱帯骨化症の成因 後縦靱帯骨化症の双生児調査. 整形外科 1993 ; 44 : 993-8.
 
19) Sakou T, Taketomi E, Matsunaga S, et al. Genetic study of ossification of the posterior longitudinal ligament in the cervical spine with human leukocyte antigen haplotype. Spine 1991 ; 16 : 1249-52.
PubMed
20) Koga H, Sakou T, Taketomi E, et al. Genetic mapping of ossification of the posterior longitudinal ligament of the spine. Am J Hum Genet 1998 ; 62 : 1460-7.
PubMed
21) Maeda S, Koga H, Matsunaga S, 他. 脊椎後縦靱帯の骨化に関する膠原α2 (XI) 遺伝子の性-特異性ハプロタイプのつながり. J Hum Genet 2001 ; 46 : 1-4.
 
22) Nakamura I, Ikegawa S, Okawa A, et al. Association of the human NPPS gene with ossification of the posterior longitudinal ligament of the spine (OPLL). Hum Genet 1999 ; 104 : 492-7.
PubMed
23) Furushima K, Shimo-Onoda K, Maeda S, et al. Large-scale screening for candidate genes of ossification of the posterior longitudinal ligament of the spine. J Bone Miner Res 2002 ; 17 : 128-37.
PubMed
24) 児玉太郎, 酒匂崇, 松永俊二, 他. 後縦靱帯骨化症患者における血中Vitamin Aとその結合蛋白の測定 (最終報告) 及び骨代謝マーカーの測定. 厚生省特定疾患研究/骨・関節系疾患調査研究班 平成9年度研究報告書 1998 : 52-4.
 
25) 山内常人, 菊野光郎, 武富栄二, 他. 頸椎後縦靱帯骨化症のDXA法による骨量の検討. 整外と災外 1994 ; 43 : 195-8.
 
26) 池田義和, 後藤澄雄, 山崎正志, 他. 頸椎後縦靱帯骨化症の骨化形態と骨代謝マーカー・骨塩量の検討. 厚生省特定疾患研究/骨・関節系疾患調査研究班 平成8年度研究報告書 1997 : 67-70.
 
27) 池川志郎. 脊柱靱帯骨化症の成因 後縦靱帯骨化症における成長ホルモン, および成長ホルモン関連蛋白. 整形外科 1993 ; 44 : 1008-11.
 
28) Akune T, Ogata N, Seichi A, et al. Insulin secretory response is positively associated with the extent of ossification of the posterior longitudinal ligament of the spine. J Bone Joint Surg Am 2001 ; 83-A : 1537-44.
PubMed
29) Goto K, Yamazaki M, Tagawa M, et al. Involvement of insulin-like growth factor I in development of ossification of the posterior longitudinal ligament of the spine. Calcif Tissue Int 1998 ; 62 : 158-65.
PubMed
30) 後藤憲一郎, 山崎正志, 金民世, 他. 脊柱靱帯骨化の発生・進展におけるIGF-Iの関与. 厚生省特定疾患研究/骨・関節系疾患調査研究班 平成8年度研究報告書 1997 : 51-7.
 
31) Tsuyama N. Ossification of the posterior longitudinal ligament of the spine. Clin Orthop 1984 ; 184 : 71-84.
PubMed
32) Matsunaga S, Sakou T, Taketomi E, et al. Clinical course of patients with ossification of the posterior longitudinal ligament : a minimum 10-year cohort study. J Neurosurg (Spine 3) 2004 ; 100 : 245-8.
 
33) 松永俊二, 酒匂崇.〔腰痛・関節痛〕頸椎症の後縦靱帯骨化症の症状と診断. 臨と研 1999 ; 76 : 695-700.
 
34) Ono K, Ota H, Tada K, et al. Ossified posterior longitudinal ligament : A clinicopathological study. Spine 1977 ; 2 : 126-38.
 
35) 寺山和雄, 黒川高秀, 関寛之. 後縦靱帯骨化症全国調査報告. 厚生省特定疾患/後縦靱帯骨化症調査研究班 昭和50年度報告書 1976 : 8-33.
 
36) Mizuno J, Nakagawa H, Matsuo N, et al. Dural ossification associated with cervical ossification of the posterior longitudinal ligament : frequency of dural ossification and comparison of neuroimaging modalities in ability to identify the disease. J Neurosurg Spine 2005 ; 2 : 425-30.
 
37) 沢村悟, 片岡治, 鷲見正敏, 他. 脊柱靱帯骨化症の治療と管理 頸椎後縦靱帯骨化症における保存的治療の適応と限界 頸椎持続牽引法を中心に. 脊椎脊髄 1993 ; 6 : 889-93.
 
38) 富永積生. 頸椎後縦靱帯骨化症の保存療法 頸椎後縦靱帯骨化症に対する保存的治療 狭窄・圧迫性頸髄症例に対して. 整形外科 1993 ; 44 : 1189-96.
 
39) 柳務. 頸髄・頸椎疾患の治療 後縦靱帯骨化症の治療 保存的療法を中心に (手術適応を含む). 神経内科治療 1991 ; 8 : 289-94.
 
40) 後藤澄雄. 頸椎後縦靱帯骨化症の保存療法 頸椎後縦靱帯骨化症における症状の推移と保存・手術治療の選択. 整形外科 1993 ; 44 : 1181-8.
 
41) 三浦幸雄, 駒形正志. 脊柱靱帯骨化症の手術適応とインフォームドコンセント. 脊椎脊髄 1993 ; 6 : 859-65.
 
42) 片岡治, 栗原章, 武部恭一, 他. 頚椎後縦靱帯骨化症の手術成績とその検討. 整形外科 1978 ; 29 : 1-9.
 
43) Tani T, Ushida T, Ishida K, et al. Relative safety of anterior microsurgical decompression versus laminoplasty for cervical myelopathy with a massive ossified posterior longitudinal ligament. Spine 2002 ; 27 : 2491-8.
PubMed
44) Kawano H, Handa Y, Ishii H, et al. Surgical treatment for ossification of the posterior longitudinal ligament of the cervical spine. J Spinal Disord 1995 ; 8 : 145-50.
PubMed
45) Goto S, Kita T. Long-term follow-up evaluation of surgery for ossification of the posterior longitudinal ligament. Spine 1995 ; 20 : 2247-56.
PubMed
46) Tomita K, Nomura S, Umeda S et al. Cervical laminoplasty to enlarge the spinal canal in multilevel ossification of the posterior longitudinal ligament with myelopathy. Arch Orthop Trauma Surg 1988 ; 107 : 148-53
 
47) 小島精, 和賀志郎, 久保和親, 他. 頸椎後縦靱帯骨化症に対する前方除圧術. 脊髄外科 1995 ; 9 : 31-6.
 
48) Yamaura I, Kurosa Y, Matuoka T, et al. Anterior floating method for cervical myelopathy caused by ossification of the posterior longitudinal ligament. Clin Orthop 1999 ; 359 : 27-34.
PubMed
49) Onari K, Akiyama N, Kondo S, et al. Long-term follow-up results of anterior interbody fusion applied for cervical myelopathy due to ossification of the posterior longitudinal ligament. Spine 2001 ; 26 : 488-93.
PubMed
50) 上小鶴正弘. 頸椎後縦靱帯骨化症に対する前方除圧術における骨化巣浮上術の意義. 日整会誌 1991 ; 65 : 431-40.
 
51) 木田浩, 田畑四郎, 高原光明, 他. 頸椎後縦靱帯骨化症に対する骨化巣非摘出前方椎間固定術と長期術後成績. 臨整外 1996 ; 31 : 251-7.
 
52) Tominaga S. The effects of intervertebral fusion in patients with myelopathy due to ossification of the posterior longitudinal ligament of the cervical spine. Int Orthop 1980 ; 4 : 183-91.
PubMed
53) Kato Y, Iwasaki M, Fuji T, et al. Long-term follow-up results of laminectomy for cervical myelopathy caused by ossification of the posterior longitudinal ligament. J Neurosurg 1998 ; 89 : 217-23.
PubMed
54) 宮崎和躬. 頸椎後縦靱帯骨化症に対する手術療法 頸椎後縦靱帯骨化症に対する椎弓切除術の成績と適応. 整形外科 1993 ; 44 : 1197-204.
 
55) 国分正一, 桜井 実, 八幡順一郎, 他.〔脊柱管内靱帯骨化の病態と治療〕頸椎後縦靱帯骨化症の手術成績 前方除圧術と後方除圧術の比較検討. 臨整外 1988 ; 23 : 543-53.
 
56) 藤村祥一, 藤原奈佳子, 原田征行, 他. 頸椎後縦靱帯骨化症に対する椎弓形成術の手術成績とQOL. 厚生省特定疾患対策研究/脊柱靱帯骨化症に関する調査研究 平成11年度研究報告書 2000 : 152-6.
 
57) 藤村祥一, 原田征行, 植山和正, 他. 頸椎後縦靱帯骨化症の手術成績とQOL. 厚生省特定疾患研究/骨・関節系疾患調査研究班 平成10年度研究報告書 1998 : 101-4.
 
58) 黒川智子, 原田征行, 植山和正, 他. 青森県内の頸椎OPLL患者のQOL調査について. 厚生省特定疾患対策研究/脊柱靱帯骨化症に関する調査研究 平成11年度研究報告書 2000 : 121-8.
 
59) 黒佐義郎, 山浦伊裟吉, 四宮謙一, 他. 頸椎後縦靱帯骨化症に対する手術療法 頸椎後縦靱帯骨化症に対する骨化浮上術の長期成績と適応. 整形外科 1993 ; 44 : 1225-32.
 
60) Baba H, Furusawa N, Chen Q, et al. Cervical laminoplasty in patients with ossification of the posterior longitudinal ligaments. Paraplegia 1995 ; 33 : 25-9.
PubMed
61) Iwasaki M, Kawaguchi Y, Kimura T, et al. Long-term results of expansive laminoplasty for ossification of the posterior longitudinal ligament of the cervical spine : more than 10 years follow up. J Neurosurg (Spine2) 2002 ; 96 : 180-9.
 
62) Takatsu T, Ishida Y, Suzuki K, et al. Radiological study of cervical ossification of the posterior longitudinal ligament. J Spinal Disord 1999 ; 12 : 271-3.
PubMed
63) 富田卓, 原田征行, 植山和正, 他. 頸椎後縦靱帯骨化症の骨化進展についてのX線学的検討 骨化進展に及ぼす手術の影響について. 臨整外 1999 ; 34 : 167-72.
 
64) Kawaguchi Y, Kanamori M, Ishihara H, et al. Progression of ossification of the posterior longitudinal ligament following en bloc cervical laminoplasty. J Bone Joint Surg Am 2001 ; 83-A : 1798-802.
PubMed
65) Matsuoka T, Yamaura I, Kurosa Y, et al. Long-term results of the anterior floating method for cervical myelopathy caused by ossification of the posterior longitudinal ligament. Spine 2001 ; 26 : 241-8.
PubMed
P.338 掲載の参考文献
1) 吉田宗人, 玉置哲也, 寺尾賢秀, 他. 型特異抗コラーゲン単クローン抗体を用いた胸椎黄色靱帯骨化の免疫組織化学的検討. 厚生省特定疾患脊柱靱帯骨化症調査研究斑, 昭和62年度研究報告書, 1988, p47-9.
 
2) Kaneyama S, Doita M, Nishida K, et al. Thoracic myelopathy due to ossification of the yellow ligament in young baseball pitchers. J Spinal Disord Tech 2008 ; 21 : 68-71.
PubMed
3) Payer M, Bruder E, Fischer JA, et al. Thoracic myelopathy due to enlarged ossified yellow ligament. Case report and review of the literature. J Neurosurg 2000 ; 92 : 105-8.
PubMed
4) Celli P, Caroli E, Trillo G, et al. Ossification of the ligamentum flavum in a Caucasian. J Neurosurg Sci 2002 ; 46 : 96-9.
 
5) 日本整形外科学会診療ガイドライン委員会, 頚椎後縦靱帯骨化症ガイドライン策定委員会, 厚生労働省特定疾患対策研究事業「脊柱靱帯骨化症に関する研究」班. 頚椎後縦靱帯骨化症診療ガイドライン, 南江堂, 2005.
 
6) 和田光司, 寺山和雄, 大塚訓喜, 他. 頸椎後縦靱帯骨化症患者における脊柱諸靱帯の骨化および脊柱以外の靱帯骨化に関するX線学的調査. 中部整災誌 1986 ; 29 : 203-5.
 
7) 佐藤哲朗, 相澤俊峰. 胸部脊髄症の現況. 脊椎脊髄 2009 ; 22 : 136-41.
 
8) 菊地誠志, 田代邦雄. 胸椎部黄色靱帯骨化症の神経症候. 脊椎脊髄 1995 ; 8 : 951-7.
 
9) 渡貴司, 米延策雄. 胸部脊髄症をきたす疾患と症候学. 脊椎脊髄 2009 ; 22 : 143-8.
 
10) 佐藤哲朗, 国分正一, 石井祐信. 胸椎部黄色靱帯骨化の形態と手術法の選択. 臨整外 1996 ; 31 : 541-5.
 
11) 川口浩, 黒川高秀, 町田秀人, 他. 脊髄障害を示す頚椎後縦靱帯骨化症の単純X線側面像-臨床症状の軽重による比較検討. 日整会誌 1991 ; 65 : 173-80.
Medical*Online
12) 里見和彦, 大熊哲夫. 脊柱靱帯骨化症の電気生理学的診断. 整形外科MOOK No50, 1987, p195-207.
 
13) 田中弘美, 黒川高秀, 小林正之, 他. 胸椎黄色靱帯骨化症の観血的治療について. 整・災外 1980 ; 23 : 779-85.
 
14) 山田博信, 平林茂, 本強矢隆生, 他. 胸椎黄色靱帯骨化症に対する正中縦割法による後方除圧の成績. 脊椎・脊髄神経手術手技 2008 ; 10 : 145-9.
 
15) 平林茂, 松下 隆, 都築暢之. 胸椎部靱帯骨化症に対する手術療法-特に後縦靱帯骨化症に関して. 脊椎脊髄 2009 ; 22 : 171-8.
 
P.344 掲載の参考文献
1) Brooks AL, Jenkins EB. Atlanto-axial arthrodesis by the wedge compression method. J Bone Joint Surg Am 1978 ; 60 : 279-84.
 
2) Casey ATH, Crockard HA. Rheumatoid arthritis. In ; Dickman CA, Spetzler RF, Sonntag VKH, eds. Surgery of the Craniovertebral Junction. New York, Thieme, 1998, p151-74.
 
3) Crossman JE, David K, Hayward R, et al. Open reduction of pediatric atlantoaxial rotatory fixation : long-term outcome study with functional measurements. J Neurosurg 2004 ; 100 (Spine 3) : 235-40.
 
4) De Iure F, Donthineni R, Boriani S. Outcomes of C1 and C2 posterior screw fixation for upper cervical spine fusion. Eur Spine J 2009 ; 18 (Suppl 1) : 2-6.
 
5) Dickman CA,Crawford NR. Biomechanics of the craniovertebral junction. In ; Dickman CA, Spetzler RF, Sonntag VKH, eds. Surgery of the Craniovertebral Junction. New York, Thieme, 1998, p59-80.
 
6) Dickman CA, Mamourian A, Sonntag VKH. Injuries involving the transverse atlantal ligament : classification and treatment guidelines based upon experience with 39 injuries. Neurosurgery 1996 ; 38 : 44-50.
 
7) Dickman CA, Sonntag VKH. Posterior C1-C2 transarticular screw fixation for atlantoaxial arthrodesis. Neurosurgery 1998 ; 43 : 275-81.
 
8) Dvorak J, Schneider E, Saldinger P, et al. Biomechanics of the craniocervical region : the alar and transverse ligament. J Orthop Res 1988 ; 6 : 452-61.
PubMed
9) Gallie WE. Fractures and dislocations of the cervical spine. Am J Surg 1939 ; 46 : 495-9.
 
10) Fielding JW, Hensinger RN, Hawkins RJ. Os odontoideum. J Bone Joint Surg Am 1980 ; 62A : 376-83.
 
11) Fujiwara K, Yonenobu K, Ochi T. Natural history of upper cervical lesions in rheumatoid arthritis. J Spinal Disord 1997 ; 10 : 275-81.
PubMed
12) Fujiwara K, Owaki H, Fujimoto M, et al. A long-term follow-up study of cervical lesions in rheumatoid arthritis. J Spinal Disord 2000 ; 13 : 519-26.
 
13) Goel A, Laheri V. Plate and screw fixation for atlanto-axial subluxation. Acta Neurochir (Wien) 1994 ; 129 : 47-53.
PubMed
14) Grauer JN, Shafi B, Hilibrand AS. Proposal of a modified, treatment-oriented classification of odontoid fractures. Spine J 2005 ; 5 : 123-9.
PubMed
15) Gunnarsson T, Massicotte EM, Govender PV, et al. The use of C1 lateral mass screws in complex cervical spine surgery : indications, techniques, and outcome in a prospective consecutive series of 25 cases. J Spinal Disord Tech 2007 ; 20 : 308-16.
 
16) Hadley MN, Dickman CA, Browner CM. Acute axis fractures. A review of 229 cases. J Neurosurg 1989 ; 71 : 642-7.
 
17) Harms J, Melcher RP. Posterior C1-C2 fusion with polyaxial screw and rod fixation. Spine 2001 ; 26 : 2467-71.
PubMed
18) Hinck VC, Hopkins CE. Mearsurement of the atlanto-dental interval in the adult. Am J Roentgenol 1960 ; 84 : 945-51.
 
19) Ishii K, Toyama Y, Nakamura M, et al. Management of chronic atlantoaxial rotatory fixation. Spine 2012 ; 37 : E278-85.
PubMed
20) Ito H, Neo M, Yoshida M, et al. Efficacy of computer-assisted pedicle screw insertion for cervical instability in RA patients. Rheumatol Int 2007 ; 27 : 567-74.
PubMed
21) Kaito T, Hosono N, Ohshima S. Effect of biological agents on cervical spine lesions in rheumatoid arthritis. Spine 2012 ; 37 : 1742-6.
PubMed
22) Karray M, M'nif N, Mestiri M, et al. Concomitant alar and apical ligament avulsion in atlanto-axial rotatory fixation. Case report and review of the literature. Acta Orthop Belg 2004 ; 70 : 189-92.
 
23) Kim DH, Hilibrand AS. Rheumatoid arthritis in the cervical spine. J Am Acad Orthop Surg 2005 ; 13 : 463-74.
PubMed
24) Kuroki H, Rengachary SS, Goel VK, et al. Biomechanical comparison of two stabilization techniques of the atlantoaxial joints : transarticular screw fixation versus screw and rod fixation. Neurosurgery 2005 ; 56 : 151-9.
PubMed
25) Laiho K, Soini I, Kautiainen H, et al. Can we rely on magnetic resonance imaging when evaluating unstable atlantoaxial subluxation? Ann Rheum Dis 2003 ; 62 : 254-6.
PubMed
26) Locke GR, Gardner JI, Van Epps EF. Atlas-dens interval (ADI) in children : a survey based on 200 normal cervical spines. Am J Roentgenol Radium Ther Nucl Med 1966 ; 97 : 135-40.
PubMed
27) Madawi AA, Casey ATH, Solanki GA, et al. Radiological and anatomical evaluation of the atlantoaxial transarticular screw fixation technique. J Neurosurg 1997 ; 86 : 961-8.
 
28) Marks JS, Sharp J. Rheumatoid cervical myelopathy. Q J Med 1981 ; 50 : 307-19.
PubMed
29) Menezes AH, Ryken TC. Craniovertebral abnormalities in Down's syndrome. Pediatr Neurosurg 1992 ; 18 : 24-33.
PubMed
30) Mikulowski P, Wollheim FA, Rotmil P, Olsen I. Sudden death in rheumatoid arthritis with atlanto-axial dislocation. Acta Med Scand 1975 ; 198 : 445-51.
PubMed
31) Nagashima C. Atlanto-axial dislocation due to agenesis of the os odontoideum or odontoid. J Neurosurg 1970 ; 33 : 270-80.
 
32) 長島親男. 環椎と軸椎の異常に対する手術. 高倉公朋監修, 脊椎・脊髄の手術. 現代医療社, 1993, p 97-123.
 
33) Nakanishi K, TanakaM, Sugimoto Y. Application of laminar screws to posterior fusion of cervical spine : measurement of the cervical vertebral arch diameter with a navigation system. Spine 2008 ; 33 : 620-3.
 
34) Neo M, Sakamoto T, Fujibayashi S, et al. A safe screw trajectory for atlantoaxial transarticular fixation achieved using an aiming device. Spine 2005 ; 30 : E236-42.
PubMed
35) Neo M, Fujibayashi S, Miyata M, et al. Vertebral artery injury during cervical spine surgery : a survey of more than 5600 operations. Spine 2008 ; 33 : 779-85.
PubMed
36) Ni B, Zhou F, Xie N. Transarticular screwand C1 hook fixation for os odontoideum with atlantoaxial dislocation. World Neurosurg 2011 ; 75 : 540-6.
PubMed
37) Niibayashi H. Atlantoaxial rotatory dislocation. A case report. Spine 1998 ; 23 : 1494-6.
PubMed
38) Oda T, Fujiwara K, Yonenobu K, et al. Natural course of cervical spine lesions in rheumatoid arthritis. Spine 1995 ; 20 : 1128-35.
PubMed
39) Parisini P, Di Silvestre M, Greggi T, et al. C1-C2 posterior fusion in growing patients : long-term follow-up. Spine 2003 ; 28 : 566-72.
PubMed
40) Riise T, Jacobsen BK, Gran JT. High mortality in patients with rheumatoid arthritis and atlantoaxial subluxation. J Rheumatol 2001 ; 28 : 2425-9.
PubMed
41) Rousselin B, Helenon O, Zingraff J, et al. Pseudotumor of the craniocervical junction during long-term hemodialysis. Arthritis Rheum 1990 ; 33 : 1567-73.
PubMed
42) Salunke P, Sharma M, Sodhi HB, et al. Congenital atlantoaxial dislocation : a dynamic process and role of facets in irreducibility. J Neurosurg Spine 2011 ; 15 : 678-85.
PubMed
43) Section on Disorders of the Spine and Peripheral Nerves of the American Association of Neurological Surgeons and the Congress of Neurological Surgeons. Guidelines for the management of acute cervical spine and spinal cord injuries, Os odontoideum. Neurosurgery 2002 ; 50 (Suppl) : S148-55.
 
44) 脊椎脊髄損傷治療・管理のガイドライン作成委員会. 特殊な病態に対する診断と治療. 脊髄外科 2005 ; 19 (Suppl 1) : 13-8.
 
45) Stillerman CB, Roy RS, Weiss MH. Cervical spine injuries : diagnosis and management. In ; Wilkins RH, Rengachary SS, eds. Neurosurgery. New York, McGraw-Hill, 1996, p2875-904.
 
46) Sonntag VKH, Dickman CA. Posterior atlantoaxial wiring techniques. In ; Dickman CA, Spetzler RF, Sonntag VKH, eds. Surgery of the craniovertebral junction. New York, Thieme, 1998, p783-94.
 
47) Wang MY. Cervical crossing laminar screws : early clinical results and complications. Neurosurgery 2007 ; 61 : 311-5.
PubMed
48) Wang S, Wang C, Yan M, et al. Novel surgical classification and treatment strategy for atlantoaxial dislocations. Spine 2013 ; 38 : E1348-56.
PubMed
49) Wasserman BR, Moskovich R, RaziAE. Rheumatoid arthritis of the cervical spine-clinical considerations. Bull NYU Hosp Jt Dis 2011 ; 69 : 136-48.
PubMed
50) Weidner A, Wahler M, Chiu ST, et al. Modification of C1-C2 transarticular screw fixation by image-guided surgery. Spine 2000 ; 25 : 2668-73.
PubMed
51) Weissman BN, Aliabadi P, Weinfeld MS, et al. Prognostic features of atlantoaxial subluxation in rheumatoid arthritis patients. Radiology 1982 ; 144 : 745-51.
PubMed
52) Wright NM, Lauryssen C. Vertebral artery injury in C1-2 transarticular screw fixation : results of a survey of the AANS/CNS section on disorders of the spine and peripheral nerves. American Association of Neurological Surgeons/Congress of Neurological Surgeons. J Neurosurg 1998 ; 88 : 634-40.
 
53) Yang SY, Boniello AJ, Poorman CE, et al. A review of the diagnosis and treatment of atlantoaxial dislocations. Global Spine J 2014 ; 4 : 197-210.
PubMed
54) Yeom JS, Buchowski JM, Kim HJ, et al. Risk of vertebral artery injury : comparison between C1-C2 transarticular and C2 pedicle screws. Spine J 2013 ; 13 : 775-85.
PubMed
55) 米延策雄. 頚椎の手術療法. 越智隆弘, 山本一彦, 龍 順之助, 編集, 関節リウマチの診療マニュアル (改訂版), 診断のマニュアルとEBMに基づく治療ガイドライン. 財団法人日本リウマチ財団, 2004, p134-42.
 
56) Yoshida M, Neo M, Fujibayashi S, et al. Comparison of the anatomical risk for vertebral artery injury associated with the C2-pedicle screw and atlantoaxial transarticular screw. Spine 2006 ; 31 : E513-7.
PubMed
57) Yoshimoto H, Ito M, Abumi K, et al. A retrospective radiographic analysis of subaxial sagittal alignment after posterior C1-C2 fusion. Spine 2004 ; 29 : 175-81.
PubMed

第6章 機能的脳神経外科疾患

P.350 掲載の参考文献
1) Jannetta PJ. Arterial compression of the trigeminal nerve at the pons in patients with trigeminal neuralgia. J Neurosurg 1967 ; 26 (Suppl) : 159-62.
 
2) Dandy WE. Concerning the cause of trigeminal neuralgia. Am J Surg 1934 ; 24 : 447-55.
 
3) Barker FG, Jannetta PJ, et al. Long-term outcome after operation for trigeminal neuralgia in patients with posterior fossa tumors. J Neurosurg 1996 ; 84 : 818-25.
PubMed
4) 仲川和彦, 他. 脳腫瘍による三叉神経痛症例の臨床的検討. No Shinkei Geka 2009 ; 37 : 863-71.
 
5) Yoshimasu F, Kurland LT, Elveback LR. Tic douloureux in Rochester, Minnesota, 1945-1969. Neurology 1972 ; 22 : 952-6.
PubMed
6) Barker FG, Jannetta PJ, et al. The long-term outcome of microvascular decompression for trigeminal neuralgia. N Engl J Med 1996 ; 334 : 1077-83.
 
7) Sindou M, et al. Micro-vascular decompression for primary Trigeminal Neuralgia (typical or atypical). Long-term effectiveness on pain ; prospective study with survival analysis in a consecutive series of 362 patients. Acta Neurochir (Wien) 2006 ; 148 : 1235-45 ; discussion 1245.
PubMed
8) Kondo A. Follow-up results of microvascular decompression intrigeminal neuralgia and hemifacial spasm. Neurosurgery 1997 ; 40 : 46-51 ; discussion 51-2.
 
9) Dhople AA, et al. Long-term outcomes of Gamma Knife radiosurgery for classic trigeminal neuralgia : implications of treatment and critical review of the literature. Clinical article. J Neurosurg 2009 ; 111 : 351-8.
PubMed
10) Kondziolka D, et al. Gamma Knife stereotactic radiosurgery for idiopathic trigeminal neuralgia. J Neurosurg 2010 ; 112 : 758-65.
PubMed
11) Chavez GD, et al. Three-dimensional fast imaging employing steady-state acquisition magnetic resonance imaging for stereotactic radiosurgery of trigeminal neuralgia. Neurosurgery 2005 ; 56 : E628 ; discussion E628.
PubMed
12) Campbell FG, Graham JG, Zilkha KJ. Clinical trial of carbazepine (tegretol) in trigeminal neuralgia. J Neurol Neurosurg Psychiatry 1966 ; 29 : 265-7.
PubMed
13) Rockliff BW, Davis EH. Controlled sequential trials of carbamazepine in trigeminal neuralgia. Arch Neurol 1966 ; 15 : 129-36.
PubMed
14) Fromm GH, Terrence CF, Chattha AS. Baclofen in the treatment of trigeminal neuralgia : double-blind study and long-term follow-up. Ann Neurol 1984 ; 15 : 240-4.
PubMed
15) Green MW, Selman JE. Review article : the medical management of trigeminal neuralgia. Headache 1991 ; 31 : 588-92.
PubMed
16) He L, Wu B, Zhou M. Non-antiepileptic drugs for trigeminal neuralgia. Cochrane Database Syst Rev 2006 ; 3 : CD004029.
PubMed
17) Fujimaki T, Fukushima T, Miyazaki S. Percutaneous retrogasserian glycerol injection in the management of trigeminal neuralgia : long-term follow-up results. J Neurosurg 1990 ; 73 : 212-6.
PubMed
18) Tatli M, et al. Various surgical modalities for trigeminal neuralgia : literature study of respective long-term outcomes. Acta Neurochir (Wien) 2008 ; 150 : 243-255.
PubMed
19) Gronseth G, et al. Practice parameter : the diagnostic evaluation and treatment of trigeminal neuralgia (an evidence-based review) : report of the Quality Standards Subcommittee of the American Academy of Neurology and the European Federation of Neurological Societies. Neurology 2008 ; 71 : 1183-90.
PubMed
20) Olson S, Atkinson L, Weidmann M. Microvascular decompression for trigeminal neuralgia : recurrences and complications. J Clin Neurosci 2005 ; 12 : 787-9.
PubMed
21) Gunther T, Samii M, et al. Microvascular decompression for trigeminal neuralgia in the elderly : long-term treatment outcome and comparison with younger patients. Neurosurgery 2009 ; 65 : 477-82 ; discussion 482.
 
22) Sarsam Z, et al. The long-term outcome of microvascular decompression for trigeminal neuralgia. Br J Neurosurg 2010 ; 24 : 18-25.
 
23) Kalkanis SN, et al. Microvascular decompression surgery in the United States, 1996 to 2000 : mortality rates, morbidity rates, and the effects of hospital and surgeon volumes. Neurosurgery 2003 ; 52 : 1251-61 ; discussion 1261-2.
 
24) Lopez BC, Hamlyn PJ, Zakrzewska JM. Stereotactic radiosurgery for primary trigeminal neuralgia : state of the evidence and recommendations for future reports. J Neurol Neurosurg Psychiatry 2004 ; 75 : 1019-24.
PubMed
25) Little AS, Shetter AG, Shetter ME, et al. Long-term pain response and quality of life in patients with typical trigeminal neuralgia treated with gamma knife stereotactic radiosurgery. Neurosurgery 2008 ; 63 : 915-23 ; discussion 923-4.
 
26) Shetter AG, et al. Gamma knife radiosurgery for recurrent trigeminal neuralgia. J Neurosurg 2002 ; 97 (5 Suppl) : 536-8.
PubMed
P.353 掲載の参考文献
1) Gardner WJ, Sava GA. Hemifacial Spasm-a Reversible Pathophysiologic State. J Neurosurg 1962 ; 19 : 240-7.
 
2) Jannetta PJ, Hackett E, Ruby JR. Electromyographic and electron microscopic correlates in hemifacial spasm treated by microsurgical relief of neurovascular compression. Surg Forum 1970 ; 21 : 449-51.
PubMed
3) Jannetta PJ, et al. Etiology and definitive microsurgical treatment of hemifacial spasm. Operative techniques and results in 47 patients. J Neurosurg 1977 ; 47 : 321-8.
PubMed
4) Auger RG, Whisnant JP. Hemifacial spasm in Rochester and Olmsted County, Minnesota, 1960 to 1984. Arch Neurol 1990 ; 47 : 1233-4.
PubMed
5) Kondo A. Follow-up results of microvascular decompression in trigeminal neuralgia and hemifacial spasm. Neurosurgery 1997 ; 40 : 46-51 ; discussion 51-2.
 
6) 福島孝徳, 玉川輝明, 宮崎紳一郎, 他. Microvascular decompressionのコツ, 合併症の防止と減圧困難例の対策. 第45回 日本脳神経外科学会総会抄録集, 1986, p450.
 
7) Barker FG, Jannetta PJ, et al. Microvascular decompression for hemifacial spasm. J Neurosurg 1995 ; 82 : 201-10.
PubMed
8) Illingworth RD, Porter DG, Jakubowski J. Hemifacial spasm : a prospective long-term follow up of 83 cases treated by microvascular decompression at two neurosurgical centres in the United Kingdom. J Neurol Neurosurg Psychiatry 1996 ; 60 : 72-7.
PubMed
9) Samii M, et al. Microvascular decompression to treat hemifacial spasm : long-term results for a consecutive series of 143 patients. Neurosurgery 2002 ; 50 : 712-8 ; discussion 718-9.
 
10) Ohta M, Kobayashi M, Wakiya K, et al. Preoperative assessment of hemifacial spasm by the coronal heavily T2-weighted MR cisternography. Acta Neurochir (Wien) 2014 ; 156 : 565-9.
PubMed
11) Oizumi T, Ohira T, Kawase T. Angiographic manifestations and operative findings with 70 cases of hemifacial spasm : relation of common trunk anomalies. Keio J Med 2003 ; 52 : 189-97.
PubMed
12) Jitpimolmard S, Tiamkao S, Laopaiboon M. Long term results of botulinum toxin type A (Dysport) in the treatment of hemifacial spasm : a report of 175 cases. J Neurol Neurosurg Psychiatry 1998 ; 64 : 751-7.
 
13) De Ridder D, et al. Is the root entry/exit zone important in microvascular compression syndromes? Neurosurgery 2002 ; 51 : 427-33 ; discussion 433-4.
 
14) Kalkanis SN, et al. Microvascular decompression surgery in the United States, 1996 to 2000 : mortality rates, morbidity rates, and the effects of hospital and surgeon volumes. Neurosurgery 2003 ; 52 : 1251-61 ; discussion 1261-2.
 
15) 永廣信治. 顔面痙攣の病態と手術. No Shinkei Geka 1998 ; 26 : 101-11.
 
16) Dannenbaum M, et al. Microvascular decompression for hemifacial spasm : long-term results from 114 operations performed without neurophysiological monitoring. J Neurosurg 2008 ; 109 : 410-5.
PubMed
17) Miller LE, Miller VM. Safety and effectiveness of microvascular decompression for treatment of hemifacial spasm : a systematic review. Br. J Neurosurg 2012 ; 26 : 438-44.
PubMed
18) Li CS. Varied patterns of postoperative course of disappearance of hemifacial spasm after microvascular decompression. Acta Neurochir (Wien) 2005 ; 147 : 617-20 ; discussion 620.
 
19) Payner TD, Tew JM Jr. Recurrence of hemifacial spasm after microvascular decompression. Neurosurgery 1996 ; 38 : 686-90 ; discussion 690-1.
 
20) McLaughlin MR, et al. Microvascular decompression of cranial nerves : lessons learned after 4400 operations. J Neurosurg 1999 ; 90 : 1-8.
PubMed
21) Huh R, et al. Microvascular decompression for hemifacial spasm : analyses of operative complications in 1582 consecutive patients. Surg Neurol 2008 ; 69 : 153-7 ; discussion 157.
 
22) Hanakita J, Kondo A. Serious complications of microvascular decompression operations for trigeminal neuralgia and hemifacial spasm. Neurosurgery 1988 ; 22 : 348-52.
PubMed
P.357 掲載の参考文献
1) Yamamoto T, Katayama Y, Hirayama T, et al. Pharmacological classification of central post-stroke pain : comparison with the results of chronic motor cortex stimulation therapy. Pain 1997 ; 72 : 5-12.
PubMed
2) Dreval ON. Ultrasonic DREZ-operations for treatment of pain following brachil plexus avulsion. Acta Neurochir (Wien) 1992 ; 122 : 76-81.
 
3) Saris SC, Iacono RP, Nashold BS Jr. Successful treatment of phantom pain and dorsal root entry zone coagulation. Appl Neurophysiol 1988 ; 51 : 188-97.
PubMed
4) Young RF. Clinical experience with radiofrequency and laser DREZ lesions. J Neurosurg 1990 ; 72 : 715-20.
PubMed
5) Taylor RS. Spinal cord stimulation in complex regional pain syndrome and refractory neuropathic back and leg pain/failed back surgery syndrome : results of a systematic review and metaanalysis. J Pain Symptom Manage 2006 ; 31 : S13-19.
PubMed
6) Kumar K, Taylor RS, Jacques L, et al. The effects of spinal cord stimulation in neuropathic pain are sustained : a 24-month follow-up of the prospective randomized controlled multicenter trial of the effectiveness of spinal cord stimulation. Neurosurgery 2008 ; 63 : 762-70.
PubMed
7) North RB, Kidd D, Shipley J, et al. Spinal cord stimulation versus reoperation for failed back surgery syndrome : a cost effectiveness and cost utility analysis based on a randomized, controlled trial. Neurosurgery 2007 ; 61 : 361-8.
PubMed
8) Manca A, Kumar K, Taylor RS, et al. Quality of life, resource consumption and costs of spinal cord stimulation versus conventional medical management in neuropathic pain patients with failed back surgery syndrome (PROCESS trial). Eur J Pain 2008 ; 12 : 1047-58.
PubMed
9) Frey ME, Manchikanti L, Benyamin RM, et al. Spinal cord stimulation for patients with failed back surgery syndrome : a systematic review. Pain Physician 2009 ; 12 : 379-97.
PubMed
10) Kemler MA, Barendse GA, van Kleef M, et al. Spinal cord stimulation in patients with chronic reflex sympathetic dystrophy. N Engl J Med 2000 ; 343 : 618-24.
PubMed
11) Kemler MA, de Vet HC, Barendse GA, et al. Effect of spinal cord stimulation for chronic complex regional pain syndrome Type I : five-year final follow-up of patients in a randomized controlled trial. J Neurosurg 2008 ; 108 : 292-8.
 
12) Taylor RS, Van Buyten JP, Buchser E. Spinal cord stimulation for complex regional pain syndrome : a systematic review of the clinical and cost-effectiveness literature and assessment of prognostic factors. Eur J Pain 2006 ; 10 : 91-101.
PubMed
13) Simpson EL, Duenas A, Holmes MW, et al. Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin : systematic review and economic evaluation. Health Technol Assess 2009 ; 13 : 1-154.
PubMed
14) Vallejo R, Kramer J, Benyamin R. Neuromodulation of the cervical spinal cord in the treatment of chronic intractable neck and upper extremity pain : a case series and review of the literature. Pain Physician 2007 ; 10 : 305-11.
 
15) Rogano L, Teixeira MJ, Lepski G. Chronic pain after spinal cord injury : clinical characteristics. Stereotact Funct Neurosurg 2003 ; 81 : 65-9.
PubMed
16) Aly MM, Saitoh Y, Hosomi K. Spinal cord stimulation for central poststroke pain. Neurosurgery 2010 ; 67 : 206-12.
 
17) Ekre O, Eliasson T, Norrsell H, et al. Electrical Stimulation versus Coronary Artery Bypass Surgery in Severe Angina Pectoris. Long-term effects of spinal cord stimulation and coronary artery bypass grafting on quality of life and survival in the ESBY study. Eur Heart J 2002 ; 23 : 1938-45.
PubMed
18) Wu M, Linderoth B, Foreman RD. Putative mechanisms behind effects of spinal cord stimulation on vascular diseases : a review of experimental studies. Auton Neurosci 2008 ; 29 : 9-23.
 
19) Borjesson M, Andrell P, Mannheimer C. Spinal cord stimulation for long-term treatment of severe angina pectoris : what does the evidence say? Future Cardiol 2011 ; 7 : 825-33.
PubMed
20) van Kleef M, Staats P, Mekhail N, et al. 24. Chronic refractory angina pectoris. Pain Pract 2011 ; 11 : 476-82.
PubMed
21) Fihn SD, Gardin JM, Abrams J, et al. American College of Cardiology Foundation/American Heart Association Task Force. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease. Circulation 2012 ; 126 : e354-471.
 
22) Ubbink DT, Vermeulen H. Spinal cord stimulation for critical leg ischemia : a review of effectiveness and optimal patient selection. J Pain Symptom Manage 2006 ; 31 : S30-5.
PubMed
23) Bittar RG, Kar-Purkayastha I, Owen SL, et al. Deep brain stimulation for pain relief : a meta-analysis. J Clin Neurosci 2005 ; 12 : 515-9.
PubMed
24) Hamani C, Schwalb JM, Rezai AR, et al. Deep brain stimulation for chronic neuropathic pain : long-term outcome and the incidence of insertional effect. Pain 2006 ; 125 : 188-96.
PubMed
25) Tsubokawa T, Katayama Y, Yamamoto T, et al. Chronic motor cortex stimulation in patients with thalamic pain. J Neurosurg 1993 ; 78 : 393-401.
 
26) Nguyen JP, Keravel Y, Feve A, et al. Treatment of deafferentation pain by chronic stimulation of the motor cortex : report of a series of 20 cases. Acta Neurochir Suppl (Wien) 1997 ; 68 : 54-60.
 
27) Saitoh Y, Shibata M, Sanada Y, et al. Motor cortex stimulation for phantom limb pain. Lancet 1999 ; 353 : 212.
PubMed
28) Carroll D, Joint C, Maartens N, et al. Motor cortex stimulation for chronic neuropathic pain : a preliminary study of 10 cases. Pain 2000 ; 84 : 431-7.
PubMed
29) Roux FE, Ibarrola D, Lazorthes Y, et al. Virtual movements activate primary sensorimotor areas in amputees : report of three cases. Neurosurgery 2001 ; 49 : 736-41.
PubMed
30) Lima MC, Fregni F. Motor cortex stimulation for chronic pain : systematic review and meta-analysis of the literature. Neurology 2008 ; 70 : 2329-37.
PubMed
31) Fontaine D, Hamani C, Lozano A. Efficacy and safety of motor cortex stimulation for chronic neuropathic pain : critical review of the literature. J Neurosurg 2009 ; 110 : 251-6.
PubMed
32) Fukaya C, Katayama Y, Yamamoto T, et al. Motor cortex stimulation in patients with post-stroke pain : conscious somatosensory response and pain control. Neurol Res 2003 ; 25 : 153-6.
PubMed
P.361 掲載の参考文献
1) Limousin P, Green J, Pollaak P, et al. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 1998 ; 339 : 1105-11.
 
2) Ashkan K, Wallace B, Bell BA, et al. Deep brain stimulation of the subthalamic nucleus in Parkinson's disease 1993-2003 : where are we 10 years on? Br J Neurosurg 2004 ; 18 : 19-34.
 
3) Katayama Y, Oshima H, Kano T, et al. Direct effect of subthalamic nucleus stimulation on levodopa-induced peak-dose dyskinesia in patients with Parkinson's disease. Stereotact Funct Neurosurg 2006 ; 84 : 176-9.
PubMed
4) Kleiner-Fisman G, Fisman DN, Sime E, et al. Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease. J Neurosurg 2003 ; 99 : 489-95.
PubMed
5) German Parkinson Study Group, Neurostimulation Section. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 2006 ; 355 : 896-908.
 
6) Weaver F, Follett K, Hur K. Deep brain stimulation in Parkinson disease : a metaanalysis of patient outcomes. J Neurosurg 2005 ; 103, 956-67.
PubMed
7) Herzog J, Volkmann J, Krack P, et al. Two-year follow-up of subthalamic deep brain stimulation in Parkinson's disease. Mov Disord 2003 ; 18 : 1332-7.
PubMed
8) Funkiewiez A, Ardouin C, Caputo E, et al. Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson's disease. J Neurol Neurosurg Psychiatry 2004 ; 75 : 834-9.
PubMed
9) Okun MS, Green J, Saben R, et al. Mood changes with deep brain stimulation of STN and GPi : results of a pilot study. J Neurol Neurosurg Psychiatry 2003 ; 74 : 1584-6.
PubMed
10) Weaver FM, Follett K, Stern M, et al, CSP 468 Study Group. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease : a randomized controlled trial. JAMA 2009 ; 301 : 63-73.
 
11) Williams A, Gill S, Varma T, et al. PD SURG Collaborative Group : Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial) : a randomised, open-label trial. Lancet Neurol 2010 ; 9 : 581-91.
 
12) Okun MS, Gallo BV, Mandybur G, et al. SJM DBS Study Group : Subthalamic deep brain stimulation with a constant-current device in Parkinson's disease : an open-label randomised controlled trial. Lancet Neurol 2012 ; 11 : 140-9.
 
13) Schuepbach WM, Rau J, Knudsen K, et al. EARLYSTIM Study Group : Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med 2013 ; 368 : 610-22.
 
14) Okun MS, Fernandez HH, Wu SS, et al. Cognition and mood in Parkinson's disease in subthalamic nucleus versus globus pallidus interna deep brain stimulation : the COMPARE trial. Ann Neurol 2009 ; 65 : 586-95.
PubMed
15) Follett KA, Weaver FM, Stern M, et al. CSP 468 Study Group : Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N Engl J Med 2010 ; 362 : 2077-2091.
 
16) Odekerken VJ, van Laar T, Staal MJ, et al. Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson's disease (NSTAPS study) : a randomised controlled trial. Lancet Neurol 2013 ; 12 : 37-44.
PubMed
17) Fukaya C, Yamamoto T. Deep brain stimulation for Parkinson's disease : recent trends and future direction. Neurol Med Chir (Tokyo) 2015 ; 55 : 422-41.
PubMed
18) St George RJ, Nutt JG, Burchiel KJ, et al. A meta-regression of the long-term effects of deep brain stimulation on balance and gait in PD. Neurology 2010 ; 75 : 1292-9.
 
19) Fukaya C, Yamamoto T. Systematic review of complications fjor proper informed consent (13) Stereotactic and functional neurosurgery. No Shinkei Geka 2014 ; 42 : 751-68.
 
20) Krack P, Batir A, Van Blercom N, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 2003 ; 349 : 1925-34.
PubMed
21) Rodriguez-Oroz MC, Obeso JA, Lang AE, et al. Bilateral deep brain stimulation in Parkinson's disease : a multicentre study with 4 years follow-up. Brain 2005 ; 128 : 2240-9.
PubMed
22) Piboolnurak P, Lang AE, Lozano AM, et al. Levodopa response in long-term bilateral subthalamic stimulation for Parkinson's disease. Mov Disord 2007 ; 22, 990-7.
PubMed
23) D'Ausilio A, Marconi S, Antonini A, et al. Cost analysis in Italy of various strategies for the treatment of Parkinson disease in the advanced phase. Recenti Prog Med 2003 ; 94 : 484-93.
 
24) Fasano A, Romito LM, Daniele A, et al. Motor and cognitive outcome in patients with Parkinson's disease 8 years after subthalamic implants. Brain 2010 ; 133 : 2664-76.
PubMed
25) Castrioto A, Lozano AM, Poon YY, et al. Ten-year outcome of subthalamic stimulation in Parkinson disease : a blinded evaluation. Arch Neurol 2011 ; 68 : 1550-6.
PubMed
26) Zibetti M, Merola A, Rizzi L, et al. Beyond nine years of continuous subthalamic nucleus deep brain stimulation in Parkinson's disease. Mov Disord 2011 ; 26 : 2327-34.
PubMed
P.365 掲載の参考文献
1) 梶龍兒. 不随意運動の診断と治療 (梶龍兒編集). 診断と治療社, 東京, 2006.
 
2) 目崎高広. ジストニアの診断指針 (総論). ジストニアの診断指針と疫学, 治療の現状 2005. 「ジストニアの疫学, 診断, 治療に関する総合的研究」班編, 2005, p1-8.
 
3) Bertrand CM. Surgical management of spasmodic torticollis and adult-onset dystonia. In ; Schmidek HH, Sweet WH, eds. Operative Neurosurgical techniques. 3rd ed, Saunders, Philadelphia, vol 2, 1995, p1649-57.
 
4) Cohen-Gadol AA, Ahlskog JE, Matsumoto JY, et al. Selective peripheral denervation for the treatment of intractable spasmodic torticollis : experience with 168 patients at the Mayo Clinic. J Neurosurg 2003 ; 98 : 1247-54.
 
5) Friedman A, Nashold BS, Sharp R, et al. Treatment of spasmodic torticollis with intradural selective rhizotomies. J Neurosurg 1993 ; 78 : 46-53.
PubMed
6) Munchau A, Good CD, McGowan S, et al. Prospective study of swallowing function in patients with cervical dystonia undergoing selective peripheral denervation. J Neurol Neurosurg Psychiatry 2001 ; 71 : 67-72.
PubMed
7) Coubes P, Roubertie A, Vayssiere N, et al. Treatment of DYT1-generalised dystonia by stimulation of the internal globus pallidus. Lancet 2000 ; 355 : 2220-1.
PubMed
8) Coubes P, Cif L, El Fertit H, et al. Electrical stimulation of the globus pallidus internus in patients with primary generalized dystonia : long-term results. J Neurosurg 2004 ; 101 : 189-94.
PubMed
9) Krauss JK, Loher TJ, Pohle T, et al. Pallidal deep brain stimulation in patients with cervical dystonia and severe cervical dyskinesias with cervical myelopathy. J Neurol Neurosurg Psychiatry 2002 ; 72 : 249-56.
PubMed
10) Parkin S, Aziz T, Gregory R, et al. Bilateral internal globus pallidus stimulation for the treatment of spasmodic torticollis. Mov Disord 2001 ; 16 : 489-93.
PubMed
11) Hung SW, Hamani C, Lozano AM, et al. Long-term outcome of bilateral pallidal deep brain stimulation for primary cervical dystonia. Neurology 2007 ; 68 : 457-9.
PubMed
12) Kiss ZH, Doig-Beyaert K, Eliasziw M, et al. Functional and Stereotactic Section of the Canadian Neurosurgical Society ; Canadian Movement Disorders Group. The Canadian multicentre study of deep brain stimulation for cervical dystonia. Brain 2007 ; 130 : 2879-86.
 
13) Bruggemann N, Kuhn A, Schneider SA. Short- and long-term outcome of chronic pallidal neurostimulation in monogenic isolated dystonia. Neurology 2015 ; 84 : 895-903.
 
14) Volkmann J, Mueller J, Deuschl G, et al. DBS study group for dystonia : Pallidal neurostimulation in patients with medication-refractory cervical dystonia : a randomised, sham-controlled trial. Lancet Neurol 2014 ; 13 : 875-84.
 
15) Schjerling L, Hjermind LE, Jespersen B, et al. A randomized double-blind crossover trial comparing subthalamic and pallidal deep brain stimulation for dystonia. J Neurosurg 2013 ; 119 : 1537-45.
 
16) Merola A, Zibetti M, Artusi CA. 80 Hz versus 130 Hz subthalamic nucleus deep brain stimulation : effects on involuntary movements. Parkinsonism Relat Disord 2013 ; 19 : 453-6.
 
17) Benabid AL, Pollak P, Gao D, et al. Chronic electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment of movement disorders. J Neurosurg 1996 ; 84 : 203-14.
PubMed
18) Koller WC, Lyons KE, Wilkinson SB, et al. Long-term safety and efficacy of unilateral deep brain stimulation of the thalamus in essential tremor. Mov Disord 2001 ; 16 : 464-8.
PubMed
19) Rehncrona S, Johnels B, Widner H, et al. Long-term efficacy of thalamic deep brain stimulation for tremor : double-blind assessments. Mov Disord 2003 ; 18 : 163-70.
PubMed
20) Pahwa R, Lyons KE, Wilkinson SB, et al. Comparison of thalamotomy to deep brain stimulation of the thalamus in essential tremor. Mov Disord 2001 ; 16 : 140-3.
PubMed
21) Kumar R, Lozano AM, Sime E, et al. Long-term follow-up of thalamic deep brain stimulation for essential and parkinsonian tremor. Neurology 2003 ; 61 : 1601-4.
PubMed
22) Pedrosa DJ, Auth M, Pauls KA, et al. Verbal fluency in essential tremor patients : the effects of deep brain stimulation. Brain Stimul 2014 ; 7 : 359-64.
 
23) Yamamoto T, Katayama Y, Kano T, et al. Deep brain stimulation for the treatment of parkinsonian, essential, and poststroke tremor : a suitable stimulation method and changes in effective stimulation intensity. J Neurosurg 2004 ; 101 : 201-9.
PubMed
24) Sitsapesan HA, Holland P, Oliphant Z, et al. Deep brain stimulation for tremor resulting from acquired brain injury. J Neurol Neurosurg Psychiatry 2014 ; 85 : 811-5.
PubMed
25) Kobayashi K, Katayama Y, Oshima H, et al. Multitarget, dualelectrode deep brain stimulation of the thalamus and subthalamic area for treatment of Holmes' tremor. J Neurosurg 2014 ; 120 : 1025-32.
 
26) Smith KM, Spindler MA. Uncommon applications of deep brain stimulation in hyperkinetic movement disorders. Tremor Other Hyperkinet Mov (N Y) 2015 ; 1-17.
 
27) Fukaya C, Yamamoto T. Systematic review of complications fjor proper informed consent (13) Stereotactic and functional neurosurgery. No Shinkei Geka 2014 ; 42 : 751768.
 
P.367 掲載の参考文献
1) Cohen LG, Hallett M, Geller BD, et al. Treatment of focal dystonias of the hand with botulinum toxin injections. J Neurol Neurosurg Psychiatry 1989 ; 52 : 355-63.
PubMed
2) Rivest J, Lees AJ, Marsden CD. Writer's cramp : Treatment with botulinum toxin injections. Mov Disord 1991 ; 6 : 55-9.
 
3) Kaji R, Rothwell JC, Katayama M, et al. Tonic vibration reflex and muscle afferent block in writer's cramp. Ann Neurol 1995 ; 38 : 155-62.
 
4) Fukaya C, Katayama Y, Kano T, et al. Thalamic deep brain stimulation for writer's cramp. J Neurosurg 2007 ; 107 : 977-82.
 
5) Siegfried J, Crowell R, Perret E. Cure of tremulous writer's cramp by stereotaxic thalamotomy. Case report. J Neurosurg 1969 ; 30 : 182-5.
 
6) Taira T, Harashima S, Hori T. Neurosurgical treatment for writer's cramp. Acta Neurochir Suppl 2003 ; 87 : 129-31.
 
7) Shibata T, Hirashima Y, Ikeda H, et al. Stereotactic voa-vop complex thalamotomy for writer's cramp. Eur Neurol 2005 ; 53 : 38-9.
 
8) Goto S, Tsuiki H, Soyama N, et al. Stereotactic selective vo-complex thalamotomy in a patient with dystonic writer's cramp. Neurology 1997 ; 49 : 1173-4.
 

第7章 てんかん

P.383 掲載の参考文献
1) 「てんかん治療ガイドライン」作成委員会, 編. てんかん治療ガイドライン 2010, 医学書院, 東京, 2010.
 
2) 飯沼一宇, 日本てんかん学会ガイドライン作成委員会. てんかんの診断ガイドライン. てんかん研究 2008 ; 26 : 110-3.
 
3) 日吉敏雄, 日本てんかん学会ガイドライン作成委員会. 成人てんかんの薬物治療終結のガイドライン. てんかん研究 2010 ; 27 : 417-22.
 
4) 笹川睦男, 日本てんかん学会ガイドライン作成委員会. 成人の初発けいれん発作に対するガイドライン. てんかん研究 2011 ; 29 : 72-4.
 
5) 井上有史, 日本てんかん学会ガイドライン作成委員会. 成人てんかんにおける薬物治療ガイドライン. てんかん研究 2005 ; 23 : 249-53.
 
6) 藤原建樹, 日本てんかん学会ガイドライン作成委員会. 新規抗てんかん薬を用いたてんかんの薬物治療ガイドライン. てんかん研究 2010 ; 28 : 48-65.
 
7) ILAE : http://www.ilae.org/visitors/centre/guidelines.cfm
 
8) American Epilepsy Society : https://www.aesnet.org/clinical_resources/guidelines
 
9) NICE : https://www.nice.org.uk/guidance/cg137
 
10) Karceski S, Morrell MJ, Carpentar D. Treatment of epilepsy in adults : expert opinion 2005. Epilepsy Behav 2005 ; 7 : S1-64.
 
11) Fisher RS, Acevedo C, Arzimanoglou A, et al. A practical clinical definition of epilepsy. Epilepsia 2014 ; 55 : 475-82.
 
12) Toledano M, Britton JW, McKeon A, et al. Utility of an immunotherapy trial in evaluating patients with presumed autoimmune epilepsy. Neurology 2014 ; 82 : 1578-86.
PubMed
13) Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies : report of the ILAE Commission on Classification and Terminology. 2005-2009. Epilepsia 2010 ; 676-85.
PubMed
14) Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981 ; 22 : 489-501.
PubMed
15) Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndrome. Epilepsia 1989 ; 30 : 389-99.
PubMed
16) 池田昭夫. 総論 1. 概念と定義 In ; 池田昭夫 編. 症例から学ぶ戦略的てんかん診断・治療, 南山堂, 東京, 2014, p2-9.
 
17) Krumhilz A, Shinnar S, French J, et al. Evidence-based guideline : Management of an unprovoked first seizure in adults : Report of the Guideline Development Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2015 ; 84 : 1705-13.
PubMed
18) 井上岳司, 池田昭夫. II-3 鑑別診断. In ; 辻貞俊 編. 神経内科外来シリーズ 4 てんかん外来, メジカルビュー社, 東京, 2016, p46-53.
 
19) McKeon A, Vaughan C, Delanty N. Seizure versus syncope. Lancet Neurol 2006 ; 5 : 171-80.
PubMed
20) 三枝隆博, 木下真幸子, 池田昭夫. 抗てんかん薬治療アルゴリズム. In ; 辻省次 編. てんかんテキストNew version, 中山書店, 東京, 2012, p352-56.
 
21) 日本てんかん学会 てんかん学用語集 第5版, 2013.
 
22) 「てんかん治療ガイドライン」作成委員会 編. てんかん治療ガイドライン 2010 追補版 (2012年度) http://www.neurology-jp.org/guidelinem/
 
23) 池田昭夫, 柴崎浩. 痙攣. In ; 杉本恒明, 小俣政男 総編集. 内科鑑別診断学 第2版, 朝倉書店, 東京, 2003, p.87-96.
 
24) 佐藤岳史, 池田昭夫, 柴崎浩. その他の症候と治療 : てんかん. In ; 橋本信夫 編. 脳神経外科臨床指針, 中外医学社, 東京, 2002, p20-33.
 
25) 小林勝哉, 池田昭夫. VIII-5 てんかん. In ; 診療ガイドライン UP-TO-DATE, メディカルレビュー社, 大阪, 2014, p477-89.
 
P.388 掲載の参考文献
1) Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy : consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010 ; 51 : 1069-77.
 
2) Kwan P, Brodie MJ. Early identification of refractory epilepsy. New Engl J Med 2000 ; 342 : 314-9.
PubMed
3) Engel J Jr, McDermott MP, Wiebe S, et al. Early surgical therapy for drug-resistant temporal lobe epilepsy : a randomized trial. JAMA 2012 ; 307 : 922-30.
PubMed
4) Tellez-Zenteno JF, Hernandez Ronquillo L, Moien-Afshari F, et al. Surgical outcomes in lesional and non-lesional epilepsy : a systematic review and meta-analysis. Epilepsy Res 2010 ; 89 : 310-8.
PubMed
5) Englot DJ, Berger MS, Barbaro NM, et al. Factors associated with seizure freedom in the surgical resection of glioneuronal tumors. Epilepsia 2012 ; 53 : 51-7.
PubMed
6) Rydenhag B, Flink R, Malmgren K. Surgical outcomes in patients with epileptogenic tumours and cavernomas in Sweden : good seizure control but late referrals. J Neurol Neurosurg Psychiatry 2013 ; 84 : 49-53.
PubMed
7) Cross JH, Jayakar P, Nordli D, et al. Proposed criteria for referral and evaluation of children for epilepsy surgery : recommendations of the Subcommission for Pediatric Epilepsy Surgery. Epilepsia 2006 ; 47 : 952-9.
PubMed
8) Ryvlin P, Cross JH, Rheims S. Epilepsy surgery in children and adults. Lancet Neurol 2014 ; 13 : 1114-26.
PubMed
9) Madhavan D, Kuzniecky R. Temporal lobe surgery in patients with normal MRI. Curr Opin Neurol 2007 ; 20 : 203-7.
PubMed
10) Sutherling WW, Mamelak AN, Thyerlei D, et al. Influence of magnetic source imaging for planning intracranial EEG in epilepsy. Neurology 2008 ; 71 : 990-6.
PubMed
11) Knowlton RC, Razdan SN, Limdi N, et al. Effect of epilepsy magnetic source imaging on intracranial electrode placement. Ann Neurol 2009 ; 65 : 716-23.
PubMed
12) LoPinto-Khoury C, Sperling MR, Skidmore C, et al. Surgical outcome in PET-positive, MRI-negative patients with temporal lobe epilepsy. Epilepsia 2012 ; 53 : 342-8.
PubMed
13) Hamiwka L, Macrodimitris S, Tellez-Zenteno JF, et al. Social outcomes after temporal or extratemporal epilepsy surgery : a systematic review. Epilepsia 2011 ; 52 : 870-9.
PubMed
14) Tellez-Zenteno JF, Dhar R, Hernandez-Ronquillo L, et al. Long-term outcomes in epilepsy surgery : antiepileptic drugs, mortality, cognitive and psychosocial aspects. Brain 2007 ; 130 : 334-45.
PubMed
15) Boshuisen K, Arzimanoglou A, Cross JH, et al. Timing of antiepileptic drug withdrawal and long-term seizure outcome after paediatric epilepsy surgery (TimeToStop) : a retrospective observational study. Lancet Neurol 2012 ; 11 : 784-91.
PubMed
16) Burch J, Marson A, Beyer F, et al. Dilemmas in the interpretation of diagnostic accuracy studies on presurgical workup for epilepsy surgery. Epilepsia 2012 ; 53 : 1294-302.
PubMed
17) Whiting P, Gupta R, Burch J, et al. A systematic review of the effectiveness and cost-effectiveness of neuroimaging assessments used to visualise the seizure focus in people with refractory epilepsy being considered for surgery. Health Technol Assess 2006 ; 10 : 1-250, iii-iv.
 
18) Henry TR, Chugani HT. Positron emission tomography. In : Engel JJ, Pedley TA, eds. Epilepsy : a comprehensive textbook, second edition. Philadelphia, Lippincott Williams & Wilkins, 2008 : p945-64.
 
19) Matsuda H, Matsuda K, Nakamura F, et al. Contribution of subtraction ictal SPECT coregistered to MRI to epilepsy surgery : a multicenter study. Ann Nucl Med 2009 ; 23 : 283-91.
PubMed
20) Ahnlide JA, Rosen I, Linden-Mickelsson Tech P, et al. Does SISCOM contribute to favorable seizure outcome after epilepsy surgery? Epilepsia 2007 ; 48 : 579-88.
PubMed
21) von Oertzen TJ, Mormann F, Urbach H, et al. Prospective use of subtraction ictal SPECT coregistered to MRI (SISCOM) in presurgical evaluation of epilepsy. Epilepsia 2011 ; 52 : 2239-48.
PubMed
22) Sharan A, Ooi YC, Langfitt J, Sperling MR. Intracarotid amobarbital procedure for epilepsy surgery. Epilepsy Behav 2011 ; 20 : 209-13.
PubMed
23) Thadani VM, Williamson PD, Berger R, et al. Successful epilepsy surgery without intracranial EEG recording : criteria for patient selection. Epilepsia 1995 ; 36 : 7-15.
PubMed
24) Haegelen C, Perucca P, Chatillon CE, et al. High-frequency oscillations, extent of surgical resection, and surgical outcome in drug-resistant focal epilepsy. Epilepsia 2013.
PubMed
25) Kunii N, Kamada K, Ota T, et al. Characteristic profiles of high gamma activity and blood oxygenation level-dependent responses in various language areas. NeuroImage 2013 ; 65 : 242-9.
PubMed
26) Tellez-Zenteno JF, Dhar R, Wiebe S. Long-term seizure outcomes following epilepsy surgery : a systematic review and meta-analysis. Brain 2005 ; 128 : 1188-98.
PubMed
27) Spencer S, Huh L. Outcomes of epilepsy surgery in adults and children. Lancet Neurol 2008 ; 7 : 525-37.
PubMed
28) de Tisi J, Bell GS, Peacock JL, et al. The long-term outcome of adult epilepsy surgery, patterns of seizure remission, and relapse : a cohort study. Lancet 2011 ; 378 : 1388-95.
 
29) Josephson CB, Dykeman J, Fiest KM, et al. Systematic review and meta-analysis of standard vs selective temporal lobe epilepsy surgery. Neurology 2013 ; 80 : 1669-76.
PubMed
30) Hu WH, Zhang C, Zhang K, et al. Selective amygdalohippo-campectomy versus anterior temporal lobectomy in the management of mesial temporal lobe epilepsy : a meta-analysis of comparative studies. Journal of neurosurgery 2013 ; 119 : 1089-97.
 
31) Hu WH, Zhang C, Zhang K, et al. Hemispheric surgery for refractory epilepsy : a systematic review and meta-analysis with emphasis on seizure predictors and outcomes. J Neurosurg 2015 ; 23 : 1-10.
 
32) Ntsambi-Eba G, Vaz G, Docquier MA, et al. Patients with refractory epilepsy treated using a modified multiple subpial transection technique. Neurosurgery 2013 ; 72 : 890-97 ; discussion 897-8.
 
33) Shimizu H, Kawai K, Sunaga S, et al. Hippocampal transection for treatment of left temporal lobe epilepsy with preservation of verbal memory. J Clin Neurosci 2006 ; 13 : 322-8.
 
34) Rolston JD, Englot DJ, Wang DD, et al. Corpus callosotomy versus vagus nerve stimulation for atonic seizures and drop attacks : A systematic review. Epilepsy Behav 2015 ; 51 : 13-7.
PubMed
35) Hader WJ, Tellez-Zenteno J, Metcalfe A, et al. Complications of epilepsy surgery-a systematic review of focal surgical resections and invasive EEG monitoring. Epilepsia 2013 ; 54 : 840-7.
PubMed
36) Spencer SS, Schramm J, Wyler A, et al. Multiple subpial transection for intractable partial epilepsy : an international meta-analysis. Epilepsia 2002 ; 43 : 141-5.
PubMed
37) Devlin AM, Cross JH, Harkness W, et al. Clinical outcomes of hemispherectomy for epilepsy in childhood and adolescence. Brain 2003 ; 126 : 556-66.
PubMed
P.394 掲載の参考文献
1) 警察庁交通局運転免許課長. 一定の病気等に係る運転免許関係事務に関する運用上の留意事項について. 警察庁丁運発 第42号, 2014.
 
2) Brown JW, Lawn ND, Lee J, et al. When is it safe to return to driving following first-ever seizure? J Neurol Neurosurg Psychiatry 2015 ; 86 : 60-4.
PubMed
3) Driving SEWGoEa. Epilepsy and driving in Europe. A report of the second European Working Group on Epilepsy and Driving, an advisory board to the Driving Licence Committee of the European Union. Final report. http://eceuropaeu/transport/home/drivinglicence/fitnesstodrive/doc/epilepsy_and_driving_in_europe_final_report_v2_enpdf 2005.
 
4) Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE official report : a practical clinical definition of epilepsy. Epilepsia 2014 ; 55 : 475-82.
PubMed
5) 日本てんかん学会. てんかんに関する医師の届け出ガイドライン. http://squareuminacjp/jes/images/jes-image/140910JES_GLpdf2014.9.
 
6) 日本医師会. 道路交通法に基づく一定の症状を呈する病気等にある者を診断した医師から公安委員会への任意の届出ガイドライン. http://dlmedorjp/dl-med/teireikaiken/20140910_1pdf2014.9.
 
7) Hauser WA, Rich SS, Lee JR, et al. Risk of recurrent seizures after two unprovoked seizures. New Engl J Med 1998 ; 338 : 429-34.
PubMed
8) Lindsten H, Stenlund H, Forsgren L. Remission of seizures in a population-based adult cohort with a newly diagnosed unprovoked epileptic seizure. Epilepsia 2001 ; 42 : 1025-30.
 
9) 松浦雅人. てんかんと運転 (医師の立場から). Epilepsy 2012 ; 6 : 19-26.
Medical*Online
10) Drazkowski JF, Fisher RS, Sirven JI, et al. Seizure-related motor vehicle crashes in Arizona before and after reducing the driving restriction from 12 to 3 months. Mayo Clin Proc 2003 ; 78 : 819-25.
PubMed
11) 日本てんかん学会. てんかんと運転に関する提言. http://squareuminacjp/jes/images/jes-image/driveteigen2pdf2012.10.
 
12) 日本てんかん学会法的問題検討委員会.「平成26年度警察庁調査研究報告書 : てんかんにかかっている者と運転免許に関する調査研究」の解説と検討. てんかん研究 2015 ; 33 : 147-58.
 
13) てんかんにかかっている者と運転免許に関する調査研究委員会. てんかんにかかっている者と運転免許に関する調査研究. 有限会社自然文化創舍, 2015.
 
14) Eddy CM, Rickards HE, Cavanna AE. The cognitive impact of antiepileptic drugs. Ther Adv Neurol Disord 2011 ; 4 : 385-407.
PubMed
15) Riss J, Cloyd J, Gates J, et al. Benzodiazepines in epilepsy : pharmacology and pharmacokinetics. Acta Neurol Scand 2008 ; 118 : 69-86.
PubMed
16) Hetland A, Carr DB. Medications and impaired driving. Ann Pharmacother 2014 ; 48 : 494-506.
PubMed
17) Faught E, Duh MS, Weiner JR, et al. Nonadherence to antiepileptic drugs and increased mortality : findings from the RANSOM Study. Neurology 2008 ; 71 : 1572-8.
PubMed
18) 一杉正仁. 薬剤と自動車運転. In ; 脳卒中・脳外傷者のための自動車運転, 三輪書店, 2013, p39-44.
 
19) 日本てんかん学会. 抗てんかん薬の薬剤情報添付文書における自動車の運転等に関する記載についての見解. http://squareuminacjp/jes/images/jes-image/141009_AntiseizureDrugspdf2014.10.
 
P.398 掲載の参考文献
1) Tomson T, Xue H, Battino D. Major congenital malformations in children of women with epilepsy. Seizure 2015 ; 28 : 40-4.
 
2) Vajda FJ, O'Brien TJ, Lander CM, et al. The teratogenicity of the newer antiepileptic drugs-an update. Acta Neurol Scand 2014 ; 130 : 234-8.
 
3) Tomson T, Battino D, Bonizzoni E, et al. Dose-dependent risk of malformations with antiepileptic drugs : an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol 2011 ; 10 : 609-17.
PubMed
4) Cunnington MC, Weil JG, Messenheimer JA, et al. Final results from 18 years of the International Lamotrigine Pregnancy Registry. Neurology 2011 ; 76 : 1817-23.
PubMed
5) Campbell E, Kennedy F, Russell A, et al. Malformation risks of antiepileptic drug monotherapies in pregnancy : updated results from the UK and Ireland epilepsy and pregnancy registers. J Neurol Neurosurg Psychiatry 2014 ; 85 : 1029-34.
PubMed
6) Mawhinney E, Craig J, Morrow J, et al. Levetiracetam in pregnancy : results from the UK and Ireland epilepsy and pregnancy registers. Neurology 2013 ; 80 : 400-5.
PubMed
7) Meador KJ, Baker GA, Browning N, et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study) : a prospective observational study. Lancet Neurol 2013 ; 12 : 244-52.
PubMed
8) Christensen J, Gronborg TK, Sorensen MJ, et al. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA 2013 ; 309 : 1696-703.
PubMed
P.402 掲載の参考文献
1) 内閣府高齢社会白書 (Online, 2015年10月31日 access) http://www8.cao.go.jp/kourei/whitepaper/index-w.html
 
2) Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota : 1935-1984. Epilepsia 1993 ; 34 : 453-68.
PubMed
3) Forsgren L, Bucht G, Eriksson S, et al. Incidence and clinical characterization of unprovoked seizures in adults : a prospective population-based study. Epilepsia 1996 ; 37 : 224-9.
PubMed
4) Olafsson E, Ludvigsson P, Gudmundsson G, et al. Incidence of unprovoked seizures and epilepsy in Iceland and assessment of the epilepsy syndrome classification : a prospective study. Lancet Neurol 2005 ; 4 : 627-34.
PubMed
5) 池田昭夫, 他. 日本てんかん学会ガイドライン作成委員会報告. 高齢者のてんかんに対する診断・治療ガイドライン. てんかん研究 2011 ; 28 : 509-14.
 
6) 日本神経学会 監修「てんかん治療ガイドライン」作成委員会 編. てんかん治療ガイドライン 2010, 医学書院, 東京, 2010.
 
7) Glauser T, Ben-Menachem E, Bourgeois B, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2013 ; 54 : 551-63.
PubMed
8) Kar ceski S, Morrell MJ, Carpenter D. Treatment of epilepsy in adults : expert opinion, 2005. Epilepsy Behav 2005 ; 7 Suppl 1 : S1-64.
 
9) Ramsay RE, Rowan AJ, Pryor FM. Special considerations in treating the elderly patient with epilepsy. Neurology 2004 ; 62 (5 Suppl 2) : S24-9.
 
10) Bladin CF, Alexandrov AV, Bellavance A, et al. Seizures after stroke : a prospective multicenter study. Arch Neurol 2000 ; 57z : 1617-22.
 
11) Mendez M, Lim G. Seizures in elderly patients with dementia : epidemiology and management. Drugs Aging 2003 ; 20 : 791-803.
PubMed
12) McBride AE, Shih TT, Hirsch LJ. Video-EEG monitoring in the elderly : a review of 94 patients. Epilepsia, 2002 ; 43 : 165-9.
PubMed
13) McKeon A, Vaughan C, Delanty N. Seizure versus syncope. Lancet Neurol, 2006 ; 5 (2) : 171-80.
PubMed
14) Lin JT, Ziegler DK, Lai CW, et al. Convulsive syncope in blood donors. Ann Neurol 1982 ; 11 : 525-8.
PubMed
15) Kutluay E, McCague K, D'Souza J, et al. Safety and tolerability of oxcarbazepine in elderly patients with epilepsy. Epilepsy Behav 2003 ; 4 : 175-80.
 
16) Rowan AJ, Ramsay RE, Collins JF, et al. Neurology. New onset geriatric epilepsy : a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology, 2005 ; 64 (11) : 1868-73.
PubMed
17) Cloyd J, Hauser W, Towne A, et al. Epidemiological and medical aspects of epilepsy in the elderly. Epilepsy Res, 2006 ; 68 Suppl 1 : S39-48.
PubMed
18) Ramsay RE, Pryor F. Epilepsy in the elderly. Neurology, 2000 ; 55 (5 Suppl 1) : S9-14.
 
19) Ramsay RE, Macias FM, Rowan AJ. Diagnosing epilepsy in the elderly. Int Rev Neurobiol, 2007 ; 81 : 129-51.
PubMed
20) Krumholz A, Wiebe S, Gronseth GS, et al. Evidence-based guideline : Management of an unprovoked first seizure in adults : Report of the Guideline Development Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2015 ; 84 : 1705-13.
PubMed
21) Saetre E, Perucca E, Isojarvi J, et al. An international multicenter randomized double-blind controlled trial of lamotrigine and sustained-release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia 2007 ; 48 : 1292-302.
PubMed
22) Brodie MJ, Overstall PW, Giorgi L. Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Res 1999 ; 37 : 81-7.
 
23) Werhahn KJ1, Trinka E, Dobesberger J, et al. Epilepsia. A randomized, double-blind comparison of antiepileptic drug treatment in the elderly with new-onset focal epilepsy. Epilepsia 2015 ; 56 : 450-9.
 
24) Mohanraj R1, Brodie MJ. Diagnosing refractory epilepsy : response to sequential treatment schedules. Eur J Neurol 2006 ; 13 : 277-82.
 
25) Perucca E, Berlowitz D, Birnbaum A, et al. Pharmacological and clinical aspects of antiepileptic drug use in the elderly. Epilepsy Res 2006 ; 68 Suppl 1 : S49-63.
 

第8章 頭痛

P.408 掲載の参考文献
1) 長光勉. 前庭性片頭痛とは. 内科 2015 ; 115 : 813-7.
 
2) Sakai F, Igarashi H. Prevalence of migraine in Japan : a nationwide survey. Cephalalgia 1997 ; 17 : 15-22.
PubMed
3) 日本神経学会・日本頭痛学会 (監), 慢性頭痛の診療ガイドライン作成委員会 (編). 慢性頭痛の診療ガイドライン 2013, 医学書院, 2013.
 
4) 日本頭痛学会・国際頭痛分類委員会 (訳). 国際頭痛分類 第3版 beta版, 医学書院, 2014.
 
5) Aiba S, Tatsumoto M, Saisu A, et al. Prevalence of typical migraine aura without headache in Japanese ophthalmology clinics. Cephalalgia 2010 ; 30 : 962-7.
PubMed
6) Takeshima T, Sakai F, Suzuki N, et al. A Simple Migraine Screening Instrument : Validation Study In Japan. 日本頭痛学会誌 2015 ; 42 : 134-43.
 
7) 清水利彦. 特別企画 3-3 片頭痛の治療新薬. 日本頭痛学会誌 2013 ; 40 : 84-6.
 
8) 荒木信夫, 増田励, 柴田護. 片頭痛の病態-CSDとvascular factorではどちらが主体か. Head Clin Sci 2015 ; 6 : 20-5.
 
9) Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans : a race against the development of cutaneous allodynia. Ann Neurol 2004 ; 55 : 19-26.
 
10) Bigal ME, Lipton RB. Excessive acute migraine medication use and migraine progression. Neurology 2008 ; 71 : 1821-8.
PubMed
P.413 掲載の参考文献
1) 日本神経学会・日本頭痛学会 (監), 慢性頭痛の診療ガイドライン作成委員会 (編). 慢性頭痛の診療ガイドライン 2013, 医学書院, 2013.
 
2) 日本頭痛学会・国際頭痛分類委員会 (訳). 国際頭痛分類 第3版 beta版, 医学書院, 2014.
 
3) Yu S, Han X. Update of chronic tension-type headache. Curr Pain Headache Rep 2015 ; 19 : 469.
 
4) 平田幸一, 辰元宗人. 緊張型頭痛の診断と治療. 日医雑誌 2015 ; 144 : 969-72.
 
5) 間中信也. 緊張型頭痛の病態生理と治療. 医学のあゆみ 1991 ; 158 : 839-41.
Medical*Online
6) Weinman D, Nicastro O, Akala O, et al. Parenteral treatment of episodic tension-type headache : a systematic review. Headache 2014 ; 54 : 260-8.
PubMed
7) 大熊壮尚. 緊張型頭痛をどう治療するか. カレントテラピー 2008 ; 26 : 874-9.
 
P.417 掲載の参考文献
1) 日本神経学会・日本頭痛学会 (監), 慢性頭痛の診療ガイドライン作成委員会 編. 慢性頭痛の診療ガイドライン 2013, 医学書院, 2013.
 
2) 日本頭痛学会・国際頭痛分類委員会 訳. 国際頭痛分類 第3版 beta版, 医学書院, 2014.
 
3) 今井昇. 群発頭痛の病態・治療治療の実際とノウハウは? Medicina 2015 ; 52 : 1316-8.
 
4) 北川泰久. 群発頭痛の病態, 診断, 治療. ペインクリニック 2015 ; 36 (別冊春号) : S251-60.
 
5) 今井昇. 群発頭痛の病態・治療治療の実際とノウハウは? Medicina 2015 ; 52 : 1316-8.
 
6) 間中信也. 群発頭痛の診断と治療. Mebio 2014 ; 31 : 46-55.
Medical*Online
7) Petersen AS, Barloese MC, Jensen RH. Oxygen treatment of cluster headache : A review. Cephalalgia 2014 ; 34 : 1079-87.
PubMed
8) Dodick DW, Rozen TD, Goadsby PJ, et al. Cluster headache. Cephalalgia 2000 ; 20 : 787-803.
PubMed
9) Siberstein SD, Lipton RB, Solomon S, et al. Classification of daily and near-daily headaches : proposed revisions to the IHS criteria. Headache 1994 ; 34 : 1-7.
 
10) 渡邉由佳, 星野雄哉, 平田幸一. 薬剤の使用過多による頭痛 (薬物乱用頭痛) どのように診断し治療するか. Medicina 2015 ; 52 : 1326-9.
 
11) 五十嵐久佳. 特別企画 3-5 薬剤の使用過多による頭痛 (薬物乱用頭痛). 日本頭痛学会誌 2015 ; 42 : 54-6.
 
12) Tassorelli C, Jensen R, Allena M, et al. A consensus protocol for the management of medication-overuse headache : Evaluation in a multicentric, multinational study. Cephalalgia 2014 ; 34 : 645-55.
 
P.428 掲載の参考文献
1) Schaltenbrand G. Neuere Anshauungen Zur Patholphisiologie der liquorzirmkulation. Zentralb Neurochir 1938 ; 3 : 290-300.
 
2) Bell WE, Joynt RJ, Sahs AL. Low spinal fluid pressure syndromes. Neurology 1960 ; 10 : 512-21.
PubMed
3) Mokri B, Posner JB. Spontaneous intracranial hypotension : the broadening clinical and imaging spectrum of CSF leaks. Neurology 2000 ; 55 : 1771-2.
PubMed
4) Rando TA, Fishman RA. Spontaneous intracranial hypotension : reports of two cases and review of the literature. Neurology 1992 ; 42 : 481-7.
PubMed
5) 小原克之, 厚東篤生. 低髄液圧症候群. 神経内科 1998 ; 48 : 20-8.
 
6) 山本知孝, 桜井正樹. 低髄液圧症候群に伴う頭痛. 内科 1998 ; 81 : 708-13.
 
7) 吾郷哲朗, 藤島正敏. 特発性低髄液圧症候群の症候と診断. 神経内科 2000 ; 53 ; 434-48.
 
8) 木下泰伸, 板倉徹. 特発性低髄液圧症候群の画像診断. 神経内科 2000 ; 53 : 439-45.
 
9) 野川茂, 厚東篤生. 特発性低髄液圧症候群の病態. 神経内科 2000 ; 53 : 426-73.
 
10) 安井敬三. 特発性低髄液圧症候群の治療. 神経内科 2000 ; 53 : 446-9.
 
11) 篠永正道, 鈴木伸一. 外傷性低髄液圧症候群 (髄液減少症) の診断と治療. 神経外傷 2003 ; 26 : 98-102.
 
12) 高里良男. 低髄液圧症候群. Clin Neurosci 2004 ; 22 : 586-7.
 
13) 中込忠好. 低髄液圧性頭痛. ペインクリニック 2004 ; 25 : 463-70.
 
14) 宮澤康一. 特発性低髄液圧症候群の診断と治療. 脳神経 2004 ; 56 : 34-40.
 
15) 村上峰子. 特発性低髄液圧症候群. In ; 脳神経外科周術期管理のすべて 改訂第2版, メジカルビュー社, 2004, p506-12.
 
16) 厚生労働省「脳脊髄液減少症の診断・治療法の確立に関する研究班」報告
 
17) Christoforidis GA, Mehta BA, Landi JL, et al. Spontaneous intracranial hypotension : reports of four cases and review of the literature. Neuroradiology 1998 ; 40 : 636-43.
PubMed
18) Horton JC, Fishman RA. Neurovisual findings in the syndrome of spontaneous intracranial hypotension from dural cerebrospinal fluid leak. Ophthalmology 1994 ; 101 : 244-51.
PubMed
19) Fishman RA, Dillon WP. Dural enhancement and cerebral displacement secondary to intracranial hypotension. Neurology 1993 ; 43 : 609-11.
PubMed
20) Renowden SA, Gregory R, Hyman N, et al. Spontaneous intracranial hupotension. J Neurol Neurosurg Psychiatry 1995 ; 59 : 511-5.
PubMed
21) Schievink WI, Meyer PB, Atkinson JL, et al. Spontaneous spinal cerebrospinal fluid leaks and intracranial hypotension. J Neurosurg 1996 ; 84 : 598-605.
 
22) 中島誠, 平野照之, 笹本奈緒, 他. 体位変換により変化しない頭痛を呈した特発性頭蓋内圧低下症の1例. 脳神経 2002 ; 54 : 991-5.
 
23) 岸 秀行. 外傷性低髄液圧症候群に対し, 自家血硬膜外注入を試みた3症例. ペインクリニック 2003 ; 24 : 1141-6.
 
24) Ali SA, Cesani F, Zuckermann JA, et al. Spinal-cerebrospinal fluid leak demonstrated by radiopharmaceutical cisternography. Clin Nucl Med 1998 ; 23 : 152-5.
PubMed
25) Miyazawa K, Shiga Y, Hasegawa T, et al. CSF hypovolemia vs intracranial hypotension in "spontaneous intracranial hypotension syndrome". Neurology 2003 ; 60 : 941-7.
PubMed
26) 日本頭痛学会・国際頭痛分類委員会共訳. 7.2 低髄液圧による頭痛, 国際頭痛学会・頭痛分類委員会, 国際頭痛分類 第3版 beta版, 2014, p87-8.
 
27) Marcelis J, Silberstein SD. Spontaneous low cerebrospinal fluid pressure headache. Headache 1990 ; 30 : 192-6.
PubMed
28) Mokri B, Piepgras DG, Miller GM. Syndrome of orthostatic headaches and diffuse pachymeningeal gadorinium enhancement. Mayo Clin Proc 1997 ; 72 : 400-13.
 
29) Khurana RK. Intracranial hypotension. Semin Neurol 1996 ; 16 : 5-10.
PubMed
30) 木下泰信, 寺下俊雄, 寺田友昭, 他. 激しい頭痛では発症し, 特徴的な神経放射線学的所見を呈したSpontaneous intracranial hypotensionの2例. No Shinkei Geka 1997 ; 25 : 437-42.
 
31) Atkinson JLD, Weinshenker BG, Miller GM, et al. Acquired Chiari I malformation secondary to spontaneous spinal cerebrospinal fluid leakage and chronic intracranial hypotension syndrome in seven cases. J Neurosurg 1998 ; 88 : 237-42.
 
32) Pannullo SC, Reich JB, Krol G, et al. MRI changes in intracranial hypotension. Neurology 1993 ; 43 : 919-26.
PubMed
33) 大田正流, 竹下岩雄, 松本健一. 視神経乳頭浮腫と複視をきたした特発性頭蓋内圧低下症の1例. 脳外誌 2001 ; 10 : 353-7.
 
34) Murakami M, Morikawa K, Matsuno A, et al. Spontaneous intracranial hypotension associated with bilateral chronic subdural hematoma-case report-. Neurol Med Chir (TOKYO) 2000 ; 40 : 484-8.
PubMed
35) Sipe JC, Zyroff J, Waltz TA. Primary intracranial hypotension and bilateral isodense subdural hematomas. Neurology 1981 ; 31 : 334-7.
PubMed
36) 島克司. 特発性低髄液症候群. 病態と診断・治療. 神経外傷 2007 ; 30 : 7-13.
 
37) 古賀正利, 岡田靖, 大坪亮一, 他. クモ膜下出血との鑑別を要した原発性低髄液圧症候群の1例. 治療 1996 ; 78 : 1806-8.
 
38) Moayeri NN, Henson JW, Schaefer PW, et al. Spinal dural enhancement on magnetic resonance imaging associated with spontaneous intracranial hypotension. Reports on three cases and review of the literature. J Neurosurg 1998 ; 88 : 912-8.
PubMed
39) 竹下岩男. MR myelography. Clin Neurosci 2006 ; 24 : 423-8.
 
40) Chen CJ, Lee TH, Hsu HL, et al. Spinal MR findings in spontaneous intracranial hypotension. Neuroradiology 2002 ; 44 : 996-1003.
PubMed
41) Matsumura A, Anno I, Kumura H, et al. Diagnosis of spontaneous intracranial hypotension by using magnetic resonance myelography. J Neurosurg 2000 ; 92 : 873-6.
 
42) Weber WE, Heidendal GA, de Krom MC. Primary intracranial hypotension and abnormal radionuclide cisternography : eports oh a case and review of the literature. Clin Neurol Neurology 1991 ; 93 : 55-60.
 
43) Moriyama E, Ogawa T, Nishida A, et al. Quantitative analysis of radioisotope cisternography in the diagnosis intracranial hypotension. J Neurosurg 2004 ; 101 : 421-6.
PubMed
44) 高橋浩一, 美馬達夫. 脳脊髄液減少症に対する漢方治療 : 特に利水剤 (五苓散)について. 脳神経外科と漢方 2015 ; 1 : 13-6.
 
45) Sugino T, Matsusaka Y, Mitsuhashi Y, et al. Intracranial hypotension due to cerebrospinal leakage detected by radioisotope cisternaphy. Neurol Med Chir 2000 ; 40 : 404-7.
PubMed
46) Drahomis S, Mokri B, MaClelland RL. The efficacy of epidural blood patch in spontaneous CSF leaks. Neurology 2001 ; 57 : 1921-3.
 
47) Kamada M, Fujita Y, Ishii R, et al. Spontaneous intracranial hypotension successfully treated by epidural patching with fibrin glue. Headache 2000 ; 40 : 844-7.
PubMed
48) 猪原匡史, 柳原千枝, 西村洋. 硬膜外自家血液注入にて完治した特発性頭蓋内圧低下症候群の1例. 臨床神経学 1998 ; 38 : 838-42.
 
49) Dillon WP, Fishman RA. Some lessons learned about the diagnosis and treatment of spontaneous intracranial hypotension. AJNR Am J Neuroradiol 1998 ; 19 : 1001-2.
 
50) Sperry RJ, Gartrell A, Johnson JO. Epidural blood patch can cause neurological deterioration. Aneshesiology 1995 ; 82 : 302-5.
 
51) Gibson BE, Wedel DJ, Faust RJ, et al. Continuous epidural saline infusion for the treatment of low CSF pressure headache. Anesthesiology 1988 ; 68 : 789-91.
PubMed
52) 川崎史朗, 山本佑司, 角南典生, 他. 持続硬膜外生食注入にて治癒した特発性頭蓋内圧低下症の1例. 脳神経 1999 ; 51 : 711-5.
 
53) 永田安徳, 本田雄二, 松岡好美. 保存的治療中に急激な症状増悪を呈した特発性頭蓋内圧低下症の1例. 脳外誌 2003 ; 12 : 737-41.
 
54) Schievink WI, Morreale VM, Atkinson JL, et al. Surgigal treatment of spontaneous spinal cerebrospinal fluid leaks. J Neurosurg 1998 ; 88 : 243-6.
 
55) Nakajima H, Sakai T, Aoki N, et al. Bilateral chronic subdural hekatomas associated with intracranial hypotension. Neurol Med Chir 1996 ; 36 : 647-9.
PubMed
56) Page F. Intracranial hypotension. Lancet 1953 ; 3 : 6749-53.
 
P.432 掲載の参考文献
1) Kline LB, Hoyt WF. The Tolosa-Hunt syndrome. J Neurosurg Psychiatry 2001 ; 71 : 577-82.
 
2) Gladstone PJ, Dodick DW. Painful ophthalmoplegia : overview with a focus on Tolosa-Hunt syndrome. Current Pain and Headache Reports 2004 ; 8 : 321-9.
 
3) 柏木聡. Tolosa-Hunt症候群 (有痛性眼筋麻痺). 日本臨床別冊 2000 ; 免疫症候群 (上巻) : 16-9.
 
4) Tolosa EJ. Periarteritic lesions of the carotid siphon with clinical features of carotid intraclinoid aneurysms. J Neurol Neurosurg Psychiatry 1954 ; 17 : 300-2.
 
5) Hunt WE, Meagher JN, Le Fever HE, et al. Painful ophthalmoplegia. Its relation to indolent inflammation of the cavernous sinus. Neurology 1961 ; 11 : 56-62.
 
6) Smith JL, Taxdal DS. Painful ophthalmoplegia. The Tolosa-Hunt syndrome. Am J ophthalmol 1966 ; 61 : 1466-72.
PubMed
7) Hunt WE. Tolosa-Hunt syndrome : one cause of painful ophthalmoplegia. J Neurosurrg 1976 ; 44 : 544-9.
 
8) Yeung MC, Kwong KL, Wong YC, et al. Paediatric Tolosa-Hunt syndrome. J Paediatr Child Helth 2004 ; 40 : 410-3.
 
9) 渡辺将平, 貞廣茂樹, 中辻祐司, 他. 目で見る神経内科, Tolosa-Hunt症候群. 神経内科 2000 ; 53 増刊 : 250-1.
 
10) 竹岡常行. 目で見る神経内科, Tolosa-Hunt症候群. 神経内科 2000 ; 53 増刊 : 48-9.
 
11) 大原千佳, 井上賢治, 沼賀二郎. 対側再発のTolosa-Hunt症候群の1例. 眼紀 2000 ; 51 : 797-800.
 
P.435 掲載の参考文献
1) 比嘉和夫, 森真由美. 帯状疱疹の発生病理と痛み. ペインクリニック 1996 ; 17 : 493-500.
 
2) 比嘉和夫, 廣田一紀, 仁田原慶一. 帯状疱疹後神経痛 : 診断と治療. ペインクリニック 2004 ; 25 : 158-65.
 
3) 石川博康, 玉井克人, 見坊公子. 多施設合同による帯状疱疹の年間統計解析の試み (2000年4月～ 2001年3月). 日皮会誌 2003 ; 113 : 1229-39.
 
4) Jung BF, Johnson RW, Griffin DR, et al. Risk factors for postherpetic neuralgia in patients with herpes zoster. Neurology 2004 ; 62 : 1545-51.
PubMed
5) Dworkin RH, Schmader KE. Treatment and prevention postherpetic neuralgia. Clin Infect Dis 2003 ; 36 : 877-82.
PubMed
6) Rice AS, Maton S : Postherpetic Neuralgia Study Group. Gabapentin in postherpetic neuralgia : randomized, double blind, placebo controlled study. Pain 2001 ; 94 : 215-24. (レベル Ia, グレード A)
 
7) Dworkin RH, Corbin AE, Young JP, et al. Pregabalin for the treatment of postherpetic neuralgia : A randomized, placebo-controlled trial. Neurology 2003 ; 60 : 1274-83. (レベル Ia, グレード A)
 
8) Watson CP, Vernich L, Chipman M, et al. Noritriptyline versusu amitriptyline in postherpetic neuralgia : a randomized trial. Neurology 1998 ; 51 : 1166-71. (レベル IIb, グレード B)
 
9) 小田真也, 那須郁子, 加藤佳子, 他. 難治性非がん性疼痛患者へのリン酸コデイン投与の経験. 日本ペインクリニック学会誌 1999 ; 6 : 198. (レベル IV, グレード C)
 
10) Watson CP, Babul N. Efficacy of oxycodone in neuropathic pain : a randomized trial in postherpetic neuralgia. Neurology 1998 ; 50 : 1837-41. (レベル Ia, グレード A)
 
11) Raja SN, Haythornthwaite JA, pappagallo M, et al. Opioid versus antidepressants in postherpetic neuralgia : a randomized, placebo-controlled trial. Neurology 2002 ; 51 : 1015-21. (レベル Ib, グレード A)
 
12) Rowbotham MC, Davies PS, Verkempink C, et al. Lidocaine patch : double-blind controlled study of a new treatment method for post-herpetic neuralgia. Pain 1996 ; 65 : 39-44. (レベル Ib, グレード A)
 
13) Baranowski AP, De Courcey J, Bonello E. A trial of intravenous lidocaine on the pain and alllodynia of postherpetic neuralgia. J Pain Symptom Manage 1999 ; 17 : 429-33. (レベル Ib, グレード A)
 
14) Hocking G, Cousins MJ. Ketamine in chronic pain management : an evidence-based review. Anesth Analg 2003 ; 93 : 1703-9.
 
15) 山村秀夫, 壇健次郎, 若杉文吉, 他. ノイロトロピン錠の帯状疱疹後神経痛に対する効果 ; プラセボを対照薬とした多施設二重盲検試験. 医学のあゆみ 1988 ; 147 : 651-64.
 
16) 大瀬戸清茂. 帯状疱疹後神経痛に対する神経ブロック療法. ペインクリニック 2003 ; 24 : 635-9.
 
17) Manabe H, Dan K, Higa K. Continuous epidural infusion of local anesthetics and shorter duration of acute zoster associated pain. Clin J Pain 1995 ; 11 : 220-8. (レベル IIIb, グレード B)
 
18) Winnie AP, Hartwell PW. Relationship between time of treatment of acute herpes zoster with sympathetic blockade and prevention of post herpetic neuralgia : clinical support for a new theory of the mechanism by which sympathetic blockade provides therapeutic benefit. Reg Aneth 1993 ; 18 : 277-82. (レベル IV, グレード C)
 
19) Johnson MD, Burchiel KJ. Peripheral stimulation for treatment of trigeminal postherpetic neuralgia and trigeminal posttaumatic neurotathic pain : a pilot study. Neurology 2004 ; 55 : 135-41. (レベル IV, グレード C)
 
P.442 掲載の参考文献
1) Fugate JE, Rabinstein AA. Posterior reversible encephalopathy syndrome : clinical and radiological manifestations, pathophysiology, and outstanding questions. Lancet Neurol 2015 ; 914-25.
PubMed
2) Li Y, Gor D, Walicki D, et al. Spectrum and potential pathogenesis of reversible posterior leukoencephalopathy syndrome. J Stroke Cerebrovasc Dis 2012 ; 21 : 873-82.
PubMed
3) Bartynski WS. Posterior reversible encephalopathy syndrome, part 1 : fundamental imaging and clinical features. AJNR Am J Neuroradiol 2008 ; 29 : 1036-42.
PubMed
4) 伊藤昌春, 草薙康城. 診療の基本 妊娠高血圧症候群. 日産婦誌 2006 ; 58 : N61-70.
 
5) Ohta K, Shinohara Y. Reversible 'anterior' leukoencephalopathy syndrome in an elderly hypertensive patient. Eur Neurol 2012 ; 67 : 386.
 
6) Li R, Mitchell P, Dowling R, et al. Is hypertension predictive of clinical recurrence in posterior reversible encephalopathy syndrome? J Clin Neurosci 2013 ; 20 : 248-52.
PubMed
7) 日本頭痛学会・国際頭痛分類委員会訳. 可逆性脳血管攣縮症候群 (RCVS) による頭痛. 国際頭痛分類 第3版 beta版 医学書院, 2014, p75-76.
 
8) Ducros A. Reversible cerebral vasoconstriction syndrome. Lancet Neurol, 2012 ; 11 : 906-17.
PubMed
9) Calabrese LH, Dodick DW, Schwedt TJ, et al. Narrative review : reversible cerebral vasoconstriction syndromes. Ann Intern Med 2007 ; 146 : 34-44.
PubMed
10) Singhal AB, Hajj-Ali RA, Topcuoglu MA, et al. Reversible cerebral vasoconstriction syndromes : analysis of 139 cases. Arch Neurol 2011 ; 68 : 1005-12.
PubMed
11) Chen SP, Fuh JL, Wang SJ, et al. Magnetic resonance angiography in reversible cerebral vasoconstriction syndromes. Ann Neurol, 2010 ; 67 : 648-56.
PubMed
12) Ducros A, Fiedler U, Porcher R, et al. Hemorrhagic manifestations of reversible cerebral vasoconstriction syndrome : frequency, features, and risk factors. Stroke 2010 ; 41 : 2505-11.
PubMed
13) Ducros A, Boukobza M, Porcher R, et al. The clinical and radiological spectrum of reversible cerebral vasoconstriction syndrome. A prospective series of 67 patients. Brain 2007 ; 130 : 3091-101.
PubMed
14) The International Classification of Headache Disorders : 2nd edition. Cephalalgia 2004 ; 24 Suppl 1 : 9-160.
 
15) Fugate JE, Ameriso SF, Ortiz G, et al. Variable presentations of postpartum angiopathy. Stroke 2012 ; 43 : 670-6.
PubMed
16) Bartynski WS. Posterior reversible encephalopathy syndrome, part 2 : controversies surrounding pathophysiology of vasogenic edema. AJNR Am J Neuroradiol 2008 ; 29 : 1043-9.
PubMed
17) Rabinstein AA, Mandrekar J, Merrell R, et al. Blood pressure fluctuations in posterior reversible encephalopathy syndrome. J Stroke Cerebrovasc Dis 2012 ; 21 : 254-8.
PubMed
18) Chen SP, Fuh JL, Wang SJ, et al. Brain-derived neurotrophic factor gene Val66Met polymorphism modulates reversible cerebral vasoconstriction syndromes. PLoS One 2011 ; 6 : e18024.
PubMed

第9章 感染症

P.447 掲載の参考文献
1) Kamei S, Takasu T. Nationwide survey of the annual prevalence of viral and other neurological infections in Japanese inpatients. Intern Med 2000 ; 39 : 894-900.
PubMed
2) 細菌性髄膜炎診療ガイドライン2014作成委員会 (作成委員会委員長 亀井聡, 他). 細菌性髄膜炎診療ガイドライン 2014, 南江堂, 東京, 2014, p1-123.
 
3) MacIntyre PB, Berkey CS, King SM, et al. Dexamethasone as adjunctive therapy in bacterial meningitis. A meta-analysis of randomized clinical trials since 1988. JAMA 1997 ; 278 : 925-31.
 
4) Mongelluzzo J, Mohamad Z, Ten Have TR, et al. Corticosteroids and mortality in children with bacterial meningitis. JAMA 2008 ; 299 : 2048-55.
PubMed
5) de Gans J, van de Beek D. Dexamethasone in adults with bacterial meningitis. N Engl J Med 2002 ; 347 : 1549-56.
PubMed
6) van de Beek D, Farrar JJ, de Gans J, et al. Adjunctive dexamethasone in bacterial meningitis : a meta-analysis of individual patient data. Lancet Neurol 2010 ; 9 : 254-63.
PubMed
7) van de Beek D, de Gans J, Spanjaard L, et al. Clinical features and prognostic factors in adults with bacterial meningitis. N Engl J Med 2004 ; 351 : 1849-59.
PubMed
8) Ishihara M, Kamei S, Taira N, et al. Hospital-based study of the prognostic factors in adult patients with acute community-acquired bacterial meningitis in Tokyo, Japan. Intern Med 2009 ; 48 : 295-300.
PubMed
P.449 掲載の参考文献
1) Brouwer MC, Coutinho JM, van de Beek D. Clinical characteristics and outcome of brain abscess : systematic review and meta-analysis. Neurology 2014 ; 82 : 806-13.
PubMed
2) Koopmans MM, Brouwer MC, van der Ende A, et al. Listeria monocytogenes sequence type 6 and increased rate of unfavorable outcome in meningitis : epidemiologic cohort study. Clin Infect Dis 2013 : 57 ; 247-53.
PubMed
3) Brouwer MC, Tunkel AR, McKhann II GM, et al. Brain abscess. N Engl J Med 2014 ; 371 : 447-56.
 
4) Lai PH, Hsu SS, Ding SW, et al. Proton magnetic resonance spectroscopy and diffusion-weighted imaging in intracranial cystic mass lesions. Surg Neurol 2007 ; 68 : Suppl 1 : S25-S36
 
5) Rosenbalum ML, Hoff JT, Norman D, et al. Nonoperative treatment of brain abscess in selected high-risk patients. J Neurosurg 1980 ; 52 : 217-25.
PubMed
6) Mamelak AN, Mampalam TJ, Obana WG, et al. Improved management of multiple brain abscess : a combined surgical and medical approach. Neurosurgery 1995 ; 36 : 76-85.
PubMed
7) Tunkel AR, Brain abcess. In ; Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of infectious disease, 2010, p1265-78.
 
P.451 掲載の参考文献
1) 谷口清洲. 無菌性髄膜炎. 日医師会誌 2004 ; 132 : 300-3.
 
2) 加地正英. エンテロウイルス性髄膜炎. 日本臨床. 領域別症候群 1999 ; 24 : 7-10.
 
3) 竹島慎一, 音成秀一郎, 姫野隆洋, 他. 成人無菌性髄膜炎の臨床的検討-流行性と起因ウイルスの同定. 臨床神経 2014 ; 54 : 791-797.
 
4) Kamei S, Takasu T. Nationwide survey of the annual prevalence vial and other neurological infections in Japanese inpatients. Internal Med 2000 ; 39 : 894-900.
 
5) 庄司紘史. 髄液所見による脳脊髄膜炎の鑑別. 臨床検査 2005 ; 49 : 367-73.
 
6) 細矢光亮. ウイルス性髄膜炎のPCR診断. 神経進歩 1999 ; 43 : 51-7.
 
7) Nagafuchi M, Nagafuchi Y, Sato R, et al. Adult meningism and viral meningitis, 1997-2004. Intern Med 2006 ; 45 : 1209-11.
PubMed
8) 中嶋秀人. 単純ヘルペスウイルス感染症. 水澤英洋編集. 神経感染症を究める. 中山書店, 東京, 2014, p 34-43.
 
9) Komagamine T, Nagashima T, Kojima M, et al. Recurrent aseptic meningitis in association with Kikuchi-Fujimoto disease : case report and literature review. BMC Neurol 2012 ; 12 : 112.
PubMed
P.455 掲載の参考文献
1) Kamei S, Takasu T. Nationwide survey of the annual prevalence viral and other neurological infections in Japanese inpatients. Internal Med 2000 ; 39 : 894-900.
PubMed
2) 庄司紘史, 立花正輝, 江島泰志, 他. 単純ヘルペス性辺縁系脳炎. 神経内科 2013 ; 79 : 582-8.
 
3) Pfender N, Jelcic I, Linnebank M, et al. Reactivation of herpesvirus under fingolimod : A case of severe herpes simplex encephalitis. Neurology 2015 ; 84 : 2377-8.
PubMed
4) 緒方正男. 同種造血幹細胞移植におけるHHV-6脳炎. Brain Nerve 2015 ; 67 : 919-30.
 
5) Sejvar JJ, et al. The long-term outcomes of human West Nile virus infection. Clin Infect Dis J 2007 ; 44 : 1617-24.
 
6) Delbue S, Ferrante P, Mariotto S, et al. Review of West Nile virus epidemiology in Italy and report of a case of West Nile virus encephalitis. J Neurovirol 2014 ; 20 : 437-41.
PubMed
7) 厚生労働省インフルエンザ脳症研究班編. インフルエンザ脳症ガイドライン (改定版), 2009, p23-32.
 
8) 庄司紘史, 立花正輝, 福嶌由尚, 他. HSV-2急性辺縁系脳炎と考えられた65歳女性例. 神経内科 2014 ; 81 : 111-4.
 
9) 松岡幹晃, 立花正輝, 松下知永, 他. Alzheimer病でみられたVZV急性辺縁系脳炎. 神経内科 2013 ; 79 : 533-5.
 
10) 特集 自己免疫性辺縁系脳炎-病態研究の進歩. Clin Neurosci 2008 ; 26 : 497-570.
 
11) Armangue T, Leypoldt F, Malaga I, et al. Herpes simplex virus encephalitis is a trigger of brain autoimmunity. Ann Neurol 2014 ; 75 : 317-23.
PubMed
12) Lim HK, Seppanen M, Hautala T, et al. TLR3 deficiency in herpes simplex encephalitis : high allelic heterogeneity and recurrence risk. Neurology 2014 ; 83 : 1888-97.
PubMed
13) 日本神経感染症学会編. ヘルペス脳炎 ; 診療ガイドラインに基づく診断基準と治療指針. 中山書店 2005, p7-16.
 
14) Tyler KL. Herpes simplex virus infections of the central nervous system : encephalitis and meningitis, including Mollaret's. Herpes 2004 ; 2 : 57A-64A.
 
15) 日本神経感染症学会. ヘルペス脳炎のガイドライン. Neuroinfection 2005 ; 10 : 78-87.
 
16) Kamei S, Sekizawa T, Shiota H, et al. Evaluation of combination therapy using aciclovir and corticosteroid in adult patients with herpes simplex virus encephalitis. J Neurol Neurosurg Psychiatry 2005 ; 76 : 1544-9.
PubMed
17) 庄司紘史. ヘルペス脳炎とその周辺. 永井書店, 大阪, 2009, p59-61.
 
18) 田宮愛, 深浦順一, 田中薫, 他. 単純ヘルペス脳炎の後遺症. 神経内科 2008 ; 69 : 478-82.
 
P.457 掲載の参考文献
1) 厚生省保健医療局エイズ結核感染症課, 監修. 結核の統計 2013, 財団法人結核予防会, 東京, 2014.
 
2) Corral I, Quereda C, Navas E, et al. Adenosine deaminase activity in cerebrospinal fluid of HIV- infected patients : limited value for diagnosis of tuberculous meningitis. Eur J Clin Microbiol Infect Dis 2004 ; 23 : 471-6.
PubMed
3) Takahashi T, Nakayama T, Tamura, et al. Nested polymerase chain reaction for assessing the clinical course of tuberculous meningitis. Neurology 2005 ; 64 : 1789-93.
PubMed
4) Simmons CP, Thwaites GE, Quyen NT, et al. Pretreatment intracerebral and peripheral blood immune responses in Vietnamese adults with tuberculous meningitis : diagnostic value and relationship to disease severity and outcome. J Immunol 2006 ; 176 : 2007-14.
PubMed
5) Abdelmalek R, Kanoun F, Kirani B, et al. Tuberculous meningitis in adults : MRI contribution to the diagnosis in 29 patients. Int J Infect Dis 2006 ; 10 : 372-7.
 
6) Thwaites G, Fisher M, Hemingway C, et al. British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children. J Infect 2009 ; 59 : 167-87.
 
7) Thwaites GE, Nguyen DB, Nguyen HD, et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med 2004 ; 351 : 1741-51.
PubMed
8) Prasad K, Singh MB. Corticosteroids for managing tuberculous meningitis. Cochrane Database Syst Rev 2008 ; 23 : CD002244.
 
9) Kalita J, Misra UK, Nair PP. Predictors of stroke and its significance in the outcome of tuberculous meningitis. J Stroke Cerebrovasc Dis 2009 ; 18 : 251-8.
PubMed
10) Erdem H, Ozturk-Engin D, Tireli H, et al. Hamsi scoring in the prediction of unfavorable outcomes from tuberculous meningitis : results of Haydarpasa-II study. J Neurol2015 ; 262 : 890-8.
 
P.459 掲載の参考文献
1) Kamei S, Takasu T. Nationwide survey of the annual prevalence of viral and other neurological infections in Japanese inpatients. Intern Med 2000 ; 39 : 894-900.
PubMed
2) Suzuki Y, Kume H, Togano T, et al. Epidemiology of visceral mycoses in autopsy cases in Japan : the data from 1989 to 2009 in the Annual of Pathological Autopsy Cases in Japan. Med Mycol 2013 ; 51 : 522-6.
PubMed
3) Pappas PG, Perfect JR, Cloud GA, et al. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis 2001 ; 33 : 690-9.
PubMed
4) Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease : 2010 update by the infectious diseases society of america. Clin Infect Dis 2010 ; 50 : 291-322.
 
5) Brouwer AE, Rajanuwong A, Chierakul W, et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis : a randomised trial. Lancet 2004 ; 363 : 1764-7.
PubMed
6) 深在性真菌症のガイドライン作成委員会. 深在性真菌症の診断・治療ガイドライン 2014, 協和企画 (発売), 2014.
 
7) Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis : 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009 ; 48 : 503-35.
 
8) 二木芳, 三鴨廣, 詫間隆, 他. 日本医真菌学会侵襲性カンジダ症の診断・治療ガイドライン Executive summary集. Med Mycol J 2013 ; 54 : 147-251.
 
9) Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis : clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008 ; 46 : 327-60.
 
10) Ecevit IZ, Clancy CJ, Schmalfuss IM, et al. The poor prognosis of central nervous system cryptococcosis among nonimmunosuppressed patients : a call for better disease recognition and evaluation of adjuncts to antifungal therapy. Clin Infect Dis 2006 ; 42 : 1443-7.
 
11) Schwartz S, Ruhnke M, Ribaud P, et al. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood 2005 ; 106 : 2641-5.
PubMed
P.462 掲載の参考文献
1) 厚生労働科学研究費補助金・難治性疾患克服研究事業「プリオン病及び遅発性ウイルス感染に関する調査研究班」 : 亜急性硬化性全脳炎 (SSPE) 診療ガイドライン. Available at : http://prion.umin.jp/guideline/guideline_sspe.html
 
2) 厚生労働科学研究費補助金・難治性疾患等克服研究事業 (難治性疾患克服研究事業) 「プリオン病及び遅発性ウイルス感染に関する調査研究班」 : 進行性多巣性白質脳症 (PML) の診断および治療ガイドライン 2013, 2013. Available at : http://prion.umin.jp/file/PML2013.pdf
 
3) 厚生労働科学研究費補助金・難治性疾患等克服研究事業 (難治性疾患克服研究事業) 「プリオン病及び遅発性ウイルス感染に関する調査研究班」及び「プリオン病のサーベイランスと感染予防に関する調査研究班 : プリオン病診療ガイドライン 2014. Available at : http://prion.umin.jp/guideline/guideline_2014.pdf
 
4) Atarashi R, et al. Ultrasensitive human prion detection in cerebrospinal fluid by real-time quaking-induced conversion. Nat Med 2011 ; 17 : 175-8.
PubMed
5) 厚生労働科学研究費補助金・難治性疾患克服研究事業・プリオン病及び遅発性ウイルス感染に関する調査研究班 : プリオン病感染予防ガイドライン, 2008. Available at : http://prion.umin.jp/guideline/cjd_2008all.pdf
 
P.466 掲載の参考文献
1) Anthony IC, et al. The Neuropathology of HIV/AIDS. Int Rev Psychiatry 2008 ; 20 : 15-24.
PubMed
2) Scaravilli F, et al. Neuropathologic contributions to understanding AIDS and the central nervous system. Brain Pathol 2007 ; 17 : 197-208.
PubMed
3) Miura Y, et al. Tumor necrosis factor-related apoptosis-inducing ligand induces neuronal death in a murine model of HIV central nervous system infection. Proc Natl Acad Sci USA 2003 ; 100 : 2777-82.
 
4) Kitayama H, et al. Human immunodeficiency virus type 1 Vpr inhibits axonal outgrowth through induction of mitochondrial dysfunction. J Virol 2008 ; 82 : 2528-42.
PubMed
5) Weed MR, Steward DJ. Neuropsychopathology in the SIV/macaque model of AIDS. Front Biosci 2005 ; 10 : 710-27.
PubMed
6) Heaton RK, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy : differences in rates, nature, and predictors. J Neurovirol 2011 ; 17 : 3-16.
PubMed
7) Sam N, et al. Controversies in HIV-associated neurocognitive disorders. Lancet Neurol 2014 ; 13 : 1139-51.
 
8) Bhaskaran K, et al. Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy. ANN Neurol 2008 ; 63 : 213-21.
PubMed
9) EACS (European AIDS Clinical Society). RACS Guidelines. Version 7.1. 2014.
 
10) 森岡悠, 他. HIV関連神経認知障害が疑われたHIV感染者の検討. 感染症誌 2014 ; 88 : 141-8.
 
11) http://www.uptodate.com/contents/hiv-associated-neurocognitive-disorders-epidemiology-clinical-manifestationsand-diagnosis
 
12) Letendre S, et al. 17th Conference on Retroviruses and Oppoturnistic Infections, 2010, Abstract 172.
 
P.470 掲載の参考文献
1) Oh U, Jacobson S. Treatment of HTLV-I-associated myelopathy/tropical spastic paraparesis : toward rational targeted therapy. Neurol Clin 2008 ; 26 : 781-97.
PubMed
2) Satake M, Yamagutchi K, Tadokoro K. Current prevalence of HTLV-1 in Japan as determined by screening of blood donors. J Medical Virology 2012 ; 84 : 327-35.
 
3) 出雲周二, 松崎敏男, 久保田龍二. HAMの新しい展開. 神経内科 2011 ; 75 : 369-73.
 
4) Yamano Y, Nagai M, Brennan M, et al. Correlation of human T-cell lymphotropic virus type 1 (HTLV-1) mRNA with proviral DNA load, virus-specific CD8 (+) T cells, and disease severity in HTLV-1-aasociated myelopathy (HAM/TSP). Blood 2002 ; 99 : 88-94.
PubMed
5) Vine AM, Witkover AD, Lloyd AL, et al. Polygenic control of human T lymphotropic virus type I (HTLV-I) provirus load and the risk of HTLV-I-associated myelopathy/tropical spastic paraparesis. J Infect Dis 2002 ; 186 : 932-9.
PubMed
6) 松崎敏男, 齋藤峰輝, 納光弘. HAMの診断と治療の進歩. 臨床検査 2005 ; 49 : 409-14.
 
7) Sato T, Coler-Reilly, Utsunomiya A, et al. CSF CXCL110, CXCL9, and Neopterin as Candidate Prognostic Biomaters for HTLV-1-associated myelopathy/Tropical Spastic Paraparesis. PLoS Negl Trop Dis 2013 ; 7 : issue 10.
 
8) Nakagawa M, Izumo S, Ijichi S, et al. HTLV-1-associated myelopathy : analysis of 213 patients based on clinical features and laboratory findings. J Neurovirol 1995 ; 1 : 50-61.
PubMed
9) Furukawa Y, Okadome T, Tara M, et al. Human T-cell Lymphotropic Virus Type-I (HTLV-I) -Associated Myelopathy/Tropical Spastic Paraparesis with Acute Type of Adult T-cell Leukemia. Inter Med 1995 ; 34 : 1130-3.
 
10) 出雲周二, 中川正法, 松崎敏男, 他. HTLV-1関連脊髄症 (HAM) の合併症とHAM診療アルゴリズムの提示. 平成26年度厚生労働科学研究費補助金 HAM及びHTLV-1関連希少難治性炎症性疾患の実態調査に基づく診療指針作成と診療基盤の構築をめざした政策研究報告書. 2015, p24- 27.
 
11) Nakagawa, M, Nakahara K, Maruyama Y, et al. Therapeutic trials in 200 patients with HTLV-1-associated myelopathy/tropical spastic paraparesis. J Neurovirol 1996 ; 2 : 345-55.
PubMed
12) Araujo AQ, Afonso CR, Leite AC, et al. Intravenous methylprednisolone in HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP). Arq Neuropsiquiatr 1993 ; 51 : 325-8.
PubMed
13) Izumo S, Goto I, Itoyama Y, et al. Interferon-alpha is effective in HTLV-I-aasociated myelopathy : a multicenter, randomized, double-blind, controlled trial, Neurology 1996 ; 46 : 1016-21.
PubMed
14) Arimura K, nakagawa M, Kaseda S et al. Saftey and efficacy of Interferon-alpha in 167 patients with human t-cell lymphotropic virus type 1-associated myelopathy. J Neurovirol 2007 ; 13 : 364-72.
 
15) Saito M, Nakagawa M, Kaseda S, et al. Decreased Human T Lymphotropic Virus Type I (HTLV-1) Provirus Load and Alteration in T Cell Phenotype after Interferon-a Therapy for HTLV-1? Associated Myelopathy/Tropical Spastic Paraparesis. J Infect Dis 2004 ; 189 : 29-40.
 
16) Kataoka A, Imai H, Inayoshi S, et al. Intermittent high-dose vitamin C therapy in patients with HTLV-I-associated myelopathy. J Neurol Neurosurg Psychiatry 1993 ; 56 : 1213-6.
PubMed
17) Matsuzaki T, Saito M, Usuku K, et al. A prospective uncontrolled trial of fermented milk drink containing viable Lactobacillus casei strain Shirota in rh treatment of HTLV-I associated myelopathy/tropical spastic paraparesis. J Neurol Sci 2005 ; 237 : 75-81.
 
18) Nakamura T, Matsuo T, Fukuda T, et al. Efficacy of prosultiamine treatment in patients with human T lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis : results from an open-label clinical trial. BMC Medicine 2013 ; 11 : 182.
PubMed
19) Enose-Akahata, Matsuura E, Tanaka Y, et al. Minpcycline modulates antigen-speccific CTL activity through inactivation of mononuclear phagocytes in patients with HTLV-I associated neurologic disease. Retroviology 2012 ; 9 : 16.
 
20) 武澤信夫, 奥田求己, 中川正法. HAMのリハビリテーション. 神経内科 2011 ; 75 : 393-401.
 
21) Yamauchi J, Coler-Reilly A, Sato T, et al. Mogamulizumab, an Anti-CCR4 Antibody, Targets Human T-lymphotropic Virus Type 1-infected CD8+ and CD4+ T cells to Treat Associated Myelopathy. J Infc Dis 2015 ; 211 : 238-48.
 
22) 今村章. Human T-Lymphotropic virus type I associated myelopathy (HAM)による神経因性膀胱の検討. 日泌尿会誌 1994 ; 85 : 1106-15.
 
23) Matsuzaki T, Nakagawa M, Nagai M, et al. HTLV-1 proviral load correlates with progression of motor disability in HAM/TSP : Analysis of 239 HAM/TSP patients including 64 patients followed up for 10 years. J Neurovirol 2001 ; 7 : 228-34.
 
P.472 掲載の参考文献
1) Suzuki Y, Kume H, Togano T, et al. Epidemiology of visceral mycoses in autopsy cases in Japan : the data from 1989 to 2009 in the Annual of Pathological Autopsy Cases in Japan. Med Mycol 2013 ; 51 : 522-6.
PubMed
2) Mencacci A, Cenci E, Boelaert JR, et al. Iron overload alters innate and T helper cell responses to Candida albicans in mice. J Infect Dis 1997 ; 175 : 1467-76.
 
3) Abe F, Inaba H, Katoh T, et al. Effects of iron and desferrioxamine on Rhizopus infection. Mycopathologia 1990 ; 110 : 87-91.
PubMed
4) Odabasi Z, Paetznick VL, Rodriguez JR, et al. Differences in beta-glucan levels in culture supernatants of a variety of fungi. Med Mycol 2006 ; 44 : 267-72.
PubMed
5) 多田恵, 岡博, 三宅一. 健康成人に発症した鼻脳型ムコール症の1例. 脳外誌 2006 ; 15 : 133-7.
 
6) Cornely OA, Arikan-Akdagli S, Dannaoui E, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect 2014 ; 20 Suppl 3 : 5-26.
 
7) 深在性真菌症のガイドライン作成委員会. 深在性真菌症の診断・治療ガイドライン : 2014, 協和企画 (発売), 2014.
 
8) Pfaller MA, Messer SA, Hollis RJ, et al. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi : report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 2002 ; 46 : 1032-7.
PubMed
9) Sun QN, Fothergill AW, McCarthy DI, et al. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother 2002 ; 46 : 1581-2.
PubMed
10) Diekema DJ, Messer SA, Hollis RJ, et al. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 2003 ; 41 : 3623-6.
PubMed
11) Vazquez JA. Clinical practice : combination antifungal therapy for mold infections : much ado about nothing? Clin Infect Dis 2008 ; 46 : 1889-901.
PubMed
12) Reed C, Bryant R, Ibrahim AS, et al. Combination polyenecaspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis 2008 ; 47 : 364-71.
PubMed
13) Spellberg B, Walsh TJ, Kontoyiannis DP, et al. Recent advances in the management of mucormycosis : from bench to bedside. Clin Infect Dis 2009 ; 48 : 1743-51.
PubMed
14) Peterson KL, Wang M, Canalis RF, et al. Rhinocerebral mucormycosis : evolution of the disease and treatment options. Laryngoscope 1997 ; 107 : 855-62.
PubMed
P.476 掲載の参考文献
1) Merritt HH, Adams RD, Solomon HC. Neurosyphilis, Oxford, New York, 1946.
 
2) Stokes JH, Beerman H, Ingraham NR. Modern Clinical Syphilology : Diagnosis, Treatment, Case study, 3rd ed, WB Saunders, Philadelphia, 1944.
 
3) IASR 2014 ; 35 : 17-8.
 
4) Savage EJ, Marsh K, Duffell S, et al. Rapid increase in gonorrhoea and syphilis diagnoses in England in 2011. Euro Surveill 2012 ; 17 : pii20224.
PubMed
5) Bash S, Hathout GM, Cohen S. Mesiotemporal T2-weighted hyperintensity : neurosyphilis mimicking herpes encephalitis. AJNR Am J Neuroradiol 2001 ; 22 : 314-6.
PubMed
6) Marra CM. Neurosyphilis. Uptodate. Version Feb 18, 2010.
 
7) Workowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 2015 ; 64 : 1.
PubMed
8) Yang CL, Lee NY, Lin YH, et al. Jarish-Herxheimer reaction after penicillin therapy among patients with syphilis in the era of the HIV infection epidemic : incidence and risk factors. Clin Infect Dis 2010 ; 51 : 976-9.
 

第10章 炎症性疾患

P.484 掲載の参考文献
1) Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica : distinction from multiple sclerosis. Lancet 2004 ; 364 : 2106-12.
PubMed
2) Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005 ; 202 : 473-7.
 
3) Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015 ; 85 : 177-89.
PubMed
4) Osoegawa M, Kira J, Fukazawa T, et al. Temporal changes and geographical differences in multiple sclerosis phenotypes in Japanese : nationwide survey results over 30 years. Mult Scler 2009 ; 15 : 159-73.
PubMed
5) International Multiple Sclerosis Genetics Consortium, Wellcome Trust Case Control Consortium 2, Sawcer S, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011 ; 476 : 214-9.
 
6) International Multiple Sclerosis Genetics Consortium (IMSGC), Beecham AH, Patsopoulos NA, et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet 2013 ; 45 : 1353-60.
PubMed
7) Roemer SF, Parisi JE, Lennon VA, et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007 ; 130 : 1194-205.
PubMed
8) Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis : 2010 revisions to the McDonald criteria. Ann Neurol 2011 ; 69 : 292-302.
 
9) Wingerchuk DM, Hogancamp WF, O'Brien PC, et al. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999 ; 53 : 1107-14.
 
10) Masjuan J, Alvarez-Cermeno JC, Garcia-Barragan N, et al. Clinically isolated syndromes : a new oligoclonal band test accurately predicts conversion to MS. Neurology 2006 ; 66 : 576-8.
 
11) Petzold A, de Boer JF, Schippling S, et al. Optical coherence tomography in multiple sclerosis : a systematic review and meta-analysis. Lancet Neurology 2010 ; 9 : 921-32.
PubMed
12) Barnes D, Hughes RA, Morris RW, et al. Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet 1997 ; 349 : 902-6.
PubMed
13) Martinelli V, Rocca MA, Annovazzi P, et al. A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS. Neurology 2009 ; 73 : 1842-8.
 
14) Oliveri RL, Valentino P, Russo C, et al. Randomized trial comparing two different high doses of methylprednisolone in MS : a clinical and MRI study. Neurology 1998 ; 50 : 1833-6.
 
15) Weiner HL, Dau PC, Khatri BO, et al. Double-blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis. Neurology 1989 ; 39 : 1143-9.
PubMed
16) Weinshenker BG, O'Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999 ; 46 : 878-86.
 
17) Keegan M, Pineda AA, McClelland RL, et al. Plasma exchange for severe attacks of CNS demyelination : predictors of response. Neurology 2002 ; 58 : 143-6.
PubMed
18) Bonnan M, Valentino R, Olindo S, et al. Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder. Mult Scler 2009 ; 15 : 487-92.
PubMed
19) Merle H, Olindo S, Jeannin S, et al. Treatment of optic neuritis by plasma exchange (add-on) in neuromyelitis optica. Arch. Ophthalmol 2012 ; 130 : 858-62.
PubMed
20) Abboud H, Petrak A, Mealy M, et al. Treatment of acute relapses in neuromyelitis optica : Steroids alone versus steroids plus plasma exchange. Mult Scler 2016 ; 22 : 185-92.
PubMed
21) The IFNB Multiple Sclerosis Study Group : Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993 ; 43 : 655-61.
 
22) Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996 ; 39 : 285-94.
 
23) Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis : results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995 ; 45 : 1268-76.
 
24) Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006 ; 354 : 899-910.
 
25) Kappos L, Radue E-W, O'Connor PW, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010 ; 362 : 387-81.
 
26) O'connor P, Filippi M, Arnason B, et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis : a prospective, randomised, multicentre study. Lancet Neurology 2009 ; 8 : 889-97.
PubMed
27) Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis : results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002 ; 359 : 1453-60.
PubMed
28) Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS : The EVIDENCE Trial. Neurology 2002 ; 59 : 1496-506.
PubMed
29) Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010 ; 362 : 402-15.
 
30) Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000 ; 343 : 898-904.
 
31) Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006 ; 67 : 1242-9.
 
32) Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study) : a randomised, double-blind, placebo-controlled trial. Lancet 2009 ; 374 : 1503-11.
PubMed
33) Kinkel RP, Dontchev M, Kollman C, et al. Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes : a 10-year follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance. Arch Neurol 2012 ; 69 : 183-90.
PubMed
34) Comi G, Martinelli V, Rodegher M, et al. Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. Mult Scler 2013 ; 19 : 1074-83.
 
35) Edan G, Kappos L, Montalban X, et al. Long-term impact of interferon beta-1b in patients with CIS : 8-year follow-up of BENEFIT. J Neurol Neurosurg Psychiatr 2014 ; 85 : 1183-9.
 
36) Goodin DS, Reder AT, Ebers GC, et al. Survival in MS : a randomized cohort study 21 years after the start of the pivotal IFN β -1b trial. Neurology 2012 ; 78 : 1315-22.
 
37) Leary SM, Miller DH, Stevenson VL, et al. Interferon beta-1a in primary progressive MS : an exploratory, randomized, controlled trial. Neurology 2003 ; 60 : 44-51.
PubMed
38) Montalban X : Overview of European pilot study of interferon b-1b in primary progressive multiple sclerosis. Mult Scler 2004 ; 10 : S62.
 
39) Lublin F, Miller DH, Freedman MS, et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS) : a phase 3, randomised, double-blind, placebo-controlled trial. Lancet, 2016.
PubMed
40) European Study Group on Interferon β -1b in Secondary Progressive MS : Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS. Lancet 1998 ; 352 : 1491-7.
 
41) The North American Study Group on Interferon beta-1b in Secondary Progressive MS : Interferon beta-1b in secondary progressive MS Results from a 3-year controlled study. Neurology 2004 ; 63 : 1788-95.
 
42) Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MS (SPECTRIMS) Study Group : Randomized controlled trial of interferon- beta-1a in secondary progressive MS : Clinical results. Neurology 2001 ; 56 : 1496-504.
 
43) Andersen O, Elovaara I, Farkkila M, et al. Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatr 2004 ; 75 : 706-10.
 
44) Shimizu J, Hatanaka Y, Hasegawa M, et al. IFN β-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum. Neurology 2010 ; 75 : 1423-7.
 
45) Ayzenberg I, Schollhammer J, Hoepner R, et al. Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder : a multicenter retrospective study. J Neurol 2016 ; 1.
PubMed
46) Kira J-I, Itoyama Y, Kikuchi S, et al. Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months : results of a phase 2 observational extension. BMC Neurol 2014 ; 14 : 21.
PubMed
47) Azzopardi L, Cox AL, McCarthy CL, et al. Alemtuzumab use in neuromyelitis optica spectrum disorders : a brief case series. J Neurol 2015 ; 263 : 25.
 
48) Bichuetti DB, Lobato de Oliveira EM, Oliveira DM, et al. Neuromyelitis optica treatment : analysis of 36 patients. Arch Neurol 2010 ; 67 : 1131-6.
PubMed
49) Elsone L, Kitley J, Luppe S, et al. Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients : a multicentre retrospective observational study from the UK. Mult Scler 2014 ; 20 : 1533-40.
PubMed
50) Jacob A, Matiello M, Weinshenker BG, et al. Treatment of neuromyelitis optica with mycophenolate mofetil : retrospective analysis of 24 patients. Arch Neurol 2009 ; 66 : 1128-33.
PubMed
51) Huh S-Y, Kim S-H, Hyun J-W, et al. Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder. JAMA Neurol 2014 ; 71 : 1372-8.
PubMed
52) Cree BAC, Lamb S, Morgan K, et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005 ; 64 : 1270-2.
 
53) Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab : retrospective analysis of 25 patients. Arch Neurol 2008 ; 65 : 1443-8.
PubMed
54) Kim S-H, Jeong IH, Hyun J-W, et al. Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica : Influence of FCGR3A Polymorphisms on the Therapeutic Response to Rituximab. JAMA Neurol 2015 ; 72 : 989-95.
PubMed
55) Kitley J, Elsone L, George J, et al. Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies. J Neurol Neurosurg Psychiatr 2013 ; 84 : 918-21.
 
56) Kageyama T, Komori M, Miyamoto K, et al. Combination of cyclosporine A with corticosteroids is effective for the treatment of neuromyelitis optica. J Neurol 2013 ; 260 : 627-34.
PubMed
57) Pittock SJ, Lennon VA, Mckeon A, et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders : an open-label pilot study. Lancet Neurology 2013 ; 12 : 554-62.
PubMed
58) Araki M, Matsuoka T, Miyamoto K, et al. Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica : a pilot study. Neurology 2014 ; 82 : 1302-6.
PubMed
59) Ringelstein M, Ayzenberg I, Harmel J, et al. Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder. JAMA 2015 ; Neurol 72 : 756.
PubMed
P.488 掲載の参考文献
1) Kira J, Yamasaki K, Kawano Y, et al. Acute myelitis associated with hyperIgEemia and atopic dermatitis. J Neurol Sci 1997 ; 148 : 199-203.
PubMed
2) Osoegawa M, Ochi H, Minohara M, et al. Myelitis with atopic diathesis : a nationwide survey of 79 cases in Japan. J Neurol Sci 2003 ; 209 : 5-11.
PubMed
3) Isobe N, Kira J, Kawamura N, et al. Neural damage associated with atopic diathesis : a nationwide survey in Japan. Neurology 2009 ; 73 : 790-7.
PubMed
4) Yoon JH, Joo IS, Li WY, et al. Clinical and laboratory characteristics of atopic myelitis : Korean experience. J Neurol Sci 2009 ; 285 : 154-8.
PubMed
5) Gregoire SM, Mormont E, Laloux P, et al. Atopic myelitis : a clinical, biological, radiological and histopathological diagnosis. J Neurol Sci 2006 ; 247 : 231-5.
PubMed
6) Buratti L, Cagnetti C, Campanati A, et al. Atopic myelitis is not restricted to Japanese patients. Neurol Sci 2014 ; 35 : 1835-7.
 
7) Tanaka M, Matsushita T, Tateishi T, et al. Distinct CSF cytokine/chemokine profiles in atopic myelitis and other causes of myelitis. Neurology 2008 ; 71 : 974-81.
PubMed
8) Sato S, Isobe N, Yoshimura S, et al. HLA-DPB1*0201 is associated with susceptibility to atopic myelitis in Japanese. J Neuroimmunol 2012 ; 251 : 110-3.
PubMed
9) Murai H, Arahata H, Osoegawa M, et al. Effect of immunotherapy in myelitis with atopic diathesis. J Neurol Sci 2004 ; 227 : 39-47.
PubMed
P.490 掲載の参考文献
1) Wucherpfennig KW, Strominger JL. Molecular mimicry in T cell-mediated autoimmunity : viral peptides activate human T cell clones specific for myelin basic protein. Cell 1995 ; 80 : 695-705.
 
2) Menge T, Hemmer B, Nessler S, et al. Acute disseminated encephalomyelitis : an update. Arch Neurol 2005 ; 62 : 1673-80.
PubMed
3) Tenembaum S, Chitnis T, Ness J, et al. Acute disseminated encephalomyelitis. Neurology 2007 ; 68 : S23-36.
PubMed
4) Leake JA, Albani S, Kao AS, et al. Acute disseminated encephalomyelitis in childhood : epidemiologic, clinical and laboratory features. Pediatr Infect Dis J 2004 ; 23 : 756-64.
PubMed
5) Wingerchuk DM. Postinfectious encephalomyelitis. Curr Neurol Neurosci Rep 2003 ; 3 : 256-64.
PubMed
6) Torisu H, Kira R, Ishizaki Y, et al. Clinical study of childhood acute disseminated encephalomyelitis, multiple sclerosis, and acute transverse myelitis in Fukuoka Prefecture, Japan. Brain Dev 2010 ; 32 : 454-62.
PubMed
7) Noorbakhsh F, Johnson RT, Emery D, et al. Acute disseminated encephalomyelitis : clinical and pathogenesis features. Neurol Clin 2008 ; 26 : 759-80, ix.
 
8) Dale RC, de Sousa C, Chong WK, et al. Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children. Brain 2000 ; 123 Pt 12 : 2407-22.
 
9) Rossi A. Imaging of acute disseminated encephalomyelitis. Neuroimaging Clin N Am 2008 ; 18 : 149-61, ix.
 
10) Poser CM, Brinar VV. Disseminated encephalomyelitis and multiple sclerosis : two different diseases - a critical review. Acta Neurol Scand 2007 ; 116 : 201-6.
 
11) Honkaniemi J, Dastidar P, Kahara V, et al. Delayed MR imaging changes in acute disseminated encephalomyelitis. AJNR Am J Neuroradiol 2001 ; 22 : 1117-24.
PubMed
12) Krupp LB, Banwell B, Tenembaum S. Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology 2007 ; 68 : S7-12.
 
13) Marchioni E, Ravaglia S, Piccolo G, et al. Postinfectious inflammatory disorders : subgroups based on prospective follow-up. Neurology 2005 ; 65 : 1057-65.
PubMed
14) Young NP, Weinshenker BG, Lucchinetti CF. Acute disseminated encephalomyelitis : current understanding and controversies. Semin Neurol 2008 ; 28 : 84-94.
PubMed
15) 伊井裕一郎, 葛原茂樹. 急性散在性脳脊髄炎の成人例の検討 : 急性ウイルス性脳炎との早期鑑別点. 臨床神経 2009 ; 47 : 1034.
 
16) Marchioni E, Marinou-Aktipi K, Uggetti C, et al. Effectiveness of intravenous immunoglobulin treatment in adult patients with steroid-resistant monophasic or recurrent acute disseminated encephalomyelitis. J Neurol 2002 ; 249 : 100-4.
PubMed
17) Kanter DS, Horensky D, Sperling RA, et al. Plasmapheresis in fulminant acute disseminated encephalomyelitis. Neurology 1995 ; 45 : 824-7.
PubMed
18) Schwarz S, Mohr A, Knauth M, et al. Acute disseminated encephalomyelitis : a follow-up study of 40 adult patients. Neurology 2001 ; 56 : 1313-8.
PubMed
19) Mastrodimos B, Barnett GH, Awad IA. Intensive care management of acute hemorrhagic leukoencephalitis with favorable neurologic outcome. Cleve Clin J Med 1992 ; 59 : 549-52.
PubMed
20) Huang CC, Chu NS, Chen TJ, et al. Acute haemorrhagic leucoencephalitis with a prolonged clinical course. J Neurol Neurosurg Psychiatry 1988 ; 51 : 870-4.
 
P.493 掲載の参考文献
1) Bickerstaff ER. Brain-stem Encephalitis*. Br Med J 1957 ; 1 : 1384-7.
PubMed
2) Yuki N. Fisher syndrome and Bickerstaff brainstem encephalitis (Fisher-Bickerstaff syndrome). J Neuroimmunol 2009 ; 215 : 1-9.
PubMed
3) Koga M, Kusunoki S, Kaida K, et al. Nationwide survey of patients in Japan with Bickerstaff brainstem encephalitis : epidemiological and clinical characteristics. [Internet]. J Neurol Neurosurg Psychiatry 2012 ; 83 : 1210-5.
PubMed
4) Ito M, Kuwabara S, Odaka M, et al. Bickerstaff 's brainstem encephalitis and Fisher syndrome form a continuous spectrum : Clinical analysis of 581 cases. J Neurol 2008 ; 255 : 674-82.
 
5) Odaka M, Yuki N, Yamada M, et al. Bickerstaff's brainstem encephalitis : Clinical features of 62 cases and a subgroup associated with Guillain-Barre syndrome. Brain 2003 ; 126 : 2279-90.
 
6) Wakerley BR, Uncini A, Yuki N, et al. Guillain-Barre and Miller Fisher syndromes-new diagnostic classification [Internet]. Nat Rev Neurol 2014 ; 10 : 537-44.
 
P.497 掲載の参考文献
1) 広畑俊成. 神経ベーチェット病の病態. 臨床神経 2001 ; 41 : 1147-9.
 
2) Akman-Demir G, Serdaroglu P, Tasci B. The Neuro-Behcet Study Group. Clinical patterns of neurological involvement in Behcet's disease : evaluation of 200 patients. Brain 1999 ; 122 : 2171-82.
 
3) Hirohata S, Isshi K, Oguchi H, et al. Cerebrospinal fluid interleukin-6 in progressive Neuro-Behcet's syndrome. Clin Immunol Immunopathol 1997 ; 82 : 12-7.
PubMed
4) Hirohata S, Kikuchi H, Sawada T, et al. Clinical characteristics of neuro-Behcet's disease in Japan : a multicenter retrospective analysis. Mod Rheumatol 2012 ; 22 : 405-13.
PubMed
5) Hirohata S, Kikuchi H, Sawada T, et al. Analysis of various factors on the relapse of acute neurological attacks in Behcet's disease. Mod Rheumatol 2014 ; 24 : 961-5.
PubMed
6) Kikuchi H, Takayama M, Hirohata S. Quantitative analysis of brainstem atrophy on magnetic resonance imaging in chronic progressive neuro-Behcet's disease. J Neurol Sci 2014 ; 337 : 80-5.
PubMed
7) Hirohata S, Suda H, Hashimoto T. Low dose weekly methotrexate therapy for progressive neuropsychiatric manifestations in Behcet's disease. J Neurol Sci 1998 ; 159 : 181-5.
 
8) Hirohata S, Kikuchi H, Sawada T, et al. Retrospective analysis of long-term outcome of chronic progressive neurological manifestations in Behcet's disease. J Neurol Sci 2015 ; 349 : 143-8.
 
9) Kikuchi H, Aramaki K, Hirohata S. Effect of infliximab in progressive Neuro-Behcet's syndrome. J Neurol Sci 2008 ; 272 : 99-105.
PubMed
10) 廣畑俊成, 菊地弘敏, 桑名正隆, 他. 神経ベーチェット病の診療のガイドライン. 厚生労働科学研究補助金 難治性疾患克服研究事業 ベーチェット病に関する調査研究事業 平成23-25年度総括・分担研究報告書 2014年, p247-52.
 
P.500 掲載の参考文献
1) Gullapalli D, Phillips LH 2nd. Neurosarcoidosis. Curr Neurol Neurosci Rep 2004 ; 4 : 441-7.
PubMed
2) 日本サルコイドーシス/肉芽腫性疾患学会, 他. サルコイドーシスの診断基準と診断の手引き-2006. 日呼吸会誌 2007 ; 46 : 768-80.
 
3) Charil A, Yousry TA, Rovaris M, et al. MRI and the diagnosis of multiple sclerosis : expanding the concept of "no better explanation". Lancet Neurol 2006 ; 5 : 841-52.
 
4) Ginat DT, Dhillon G, Almast J. Magnetic resonance imaging of neurosarcoidosis. J Clin Imaging Sci 2011 ; 1 : 15.
PubMed
5) Terushkin V, Stern BJ, Judson MA, et al. Neurosarcoidosis : presentations and management. Neurologist 2015 ; 16 : 2-15.
 
6) Pawate S, Moses H, Sriram S. Presentations and outcomes of neurosarcoidosis : a study of 54 cases. QJM 2009 ; 102 : 449-60.
PubMed
7) 厚生省科学研究特定疾患対策事業-びまん性肺疾患研究班. サルコイドーシス治療に関する見解-2003. 日本サルコイドーシス/肉芽腫性疾患学会雑誌 2003 ; 23 : 105-14.
 
8) Pettersen JA, Zochodne DW, Bell RB, et al. Refractory neurosarcoidosis responding to infliximab. Neurology 2002 ; 59 : 1660-1.
PubMed
9) Carter JD, Valeriano J, Vasey FB, et al. Refractory neurosarcoidosis : a dramatic response to infliximab. Am J Med 2004 ; 117 : 277-9.
PubMed
10) Sollberger M, Fluri F, Baumann T, et al. Successful treatment of steroid-refractory neurosarcoidosis with infliximab. J Neurol 2004 ; 251 : 760-1.
PubMed
11) Callebaut J, Dormont D, Dubois B, et al. Contrast-enhanced MR imaging of tuberculous pachymeningitis cranialis hypertrophica : case report. AJNR Am J Neuroradiol 1990 ; 11 : 821-2.
PubMed
12) Murai H, Kira J, Kobayashi T, et al. Hypertrophic cranial pachymeningitis due to Aspergillus flavus. Clin Neurol Neurosurg 1992 ; 94 : 247-50.
PubMed
13) Ranoux D, Devaux B, Lamy C, et al. Meningeal sarcoidosis, pseudo-meningioma, and pachymeningitis of the convexity. J Neurol Neurosurg Psychiatry 1992 ; 55 : 300-3.
PubMed
14) River Y, Schwartz A, Gomori JM, et al. Clinical significance of diffuse dural enhancement detected by magnetic resonance imaging. J Neurosurg 1996 ; 85 : 777-83.
PubMed
15) Yokoseki A, Saji E, Arakawa M, et al. Hypertrophic pachymeningitis : significance of myeloperoxidase anti-neutrophil cytoplasmic antibody. Brain 2014 ; 137 : 520-36.
PubMed
16) Chan SK, Cheuk W, Chan KT, Chan JK. IgG4-related sclerosing pachymeningitis : a previously unrecognized form of central nervous system involvement in IgG4-related sclerosing disease. Am J Surg Pathol 2009 ; 33 : 1249-52.
PubMed
17) 陸 重夫, 橋詰良夫, 吉田眞理, 他. 肥厚性硬膜炎は「IgG4関連疾患」か? 臨床神経学 2009 ; 49 : 594-6.
 
P.504 掲載の参考文献
1) Moore PM. Central nervous system vasculitis. Curr Opin Neurol 1998 ; 11 : 241-6.
PubMed
2) Hirohata S, Tanimoto K, Ito K. Elevation of cerebrospinal fluid interleukin-6 activity in patients with vasculitides and central nervous system involvement. Clin Immunol Immunopathol 1993 ; 66 : 225-9.
PubMed
3) Shanahan EM, Hutchinson M, Hanley SD, et al. Giant cell arteritis presenting as lateral medullary syndrome. Rheumatology 1999 ; 38 : 188-9.
PubMed
4) Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum1990 ; 33 : 1122-8.
PubMed
5) 西岡淳一, 中井秀紀, 七川歓次, 他. わが国におけるリウマチ性多発筋痛症 (polymyalgia rheumatica) の病態調査と日本人における診断基準設立の必要性への示唆. リウマチ 1985 ; 25 : 265-73.
 
6) Bird HA, Esselinckx W, Dixon AS, et al. An evaluation of criteria for polymyalgia rheumatica. Ann Rheum Dis 1979 ; 38 : 434-9.
PubMed
7) Dasgupta B, Cimmino MA, Kremers HM, et al. 2012 Provisional classification criteria for polymyalgia rheumatica : a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis Rheum 2012 ; 64 : 943-54.
PubMed
P.508 掲載の参考文献
1) Harris EN, Hughes GR. Cerebral disease in systemic lupus erythematosus. Springer Semin Immunopathol 1985 ; 8 : 251-66.
PubMed
2) ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature. The American College of Rheumatology nomenclature and classification and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999 ; 42 : 599-608.
 
3) Hirohata S, Hirose S, Miyamoto T. Cerebrospinal fluid IgM, IgA and IgG indexes in systemic lupus erythematosus. Arch Intern Med 1985 ; 145 : 1843-6.
PubMed
4) Hirohata S, Miyamoto T. Elevated levels of interleukin-6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous system involvement. Arthritis Rheum 1990 ; 33 : 644-9.
PubMed
5) Shiozawa S, Kuroki Y, Kim M, et al. Interferon-alpha in lupus psychosis. Arthritis Rheum 1992 ; 35 : 417-22.
PubMed
6) Isshi K, Hirohata S. Differential roles of the anti-ribosomal P antibody and antineuronal antibody in the pathogenesis of central nervous system involvement in systemic lupus erythematosus. Arthritis Rheum 1998 ; 41 : 1819-27.
PubMed
7) Nagai T, Arinuma Y, Yanagida T, et al. Anti-ribosomal P protein antibody in human systemic lupus erythematosus up-regulates the expression of proinflammatory cytokines by human peripheral blood monocytes. Arthritis Rheum 2005 ; 52 : 847-55.
PubMed
8) Hirohata S, Arinuma Y, Takayama M, et al. Association of cerebrospinal fluid anti-ribosomal P protein antibodies with diffuse psychiatric/neuropsychological syndromes in systemic lupus erythematosus. Arthritis Res Ther 2007 ; 9 : R44.
 
9) Arinuma Y, Yanagida T, Hirohata S. Association of cerebrospinal fluid anti-NR2 with diffuse psychiatric/neuropsychological syndromes in systemic lupus erythematosus. Arthritis Rheum 2008 ; 58 : 1130-5.
PubMed
10) Hirohata S, Sakuma Y, Yanagida T, et al. Association of cerebrospinal fluid anti-Sm antibodies with acute confusional state in systemic lupus erythematosus. Arthritis Res Ther 2014 ; 16 : 450.
PubMed
11) 広畑俊成. ループス精神病の分類基準. 厚生労働科学免疫アレルギー疾患予防・治療研究事業 免疫疾患の合併症とその治療法に関する研究「診療ガイドライン」, 2005, p8-13.
 
12) 広畑俊成. 第2章 難治性神経筋疾患 I. CNSループス. 厚生労働科学免疫アレルギー疾患予防・治療研究事業 全身性自己免疫疾患における難治性病態の診断と治療に関する研究 「全身性自己免疫疾患における難治性病態の診療ガイドライン」, 2005, p5-9.
 
13) Rosa C, Alves M, Queiros MV, et al. Neurologic involvement in patients with rheumatoid arthritis with atlantoaxial subluxationa clinical and neurophysiological study. J Rheumatol 1993 ; 20 : 248-52.
PubMed
14) Provenzale JM, Allen NB. Neuroradiologic findings in polyarteritis nodosa. AJNR Am J Neuroradiol 1996 ; 17 : 1119-26.
PubMed
15) Hirohata S, Tanimoto K, Ito K. Elevation of cerebrospinal fluid interleukin-6 activity in patients with vasculitides and central nervous system involvement. Clin Immunol Immunopathol 1993 ; 66 : 225-9.
PubMed
16) Oran I, Memis A, Parildar M, et al. Multiple intracranial aneurysms in polyarteritis nodosa : MRI and angiography. Neuroradiology 1999 ; 41 : 436-9.
PubMed
17) Akkara Veetil BM, Schimmer BM. A case of limited systemic sclerosis with p-ANCA, complicated by multiple cerebral hemorrhages. Rheumatol Int 2009 ; 29 : 325-9.
 
18) Provenzale JM, Allen NB. Wegener granulomatosis : CT and MR findings. AJNR Am J Neuroradiol 1996 ; 17 : 785-92.
 
19) Saeki T, Fujita N, Kourakata H, et al. Two cases of hypertrophic pachymeningitis associated with myeloperoxidase antineutrophil cytoplasmic autoantibody (MPO-ANCA) -positive pulmonary silicosis in tunnel workers. Clin Rheumatol 2004 ; 23 : 76-80.
PubMed
20) Fam AG, Lavine E, Lee L, et al. Cranial pachymeningitis : an unusual manifestation of Wegener's granulomatosis. J Rheumatol 2003 ; 30 : 2070-4.
 
21) Nakamura T, Hirakawa K, Higashi S, et al. CD8+ T lymphocytes infiltrate predominantly in the inflammatory foci of MPOANCA-positive thoracic hypertrophic pachymeningitis in a patient with HLA-A24. Mod Rheumatol 2007 ; 17 : 75-80.
 

第11章 変性疾患

P.513 掲載の参考文献
1) 目黒謙一. 脳血管性認知症の概念. 血管性認知症 (目黒謙一, 著), 東京, ワールドプランニング, 2008, p20-32.
 
2) Fisher CM. Lacunar strokes and infarcts : a review. Neurology 1982 ; 32 : 871-6.
PubMed
3) Kalaria R, et al. Similarities between Alzheimer's disease and vascular dementia. J Neurol Sci 2002 ; 203-204 : 29-34.
 
4) Korczyn AD, et al. Mixed dementia-the most common cause of dementia. Ann N Y Acad Sci 2002 ; 977 : 129-34.
PubMed
5) Roman GC, et al. Vascular dementia : diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993 ; 43 : 250-60.
 
6) Hachinski VC, Bowler J. Vascular dementia. Neurology 1993 ; 43 : 2159-60.
PubMed
7) Erkinjuntti T, Inzitari D, Pantoni L, et al. Research criteria for subcortical vascular dementia in clinical trials. J Neural Transm 2000 ; Suppl 59 : 23-30.
 
8) Kiyohara Y, Yoshitake T, Kato I, et al. Changing patterns in the prevalence of dementia in a Japanese community : the Hisayama study. Gerontology 1994 ; 40 : S29-35.
 
9) Yamada M, Sasaki H, Mimori Y, et al. Prevalence and risks of dementia in the Japanese population : RERF's adult health study Hiroshima subjects. Radiation Effects Research Foundation. J Am Geriatr Soc 1999 ; 47 : 189-95.
 
10) 清原裕. 久山町疫学調査. 日本臨牀 2004 ; 62 s4 : 133-7.
 
11) Gorelick PB. Status of risk factors for dementia associated with stroke. Stroke 1997 ; 28 : 459-63.
PubMed
12) Vermeer SE, Prins ND, den Heijier T, et al. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003 ; 348 : 1215-22.
 
13) Chui HG, Victoroff JI, Margolin D, et al. Criteria for thediagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers. Neurology 1992 ; 42 : 473-80.
 
14) Gold G, Bouras C, Canuto A, et al. Clinicopathological validation study of four sets of crinical criteria for vascular dementia. Am J Psychiatry 2002 ; 159 : 82-7.
 
15) 脳卒中治療ガイドライン 2015. VI その他の脳血管障害 12 血管性認知症, 血管性認知障害. 265-7.
 
16) Skoog I, Lernfelt B, Landahl S, et al. 15-year longitudinal study of blood pressure and dementia. Lancet 1996 ; 347 : 1141-5.
PubMed
17) Tzourio C, Dufouil C, Ducimetiere P, et al. Cognitive decline in individuals with high blood pressure : a longitudinal study in the elderly. EVA Study Group. Epidemiology of vascular Aging. Nurology 1999 ; 53 : 1948-52.
 
18) Forette F, Seux ML, Staessen JA, et al. Prevention of dementia in randomized double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998 ; 352 : 1347-51.
PubMed
19) Tzourio C, Anderson C, Chapman N, et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003 ; 163 : 1069-75.
PubMed
20) Peters R, Beckett N, Forette F, et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG) : a double-blind, placebo controlled trial. Lancet Neurol 2008 ; 7 : 683-9.
PubMed
21) Yoshitake T, Kiyohara Y, Kato I, et al. Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population : the Hisayama Study. Neurology 1995 ; 45 : 1161-8.
 
22) Ott A, Stolk RP, van Harskamp F, et al. Diabetes mellitus and the risk of dementia : The Rotterdam Study. Neurology 1999 ; 53 : 1937-42.
PubMed
23) Xu WL, Qiu CX, Wahlin A, et al. Diabetes mellitus and risk of dementia in the Kungsholmen project : a 6-year follow-up study. Neurology 2004 ; 63 : 1181-6.
 
24) Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitazone Clinical Trial In maroVasculae Events) : a randomized controlled trial. Lancet 2005 ; 366 : 1279-89.
PubMed
25) Moroney JT, Tang MX, Berglund L, et al. Low-density lipoprotein cholesterol and the risk of dementia with stroke. JAMA 1999 ; 282 : 254-60.
PubMed
26) Shinohara Y, Gotoh F, Tohgi H, et al. Antiplatelet cilostazol is beneficial in diabetic and/or hypertensive ischemic stroke patients. Subgroup analysis of the cilostazole stroke prevention study. Cerebrovasc Dis 2008 ; 26 : 63-70.
PubMed
27) 認知症疾患治療ガイドライン 2010. 第6章 血管性認知症. 251-94.
 
28) Hackett ML, Anderson CS, House AO : Management of depression after stroke : a systematic review of pharmacological therapies. Stroke 2005 ; 36 : 1098-103.
PubMed
29) Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia : a review of the evidence. JAMA 2005 ; 293 : 596-608.
PubMed
30) Varpetian A, Gonthier R, Chui H. Natural history of vascular dementia. In ; Erkinjuntti T, Gauthier S, eds. Vascular cognitive impairment, Taylor & Francis Group, 2002, p541-55.
 
P.517 掲載の参考文献
1) Ikejima C, Hisanaga A, Meguro K, et al. Multicentre population-based dementia prevalence survey in Japan : a preliminary report. Psychogeriatrics 2012 ; 12 : 120-3.
PubMed
2) 認知症疾患治療ガイドライン作成合同委員会. "認知症疾患治療ガイドライン 2010" コンパクト版 2012, 医学書院, 東京, 2012.
 
3) Qiu C, et al. Twenty-year changes in dementia occurrence suggest decreasing incidence in central Stockholm, Sweden. Neurology 2013 ; 80 : 1888-94.
PubMed
4) Matthews FE, et al. A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England : results of the Cognitive Function and Ageing Study I and II. Lancet 2013 ; 382 : 1405-12.
 
5) Sperling RA, et al. Towards defining the preclinical stage of Alzheimer's disease : recommendations from the National Institute on Aging and the Alzheimer's Association workgroup. Alzheimer's Dement 2011 ; 7 : 280-92.
 
6) McKhann GM, et al. The diagnosis of dementia due to Alzheimer's disease : Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup. Alzheimer's Dement 2011 ; 7 : 263-9.
 
7) American Psychiatric Association. Diagnostic and statistical manual of mental disorders, Fifth Edition. Washington DC : American Psychiatric Association. 2013.
 
8) 日本精神神経学会. 日本語版用語慣習 : DSM-5 精神疾患の診断・統計マニュアル, 医学書院, 2014.
 
9) Dubois B, Feldman HH, Jacova C, et al. Advqancing research diagnostic criteria for Alzheimer's disease : the IWG-2 criteria. Lancet Neurol 2014 ; 13 : 614-29.
PubMed
P.520 掲載の参考文献
1) The Lund and Manchester Groups. Clinical and neuropathological criteria for frontotemporal dementia. J Neurol Neurosurg Psychiatry 1994 ; 57 : 416-8.
PubMed
2) Snowden JS, Neary D, Mann DMA. Fronto-temporal lobar degeneration : Fronto-temporal dementia, progressive aphasia, semantic dementia. In ; Clinical Neurology and Neurosurgery Monographs. New York, Churchill Livingstone, 1996.
 
3) Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration : A consensus on clinical diagnostic criteria. Neurology 1998 ; 51 : 546-54.
 
4) Cairns NJ, Ghoshal N. FUS : A new actor on the frontotemporal lobar degeneration stage. Neurology 2010 ; 74 : 354-6.
 
5) Graham A. Epidemiology of frontotemporal dementia. In ; Hodges JR, ed. Frontotemporal dementia syndrome. Cambridge, Cambridge University Press, 2007, p25-37.
 
6) Ikeda M, Ishikawa T, Tanabe H. Epidemiology of frontotemporal lobar degeneration. Dement Geriatr Cogn Disord 2004 ; 17 : 265-8.
PubMed
7) Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011 ; 134 : 2456-77.
PubMed
8) 日本神経学会. 認知症疾患治療ガイドライン 2010, 医学書院, 2010, p323-9.
 
9) 池田学. 前頭側頭葉変性症 : 治療とケア. 認知症テキストブック, 中外医学社, 2008, p308-9.
 
10) Swartz JR, Miller BL, Lesser IM, et al. Frontotemporal dementia : treatment response to serotonin selective reuptake inhibitors. J Clin Psychiatry 1997 ; 58 : 212-6.
PubMed
11) Ikeda M, Shigenobu K, Fukuhara R, et al. Efficacy of fluvoxamine as a treatment for behavioral symptoms in frontotemporal lobar degeneration patients. Dement Geriatr Cogn Disord 2004 ; 17 : 117-21.
PubMed
12) Deakin JB, Rahman S, Nestor PJ, et al. Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia : a double-blind randomized controlled trial. Psychopharmacology 2004 ; 172 : 400-8.
 
13) 西川隆, 池尻義隆, 正木慶大, 他. Pick病の反復行動に対する選択的セロトニン再取込み阻害薬の効果. 精神医学 2001 ; 43 : 251-8.
 
14) 石川博康, 下村辰雄, 清水徹男. 常同行動と疼痛の強迫的な訴えにfluvoxamineが著効した前頭側頭型認知症の2症例. 精神経誌 2006 ; 108 : 1029-35.
 
15) Mendez MF, Shapira JS, et al. Preliminary findings : behavioral worsening on donepezil in patients with frontotemporal dementia. Am J Geriatr Psychiat 2007 ; 15 : 84-7.
 
P.524 掲載の参考文献
1) Perry R, McKeith IG, Perry E. Dementia with Lewy Bodies. Cambridge University Press, Cambridge, 1996.
 
2) McKeith I, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathological diagnosis of dementia with Lewy bodies (DLB). Neurology1996 ; 47 : 1113-24.
PubMed
3) Kosaka K, Yoshimura M, Ikeda K, et al. Diffuse type of Lewy body disease. A progressive dementia with numerous cortical Lewy bodies and senile changes of various degree. A new disease? Clin Neuropathol 1984 ; 3 : 185-92.
PubMed
4) Kosaka K. Diffuse Lewy body disease in Japan. J Neurol 1990 ; 237 : 197-204.
PubMed
5) McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies : third report of the DLB consortium. Neurology 2007 ; 65 : 1863-72.
 
6) 小阪憲司, 松下正明, 小柳新策, 他. Lewy小体病の臨床病理学的研究. 精神経誌 1980 ; 82 : 292-311.
 
7) Kosaka K, Iseki E. Diffuse Lewy body disease within the spectrum of Lewy body disease. In : Perry R, McKeith I, Perry I, eds. Dementia with Lewy Bodies, Cambridge University Press, 1996, p238-47.
 
8) Kosaka K. Diffuse Lewy body disease. Neuropathology.
 
9) 小阪憲司, 井関栄三, 都甲隆, 他. レビー小体型認知症. 精神経誌 2005 ; 107 : 529-44.
 
10) 小阪憲司. レビー小体型認知症. 臨床精神医学 2006 ; 35 (増刊号) : 26-9.
 
11) 小阪憲司. レビー小体型認知症の発見から現在まで-臨床診断基準書改訂版を含めて. 精神医学 2007 ; 47 : 703-7.
 
12) Lippa CF, Duda JE, Grossman M, et al. DLB and PDD boundary issues. Diagnosis, treatment, molecular pathology, and biomarkers. Neurology 2007 ; 68 : 812-8.
PubMed
13) 小阪憲司. 最近のレビー小体病の概念. 神経心理学 2008 ; 24 : 230-4.
 
14) Kosaka K, Iseki E, Odawara T, et al. Cerebral type of Lewy body disease. Neuropathology 1996 ; 17 : 32-5.
 
15) Kosaka K. [Panel Discussion] Do most patients with PDD have DLB? 第45回日本神経学会, 東京, 2004.
 
16) 小阪憲司. DLBの初期診断. Modern Physician 2006 ; 26 : 1869-71.
 
17) 小阪憲司, 朝田隆. 認知症における早期介入の現在と将来. 精神医学 2008 ; 50 : 237-44.
 
18) McKeith I. Dementia with Lewy bodies. Kobe Confrence, International Neuropsychiatry Association, 2009, 9.
 
19) 小阪憲司. レビー小体型痴呆の治療. Brain Medical 2004 ; 16 : 48-52.
Medical*Online
20) 小阪憲司. レビー小体型認知症の新しい診断基準とその治療. 治療学 2008 ; 42 : 587-691.
 
21) 小阪憲司, 池田学. レビー小体型認知症に対する薬物療法. 精神医学 2014 ; 56 : 191-7.
 
22) Aarsland D, Laake K, Larsen JP, et al. Donepezil for cognitive impairment in Parkinson's disease : a randomized controlled 445 study. J Neurol Neurosurg Psychiatry 2002 ; 72 : 708-12.
 
23) Leroi I, Brandt J, Reich SG, et al. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int J Geriatr Psychiatry 2004 ; 19 : 1-8.
 
24) Ravina B, Putt M, Siderowf A, et al. Donepezil for dementia in Parkinson's disease : a randomized, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry 2005 ; 76 : 934-9.
PubMed
25) Thomas AJ, Burn DJ, Rowan EN, et al. A comparison of the efficacy of donepezil in Parkinson's disease with dementia and dementia with Lewy bodies. Int J Geriat Psychiatry 2005 ; 20 : 938-44.
 
26) Minett TSC, Thomas A, Wilkinson LM, et al. What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia. Int J Geriatr Psychiatry 2003 ; 18 : 988-93.
 
27) Mori S, Mori E, Iseki E, et al. Efficacy and safety of donepezil in patients with dementia with Lewy bodies : preliminary findings from an open-label study. Psychiatry Clin Neurosci 2006 ; 60 : 190-5.
PubMed
28) Mori E, Ikeda M, Kosaka K. Donepezil for dementia with Lewy bodies : a randomized, placebo-controlled trial. Ann Neurol 2012 ; 72 : 41-52.
PubMed
29) Ikeda M, Mori E, Kosaka K, et al. Long-term safety and efficacy of donepezil in patients with dementia with Lewy bodies : results from a 52-week, open-label, multicenter extension study. Dement Geriatr Cogn Disord 2013 ; 36 : 229-41.
PubMed
30) 日本神経学会. 日本神経学会治療ガイドライン. パーキンソン病治療ガイドライン 2002. 臨床神経学 2002 ; 42 : 430-94.
 
31) Ikeda M, Mori E, Matsuo K, et al. Donepezil for dementia with Lewy bodies : a randomized, placebo-controlled, confirmatory phase III trial. Alzheimers Res Ther. 2015 ; 7 : 4.
PubMed
32) McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies. A randomized, double-blind, placebo-controlled international study. Lancet 2000 ; 356 : 2031-6.
 
33) Iwasaki K,Kosaka K,Okitsu R, et al. Efficacy and safety of yokukansan, a traditional Japanese medicine, in patients with dementia Lewy bodies : a multicenter open label study. Psychogeriatrics 2012 ; 12 : 235-41.
PubMed
P.536 掲載の参考文献
1) 日本神経学会パーキンソン病治療ガイドライン作成小委員会. パーキンソン病治療ガイドライン 2002. 臨床神経学 2002 ; 42 : 430-94.
 
2) Calne DB, Gibb WR. Research diagnostic criteria for Parkinson's disease. Ann Neurol 1992 ; 32 : S125-7.
 
3) 厚生省特定疾患・神経変性疾患調査研究班 (班長 : 柳沢信夫) 1995年度研究報告書, 22, 1996.
 
4) 中島健二, 他. パーキンソン病の疫学. Pharma Medica 1998 ; 16 : 21-5.
Medical*Online
5) Whone AL, Watts RL, Stoessl AJ, et al ; REAL-PET Study Group. Slower progression of Parkinson's disease with ropinirole versus levodopa : The REAL-PET study. Ann Neurol 2003 ; 54 : 93-101.
 
6) 柴香保里, 服部信孝. 家族性パーキンソン病の分子生物学. 日本臨床 2004 ; 62 : 1617-22.
 
7) 今居謙. パーキンソン病原因遺伝子研究の進展. 最新医学 2010 ; 65 : 799-805.
 
8) 戸田達史. 孤発型パーキンソン病のリスク遺伝子. 最新医学 2010 ; 65 : 806-13.
 
9) Stefanova N, Bucke P, Duerr S, et al. Multiple system atrophy : an update. Lancet Neurol 2009 ; 8 : 1172-8, Review.
PubMed
10) Bannister R, Oppenheimer D. Parkinsonism, system degenerations and autonomic failure. In, Marsden CD, Fahn S, eds. Movement Disorders. Neurology Series 2. London, Butterworth, 1982, p174-90.
 
11) Higgins JJ, Golbe LI, De Bias A, et al. An extended 5'-tau susceptibility haplotype in progressive supranuclear palsy. Neurology 2000 ; 55 : 1364-7.
 
12) Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) : report of the MINDS-SPSP international workshop. Neurology 1996 ; 47 : 1-9.
 
13) Williams DR, Lees AJ. What features improve the accuracy of the clinical diagnosis of progressive supranuclear palsy-parkinsonism (PSP-P) ? Mov Disord 2010 ; 25 : 357-62.
PubMed
14) Imai H. Clinicophysiological features of akinesia. Eur Neurol 1996 ; 36 (Suppl 1) : 9-12, Review.
 
15) Arima K, Uesugi H, Fujita I, et al. Corticonigral degeneration with neuronal achromasia presenting with primary progressive aphasia : ultrastructural and immunocytochemical studies. J Neurol Sci 1994 ; 127 : 186-97.
PubMed
16) Feany MB, Dickson DW. Widespread cytoskeletal pathology characterizes corticobasal degeneration. Am J Pathol 1995 ; 146 : 1388-96.
PubMed
17) Wenning GK, Litvan I, Jankovic J, et al. Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination. J Neurol Neurosurg Psychiatry 1998 ; 64 : 184-9.
PubMed
18) Foster NL, Wilhelmsen K, Sima AA, et al. Fronto-temporal dementia and parkinsonism linked to chromosome 17 : a consensus conference. Ann Neurol 1997 ; 41 : 706-15.
 
19) Hutton M, Lendon CL, Rizzu P, et al. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998 ; 393 : 702-5.
PubMed
20) Rabinovici GD, Miller BL. Frontotemporal lobar degeneration : epidemiology, pathophysiology, diagnosis and management. CNS Drugs 2010 ; 24 : 375-98.
PubMed
21) Trussart V, Lebouchq N, Carlander B, et al. Hallervorden-Spatz syndrome and MRI : the "tiger's eye". One case. J Neuroradiol 1993 ; 20 : 70-5.
 
22) Zhou B, Westaway SK, Levinson B, et al. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome Nat Genet 2001 ; 28 : 345-9.
 
23) Lorenz D, Deuschl G. Update on pathogenesis and treatment of essential tremor. Curr Opin Neurol 2007 ; 20 : 447-52, Review.
PubMed
24) 葛原茂樹. 薬剤性パーキンソン症候群. 日本臨床 領域別症候群 1999 ; 27 : 29-31.
 
25) 東儀英夫. 血管性Parkinson症候群. 医学のあゆみ 1998 ; 186 : 69-73.
Medical*Online
P.540 掲載の参考文献
1) Zesiewicz TA, Elble R, Louis ED, et al. Practice parameter : therapies for essential tremor : report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2005 ; 64 : 2008-20.
PubMed
2) Zesiewicz TA, Elble RJ, Louis ED, et al. Evidence-based guideline update : treatment of essential tremor : report of the Quality Standards subcommittee of the American Academy of Neurology. Neurology 2011 ; 77 : 1752-5.
PubMed
3) Elias WJ, Shah BB. Tremor. JAMA 2014 ; 311 : 948-54.
PubMed
4) Lee KS, Kim JS, Kim JW, et al. A multicenter randomized crossover multiple-dose comparison study of arotinolol and propranolol in essential tremor. Parkinsonism Relat Disord 2003 ; 9 : 341-7.
PubMed
5) Sechi G, Agnetti V, Sulas FM, et al. Effects of topiramate in patients with cerebellar tremor. Prog Neuropsychopharmacol Biol Psychiatry 2003 ; 27 : 1023-7.
PubMed
6) Striano P, Coppola A, Vacca G, et al. Levetiracetam for cerebellar tremor in multiple sclerosis : an open-label pilot tolerability and efficacy study. J Neurol 2006 ; 253 : 762-6.
PubMed
7) Bain PG. Tremor. Parkinsonism Relat Disord 2007 ; 13 : S369-74.
PubMed
8) Ferlazzo E, Morgante F, Rizzo V, et al. Successful treatment of Holmes tremor by levetiracetam. Mov Disord 2008 ; 23 : 2101-3.
PubMed
9) Suda S, Yamazaki M, Katsura K, et al. Dramatic response to zonisamide of post-subarachnoid hemorrhage Holmes' tremor. J Neurol 2012 ; 259 : 185-7.
 
10) Hawkes E, Bain P. The treatment of dystonic tremor syndromes. Parkinsonism Relat Disord 2007 ; 13 : S68-9.
 
11) Rodrigues JP, Edwards DJ, Walters SE, et al. Blinded placebo crossover study of gabapentin in primary orthostatic tremor. Mov Disord 2006 ; 21 : 900-5.
PubMed
12) Ganos C, Maugest L, Apartis E, et al. The long-term outcome of orthostatic tremor. J Neurol Neurosurg Psychiatry 2015 Mar 13. pii : jnnp-2014-309942. doi : 10.1136/jnnp-2014-309942. [Epub ahead of print].
 
P.546 掲載の参考文献
1) Orr HT, Chung M-Y, Banfi S, et al. Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1. Nat Genet 1993 ; 4 : 221-6.
PubMed
2) Pulst S-M, Nechiporuk A, Nechiporuk T, et al. Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. Nat Genet 1996 ; 14 : 269-76.
PubMed
3) Kawaguchi Y, Okamoto T, Taniwaki M, et al. CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat Genet 1994 ; 8 : 221-7.
 
4) Flanigan K, Gardner K, Alderson K, et al. Autosomal dominant spinocerebellar ataxia with sensory axonal neuropathy (SCA4) : Clinical description and genetic localization to chromosome 16q22.1. Am J Hum Genet 1996 ; 59 : 392-9.
PubMed
5) Ranum LPW, Schut L, Lundgren J, et al. Spinocerebellar ataxia type 5 in a family descended from the grandparents of president Lincoln maps to chromosome 11. Nat Genet 1994 ; 8 : 280-4.
 
6) Zhunchenko O, Bailey P, Bonnen P, et al. Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the α 1A-voltage-dependent calcium channel. Nat Genet 1997 ; 15 : 62-9.
 
7) David G, Abbas N, Stevanin G, et al. Cloning of the SCA7 gene reveals a highly unstable CAG repeat expansion. Nat Genet 1997 ; 17 : 65-70.
PubMed
8) Koob MD, Moseley ML, Schut LJ, et al. An untranslated CTG expansion causes a novel form of spinocerebellar ataxia (SCA8). Nat Genet 1999 ; 21 : 379-84.
PubMed
9) Matsuura T, Yamagata T, Burgess DL, et al. Large expansion of the ATTCT pentanucleotide repeat in spinocerebellar ataxia type 10. Nat Genet 2000 ; 26 : 191-4.
PubMed
10) Houlden H, Johnson J, Gardner-Thorpe C, et al. Mutations in TTBK2, encoding a kinase implicated in tau phosphorylation, segregate with spinocerebellar ataxia type 11. Nat Genet 2007 ; 39 : 1434-6.
PubMed
11) Holmes SE, O'Hearn EE, Mclnnis MG, et al. Expansion of a novel CAG trinucleotide repeat in the 5' region of PPP2R2B is associated with SCA12. Nat Genet 1999 ; 23 : 391-2.
 
12) Waters MF, Minassian NA, Stevanin G, et al. Mutations in voltage-gated potassium channel KCNC3 cause degenerative and developmental central nervous system phenotypes. Nat Genet 2006 ; 38 : 447-51.
PubMed
13) Chen D-H, Brkanac Z, Verlinde CLMJ, et al. Missense mutations in the regulatory domain of PKC-gamma : a new mechanism for dominant nonepisodic cerebellar ataxia. Am J Hum Genet 2003 ; 72 : 839-49.
 
14) van de Leemput J, Chandran J, Knight MA, et al. Deletion at ITPR1 underlies ataxia in mice and spinocerebellar ataxia 15 in humans. PLoS Genet 2007 ; 3 : e108.
PubMed
15) Koide R, Kobayashi S, Shimohata T, et al. A neurological disease caused by an expanded CAG trinucleotide repeat in the TATA-binding protein gene : a new polyglutamine disease?. Hum Mol Genet 1999 ; 8 : 2047-53.
 
16) Brkanac Z, Spencer D, Shendure J, et al. IFRD1 is a candidate gene for SMNA on chromosome 7q22-q23. Am J Hum Genet 2009 ; 84 : 692-7.
PubMed
17) Schelhaas HJ, Verbeek DS, Van de Warrenburg BP, et al. SCA19 and SCA22 : evidence for one locus with a worldwide distribution. Brain 2004 ; 127 : E6.
PubMed
18) Verbeek DS, Schelhaas JH, Ippel EF, et al. Identification of a novel SCA locus (SCA19) in a Dutch autosomal dominant cerebellar ataxia family on chromosome region 1p21-q21.Hum Genet 2002 ; 111 : 388-93.
 
19) Chung MY, Lu YC, Cheng NC, et al. novel autosomal dominant spinocerebellar ataxia (SCA22) linked to chromosome 1p21-q23. Brain 2003 ; 126 : 1293-9.
PubMed
20) Knight MA, Gardner RJ, Bahlo M, et al. Dominantly inherited ataxia and dysphonia with dentate calcification : spinocerebellar ataxia type 20. Brain 2004 ; 127 : 1172-81.
PubMed
21) Delplanque J, Devos D, Huin V, et al. TMEM240 mutations cause spinocerebellar ataxia 21 with mental retardation and severe cognitive impairment. Brain 2014 ; 137 : 2657-63.
PubMed
22) Verbeek DS, van de Warrenburg BP, Wesseling P, et al. Mapping of the SCA23 locus involved in autosomal dominant cerebellar ataxia to chromosome region 20p13-12.3. Brain 2004 ; 127 : 2551-7.
PubMed
23) Stevanin G, Bouslam N, Thobois S, et al. Spinocerebellar ataxia with sensory neuropathy (SCA25) maps to chromosome 2p. Ann Neurol 2004 ; 55 : 97-104.
PubMed
24) Hekman KE, Yu GY, Brown CD, et al. A conserved eEF2 coding variant in SCA26 leads to loss of translational fidelity and increased susceptibility to proteostatic insult. Hum Mol Genet 2012 ; 21 : 5472-83.
PubMed
25) van Swieten JC, Brusse E, de Graaf BM, et al. A mutation in the fibroblast growth factor 14 gene is associated with autosomal dominant cerebellar ataxia. Am J Hum Genet 2003 ; 72 : 191-9.
PubMed
26) Di Bella D, Lazzaro F, Brusco A, et al. Mutations in the mitochondrial protease gene AFG3L2 cause dominant hereditary ataxia SCA28. Nat Genet 2010 ; 42 : 313-21.
PubMed
27) Huang L, Chardon JW, Carter MT, et al. Missense mutations in ITPR1 cause autosomal dominant congenital nonprogressive spinocerebellar ataxia. Orphanet J Rare Dis 2012 ; 7 : 67.
PubMed
28) Storey E, Bahlo M, Fahey M, et al. A new dominantly inherited pure cerebellar ataxia, SCA 30. J Neurol Neurosurg Psychiatry 2009 ; 80 : 408-11.
 
29) Sato N, Amino T, Kobayashi K, et al. Spinocerebellar ataxia type 31 is associated with "inserted" penta-nucleotide repeats containing (TGGAA) n. Am J Hum Genet 2009 ; 85 : 544-57.
 
30) Jiang H, Zhu H-P, Gomez CM. SCA32 : an autosomal dominant cerebellar ataxia with azoospermia maps to chromosome 7q32-q33. (Abstract) Mov Disord 2010 ; 25 : S192 only.
 
31) Cadieux-Dion M, Turcotte-Gauthier M, Noreau A, et al. Expanding the clinical phenotype associated with ELOVL4 mutation : study of a large French-Canadian family with autosomal dominant spinocerebellar ataxia and erythrokeratodermia. JAMA Neurol 2014 ; 71 : 470-5.
PubMed
32) Wang JL, Yang X, Xia K, et al. TGM6 identified as a novel causative gene of spinocerebellar ataxias using exome sequencing. Brain 2010 ; 133 : 3510-8.
PubMed
33) Kobayashi H, Abe K, Matsuura T, et al. Expansion of intronic GGCCTG hexanucleotide repeat in NOP56 causes SCA36, a type of spinocerebellar ataxia accompanied by motor neuron involvement. Am J Hum Genet 2011 ; 89 : 121-30.
PubMed
34) Serrano-Munuera C, Corral-Juan M, Stevanin G, et al. New subtype of spinocerebellar ataxia with altered vertical eye movements mapping to chromosome 1p32. JAMA Neurol 2013 ; 70 : 764-71.
PubMed
35) Di Gregorio E, Borroni B, Giorgio E, et al. ELOVL5 mutations cause spinocerebellar ataxia 38. Am J Hum Genet 2014 ; 95 : 209-17.
PubMed
36) Johnson JO, Stevanin G, van de Leemput J, et al. A 7.5-Mb duplication at chromosome 11q21-11q22.3 is associated with a novel spastic ataxia syndrome. Mov Disord 2015 ; 30 : 262-6.
PubMed
37) Tsoi H, Yu AC, Chen ZS, et al. A novel missense mutation in CCDC88C activates the JNK pathway and causes a dominant form of spinocerebellar ataxia. J Med Genet 2014 ; 51 : 590-5.
PubMed
38) Fogel BL, Hanson SM, Becker EB. Do mutations in the murine ataxia gene TRPC3 cause cerebellar ataxia in humans?. Mov Disord 2015 ; 30 : 284-6.
PubMed
39) Koide R, Ikeuchi T, Onodera O, et al. Unstable expansion of CAG repeat in hereditary dentatorubral-pallidoluysian atrophy (DRPLA). Nat Genet 1994 ; 6 : 9-13.
PubMed
40) Winkelmann J, Lin L, Schormair B, et al. Mutations in DNMT1 cause autosomal dominant cerebellar ataxia, deafness and narcolepsy. Hum Mol Genet 2012 ; 21 : 2205-10.
PubMed
41) Browne DL, Gancher ST, Nutt JG, et al. Episodic ataxia/myokymia syndrome is associated with point mutations in the human potassium channel gene, KCNA1. Nat Genet 1994 ; 8 : 136-40.
PubMed
42) Jodice C, Mantuano E, Veneziano L, et al. Episodic ataxia type 2 (EA2) and spinocerebellar ataxia type 6 (SCA6) due to CAG repeat expansion in the CACNA1A gene on chromosome 19p. Hum Mol Genet 1997 ; 6 : 1973-8.
PubMed
43) Steckley JL, Ebers GC, Cader MZ, et al. An autosomal dominant disorder with episodic ataxia, vertigo, and tinnitus. Neurology 2001 ; 57 : 1499-502.
PubMed
44) Damji KF, Allingham RR, Pollock SC, et al. Periodic vestibulocerebellar ataxia, an autosomal dominant ataxia with defective smooth pursuit, is genetically distinct from other autosomal dominant ataxias. Arch Neurol 1996 ; 53 : 338-44.
PubMed
45) Escayg A, De Waard M, Lee DD, et al. Coding and noncoding variation of the human calcium-channel beta4-subunit gene CACNB4 in patients with idiopathic generalized epilepsy and episodic ataxia. Am J Hum Genet 2000 ; 66 : 1531-9.
PubMed
46) Jen JC, Wan J, Palos TP, et al. Mutation in the glutamate transporter EAAT1 causes episodic ataxia, hemiplegia, and seizures. Neurology 2005 ; 65 : 529-34.
PubMed
47) Kerber KA, Jen JC, Lee H, et al. A new episodic ataxia syndrome with linkage to chromosome 19q13. Arch Neurol 2007 ; 64 : 749-52.
 
48) Bourassa CV, Meijer IA, Merner ND, et al. VAMP1 mutation causes dominant hereditary spastic ataxia in Newfoundland families. Am J Hum Genet 2012 ; 91 : 548-52.
PubMed
49) Timby N, Stattin EL, Kristiansen I, et al. Early onset autosomal dominant spinocerebellar ataxia with miosis : four cases. Eur J Paediatr Neurol 2008 ; 12 : 38-40.
PubMed
50) Campuzano V, Montermini L, Molto MD, et al. Friedreich's ataxia : Autosomal recessive disorder caused by an intronic GAA triplet repeat expansion. Science 1996 ; 271 : 1423-7.
 
51) Engert JC, Berube P, Mercier J, et al. ARSACS, a spastic ataxia common in northeastern Quebec, is caused by mutations in a new gene encoding an 11.5-kb ORF. Nat Genet 2000 ; 24 : 120-5.
 
52) Hentati A, Deng HX, Hung WY, et al. Human alpha-tocopherol transfer protein : gene structure and mutations in familial vitamin E deficiency. Ann Neurol 1996 ; 39 : 295-300.
PubMed
53) Nikali K, Suomalainen A, Saharinen J, et al. Infantile onset spinocerebellar ataxia is caused by recessive mutations in mitochondrial proteins Twinkle and Twinky. Hum Mol Genet 2005 ; 14 : 2981-90.
PubMed
54) Date H, Onodera O, Tanaka H, et al. Early-onset ataxia with ocular motor apraxia and hypoalbuminemia is caused by mutations in a new HIT superfamily gene. Nat Genet 2001 ; 29 : 184-8.
 
55) Moreira MC, Klur S, Watanabe M, et al. Senataxin, the ortholog of a yeast RNA helicase, is mutant in ataxia-ocular apraxia 2. Nat Genet 2004 ; 36 : 225-7.
PubMed
56) Delague V, Bareil C, Bouvagnet P, et al. Nonprogressive autosomal recessive ataxia maps to chromosome 9q34-9qter in a large consanguineous Lebanese family. Ann Neurol 2001 ; 50 : 250-3.
 
57) Bomont P, Watanabe M, Gershoni-Barush R, et al. Homozygosity mapping of spinocerebellar ataxia with cerebellar atrophy and peripheral neuropathy to 9q33-34, and with hearing impairment and optic atrophy to 6p21-23. Eur J Hum Genet 2000 ; 8 : 986-90.
PubMed
58) Swartz BE, Burmeister M, Somers JT, et al. A form of inherited cerebellar ataxia with saccadic intrusions, increased saccadic speed, sensory neuropathy, and myoclonus. Ann N Y Acad Sci 2002 ; 956 : 441-4.
PubMed
59) Nicolas E, Poitelon Y, Chouery E, et al. CAMOS, a nonprogressive, autosomal recessive, congenital cerebellar ataxia, is caused by a mutant zinc-finger protein, ZNF592. Eur J Hum Genet 2010 ; 18 : 1107-13.
 
60) Tranebjaerg L, Teslovich TM, Jones M, et al. Genome-wide homozygosity mapping localizes a gene for autosomal recessive non-progressive infantile ataxia to 20q11-q13. Hum Genet 2003 ; 113 : 293-5.
PubMed
61) Sun Y, Almomani R, Breedveld GJ, et al. Autosomal recessive spinocerebellar ataxia 7 (SCAR7) is caused by variants in TPP1, the gene involved in classic late-infantile neuronal ceroid lipofuscinosis 2 disease (CLN2 disease). Hum Mutat 2013 ; 34 : 706-13.
PubMed
62) Gros-Louis F, Dupre N, Dion P, et al. Mutations in SYNE1 lead to a newly discovered form of autosomal recessive cerebellar ataxia. Nat Genet 2007 ; 39 : 80-5.
PubMed
63) Vermeer S, Hoischen A, Meijer RP, et al. Targeted next-generation sequencing of a 12.5 Mb homozygous region reveals ANO10 mutations in patients with autosomal-recessive cerebellar ataxia. Am J Hum Genet 2010 ; 87 : 813-9.
PubMed
64) Doi H, Yoshida K, Yasuda T, et al. Exome sequencing reveals a homozygous SYT14 mutation in adult-onset, autosomal-recessive spinocerebellar ataxia with psychomotor retardation. Am J Hum Genet 2011 ; 89 : 320-7.
PubMed
65) Gribaa M, Salih M, Anheim M, et al. A new form of childhood onset, autosomal recessive spinocerebellar ataxia and epilepsy is localized at 16q21-q23. Brain 2007 ; 130 : 1921-8.
PubMed
66) Guergueltcheva V, Azmanov DN, Angelicheva D, et al. Autosomal-recessive congenital cerebellar ataxia is caused by mutations in metabotropic glutamate receptor 1. Am J Hum Genet 2012 ; 91 : 553-64.
PubMed
67) Lise S, Clarkson Y, Perkins E, et al. Recessive mutations in SPTBN2 implicate β-III spectrin in both cognitive and motor development. PLoS Genet 2012 ; 8 : e1003074.
 
68) Assoum M, Salih MA, Drouot N, et al. Rundataxin, a novel protein with RUN and diacylglycerol binding domains, is mutant in a new recessive ataxia. Brain 2010 ; 133 : 2439-47.
 
69) Shi Y, Wang J, Li JD, et al. Identification of CHIP as a novel causative gene for autosomal recessive cerebellar ataxia. PLoS One 2013 ; 8 : e81884.
 
70) Yapici Z, Eraksoy M. Non-progressive congenital ataxia with cerebellar hypoplasia in three families. Acta Paediatr 2005 ; 94 : 248-53.
PubMed
71) Utine GE, Haliloglu G, Salanci B, et al. A homozygous deletion in GRID2 causes a human phenotype with cerebellar ataxia and atrophy. J Child Neurol 2013 ; 28 : 926-32.
PubMed
72) Guissart C, Li X, Leheup B, et al. Mutation of SLC9A1, encoding the major Na+/H+ exchanger, causes ataxia-deafness Lichtenstein-Knorr syndrome. Hum Mol Genet 2015 ; 24 : 463-70.
 
73) Thomas AC, Williams H, Seto-Salvia N, et al. Mutations in SNX14 cause a distinctive autosomal-recessive cerebellar ataxia and intellectual disability syndrome. Am J Hum Genet 2014 ; 95 : 611-21.
 
74) Fiskerstrand T, H'mida-Ben Brahim D, Johansson S, et al. Mutations in ABHD12 cause the neurodegenerative disease PHARC : An inborn error of endocannabinoid metabolism. Am J Hum Genet 2010 ; 87 : 410-7.
 
75) Spiegel R, Pines O, Ta-Shma A, et al. Infantile cerebellar-retinal degeneration associated with a mutation in mitochondrial aconitase, ACO2. Am J Hum Genet 2012 ; 90 : 518-23.
PubMed
76) Bomar JM, Benke PJ, Slattery EL, et al. Mutations in a novel gene encoding a CRAL-TRIO domain cause human Cayman ataxia and ataxia/dystonia in the jittery mouse. Nat Genet 2003 ; 35 : 264-9.
 
77) Boycott KM, Flavelle S, Bureau A, et al. Homozygous deletion of the very low density lipoprotein receptor gene causes autosomal recessive cerebellar hypoplasia with cerebral gyral simplification. Am J Hum Genet 2005 ; 77 : 477-83.
PubMed
78) Gulsuner S, Tekinay AB, Doerschner K, et al. Homozygosity mapping and targeted genomic sequencing reveal the gene responsible for cerebellar hypoplasia and quadrupedal locomotion in a consanguineous kindred. Genome Res 2011 ; 21 : 1995-2003.
 
79) Turkmen S, Guo G, Garshasbi M, et al. CA8 mutations cause a novel syndrome characterized by ataxia and mild mental retardation with predisposition to quadrupedal gait. PLoS Genet 2009 ; 5 : e1000487.
 
80) Onat OE, Gulsuner S, Bilguvar K, et al. Missense mutation in the ATPase, aminophospholipid transporter protein ATP8A2 is associated with cerebellar atrophy and quadrupedal locomotion. Eur J Hum Genet 2013 ; 21 : 281-5.
PubMed
81) Depienne C, Bugiani M, Dupuits C, et al. Brain white matter oedema due to ClC-2 chloride channel deficiency : an observational analytical study. Lancet Neurol 2013 ; 12 : 659-68.
PubMed
82) Rajadhyaksha AM, Elemento O, Puffenberger EG, et al. Mutations in FLVCR1 cause posterior column ataxia and retinitis pigmentosa. Am J Hum Genet 2010 ; 87 : 643-54.
PubMed
83) Sellick GS, Barker KT, Stolte-Dijkstra I, et al. Mutations in PTF1A cause pancreatic and cerebellar agenesis. Nat Genet 2004 ; 36 : 1301-5.
PubMed
84) Takashima H, Boerkoel CF, John J, et al. Mutation of TDP1, encoding a topoisomerase I-dependent DNA damage repair enzyme, in spinocerebellar ataxia with axonal neuropathy. Nat Genet 2002 ; 32 : 267-72.
PubMed
85) Scholl UI, Choi M, Liu T, et al. Seizures, sensorineural deafness, ataxia, mental retardation, and electrolyte imbalance (SeSAME syndrome) caused by mutations in KCNJ10. Proc Natl Acad Sci U S A 2009 ; 106 : 5842-7.
PubMed
86) Dor T, Cinnamon Y, Raymond L, et al. KIF1C mutations in two families with hereditary spastic paraparesis and cerebellar dysfunction. J Med Genet 2014 ; 51 : 137-42.
PubMed
87) Bayat V, Thiffault I, Jaiswal M, et al. Mutations in the mitochondrial methionyl-tRNA synthetase cause a neurodegenerative phenotype in flies and a recessive ataxia (ARSAL) in humans. PLoS Biol 2012 ; 10 : e1001288.
 
88) Crosby AH, Patel H, Chioza BA, et al. Defective mitochondrial mRNA maturation is associated with spastic ataxia. Am J Hum Genet 2010 ; 87 : 655-60.
PubMed
89) Pierson TM, Adams D, Bonn F, et al. Whole-exome sequencing identifies homozygous AFG3L2 mutations in a spastic ataxia-neuropathy syndrome linked to mitochondrial m-AAA proteases. PLoS Genet 2011 ; 7 : e1002325.
 
90) Savitsky K, Sfez S, Tagle DA, et al. The complete sequence of the coding region of the ATM gene reveals similarity to cell cycle regulators in different species. Hum Mol Genet 1995 ; 4 : 2025-32.
PubMed
91) Anttonen AK, Mahjneh I, Hamalainen RH, et al. The gene disrupted in Marinesco-Sjogren syndrome encodes SIL1, an HSPA5 cochaperone. Nat Genet 2005 ; 37 : 1309-11.
PubMed
92) Mihalik SJ, Morrell JC, Kim D, et al. Identification of PAHX, a Refsum disease gene. Nat Genet 1997 ; 17 : 185-9.
PubMed
93) Quinzii C, Naini A, Salviati L, et al. A mutation in para-hydroxybenzoate-polyprenyl transferase (COQ2) causes primary coenzyme Q10 deficiency. Am J Hum Genet 2006 ; 78 : 345-9.
PubMed
94) Mollet J, Giurgea I, Schlemmer D, et al. Prenyldiphosphate synthase, subunit 1 (PDSS1) and OH-benzoate polyprenyltransferase (COQ2) mutations in ubiquinone deficiency and oxidative phosphorylation disorders. J Clin Invest 2007 ; 117 : 765-72.
PubMed
95) Lopez LC, Schuelke M, Quinzii CM, et al. Leigh syndrome with nephropathy and CoQ10 deficiency due to decaprenyl diphosphate synthase subunit 2 (PDSS2) mutations. Am J Hum Genet 2006 ; 79 : 1125-9.
PubMed
96) Mollet J, Delahodde A, Serre V, et al. CABC1 gene mutations cause ubiquinone deficiency with cerebellar ataxia and seizures. Am J Hum Genet 2008 ; 82 : 623-30.
PubMed
97) Duncan AJ, Bitner-Glindzicz M, Meunier B, et al. A nonsense mutation in COQ9 causes autosomal-recessive neonatal-onset primary coenzyme Q10 deficiency : a potentially treatable form of mitochondrial disease. Am J Hum Genet 2009 ; 84 : 558-66.
PubMed
98) Heeringa SF, Chernin G, Chaki M, et al. COQ6 mutations in human patients produce nephrotic syndrome with sensorineural deafness. J Clin Invest 2011 ; 121 : 2013-24.
PubMed
99) Brea-Calvo G, Haack TB, Karall D, et al. COQ4 mutations cause a broad spectrum of mitochondrial disorders associated with CoQ10 deficiency. Am J Hum Genet 2015 ; 96 : 309-17.
 
100) Guyant-Marechal L, Verrips A, Girard C, et al. Unusual cerebrotendinous xanthomatosis with fronto-temporal dementia phenotype. Am J Med Genet A 2005 ; 139A : 114-7.
PubMed
101) Jacquemont S, Hagerman RJ, Leehey MA, et al. Penetrance of the fragile X-associated tremor/ataxia syndrome in a premutation carrier population. JAMA 2004 ; 291 : 460-9.
 
102) Najm J, Horn D, Wimplinger I, et al. Mutations of CASK cause an X-linked brain malformation phenotype with microcephaly and hypoplasia of the brainstem and cerebellum. Nat Genet 2008 ; 40 : 1065-7.
 
103) Billuart P, Bienvenu T, Ronce N, et al. Oligophrenin-1 encodes a rhoGAP protein involved in X-linked mental retardation. Nature 1998 ; 392 : 923-6.
 
104) Tarpey PS, Smith R, Pleasance E, et al. A systematic, large-scale resequencing screen of X-chromosome coding exons in mental retardation. Nat Genet 2009 ; 41 : 535-43.
 
105) Zanni G, Bertini E, Bellcross C, et al. X-linked congenital ataxia : a new locus maps to Xq25-q27.1. Am J Med Genet A 2008 ; 146A : 593-600.
PubMed
106) Allikmets R, Raskind WH, Hutchinson A, et al. Mutation of a putative mitochondrial iron transporter gene (ABC7) in X-linked sideroblastic anemia and ataxia (XLSA/A). Hum Mol Genet 1999 ; 8 : 743-9.
 
107) Sanpei K, Takano H, Igarashi S, et al. Identification of the gene for spinocerebellar ataxia type 2 (SCA2) using a direct identification of repeat expansion and cloning technique (DIRECT). Nat Genet 1996 ; 14 : 277-84.
PubMed
108) ImbertG, Saudou F, Yvert G, et al. Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats. Nat Genet 1996 ; 14 : 285-91.
PubMed
109) Nagafuchi S, Yanagisawa H, Sato K, et al. Dentatorubral and pallidoluysian atrophy expansion of an unstable CAG trinucleotide on chromosome 12p. Nat Genet 1994 ; 6 : 14-8.
PubMed
110) Nakamura K,Jeong S-Y, Uchihara T, et al. SCA17, a novel autosomal dominant cerebellar ataxia caused by an expanded polyglutamine in TATA-binding protein. Hum Mol Genet 2001 ; 10 : 1441-8.
PubMed
111) Worth PF, Giunti P, Gardner-Thorpe C, et al. Autosomal dominant cerebellar ataxia type III : linkage in a large British family to a 7.6-cM region on chromosome 15q14-21.3. Am J Hum Genet 1999 ; 65 : 420-6.
 
112) Yabe I, Sasaki H, Chen D-H, et al. Spinocerebellar ataxia type 14 caused by a mutation in protein kinase C gamma. Arch Neurol 2003 ; 60 : 1749-51.
PubMed
113) Ikeda Y, Dick KA, Weatherspoon MR, et al. Spectrin mutations cause spinocerebellar ataxia type 5. Nature Genet 2006 ; 38 : 184-90.
PubMed
114) Yokota T, Wada Y, Furukawa T, et al. Adult-onset spinocerebellar syndrome with idiopathic vitamin E deficiency. Ann Neurol 1987 ; 22 : 84-7.
PubMed
115) 辻省次. 遺伝性脊髄小脳変性症-序論. 神経内科 2004 ; 60 : 459-61.
 
116) Tsuji S, Onodera O, Goto J, et al. Sporadic ataxias in Japan-a population- based epidemiological study. Cerebellum 2008 ; 7 : 189-97.
PubMed
117) 阿部康二. Triplet Repeat病の分類. 日本臨床 1999 ; 57 : 768-70.
Medical*Online
118) 矢部一郎, 佐々木秀直, 田代邦雄. 北海道における遺伝性脊髄小脳変性症の特異性. 神経内科 2000 ; 53 : 91-8.
 
119) 小野寺好明, 津田丈秀, 糸山泰人. 東北地方における遺伝性脊髄小脳変性症の特異性. 神経内科 2000 ; 53 : 99-103.
 
120) 市川弥生子, 後藤順. 関東地方における遺伝性脊髄小脳変性症の特異性. 神経内科 2000 ; 53 : 104-10.
 
121) 下畑光輝, 小野寺理, 辻省次. 信越, 北陸地方における遺伝性脊髄小脳変性症の特異性. 神経内科 53 : 111-115, 2000.
 
122) 田中章景, 渡邊英孝, 祖父江元. 東海地方における遺伝性脊髄小脳変性症の特異性. 神経内科 2000 ; 53 : 116-21.
 
123) 二村直伸, 松村隆介, 上野聡. 近畿地方における遺伝性脊髄小脳変性症の特異性. 神経内科 2000 ; 53 : 122-6.
 
124) 丸山博文, 川上秀史, 中村重信. 中国, 四国地方における遺伝性脊髄小脳変性症の特異性. 神経内科 2000 ; 53 : 127-9.
 
125) 池田賢一, 中川正法, 納光弘. 南九州, 沖縄地方における遺伝性脊髄小脳変性症の特異性. 神経内科 2000 ; 53 : 130-3.
 
126) 足立芳樹, 大田誠, 森昌忠, 他. 脊髄小脳萎縮症7型 (SCA7) の1日本人家系. 神経内科 1998 ; 49 : 303-4.
 
127) Ikeda, Y, Shizuka, M, watanabe, M, et al. Molecular and clinical analyses of spinocerebellar ataxia type 8 in Japan. Neurology 2000 ; 54 : 950-5.
PubMed
128) Inaba H, Yabe I, Yashima M, et al. Unusual retinal phenotypes in an SCA7 family. Inten Med 2009 ; 48 : 1461-4.
 
129) Watanabe M, Sugai Y, Concannon P, et al. Familial spinocerebellar ataxia with cerebellar atrophy, peripheral neuropathy, and elevated level of serum creatine kinase, gamma-globulin, and alpha-fetoprotein. Ann Neurol 1998 ; 44 : 265-9.
PubMed
130) Hara K, Fukushima T, Suzuki T, et al. Japanese SCA families with an unusual phenotype linked to a locus overlapping with SCA15 locus. Neurology 2004 ; 62 : 648-51.
PubMed
131) Yamada T, Miyoshi Y, Yamamoto K, et al. A novel type of autosomal dominant cerebellar ataxia linked to chromosome 8q. Ann Neurol 2000 ; 48 : 438.
 
132) Ogawa T, Takiyama Y, Sakoe K, et al. Identification of a SACS gene missense mutation in ARSACS. Neurology 2004 ; 62 : 107-9.
PubMed
133) Sasaki H, Yabe I, Tashiro K. The hereditary spinocerebellar ataxias in Japan. Cytogenet Genome Res 2003 ; 100 : 198-205.
PubMed
134) Yabe I, Sasaki H, Takeichi N, et al. Positional vertigo and macroscopic downbeat positioning nystagmusin spinocerebellar ataxia type 6 (SCA6). J Neurol 2003 ; 250 : 440-3.
PubMed
135) Trouillas P, Takayanagi T, Hallett M, et al. International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology. J Neurol Sci 1997 ; 145 : 205-11.
PubMed
136) Storey E, Tuck K, Hester R, et al. Inter-rater reliability of the International Cooperative Ataxia Rating Scale (ICARS). Mov Disord 2004 ; 19 : 190-2.
 
137) Schmitz-Hubsch T, du Montcel ST, Baliko L, et al. Scale for the assessment and rating of ataxia : development of a new clinical scale. Neurology 2006 ; 66 : 1717-20.
PubMed
138) Weyer A, Abele M, Schmitz-Hubsch T, et al. Reliability and validity of the scale for the assessment and rating of ataxia : a study in 64 ataxia patients. Mov Disord 2007 ; 22 : 1633-7.
PubMed
139) Yabe I, Matsushima M, Soma H, et al. Usefulness of the Scale for Assessment and Rating of Ataxia (SARA). J Neurol Sci 2008 ; 266 : 164-6.
 
140) 佐藤和則, 矢部一郎, 相馬広幸, 他. 新しい小脳性運動失調の重症度評価スケールScale for the Assessment and Rating of Ataxia (SARA) 日本語版の信頼性に関する検討. BRAIN and NERVE 2009 ; 61 : 591-5.
 
141) 祖父江逸郎, 高柳哲也, 中西孝雄, 他. 脊髄小脳変性症に対するThyrotropin Releasing Hormone Tartrateの治療研究-二重盲検比較臨床試験による検討-. 神経進歩 1982 ; 26 : 1190-214.
 
142) Sobue I, Takayanagi T, Nakanishi T, et al. Controlled trial of thyrotropin releasing hormone tartrate in ataxia of spinocerebellar degenerations. J Neurol Sci 1983 ; 61 : 235-48.
PubMed
143) 金澤一郎, 里吉栄二郎, 平山恵三, 他. Taltirelin hydrate (TA-0910) の脊髄小脳変性症に対する臨床評価-プラセボを対照とした臨床第III相二重盲検比較試験-. 臨床医薬 1997 ; 13 : 4169-224.
 
144) Artuch R, Aracil A, Mas A, et al. Friedreich's ataxia : idebenone treatment in early stage patients. Neuropediatrics 2002 ; 33 : 190-3.
 
145) Rustin P, Rotig A, Munnich A, et al. Heart hypertrophy and function are improved by idebenone in Friedreich's ataxia. Free Radic Res 2002 ; 36 : 467-9.
 
146) Schulz JB, Di Prospero NA, Fischbeck K. Clinical experience with high-dose idebenone in Friedreich ataxia. J Neurol 2009 ; 256 : 42-5.
PubMed
147) Boesch S, Sturm B, Hering S, et al. Friedreich's ataxia : clinical pilot trial with recombinant human erythropoietin. Ann Neurol 2007 ; 62 : 521-4.
 
148) Boesch S, Sturm B, Hering S, et al. Neurological effects of recombinant human erythropoietin in Friedreich's ataxia : a clinical pilot trial. Mov Disord 2008 ; 23 : 1940-4.
 
149) Pandolfo M, Arpa J, Delatycki MB, et al. Deferiprone in Friedreich ataxia : a 6-month randomized controlled trial. Ann Neurol 2014 ; 76 : 509-21.
PubMed
150) Gazulla J, Errea JM, Benavente I, et al. Treatment of ataxia in cortical cerebellar atrophy with the GABAergic drug gabapentin. A preliminary study. Eur Neurol 2004 ; 52 : 7-11.
PubMed
151) Nakamura K, Yoshida K, Miyazaki D, et al. Spinocerebellar ataxia type 6 (SCA6) : clinical pilot trial with gabapentin. J Neurol Sci 2009 ; 278 : 107-11.
PubMed
152) Takei A, Hamada T, Yabe I, et al. Treatment of cerebellar ataxia with 5-HT1A agonist. Cerebellum 2005 ; 4 : 211-5.
PubMed
153) Friedman JH. Machado-Joseph disease/spinocerebellar ataxia 3 responsive to buspirone. Mov Disord 1997 ; 12 : 613-4.
PubMed
154) Assadi M, Campellone JV, Janson CG, et al. Treatment of spinocerebellar ataxia with buspirone. J Neurol Sci 2007 ; 260 : 143-6.
PubMed
155) Trouillas P, Xie J, Adeleine P, et al. Buspirone, a 5-hydroxytryptamine 1A agonist, is active in cerebellar ataxia. Results of a double-blind drug placebo study in patients with cerebellar cortical atrophy. Arch Neurol1997 ; 54 : 749-52.
 
156) Lou JS, Goldfarb L, McShane L, et al. Use of buspirone for treatment of cerebellar ataxia. An open-label study. Arch Neurol 1995 ; 52 : 982-8.
PubMed
157) Ristori G, Romano S, Visconti A, et al. Riluzole in cerebellar ataxia : a randomized, double-blind, placebo-controlled pilot trial. Neurology 2010 ; 74 : 839-45.
PubMed
158) Saute JA, de Castilhos RM, Monte TL, et al. A randomized, phase 2 clinical trial of lithium carbonate in Machado-Joseph disease. Mov Disord 2014 ; 29 : 568-73.
PubMed
159) 厚生労働科学研究補助金 難治性疾患克服事業「脊髄小脳変性症の画期的診断・治療法に関する研究」平成15年度 総括・分担研究報告書 (主任研究者 : 辻貞俊).
 
160) Miyai I, Ito M, Hattori N, et al. Cerebellar ataxia rehabilitation trial in degenerative cerebellar diseases. Neurorehabil Neural Repair 2012 ; 26 : 515-22.
PubMed
161) Mendonca LS, Nobrega C, Hirai H, et al. Transplantation of cerebellar neural stem cells improves motor coordination and neuropathology in Machado-Joseph disease mice. Brain 2015 ; 138 : 320-35.
PubMed
P.557 掲載の参考文献
1) 祖父江元, 熱田直樹, 伊藤瑞規, 他. 臨床調査個人票からみた我が国のALS. 厚生労働科学研究費補助金神経変性疾患に関する調査研究班報告書. 2007, 37-40.
 
2) Lunn MR, Wang CH. Spinal muscular atrophy. Lancet 2008 ; 371 : 2120-33.
PubMed
3) Mostacciuolo ML, Danieli GA, Trevisan C, et al. Epidemiology of Spinal Muscular Atrophies in a Sample of the Italian Population. Neuroepidemiology 1992 ; 11 : 34-8.
 
4) Pearn J. Incidence, prevalence, and gene frequency studies of chronic childhood spinal muscular atrophy. J Med Genet 1978 ; 15 : 409-13.
PubMed
5) Kim WK, Liu X, Sandner J, et al. Study of 962 patients indicates progressive muscular atrophy is a form of ALS. Neurology 2009 ; 73 : 1686-92.
PubMed
6) Miller RG, Rosenberg JA, Gelinas DF, et al. Practice parameter : the care of the patient with amyotrophic lateral sclerosis (an evidence-based review). Neurology 1999 ; 52 : 1311-23.
PubMed
7) Miller RG, Jackson CE, Kasarskis EJ, et al. Results : Practice parameter update : The care of the patient with amyotrophic lateral sclerosis : multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review) : report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009 ; 73 : 1227-33.
PubMed
8) Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update : The care of the patient with amyotrophic lateral sclerosis : drug, nutritional, and respiratory therapies (an evidence-based review) : report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009 ; 73 : 1218-26.
PubMed
P.560 掲載の参考文献
1) ShyGM, Drager GA. A neurological syndrome associated with orthostatic hypotension : a clinical-pathologic study. Arch Neurol 1960 ; 2 : 511-27.
PubMed
2) Graham JG, Oppenheimer DR. Orhtostatic hypotension and nicotine sensitivity in a case of multiple system atrophy. J Neurol Neurosurg Psychiatry 1969 ; 32 : 28-34.
 
3) Papp MI, Kahn JE, Lantos PL. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci 1989 ; 94 : 79-100.
PubMed
4) The Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Consensus statement on the definition of orthostatic hyopotension, pure autonomic failure, and multiple system atrophy. Neurology 1996 ; 46 : 1470.
 
5) Gilman S, Low P, Albanese A, et al. Consensus statement on the diagnosis of multiple system atrophy. Clin Atuton Res 1998 ; 8 : 359-62.
 
6) Gilman S, Low P, Brooks DJ, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008 ; 71 : 670-6.
 
7) 難病情報センター ホームページ http://www.nanbyou.or.jp/
 
8) Wenning GK, Geser F, Stampfer-Kountchev M, et al. Multiple system atrophy : A update. Mov Disord 2003 ; 18 (Suppl 6) : S34-42.
 
9) 祖父江逸郎, 千田康博, 平山恵造, 他. Shy-Drager症候群および関連疾患に対するL-threo-3,4-dihydroxyphenylserine (L-DOPS) の薬効評価-プラセボを対照とした多施設二重盲検法による比較検討. 医学のあゆみ 1987 ; 141 : 353-78.
 
10) Mathias CJ, Senard J-M, Braune S, et al. L-threo-3,4-dihydroxyphenylserine (L-threo-DOPS ; droxidopa) in the management of neurogenic orthostatic hypotension : a multinational, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure. Clin Auton Res 2001 ; 11 : 235-42.
 
11) Low PA, Gilden JL, Freeman R, et al. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. JAMA 1997 ; 277 : 1046-51.
PubMed
12) 金澤一郎, 里吉栄二郎, 平山恵造, 他. Taltirelin hydrate (TA-0910) の脊髄小脳変性症に対する臨床評価-プラセボを対照とした臨床第III相二重盲検比較試験-. 臨床医薬 1997 ; 13 : 4169-224.
 
P.564 掲載の参考文献
1) 難病情報センター ホームページ http://www.nanbyou.or.jp/
 
2) 金澤一郎. ハンチントン病を追って-臨床から遺伝子治療まで. 共立印刷, 東京, 2006.
 
3) Gusella JF, Wexler NS, Conneally PM, et al. A polymorphic DNA marker genetically linked to Huntington's disease. Nature 1983 ; 306 : 234-8.
 
4) The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993 ; 72 : 971-83.
 
5) 貫名信行. ハンチントン病. 日本認知症学会編, 認知症テキストブック, 中外医学社, 東京, 2008, p334-8.
 
6) Nakashima K, Watanabe Y, Kusumi M, et al. Epidemiological and genetic studies of Huntington's disease in the San-in area of Japan. Neuroepidemiology 1996 ; 15 : 126-31.
 
7) 日本神経学会神経疾患の遺伝子診断ガイドライン作成委員会. 神経疾患の遺伝子診断ガイドライン 2009 (http://www.neurologyjp.org/guidelinem/sinkei_gl.html)
 
8) Mestre T, Ferreira J, Coelho MM, et al. Therapeutic interventions for symptomatic treatment in Huntington's disease. Cochrane Database Syst Rev. CD006456, 2009.
 
9) Burgunder JM, Guttman M, Perlman S, et al. An International Survey-based Algorithm for the Pharmacologic Treatment of Chorea in Huntington's Disease. PLoS Curr 2011 ; 3 : RRN1260.
 
10) Armstrong MJ, Miyasaki JM. Evidence-based guideline : Pharmacologic treatment of chorea in Huntington disease. Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2012 ; 79 : 597-603.
PubMed
11) Reilmann R. Pharmacological treatment of chorea in Huntington's disease-Good clinical practice versus evidence-based guideline. Mov Disord 2013 ; 28 : 1030-3.
 
12) Zielonka D, Mielcarek M, Landwehrmeyer GB. Update on Huntington's disease : Advances in care and emerging therapeutic options. Parkinsonism Relat Disord 2015 ; 21 : 160-78.
 
13) Moulton CD, Hopkins CW, Bevan-Jones WR. Systematic Review of pharmacological treatments for depressive symptoms in Huntington's disease. Mov Disord 2014 ; 29 : 1556-61.
 
14) "認知症疾患治療ガイドライン" 作成合同委員会. "認知症疾患治療ガイドライン 2010" コンパクト版 2012, 医学書院, 2012, 東京.
 
15) Bilney B, Morris ME, Perry A. Effectiveness of physiotherapy, occupational therapy, and speech pathology for people with Huntington's disease : A systematic review. Neurorehabil Neural Repair 2003 ; 17 : 12-24.
 

第12章 後天性 / 先天性代謝疾患

P.568 掲載の参考文献
1) Russel RM. Vitamin and trace mineral deficiency and excess. Harrison's Principles of Internal Medicine 16th ed, McGraw-Hill, 2004, p403-11.
 
2) 花岡直子. ビタミンB1欠乏の原因と病型. Annual Review神経, 中外医学社, 東京, 1998, p220-7.
 
3) 橋本隆. ナイアシンの臨床. Modern Physician 2007 ; 27 : 1225-7.
 
4) 依田卓, 堀内勁. ビタミンB6の臨床. Modern Physician 2007 ; 27 : 1208-11.
 
5) 永石彰子, 黒田康夫. ビタミンB12の吸収・代謝・利用と神経障害. 神経内科 2004 ; 61 : 319-23.
 
6) 鳥居剛, 満岡恭子, 渡辺千種. ビタミンB12欠乏と末梢神経障害. 神経内科 2004 ; 61 : 324-8.
 
7) 田口朋広, 中野今治. ビタミンB12欠乏と亜急性脊髄連合変性症. 神経内科 2004 ; 61 : 329-33.
 
8) 森田修平, 近藤智善. ビタミンB12欠乏性大脳白質脳症. 神経内科 2004 ; 61 : 353-7.
 
9) 佐々木良元, 葛原茂樹. ビタミンB12欠乏性神経障害. 別冊日本臨牀 領域別シリーズ No29 神経症候群, 日本臨牀社, 大阪, 2000, p95-7.
 
10) 横田孝徳. 家族性特発性ビタミンE欠乏症の発見と発症機序の解明および治療法の確立. ビタミン 2004 ; 78 : 87-92.
 
P.571 掲載の参考文献
1) Victor M, Adams RD, Collins GH. The Wernicke-Korsakoff syndrome. In ; Davis FA, ed. Contemporary Neurology Series 7, Philadelphia, 1971, p15-60.
 
2) 星野晴彦. Wernicke脳症. 日内会誌 1999 ; 88 : 4-8.
 
3) 山崎峰男 : Wernicke-Korsakoff症候群. 神経内科 1996 ; 45 : 288-95.
 
4) 福田準, 木谷光博, 岸本弘之. 胃空腸吻合術後, 中心静脈栄養と経口食併用中に発症したWernicke-Korsakoff症候群. 神経内科 1996 ; 45 : 55-8.
 
5) 巌本靖道, 奥田文悟, 宮田靖, 他. 妊娠悪阻により発症し, ステロイド大量療法が有効であったWernicke-Korsakoff症候群の1例. 臨床神経 1994 ; 34 : 599-601.
 
6) Kon C, Dong-Wha K, Ham-Joon K, et al. Diffusion-weighted imaging abnormalities in Wernicke encephalopathy. Arch Neurol 2002 ; 59 : 123-7.
 
7) 小坂憲司. Wernicke-Korsakoff脳症をめぐって. 精神経誌 2007 ; 109 : 509-15.
 
P.574 掲載の参考文献
1) Schafer DF, Jones EA. Hepatic encephalopathy and the gammaaminobutyric acid neurotransmitter system. Lancet 1982 ; 1 : 18-20.
 
2) Ong JP, Aggarwal A, Krieger D, et al. Correlation between ammonia levels and the severity of hepatic encephalopathy. Am J Med 2003 ; m114 : 237-8.
 
3) Kulisevsky J, Pujol J, Balauzo J. Pallidal hypersensitivity on magnetic resonance imaging in cirrhotic patients. clinical correlations. Hepatology 1992 ; 16 : 1382-8.
 
4) Uribe M, Marquez A, Garcia Ramos G, et al. Treatment of chronic portal-systemic encephalopathy with vegetable and animal protein diets : a controlled crossover study. Dig Dis Sci 1982 ; 27 : 1109-16.
 
5) Aoyama K, Tsuchiya M, Mori K, et al. Effect of a late evening snack on outpatients with liver cirrhosis. Hepatol Res 2007 ; 37 : 608-14.
PubMed
6) 戸田剛太郎, 藤原研司, 熊田博光, 他. P-511 (ラクツロース高純度粉末) の高アンモニア血症に対する一般臨床試験. 医学と薬学 1999 ; 41 : 911-29.
Medical*Online
7) Dawson AM, McLaren J, Scherlock S. Neomycin in the treatment of hepatic coma. Lancet 1957 ; ii : 1263-8.
 
8) Orlandi F, Feddara U, Candelaresi MT, et al. Comparison between neomysin and lactulose in 173 patients with hepatic encephalopathy : a randomized clinical study. Dig Dis Sci 1981 ; 26 : 498-506.
PubMed
9) Eriksson LS, Conn HO. Branched-chain amino acids in the management of hepatic encephalopathy : an analysis of variants. Hepatology 1989 ; 10 : 228-46.
PubMed
10) Morgan MY. Branched chain amino acids in the management of chronic liver disease. Facts and fantasies. J Hepatol 1990 ; 11 : 133-41.
PubMed
11) Basile AS, Harrison PM, Hughes RD, et al. Relationship between plasma benzodiazepine receptor ligands concentration and hepatic encephalopathy. Hepatology 1994 ; 19 : 112-21.
 
12) Pomer-Layrague SG, Giguere JF, Lavoie J, et al. Flumazenil in cirrhotic patients in hepatic coma : a randomized double-blind placebo-controlled trial. Hepatology 1995 ; 19 : 32-7.
 
13) Trey C, Burns DG, Saunders SJ. Treatment of hepatic coma by exchange blood transfusion. N Engl J Med 1966 ; 274 : 473-81.
PubMed
14) 兼坂残, 飯塚一秀, 高橋愛樹, 他. 劇症肝炎に対する人工肝補助療法. 日救急医会誌 1996 ; 7 : 11-20.
 
15) O'Grady JG, Gimson AE, O'Brien CJ, et al. Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterolgy 1988 ; 94 (5 Pt 1) : 1186-92.
 
16) Woolf GM, Redeker AG. Treatment of fulminant hepatic failure with insulin and glucagon a randomized, controlled trial. Dig Dis Sci 1991 ; 63 : 92-6.
 
17) Kato T, Uematsu T, Nishigaki Y, et al. Therapeutic effect of balloon-occuluded retrograde transvenous obliteration on portal-systemic encephalopathy in patients with liver cirrhosis. Intern Med 2001 ; 40 : 688-91.
 
18) Kobayashi K, Sinasac DS, Iijima M, et al. The gene mutated in adult-onset type II citrullinemia encodes a putative mitochondrial carrier protein. Nat Genet 1999 ; 22 : 159-63.
PubMed
19) Yazaki M, Takei Y, Kobayashi K, et al. Risk of worsened encephalopathy after intravenous glycerol therapy in patients with adultonset type II citrullinemia (CTLN2). Intern Med 2005 ; 44 : 188-195.
 
20) Ikeda S, Yazaki M, Takei Y, et al. Type II (adult onset) citrullinemiae : clinical pictures and the therapeutic effect of liver transplantation. J Neurol Neurosurg Psychiatry 2001 ; 71 : 663-70.
PubMed
21) Imamura Y, Kobayashi K, Shibatou T, et al. Effectiveness of carbohydrate-restricted diet and arginine granules therapy for adult-onset type II citrullinemia : a case report of siblings showing homozygous SLC25A13 mutation with and without the disease. Hepatol Res 2003 ; 26 : 68-72.
PubMed
22) Fukushima K, Yazaki M, Nakamura M, et al. Conventional diet therapy for hyperammonemia is risky in the treatment of hepatic encephalopathy associated with citrin deficiency. Intern Med 2010 ; 49 : 243-7.
PubMed
23) 松本博之. 肝性脳症. EBMに基づく脳神経疾患の基本治療指針 改訂第2版, メジカルビュー社, 東京, 2006, p419-21.
 
P.576 掲載の参考文献
1) De Deyn PP, Vanholder R, Eloot S, et al. Guanidino compounds as uremic (neuro) toxins. Semin Dial 2009 ; 22 : 340-45.
PubMed
2) Gejyo F, Homma N, Higuchi N, et al. Japanese Society of Nephrology. A novel type of encephalopathy associated with mushroom Sugihiratake ingestion in patients with chronic kidney diseases. Kidney Int 2005 ; 68 : 188-92.
PubMed
3) Arieff AI. Dialysis disequilibrium syndrome : current concepts on pathogenesis and prevention. Kidney Int 1994 ; 45 : 629-35.
PubMed
4) Raskin NH, Fishman RA. Neurologic disorders in renal failure. N Engl J Med 1976 ; 294 : 143-8.
PubMed
5) Kalousova M, Kielstein JT, Hodkova M, et al. No benefit of hemodiafiltration over hemodialysis in lowering elevated levels of asymmetric dimethylarginine in ESRD patients. Blood Purif 2006 ; 24 : 439-44.
PubMed
6) Mahoney CA, Arieff AI. Uremic encephalopathies : clinical, biochemical, and experimental features. Am J Kidney Dis 2 : 324-36, 1982.
PubMed
7) Israni RK, Kasbekar N, Haynes K, et al. Use of antiepileptic drugs in patients with kidney disease. Semin. Dial 2006 ; 19 : 408-16.
 
8) Lacerda G, Krummel T, Sabourdy C, et al. Optimizing therapy of seizures in patients with renal or hepatic dysfunction. Neurology 2006 ; 67 : S28-33.
PubMed
9) Griva K, Thompson D, Jayasena D, et al. Cognitive functioning pre- to post-kidney transplantation-a prospective study. Nephrol Dial Transplant 2006 ; 21 : 3275-82.
PubMed
10) Teschan PE, Ginn HE, Bourne JR, et al. Quantitative indices of clinical uremia. Kidney Int 1979 ; 15 : 676-97.
PubMed
P.581 掲載の参考文献
1) 神経疾患 最新の治療 2015-2017, 南江堂, 2015.
 
2) 日本糖尿病学会 編著. 糖尿病治療ガイド 2014-2015, 文光堂, 2014.
 
3) 日本糖尿病学会 編. 根拠に基づく糖尿病診療ガイドライン 2013, 南江堂, 2013.
 
4) 糖尿病最新の治療 2013-2015, 南江堂, 2013.
 
5) ここが知りたい! 糖尿病診療ハンドブック Ver.2, 中外医学社, 2015.
 
P.586 掲載の参考文献
1) 日本甲状腺学会. バセドウ病の診断ガイドライン http://www.japanthyroid.jp/doctor/guideline/japanese.html
 
2) 「甲状腺クリーゼの診断基準の作成と全国調査」班. 甲状腺クリーゼ診断基準 (第2版). http://square.umin.ac.jp/endocrine/rinsho_juyo/pdf/koujosen01.pdf]
 
3) 「バセドウ病悪性眼球突出症の診断基準と治療指針」作成委員会, 廣松雄治委員長. バセドウ病悪性眼球突出症 (甲状腺眼症) の診断基準と治療指針.
 
4) 田上哲也. 甲状腺中毒性ミオパチー. 別冊日本臨牀 内分泌症候群 (第2版), 日本臨牀社, 東京, 2006, p319-20.
 
5) 田上哲也. 甲状腺中毒性周期性四肢麻痺. 別冊日本臨牀 内分泌症候群 (第2版), 日本臨牀社, 東京, 2006, p316-8.
 
6) 田中祐司, 白石美絵乃, 大野洋介, 他. 粘液水腫性昏睡の診断基準と治療方針. 日甲状腺会誌 2013 ; 4 : 47-52.
 
7) Yamamoto T, Fukuyama J, Fujiyoshi A. Factor associated with mortality of myxedema coma : report of eight cases and literature survey. Thyroid 1999 ; 9 : 1167-72.
 
8) 甲状腺粘液水腫性昏睡の診断基準と治療指針の作成 (担当者責任者 ; 笠井貴久男). 粘液水腫性昏睡診断基準第3次案 (2010年12月). http://www. japanthyroid, jp/doctor/img/shindan.pdf
 
9) 内野誠. 内分泌・代謝性疾患に伴う神経障害 甲状腺機能低下症. Clin Neurosci 2006 ; 24 : 40-2.
 
10) 栗山勝. 甲状腺機能低下症. 臨床神経内科学 (廣瀬源二郎, 田代邦雄, 葛原茂樹, 編), 南山堂, 東京, 2006, p570-3.
 
11) Shaw PJ. Neurological abnormalities associated with thyroid disease. In ; Vinken PJ, Bruyn GW, eds. Handbook of clinical neurology-revised series 26 (70) : Systemic diseases Part II. Amsterdam, Elsevier, 1998, p81-110.
 
12) Duyff RF, Van den Bosch J, Laman DM, et al. Neuromuscular findings in thyroid dysfunction : a prospective clinical and electrodiagnostic study. J Neurol Neurosurg Psychiatry 2000 ; 68 : 750.
PubMed
13) Torres CF, Moxley RT. Hypothyroid neuropathy and myopathy : clinical and electrodiagnostic longitudinal findings. J Neurol 1990 ; 237 : 271-4.
PubMed
14) 松本博之. 甲状腺機能低下症の神経・筋症状. 神経内科 1996 ; 45 : 445-51.
 
15) Beghi PJ, Lambert EH. Polyneuropathy associated with hypothyroidism. J Neuropathol Exp Neurol 1970 ; 29 : 631-58.
 
16) Kececi H, Degirmenci Y. Hormone replacement therapy in hypothyroidism and nerve conduction study. Neurophysiol Clin 2006 ; 36 : 79-83.
PubMed
17) Haggerty JJ Jr, Stern RA, Mason GA, et al. Subclinical hypothyroidism : a modifiable risk factor for depression? Am J Psychiatry 1993 ; 150 : 508-510.
PubMed
18) Bono G, Fancellu R, Blandini F, et al. Cognitive and affective status in mild hypothyroidism and interactions with L-thyroxine treatment. Acta Neurol Scand 2004 ; 110 : 59-66.
 
19) Shaw PJ, Walls TJ, Newman PK, et al. Hashimoto's encephalopathy : a steroid-responsive disorder associated with anti-thyroid antibody titers - report of 5 cases. Neurology 1991 ; 41 : 228-33.
 
20) Yoneda M, Fujii A, Ito A, et al. High prevalence of serum autoantibodies against the amino terminal of α-enolase in Hashimoto's encephalopathy. J Neuroimmunol 2007 ; 185 : 195-200.
 
21) 米田誠. 橋本脳症と抗体. Brain Nerve 2013 ; 65 : 365-76.
 
22) Drulovic J, Andrejevic S, Bonaci-Nikolic B, et al. Hashimoto's encephalopathy : a long-lasting remission induced by intravenous immunoglobulins. Vojnosanit Pregl 2011 ; 68 : 452-4.
 
23) 安藤隆雄, 江口勝美. 甲状腺機能亢進症に伴う重症筋無力症. 別冊日本臨牀 内分泌症候群 (第2版), 日本臨牀社, 東京, 2006, p321-33.
 
24) Tellez-Zenteno JF, Cardenas G, Estanol B, et al. Associated conditions in myasthenia gravis : response to thymectomy. Eur J Neurol 2004 ; 11 : 767-73.
PubMed
25) 森川賢治, 田上哲也. 甲状腺疾患と薬剤. 甲状腺疾患診療マニュアル 改訂2版, 診断と治療社, 東京, 2014, p94-9.
 
P.588 掲載の参考文献
1) American Psychiatric Association. Diagnostic and statistical manual of mental disorders-text revision (DSM-IV). 4th ed, Washington DC, American Psychiatric Association, 2000.
 
2) Kopelman MD, Thomson AD, Guerrini I, et al. The Korsakoff syndrome : Clinical Aspects, Psychology and Treatment. Alcohol Alcohol 2009 ; 44 : 148-54.
PubMed
3) Zuccoli G, Santa Cruz D, Bertolini M, et al. MR imaging findings in 56 patients with Wernicke encephalopathy : Nonalcoholics may differ from alcoholics. AJNR Am J Neuroradiol 2009 ; 30 : 171-6.
PubMed
4) Schuckit MA. Alcohol-use disorders. Lancet 2009 ; 373 : 492-501.
PubMed
5) Fitzpatrick LE, Jacson M, Crowe SF. The relationship between alcoholic cerebellar degeneration and cognitive and emotional functioning. Neurosci Biobehav Rev 2008 ; 32 : 466-85.
 
6) Yokota O, Tsuchiya K, Terada S, et al. Frequency and clinicopathological characteristics of alcoholic cerebellar degeneration in Japan : a cross-sectional study of 1,509 postmortems. Acta Neuropath 2006 ; 112 : 43-51.
PubMed
7) Yokota O, Tsuchiya K, Terada S, et al. Alcoholic cerebellar degeneration : A clinicopathological study of six Japanese autopsy cases and proposed potential progression pattern in the cerebellar lesion. Neuropath 2007 ; 27 : 99-113.
 
8) Harper C, Matsumoto I. Ethanol and brain damage. Curr Opin Pharmacol 2005 ; 5 : 73-8.
PubMed
9) Vittadini G, Buonocore M, Colli G, et al. Alcoholic polyneuropathy : A clinical and epidemiological study. Alcohol Alcohol 2001 ; 36 : 393-400.
PubMed
10) Koike H, Mori K, Misu K, et al. Painful alcoholic polyneuropathy with predominant small-fiber loss and normal thiamine status. Neurology 2001 ; 56 : 1727-32.
PubMed
11) Fernandez-Sola J, Preedy VR, Lang CH, et al. Molecular and cellular events in alcohol-induced muscle disease. Alcohol Clin Exp Res 2007 ; 31 : 1953-62.
PubMed
12) Preedy VR, Adachi J, Ueno Y, et al. Alcoholic skeletal muscle myopathy : definitions, features, contribution of neuropathy, impact and diagnosis. Eur J Neurol 2001 ; 8 : 677-87.
PubMed
P.598 掲載の参考文献
1) Clouston PD, DeAngelis LM, Posner JB. The spectrum of neurological disease in patients with systemic cancer. Ann Neurol 1992 ; 31 : 268-73.
PubMed
2) Posner JB. Neurologic complications of cancer. F.A. Davis Co, Philadelphia, 1995.
 
3) 酒井宏一郎, 廣瀬源二郎. 内科疾患に伴う神経症状 : 悪性腫瘍. 内科 2003 ; 91 : 681-6.
 
4) Graus F, Rogers LR, Posner JB. Cerebrovascular complications in cancer patients. Medicine 1985 ; 64 : 16-35.
PubMed
5) Bushnell CD, Goldstein LB. Risk of ischemic stroke with tamoxifen treatment for breast cancer. Neurology 2004 ; 63 : 1230-3.
PubMed
6) Dorrestein LDA, Kappelle AC, Scholz NMJ, et al. Increased carotid wall thickening after radiotherapy on neck. Eur J Cancer 2005 ; 41 : 1026-30.
 
7) 清水優子, 内山真一郎, 森豪志, 他. 子宮体癌により血管炎とTrousseau症候群を呈した若年性脳梗塞. 臨床神経 2002 ; 42 : 227-31.
 
8) Adess M, Eisner R, Nand S, et al. Thromboembolism in cancer patients : pathogenesis and treatment. Thromb Hemost 2006 ; 12 : 254-66.
PubMed
9) 内山真一郎, 赫洋美, 清水優子, 他. 抗リン脂質抗体症候群とTrousseau症候群. 脳卒中 2005 ; 27 : 547-51.
Medical*Online
10) 赫洋美, 内山真一郎, 岩田誠. がん治療と脳血管障害. Brain nerve 2008 ; 60 : 143-7.
 
11) Cestari DM, Weine DM, Panageas KS, et al. Stroke patients with cancer incidence and etiology. Neurology 2004 ; 62 : 2025-30.
PubMed
12) Dubec JJ, Munk PL, Tsang V, et al. Carotid artery stenosis in patients who have undergone radiation therapy for head and neck malignancy. Am J Surg 1999 ; 178 : 323-8.
 
13) 浅井昭雄, 河本圭司. 放射線照射による脳障害. Brain Nerve 2008 ; 60 : 123-9.
 
14) Goldwein JW. Radiation myelopathy : a review. Med Pediatr Oncol 1987 ; 15 : 89-95.
PubMed
15) Thomas P, Kbernd H. Peripheral neuropathy due to physical agent. In ; Dyck PJ, et al, eds. Peripheral Neuropathy, 3rd ed, WB Saunders, Philadelphia, 1993, p1000-8.
 
16) Kori SH, Foley KM, Posner JB : Brachial plexux lesions in patients with cancer : 100 cases. Neurology 1981 ; 31 : 145-50.
 
17) Brennan MJ. Breast cancer recurrence in a patient with a previous history of radiation injury of the brachial plexus : a case report. Arch Phys Med Rehabil 1995 ; 76 : 974-6.
 
18) 佐竹真理恵, 橋口良也, 法化図陽一, 他. 放射性神経障害. 日本臨牀 別冊 神経症候群 V, 日本臨牀社, 東京, 2000, p563-8.
 
19) 犬塚貴. 傍腫瘍性神経症候群の分子機構. In ; 日本老年医学会雑誌編集員会 編, 老年医学 update 2004-05. メジカルビュー社, 東京, 2004, p174-81.
 
20) Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004 ; 75 : 1135-40.
PubMed
21) Vedeler CA, Antoine JC, Giometto B, et al. Paraneoplastic Neurological Syndrome Euronetwork. Management of paraneoplastic neurological syndromes : report of an EFNS Task Force. Eur J Neurol, 2006 ; 13 : 682-90.
PubMed
22) Giometto B, Grisold W, Vitaliani R, et al. Paraneoplastic neurologic syndrome in the PNS Euronetwork database : a European study from 20 centers. Arch Neurol 2010 ; 67 : 330-5.
PubMed
23) Didelot A, Honnorat J. Update on paraneoplastic neurological syndromes. Curr Opin Oncol 2009 ; 21 : 566-72.
PubMed
24) 清水文崇, 神田隆. 傍腫瘍性脳脊髄炎. 別冊 神経症候群 (第2版) II, 日本臨牀社, 東京, 2014, p737-41.
 
25) Honnorat J, Antoine JC. Paraneoplastic neurological syndromes. Orphanet J Rare Dis 2007 ; 2 : 22.
PubMed
26) Graus F, Keime-Guibert F, Rene R, et al. Anti-Hu-associated paraneoplastic encephalomyelitis : analysis of 200 patients. Brain 2001 ; 124 : 1138-48.
PubMed
27) Ances BM, Vitaliani R, Taylor RA, et al. Treatment-responsive limbic encephalitis identified by neuropil antibodies : MRI and PET correlates. Brain 2005 ; 128 : 1764-77.
PubMed
28) Vincent A, Buckley C, Schott JM, et al. Potassium channel antibody-associated encephalopathy : a potentially immunotherapy-responsive form of limbic encephalitis. Brain 2004 ; 127 : 701-12.
PubMed
29) Thieben MJ, Lennon VA, Boeve BF, et al. Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody. Neurology 2004 ; 62 : 1177-82.
PubMed
30) 渡邊修, 有村公良. 傍腫瘍性神経症候群 : 診断と治療の進歩 最近の話題 抗チャネル抗体. 日内会誌 2008 ; 97 : 1838-43.
 
31) 田中恵子. 傍腫瘍性小脳変性症. 日本臨牀 別冊 神経症候群 (第2版) II, 日本臨牀社, 東京, 2014 ; p747-50.
 
32) 松本英之, 宇川義一. 傍腫瘍性オプソクローヌス・ミオクローヌス症候群. 日本臨牀 別冊 神経症候群 (第2版) II, 日本臨牀社, 東京, 2014, p755-8.
 
33) Korfei M, Fuhlhuber V, Schmidt-Woll T, et al. Functional characterisation of autoantibodies from patients with pediatric opsoclonus-myoclonus-syndrome. J Neuroimmunol 2005 ; 170 : 150-7.
PubMed
34) Koike H, Sobue G. Paraneoplastic neuropathy. Handb Clin Neurol 2013 ; 115 : 713-26.
PubMed
35) Chinn JS, Schuffler MD. Paraneoplastic visceral neuropathy as a cause of severe gastrointestinal motor dysfunction. Gastroenterology 1988 ; 95 : 1279-86.
PubMed
36) Koike H, Watanabe H, Sobue G. The spectrum of immune-mediated autonomic neuropathies : insights from the clinicopathological features. J Neurol Neurosurg Psychiatry 2013 ; 84 : 98-106.
PubMed
37) 石井亜紀子. Stiff-person症候群とその他の脊髄症. Brain Nerve 2010 ; 62 : 377-85.
 
38) Irani SR, Alexander S, Waters P, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 2010 ; 133 : 2734-48.
 
39) Hart IK, Maddison P, Newsom-Davis J, et al. Phenotypic variants of autoimmune peripheral nerve hyperexcitability. Brain 2002 ; 125 : 1887-95.
PubMed
40) 渡邊修. Issacs症候群の診断, 疫学および病態解明に関する研究. 厚生労働科学研究費補助金 難治性疾患等克服研究事業 免疫性神経疾患に関する調査研究 平成24年度総括・分担研究報告書, 2013, p78-9.
 
41) Irani SR, Pettingill P, Kleopa KA, et al. Morvan syndrome : clinical and serological observations in 29 cases. Ann Neurol 2012 ; 72 : 241-55.
PubMed
P.601 掲載の参考文献
1) Chen RS, Huang CC, Chu NS. Coenzyme Q10 treatment in mitochondrial encephalomyopathies. Short-term double-blind, crossover study. European Neurology 1997 ; 37 : 212-8.
PubMed
2) Muller W, Reimers CD, Berninger T, et al. Coenzyme Q10 in ophthalmoplegia plus-a double blind, cross over therapeutic trial. Journal of the Neurological Sciences 1990 ; 98 Suppl : 442.
 
3) Tarnopolsky MA, Roy BD, MacDonald JR. A randomized controlled trial of creatine monohydrate in patients with mitochondrial cytopathies. Muscle Nerve 1997 ; 20 : 1502-9.
PubMed
4) Klopstock T, Querner V, Schmidt F, et al. A placebo-controlled crossover trial of creatine in mitochondrial diseases. Neurology 2000 ; 55 : 1748-51.
 
5) De Stefano N, Matthews PM, Ford B, et al. Short-term dichloracetate treatment improves indices of cerebral metabolism in patients with mitochondrial disorders. Neurology 1995 ; 45 : 1193-8.
 
6) Liet JM, Pelletier V, Robinson BH, et al. The effect of short-term dimethylglycine treatment on oxygen consumption in cytochrome oxidase deficiency : a double blind randomized crossover clinical trial. Journal of Pediatrics 2003 ; 142 : 62-6.
PubMed
7) Chinnery P, Majamaa K, Turnbull D, et al. Treatment for mitochondrial disorders. Cochrane Database Syst Rev 2006 ; 25 : CD004426.
 
8) Avula S, et al. Treatment of Mitochondrial Disorders. Neurol 2014 ; 16 : 292-312.
PubMed
9) Nonaka I. Mitochondrial diseases. Curr Opin Neurol Neurosurg 1992 ; 5 : 622-32.
PubMed
10) Suomalinen A, et al. FGF-21 as a biomarker for muscle-manifesting mitochondrial respiratory chain deficiencies : a diagnostic study. Lancet Neurol 2011 ; 10 : 806-18.
PubMed
11) Martin G, et al. A randomized trial of coenzyme Q10 in mitochondrial disorders. Muscle Nerve 2010 ; 42 : 739-48.
 
12) Kornblum C, Schroder R, Muller K, et al. Creatine has no beneficial effect on skeletal muscle energy metabolism in patients with single mitochondrial DNA deletions : a placebo-controlled, double-blind 31P-MRS crossover study. Eur J Neurol 2005 ; 12 : 300-9.
PubMed
13) Mermigkis C, et al. Medical treatment with thiamine, coenzyme Q, vitamins E and C, and carnitine improved obstructive sleep apnea in an adult case of Leigh disease. Sleep Breath 2013 ; 17 : 1129-35.
 
14) Kaufmann P, Engelstad K, Wei Y, et al. Dichloroacetate causes toxic neuropathy in MELAS : a randomized, controlled clinical trial. Neurology 2006 ; 66 : 324-30.
 
15) Koga Y, Akita Y, Nishioka J, et al. L-arginine improves the symptoms of strokelike episodes in MELAS. Neurology 2005 ; 64 : 710-2.
PubMed
16) Koga Y, Ishibashi M, Ueki I, et al. Effects of L-arginine on the acute phase of strokes in three patients with MELAS. Neurology 2002 ; 58 : 827-8.
PubMed
17) Martinelli D, et al. EPI-743 reverse the progression of the pediatric mitochondrial disease-genetically defined Leigh Syndrome. Mol Genet Metab 2012 ; 107 : 383-8.
 
18) Enns GM, et al. Initial experience in the treatment of inherited mitochondrial disease with EPI-743. Mol Genet Metab 2012 ; 105 : 91-102.
PubMed
19) 杉江秀夫, 他. 代謝性ミオパチー : 150-1.
 
P.605 掲載の参考文献
1) Moser HW, Loes DJ, Melhem ER, et al. X-Linked adrenoleukody-strophy : overview and prognosis as a function of age and brain magnetic resonance imaging abnormality. A study involving 372 patients. Neuropediatrics 2000 ; 31 : 227-39.
 
2) Takemoto Y, Suzuki Y, Tamakoshi A, et al. Epidemiology of X-linked adrenoleukodystrophy in Japan. J Hum Genet 2002 ; 47 : 590-3.
PubMed
3) Moser HW, Mahmood A, Raymond GV. X-linked adrenoleukodystrophy. Nat Rev Neurol 2007 ; 3 : 140-51.
 
4) Aubourg P, Blanche S, Jambaque I, et al. Reversal of Early Neurologic and Neuroradiologic Manifestations of X-Linked Adrenoleukodystrophy by Bone Marrow Transplantation. N Engl J Med 1990 ; 322 : 1860-6.
PubMed
5) Shapiro, E, Krivit W, Lockman L, et al. Long-term effect of bonemarrow transplantation for childhood-onset cerebral X-linked adrenoleukodystrophy. Lancet 2000 ; 356 (9231) : 713-8.
 
6) Peters C, Charnas LR, Tan Y, et al. Cerebral X-linked adrenoleukodystrophy : the international hematopoietic cell transplantation experience from 1982 to 1999. Blood 2004 ; 104 : 881-8.
PubMed
7) Cartier N, Aubourg P. Hematopoietic Stem Cell Transplantation and Hematopoietic Stem Cell Gene Therapy in X-Linked Adrenoleukodystrophy. Brain Pathol 2010 ; 20 : 857-62.
 
8) Cartier N, Hacein-Bey-Abina S, Bartholomae CC, et al. Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy. Science 2009 ; 326 (5954) : 818-23.
 
9) Krivit W, Shapiro E, Kennedy W, et al. Treatment of Late Infantile Metachromatic Leukodystrophy by Bone Marrow Transplantation. N Engl J Med 1990 ; 322 : 28-32.
PubMed
10) Krivit W, Shapiro EG, Peters C, et al. Hematopoietic Stem-Cell Transplantation in Globoid-Cell Leukodystrophy. N Engl J Med 1998 ; 338 : 1119-27.
PubMed
11) William K, Peters C, Shapiro EG. Bone marrow transplantation as effective treatment of central nervous system disease in globoid cell leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartyl-glucosaminuria, Hurler, Maroteaux-Lamy, and Sly syndromes, and Gaucher disease type III. Cur Opinion Neurol, 1999 ; 12 : 167-76.
 
12) Peters C, Steward CG. Hematopoietic cell transplantation for inherited metabolic d iseases : an overview of outcomes and practice guidelines. Bone Marrow Transplant 2003 ; 31 : 229-39.
 
13) Prasad VK, Kurtzberg J. Cord blood and bone marrow transplantation in inherited metabolic diseases : scientific basis, current status and future directions. Br J Haematol 2009 ; 148 : 356-72.
PubMed
14) Boelens JJ, Prasad VK, Tolar J, Wynn RF, Peters C. Current International Perspectives on Hematopoietic Stem Cell Transplantation for Inherited Metabolic Disorders. Pediatr Clin North Am 2010 ; 57 : 123-45.
PubMed
P.610 掲載の参考文献
1) Aoki T, Suzuki M, Fujioka Y, et al. Nationwide survey of clinical feature of Wilson's disease in Japan. In ; Lam STS, Pang CCP, eds. Neonatal and Perinatal Screening : The Asian Pacific Perspectives, The Chinese University Press, Hong Kong, 1996, p25-8.
 
2) 清水教一. VIII 遺伝と代謝 銅代謝異常症-Wilson病-. 肝・胆道系症候群 (第2版) I 肝臓編 (上) -その他の肝・胆道系疾患を含めて-. 別冊日本臨牀 新領域症候群シリーズ No.13, 日本臨牀社, 大阪, 2010, 490-4.
 
3) 清水教一. Wilson病などの銅代謝異常症. 小児神経学の進歩 2015 ; 44 : 109-15.
 
4) 清水教一, 鈴木真理子, 山口之利, 他. 全国調査からみた神経型・肝神経型Wilson病の臨床像および肝銅含量に関する検討. 脳と発達 1996 ; 28 : 391-7.
 
5) 藤井秀樹. 発症前型Wilson病のセルロプラスミン及び銅代謝に関する研究, 診断基準作成の試み. Biomed Res Trace Elements 1997 ; 8 : 75-83.
 
6) Shimizu N, Nakazono H, Watanabe A, et al. Molecular diagnosis of Wilson's disease. Lancet 1997 ; 349 : 1811-2.
 
7) Shimizu N, Takeshita Y, Watanabe A, et al. Molecular diagnosis for presymptomatic patients with Wilson disease. Biomed Res Trace Elements 2005 ; 16 : 315-7.
 
8) Nakamura H, Hemmi H, Shimizu N. Molecular diagnosis of Wilson disease in Japanese patients. J Med Soc Toho 2009 ; 56 : 65-70.
 
9) 藤澤知雄. わが国におけるWilson病の肝移植, 適応と移植成績. 医学のあゆみ 2006 ; 216 : 823-7.
Medical*Online
10) Walshe JM. Penicillamine a new oral therapy for Wilson's disease. Am J Med 1956 ; 21 : 487-95.
 
11) Shimizu N, Yamaguchi Y, Aoki T. Treatment and management of Wilson's disease. Peditr Intr, 1999 ; 41 : 419-22.
 
12) Brewer GJ, Askari FK. Wilson's disease : clinical management and therapy. J Hepatol 2005 ; 42 : S13-21.
 
13) 清水教一, 青木継稔. 神経症状を呈したWilson病症例に対する銅キレート薬治療に関する検討. 日小児臨薬理会誌 2004 ; 17 : 95-7.
 
14) Lee D-Y, Brewer GJ, Wang Y. Treatment of Wilson's disease with zinc. VII. Protection of the liver from copper toxicity by zinc-induced metallothionein in a rat model. J Lab Clin Med 1989 ; 114 : 639-45.
 
15) Yuzbasiyan-Gurkan V, Grider A, Nostrant T, et al. Treatment of Wilson's disease with zinc : X. Intestinal metallothionein induction. J Lab Clin Med 1992 ; 120 : 380-6.
 
16) 清水教一, 藤原順子, 山口之利, 他. 本邦におけるWilson病に対する酢酸亜鉛製剤 (NPC-02) の有効性と安全性に関する検討. 日先天代謝異常会誌 2008 ; 24 : 71-80.
 
17) Shimizu N, Fujiwara J, Ohnishi S, et al. Effects of long-term zinc treatment in Japanese patients with Wilson disease : efficacy, stability, and copper metabolism. Transl Res 2010 ; 156 : 350-7.
PubMed
18) Brewer GJ. Wilson Disease. Harrison's Principles of Internal Medicine. 16th ed, 2005, p2313-5.
 
19) Brewer GJ, Askari FK. Wilson's disease : clinical management and therapy. J Hepatol 2005 ; 42 : S13-21
 
20) Roberts EA, Schilsky ML. American Association for Study of Liver Diseases (AASLD). Diagnosis and treatment of Wilson disease : an update. Hepatology 2008 ; 47 : 2089-111.
 
21) 清水教一. Wilson病患者に対する治療食の実際. 治療 2006 ; 88 : 2017-20.
Medical*Online
22) Schilsky ML, Scheinberg IH, Sternlieb I. Liver transplantation for Wilson disease : indication and outcome. Hepatology 1994 ; 19 : 583-7.
 
P.613 掲載の参考文献
1) Oldfors A, DiMaruo S. New insights in the field of muscle glycogenosis. Curre Opin Neurol 2013 ; 26 : 544-53.
 
2) John Hicks et al. Glycogen Storage Disease : A Brief Review and Update on Clinical Features, Genetic Abnormalities, Pathologic Features, and Treatment. Ultrast Pathol 2011 ; 35 : 183-96.
PubMed
3) 福田冬季子, 杉江秀夫, 他. 筋型糖原病の全国調査および浜松市発達医療総合センターにおける筋型糖原病診断症例の比較検討. 臨床神経 2003 ; 43 : 243-8.
 
4) Hirschhorn R, Reuser AJJ. Glycogen storage type II : acid alpha-glucosidase (acid maltase) deficiency. In ; Scriver CR, et al, eds. The Metabolic and Molecular bases of Inherited Disease. 8thed. New York, McGraw-Hill, 2001, p3389-420.
 
5) Ausems MG, et al. Frequency of glycogen storage disease type II in The Netherlands : implications for diagnosis and genetic counseling. Eur J Hum Genet 1999 ; 7 : 713-6.
PubMed
6) Martiniuk F, et al. Carrier frequency for glycogen storage disease type II in Ney York and estimates of affected indivisuals born with the disease. Am J Med Genet 1998 ; 9 : 69-72.
 
7) Engel AG, Franzini-Armstrong C, et al. Myology Volume II, 3rd ed, 2004, pp1535-86.
 
8) American association of neuromuscular & electrodiagnostic medicine : Diagnostic criteria for late-onset childhood and adult Pompe disease. Muscle Nerve 2009 ; 40 : 149-60.
 
9) 埜中征哉. 臨床のための筋病理 第3版, 日本医事新報社, 2005, p107-14.
 
10) Van der Ploeg AT, Reuser AJ. Pompe's disease. Lancet 2008 ; 372 : 1342-53.
 
11) Muller-Felber W, Horvath R, et al. Late onset Pompe disease : Clinical and neurophysiological spectrum of 38 patients including long-term follow up in 18 patients. Neuromuscul Disord 2007 ; 17 : 698-706.
PubMed
12) Kishnani PS, et al. Recombinant human acid alpha-glucosidase : major clinical benefits in infantile onset Pompe disease. Neurology 2007 ; 68 : 99-109.
PubMed
13) Van Der Ploeg AT, Marsden DL. Response to treatment with Myozyme in juvenile patients with Pompe disease. Mol Genet Metab 2007 ; 90 : 257-8.
 
14) Zhu Y, Jiang JL, Gumlaw NK, et al. Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease. Mol Ther 2009 ; 17 : 954-63.
 
15) Maga JA, Zhou J, et al. Glycosylation-independent Lysosomal Targeting of Acid α-Glucosidase Enhanses Muscle Glycogen Clearance in Pompe Mice. J Biol Chem 2013 ; 288 : 1428-38.
 
16) Todd AG, et al. Correcting Neuromuscular Deficits With Gene Therapy in Pompe Disease. ANN NEUROL 2015 ; 78 : 222-34.
PubMed
17) Kishmani PS, et al. Glycogen storage disease type III diagnosis and management guidelines. Genet Med 2010 ; 12 : 446-62.
 
18) Tsujino S, et al. The molecular genetic basis of myophosphorylase deficiency (McArdle's disease). Muscle Nerve 1995 ; Suppl 3 : S23-7.
 
19) Sato S, et al. Confirmation of the efficacy of vitamin B6 supplementation for McArdle disease by follow-up muscle biopsy. Muscle Nerve 2012 ; 45 : 436-40.
PubMed
20) Quinlivan RM, et al. Pharmacological and nutritional treatment trials in McArdle disease. Acta Myol 2007 ; 26 : 58-60.
PubMed
21) Tarui S, Okuno G, et al. Phosphofructokinase deficiency in skeletal muscle : A new type of glycogenosis. Biochem Biophys Res Commun 1965 ; 19 : 517-23.
 
22) DiMauro S, Lamperti C. Muscle glycogenoses. Muscle Nerve 2001 ; 24 : 984-99.
PubMed
P.619 掲載の参考文献
1) Spasovski G, Vanholder R, Allolio B, et al. Clinical practice guideline on diagnosis and treatment of hyponatraemia. Eur J Endocrinol 2014 ; 170 : G1-47.
PubMed
2) Martin RJ. Central pontine and extrapontine myelinolysis : the osmotic demyelination syndromes. J Neurol Neurosurg Psychiatry 2004 ; 75 (suppl III) : iii22-8.
 
3) Ruzek KA, Campeau NG, Miller GM. Early diagnosis of central pontine myelinolysis with diffusion-weighted imaging. Am J Neuroradiol 2004 ; 25 : 210-3.
PubMed
4) Sterns RH, Hix JK. Overcorrection of hyponatremia is a medical emergency. Kidney Int 2009 ; 76 : 587-9.
PubMed
5) Menger H, Jorg J. Outcome of central pontine and extrapontine myelinolysis (n=44). J Neurol 1999 ; 246 : 700-5.
PubMed

第13章 末梢神経障害

P.624 掲載の参考文献
1) van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barre syndrome. Lancet Neurol 2008 ; 7 : 939-50.
 
2) 楠進. 臨床免疫学 基礎研究の進歩と最新の臨床 Guillain-Barre症候群. 日本臨床 2005 ; 63 : 427-31.
 
3) Hughes RA, Cornblath DR. Guillain-Barre syndrome. Lancet 2005 ; 366 (9497) : 1635-66.
 
4) Hadden RD, Cornblath DR, Hughes RA, et al. Electrophysiological classification of Guillain-Barre syndrome : clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group. Ann Neurol 1998 ; 44 : 780-8.
PubMed
5) Ogawara K, Kuwabara S, Mori M, et al. Axonal Guillain-Barre syndrome : relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Ann Neurol 2000 ; 48 : 624-31.
PubMed
6) Kuwabara S. Guillain-Barre syndrome. Curr Neurol Neurosci Rep 2007 ; 7 : 57-62.
PubMed
7) Forsberg A, Press R, Einarsson U, et al. Impairment in Guillain-Barre syndrome during the first 2 years after onset : a prospective study. J Neurol Sci 2004 ; 227 : 131-8.
PubMed
8) 宮本勝一, 楠進. 免疫介在性ポリニューロパチー. 綜合臨牀 2006 ; 55 : 2197-200.
 
9) Ho TW, Mishu B, Li CY, et al. Guillain-Barre syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain1995 ; 118 : 597-605.
PubMed
10) 宮本勝一, 楠進. Guillain-Barre症候群. 神経疾患最新の治療 2009-2011, 南江堂, 2009, p251-5.
 
11) Chiba A, Kusunoki S, Obata H, et al. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barre syndrome : clinical and immunohistochemical studies. Neurology 1993 ; 43 : 1911-7.
PubMed
12) Odaka M, Yuki N, Yamada M, et al. Bickerstaff's brainstem encephalitis : clinical features of 62 cases and a subgroup associated with Guillain-Barre syndrome. Brain 2003 ; 126 : 2279-90.
 
13) Yuki N, Susuki K, Koga M, et al. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barre syndrome. Proc Natl Acad Sci U S A 2004 ; 101 : 11404-9.
PubMed
14) Koga M, Gilbert M, Takahashi M, et al. Comprehensive analysis of bacterial risk factors for the development of Guillain-Barre syndrome after Campylobacter jejuni enteritis. J Infect Dis 2006 ; 193 : 547-55.
PubMed
15) Kaida K, Morita D, Kanzaki M, et al. Ganglioside complexes as new target antigens in Guillain-Barre syndrome. Ann Neurol 2004 ; 56 : 567-71.
 
16) Kaida K, Morita D, Kanzaki M, et al. Anti-ganglioside complex antibodies associated with severe disability in GBS. J Neuroimmunol 2007 ; 182 : 212-8.
PubMed
17) 日本神経学会監修. ギラン・バレー症候群, フィッシャー症候群診療ガイドライン 2013, 南江堂, 2013.
 
18) Hughes RA, Wijdicks EF, Barohn R, et al. Practice parameter : immunotherapy for Guillain-Barre syndrome : report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2003 ; 61 : 736-40.
PubMed
19) 濱口勝彦, 野村恭. ギラン・バレー症候群における献血ベニロン-Iの使用成績調査中間報告. 診療と新薬 2006 ; 43 : 1175-90.
 
20) Hughes RA, Swan AV, Raphael JC, et al. Immunotherapy for Guillain-Barre syndrome : a systematic review. Brain 2007 ; 130 (Pt 9) : 2245-57.
PubMed
21) van den Berg B, Bunschoten C, van Doorn PA, et al. Mortality in Guillain-Barre syndrome. Neurology 2013 ; 80 : 1650-4.
PubMed
22) Garssen MP, Van Koningsveld R, Van Doorn PA. Residual fatigue is independent of antecedent events and disease severity in Guillain-Barre syndrome. J Neurol 2006 ; 253 : 1143-6.
PubMed
23) van Koningsveld R, Steyerberg EW, Hughes RA, et al. A clinical prognostic scoring system for Guillain-Barre syndrome. Lancet Neurol 2007 ; 6 : 589-94.
PubMed
24) Walgaard C, Lingsma HF, Ruts L, et al. Early recognition of poor prognosis in Guillain-Barre syndrome. Neurology 2011 ; 76 : 968-75.
PubMed
25) Walgaard C, Lingsma HF, Ruts L, et al. Prediction of respiratory insufficiency in Guillain-Barre syndrome. Ann Neurol 2010 ; 67 : 781-7.
PubMed
26) Kuitwaard K, de Gelder J, Tio-Gillen AP, et al. Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barre syndrome. Ann Neurol 2009 ; 66 : 597-603.
PubMed
27) 海田賢一, 楠進. ギラン・バレー症候群 : IGOS. Brain Nerve 2014 ; 66 : 1496-502.
 
28) 楠進. Guillain-Barre症候群とFisher症候群. 免疫性神経疾患ハンドブック, 南江堂, 2013, p127-45.
 
P.629 掲載の参考文献
1) Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Neurology 1991 ; 41 : 617-8.
 
2) 楠進. 免疫学的病態から見た慢性炎症性脱髄性多発ニューロパチー (CIPD). 神経治療 2004 ; 21 : 675-8.
 
3) 日本神経学会監修. 慢性炎症性脱髄性多発根ニューロパチー. 多巣性運動ニューロパチー診療ガイドライン 2013, 南江堂, 2013.
 
4) Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy : Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J Peripher Nerv Syst 2005 ; 10 : 220-8.
PubMed
5) Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of multifocal motor neuropathy : Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J Peripher Nerv Syst 2006 ; 11 : 1-8.
PubMed
6) Olney RK, Lewis RA, Putnam TD, et al. Consensus criteria for the diagnosis of multifocal motor neuropathy. Muscle Nerve 2003 ; 27 : 117-21.
 
7) 園生雅弘, 三浦孝顕. 多巣性運動ニューロパチーとLewis-Sumner症候群. Brain Med 2006 ; 18 : 159-66.
Medical*Online
8) Oh SJ, Claussen GC, Kim DS. Motor and sensory demyelinating mononeuropathy multiplex (multifocal motor and sensory demyelinating neuropathy) : a separate entity or a variant of chronic inflammatory demyelinating polyneuropathy? J Peripher Nerv Syst 1997 ; 2 : 362-9.
PubMed
9) Gorson KC. Clinical features, evaluation, and treatment of patients with polyneuropathy associated with monoclonal gammopathy of undetermined significance (MGUS). J Clin Apher 1999 ; 14 : 149-53.
PubMed
10) 宮本勝一, 楠進. 慢性炎症性脱髄性多発根ニューロパチー (CIDP) の治療戦略. EBM神経疾患の治療 2009-2010, 中外医学社, 2009, p445-9.
 
11) 宮本勝一, 楠進. 慢性炎症性脱髄性多発ニューロパチー. 神経疾患最新の治療 2006-2008, 南江堂, 2006, p219-21.
 
12) 鈴木秀和, 桑原基, 山藤聖子, 他. 慢性炎症性脱髄性多発ニューロパチーの臨床的および血清学的解析. 神経治療学 2013 ; 30 : 173-9.
Medical*Online
13) Dyck PJ, Litchy WJ, Kratz KM, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994 ; 36 : 838-45.
PubMed
14) Hahn AF, Bolton CF, Zochodne D, et al. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. a double-blind, placebo-controlled, cross-over study. Brain 1996 ; 119 : 1067-77.
PubMed
15) Mendell JR, Barohn RJ, Freimer ML, et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2001 ; 56 : 445-9.
PubMed
16) Hughes RA, Donofrio P, Bril V, et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study) : a randomised placebo-controlled trial. Lancet Neurol 2008 ; 7 : 136-44.
PubMed
17) 久堀保. NI-08 (乾燥ポリエチレングリコール処理ヒト免疫グロブリン) の慢性炎症性脱髄性多発神経炎における治療効果-第II相多施設共同試験. 脳神経 1999 ; 51 : 127-35.
 
18) Dyck PJ, Daube J, O'Brien P, et al. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 1986 ; 314 : 461-5.
 
19) Hahn AF, Bolton CF, Pillay N, et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. a doubleblind, sham-controlled, cross-over study. Brain 1996 ; 119 : 1055-66.
 
20) Dyck PJ, O'Brien PC, Oviatt KF, et al. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 1982 ; 11 : 136-41.
 
21) Hughes R, Bensa S, Willison H, et al. Randomized controled trial of intravenous immunoglobulin versus oral prednisone in chronic inflammatory demyelinating polyneuropathy. Ann Neurol 2001 ; 50 : 195-201.
 
22) Nobile-Orazio E, Cocito D, Jann S, et al. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy : a randomised controlled trial. Lancet Neurol 2012 ; 11 : 493-502.
PubMed
23) Eftimov F, Vermeulen M, van Doorn PA, et al. Long-term remission of CIDP after pulsed dexamethasone or short-term prednisolone treatment. Neurology 2012 ; 78 : 1079-84.
PubMed
24) Matsuda M, Hoshi K, Gono T, et al. Cyclosporin A in treatment of refractory patients with chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Sci 2004 ; 224 : 29-35.
PubMed
25) Cocito D, Grimaldi S, Paolasso I, et al. Immunosuppressive treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy. A nationwide retrospective analysis. Eur J Neurol 2011 ; 18 : 1417-21.
PubMed
26) Kaji R, Shibasaki H, Kimura J. Multifocal demyelinating motor neuropathy : cranial nerve involvement and immunoglobulin therapy. Neurology 1992 ; 42 : 506-9.
PubMed
P.636 掲載の参考文献
1) Ekins S, Litterman NK, Arnold RJ, et al. A brief review of recent Charcot-Marie-Tooth research and priorities. F1000Res 2015 ; 4 : 53.
PubMed
2) 樋口雄二郎, 橋口昭大, 袁 軍輝, 他. 臨床的にCharcot-Marie-Tooth病が疑われた304例のエクソーム解析による網羅的遺伝子診断. 末梢神経 2014 ; 25 : 93-9.
Medical*Online
3) Dortch RD, Dethrage LM, Gore JC, et al. Proximal nerve magnetization transfer MRI relates to disability in Charcot-Marie-Tooth diseases. Neurology 2014 ; 83 : 1545-53.
PubMed
4) Lee S, Amici S, Tavori H, et al. PMP22 is critical for actin-mediated cellular functions and for establishing lipid rafts. J Neurosci 2014 ; 34 : 16140-52.
PubMed
5) Lewis RA, McDermott MP, Herrmann DN, et al. High-dosage results of a randomized, double-masked, controlled trial. JAMA Neurol 2013 ; 70 : 981-7.
PubMed
6) Sahenk Z, Galloway G, Clark KR, et al. AAV1.NT-3 Gene Therapy for Charcot-Marie-Tooth Neuropathy. Mol Ther 2014 ; 22 : 511-21.
PubMed
7) Attarian S, Vallat JM, Magy L, et al. An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT-3003) in patients with Charcot-Marie-Tooth disease type 1A. Orphanet J Rare Dis 2014 ; 9 : 199.
 
8) Inglese J, Dranchak P, Moran JJ, et al. Genome editing-enabled HTS assays expand drug target pathways for Charcot-Marie-tooth disease. ACS Chem Biol 2014, 9 : 2594-2602.
PubMed
9) Fledrich R, Stassart RM, Klink A, et al. Soluble neuregulin-1 modulates disease pathogenesis in rodent models of Charcot-Marie-Tooth disease 1A. Nat Med 2014, 20 : 1055-1061.
PubMed
10) Patzko A, Bai Y, Saporta MA, et al. Curcumin derivatives promote Schwann cell differentiation and improve neuropathy in R98C CMT1B mice. Brain 2012 ; 135 : 3551-66.
PubMed
11) Okamoto Y, Pehlivan D, Wiszniewski W, et al. Curcumin facilitates a transitory cellular stress response in Trembler-J mice. Hum Mol Genet 2013 ; 22 : 4698-705.
 
12) Sargiannidou I, Kagiava A, Bashiardes S, et al. Intraneural GJB1 gene delivery improves nerve pathology in a model of X-linked Charcot-Marie-Tooth disease. Ann Neurol 2015 ; 78 : 303-16.
 
13) d'Ydewalle C, Krishnan J, Chiheb DM, et al. HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot-Marie-Tooth disease. Nat Med 2011 ; 17 : 968-74.
 
14) Mussche S, Devreese B, Nagabhushan Kalburgi S, et al. Restoration of cytoskeleton homeostasis after gigaxonin gene transfer for giant axonal neuropathy. Hum Gene Ther 2013 ; 24 : 209-19.
PubMed
15) Zou J, Hu B, Arpag S, et al. Reactivation of Lysosomal Ca2+ Efflux Rescues Abnormal Lysosomal Storage in FIG4-Deficient Cells. J Neurosci 2015 ; 35 : 6801-12.
 
16) Saporta MA, Dang V, Volfson D, et al. Axonal Charcot-Marie-Tooth disease patient-derived motor neurons demonstrate disease-specific phenotypes including abnormal electrophysiological properties. Exp Neurol 2015 ; 263 : 190-9.
PubMed
17) Mazzeo A, Stancanelli C, Russo M, et al. Subacute inflammatory demyelinating polyneuropathy disclosed by massive nerve root enhancement in CMT1A. Muscle Nerve 2012 ; 45 : 451.
PubMed
18) Chetlin RD, Mancinelli CA, Gutmann L. self-reported follow-up post-intervention adherence to resistance exercise training in charcot-marie-tooth disease patients. Muscle Nerve 2010 ; 42 : 456.
PubMed
19) Dufek JS, Neumann ES, Hawkins MC, et al. Functional and dynamic response characteristics of a custom composite ankle foot orthosis for Charcot-Marie-Tooth patients. Gait Posture 2014 ; 39 : 308-13.
PubMed
20) CMT診療マニュアル編集委員会 編. シャルコー・マリー・トゥース病診療マニュアル 改訂版, 2010, 金芳堂, 京都, 2015.
 
P.640 掲載の参考文献
1) Connors LH, Lim A, Prokaeva T, et al. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid 2003 ; 10 : 160-84.
PubMed
2) Ikeda S, Nakazato M, Ando Y, et al. Familial transthyretin-type amyloid polyneuropathy in Japan : Clinical and genetic heterogeneity. Neurology 2002 ; 58 : 1001-7.
PubMed
3) Ikeda S, Hanyu N, Hongo M, et al. Hereditary generalized amyloidosis with polyneuropathy. Clinicopathological study of 65 Japanese patients. Brain 1987 ; 110 : 315-37.
PubMed
4) Misu K, Hattori N, Nagamatsu M, et al. Late-onset familial amyloid polyneuropathy type (I transthyretin Met30-associated familial amyloid polyneuropathy) unrelated to endemic focus in Japan : Clinicopathological and genetic features. Brain 1999 ; 122 : 105-10.
 
5) Hattori T, Takei Y, Koyama J, et al. Clinical and pathological studies of cardiac amyloidosis in transthyretin type familial amyloid polyneuropathy. Amyloid 2003 ; 10 : 229-39.
PubMed
6) Jin K, Sato S, Takahashi T, et al. Familial leptomeningeal amyloidosis with a transthyretin variant Asp18Gly presenting repeated subarachnoid haemorrhages with superficial siderosis. J Neurol Neurosurg Psychiatry 2004 ; 75 : 1463-6.
 
7) Shimizu Y, Takeuchi M, Matsumura M, et al. A case of biopsyproven leptomeningeal amyloidosis and intravenous Ig-responsive polyneuropathy associated with the Ala25thr transthyretin gene mutation. Amyloid 2006 ; 13 : 37-41.
 
8) Ikeda S, Nakano T, Yanagisawa N, et al. Asymptomatic homozygous gene carrier in a family with type I familial amyloid polyneuropathy. Eur Neurol 1992 ; 32 : 308-13.
 
9) Tachibana N, Tokuda T, Yoshida K, et al. Usefulness of MALDI/TOF mass spectrometry of immunoprecipitated serum variant transthyretin in the diagnosis of familial amyloid polyneuropathy. Amyloid 1999 ; 6 : 282-6.
 
10) Holmgren G, Steen L, Ekstedt J, et al. Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic poluneuropathy (FAP-met30). Clin Genet 1991 ; 40 : 242-6.
PubMed
11) Takei Y, Ikeda S, Hashikura Y, et al. Partial-liver transplantation to treat familial amyloid polyneuropathy : follow-up of 11 patients. Ann Intern Met 1999 ; 131 : 592-5.
 
12) Takei Y, Ikeda S, Ikegami T, et al. Ten years of experience with liver transplantation for familial amyloid polyneuropathy in Japan : outcomes of living donor liver transplantations. Intern Med 2005 ; 44 : 1151-6.
PubMed
13) Ando Y, Tanaka Y, Ando E, et al. Effect of liver transplantation on autonomic dysfunction in familial amyloidotic polyneuropathy type I. Lancet 1995 ; 345 : 195-6.
PubMed
14) Ando Y, Tanaka Y, Nakazato M, et al. Change in variant transthyretin levels in patients with familial amyloidotic polyneuropathy type I following liver transplantation. Biochem Biophys Res Commun 1995 ; 211 : 354-8.
PubMed
15) Tsuchiya A, Yazaki M, Kametani F, et al. Marked regression of abdominal fat amyloid in patients with familial amyloid polyneuropathy during long-term follow-up after liver transplantation. Liver Transpl 2008 ; 14 : 563-70.
PubMed
16) Ando Y, Ando E, Tanaka Y, et al. De novo amyloid synthesis in ocular tissue in familial amyloidotic polyneuropathy after liver transplantation. Transplantation 1996 ; 62 : 1097-8.
 
17) Dubrey SW, Davidoff R, Skinner M, et al. Progression of ventricular wall thickening after liver transplantation. Transplantation 1997 ; 64 : 74-80.
PubMed
18) Stangou AJ, Hawkins PN, Healton ND, et al. Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy. Transplantation 1998 ; 66 : 229-33.
 
19) Yazaki M, Tokuda T, Nakamura A, et al. Cardiac amyloid in patients with familial amyloid polyneuropathy consists of abundant wild-type transthyretin. Biochem Biophys Res Commun 2000 ; 274 : 702-6.
PubMed
20) Miller SR, Sekijima Y, Kelly JW. Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. Lab Invest 2004 ; 84 : 545-52.
PubMed
21) Berk JL, Suhr OB, Obici L, et al. Repurposing diflunisal for familial amyloid polyneuropathy : a randomized clinical trial. JAMA 2013 ; 310 : 2658-67.
PubMed
22) Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy : a randomized, controlled trial. Neurology 2012 ; 79 : 785-92.
PubMed
P.646 掲載の参考文献
1) Anderson KE, Sassa S, Bishop DE, et al. Disorders of heme biosynthesis : X-linked sideroblastic anemia and porphyrias. In ; Scriver CR, Beaudet AL, Valle D, Sly WS, eds. The Metabolic and Mlecular Basis of inheritaed Disease. 8th ed, McGraw-Hill Inc, NY, 2001, p2991-3062.
 
2) Hrdinka M, Puy H, Martasek P. May 2006 Update in porphobilinogen deaminase gene polymorphisms and mutations causing acute intermittent porphyria. Comparison with the situation in Slavic population. Physol Res 2006 ; S119-36.
 
3) Marcus DL, Nadel H, Lew G, et al. Cimetidine suppresses chemically induced experimental hepatic porphyrias. Am J Med Sci 1990 ; 300 : 214-7.
PubMed
P.649 掲載の参考文献
1) Gilden DH. Clinical practice. Bell's Palsy. N Engl J Med 2004 ; 351 : 1323-31.
 
2) Murakami S, Mizobuchi M, Nakashiro Y, et al. Bell's palsy and herpes simplex virus : Identification if viral DNA in endoneurial fluid and muscle. Ann Intern Med 1996 ; 124 : 27-30.
 
3) Adour KK. Otological complications of herpes zoster. Ann Neurol 1994 ; 35 (suppl) : S62-4.
PubMed
4) Sweeney CJ, Gilden DH. Ramsay Hunt syndrome. J Neurol Neurosurg Psychiatry 2001 ; 71 : 149-54.
PubMed
5) Furuta Y, Ohtani F, Kawabata H, et al. High prevalence of varicella-zoster virus reactivation in herpes simplex virus-seronegative patients with acute peripheral facial palsy. Clin Infect Dis 2000 ; 30 : 529-33.
PubMed
6) 日本顔面神経研究会. 末梢性顔面神経麻痺の治療効果判定についての申し合わせ事項試案. Facial N Res Jpn 1995 ; 15 : 227-30.
 
7) Peitersen E. Bell's palsy : the spontaneous course of 2,500 peripheral facial nerve palsies of different etiologies. Acta Otolaryngol Supp 2002 ; (l549) : 4-30.
 
8) Engstrom M, Jonsson L, Grindlund M, et al. House-Brackmann and Yanagihara grading scores in relation to electroneurographic results in the time course of Bell's palsy. Acta Otolaryngol 1998 ; 118 : 783-9.
 
9) Dumitru D, Walsh NE, Porter LD. Electrophysiologic evaluation of the facial nerve in Bell's palsy. A review. Am J Phys Med Rehabil 1988 ; 67 : 137-44.
 
10) Sullivan FM, Swan IR, Donnan PT, et al. Early treatment with prednisolone or acyclovir in Bell's palsy. N Engl J Med 2007 ; 351 : 1598-607.
 
11) Kawaguchi K, Inamura H, Abe Y, et al. Reactivation of herpes simplex virus type 1 and varicella-zoster virus and therapeutic effects of combination therapy with prednisolone and valacyclovir in patients with Bell's palsy. Laryngoscope 2007 ; 117 : 147-56.
 
12) Hato N, Yamada H, Kohno H, et al. Valacyclovir and prednisolone treatment for Bell's palsy : a multicenter, randomized, placebo-controlled study. Otol Neurotol 2007 ; 28 : 408-13.
 
13) Engstrom M, Berg T, Stjernquist-Desatnik A, et al. Prednisolone and valaciclovir in Bell's palsy : a randomised, double-blind, placebo-controlled, multicentre trial. Lancet Neurol 2008 ; 7 : 993-1000.
 
14) Yeo SG, Lee YC, Park DC, et al. Acyclovir plus steroid vs steroid alone in the treatment of Bell's palsy. Am J Otolaryngol 2008 ; 29 : 163-6.
 
15) Minnerop M, Herbst M, Fimmers R, et al. Bell's palsy : combined treatment of famciclovir and prednisone is superior to prednisone alone. J Neurol 2008 ; 255 : 1726-30.
 
16) Gronseth GS, Paduga R. Evidence-based guideline update : Steroids and antivirals for Bell palsy. Neurology 2012 ; 79 : 2209-13.
PubMed
17) Baugh RF, Basura GJ, Ishii LE, et al. Clinical Practice Guideline : Bell's Palsy. Otolaryngol Head Neck Surg 149 (suppl 3) : S1-27, 2013
 
18) Lockhart P, Daly F, Pitkethly M, et al. Antiviral treatment for Bell's palsy (idiopathic facial paralysis). Cochrane Database Syst Rev 2009 ; CD001869.
 
19) de Almeida JR, Al Khabori M, Guyatt GH, et al. Combined corticosteroid and antiviral treatment for Bell palsy : a systematic review and meta-analysis. JAMA 2009 ; 302 : 985-993.
PubMed
20) Quant EC, Jeste SS, Muni RH, et al. The benefits of steroids versus steroids plus antivirals for treatment of Bell's palsy : a metaanalysis. BMJ 2009 ; 339 : b3354.
 
21) Goudakos JK, Markou KD : Corticosteroids vs corticosteroids plus antiviral agents in the treatment of Bell palsy : a systematic review and meta-analysis. Arch Otolaryngol Head Neck Surg 2009 ; 135 : 558-64.
PubMed
22) Patel DK, Levin KH. Bell palsy : Clinical examination and management. Cleveland Clinic Journal of Medicine 2015 ; 82 : 419-26.
PubMed
23) Axelsson S, Berg T, Jonsson L, et al. Bell's palsy-the effect of prednisolone and/or valaciclovir versus placebo in relation to baseline severity in a randomised controlled trial. Clin Otolaryngol 2012 ; 37 : 283-90.
 
P.652 掲載の参考文献
1) Kopell HP, Thompson WAL. Peripheral entrapment neuropathies. In ; Robert E. Krieger Publishing Company, Malabar, Florida, 1963.
 
2) 廣谷速人. 手根管症候群. In ; 廣谷速人 編. しびれと痛み 末梢神経絞扼障害 第1版, 金原出版, 1997, p25-54.
 
3) 平澤泰介. 正中神経損傷および絞扼性神経障害 手根管症候群. In ; 平澤泰介 編. 臨床医のための末梢神経損傷・障害の治療 第1版, 金原出版, 東京, 2000, p115-22.
 
4) 奥井伸幸, 平田仁. 手根管症候群の診断・治療指針. In ; 中村耕三 編. 運動器診療 最新ガイドライン, 初版, 総合医学社, 東京, 2012, 462-4.
 
5) Page MJ, Massy-Westropp N, O'Connor D, et al. Splinting for carpal tunnel syndrome. Cochrane Database Syst Rev 2012 ; 7 : Cd010003.
 
6) Sayegh ET, Strauch RJ. Open versus endoscopic carpal tunnel release : a meta-analysis of randomized controlled trials. Clin Orthop Relat Res 2015 ; 473 : 1120-32.
PubMed
7) Zuo D, Zhou Z, Wang H, et al. Endoscopic versus open carpal tunnel release for idiopathic carpal tunnel syndrome : a meta-analysis of randomized controlled trials. J Orthop Surg Res 2015 ; 10 : 12.
PubMed
8) Gerritsen AM, de Vet HW, Scholten RM, et al. Splinting vs surgery in the treatment of carpal tunnel syndrome : A randomized controlled trial. JAMA 2002 ; 288 : 1245-51.
 
9) Louie DL, Earp BE, Collins JE, et al. Outcomes of Open Carpal Tunnel Release at a Minimum of Ten Years. J Bone Joint Surg 2013 ; 95 : 1067-73.
 
10) 廣谷速人, 肘部管症候群. In ; 廣谷速人 編. しびれと痛み 末梢神経絞扼障害 第1版, 金原出版, 東京, 1997, p63-87.
 
11) 原友紀, 落合直之. 肘部管症候群の診断・治療指針. In ; 中村耕三 編. 運動器診療 最新ガイドライン 初版, 総合医学社, 東京, 2012, 408-10.
 
12) 田尻康人.【ロコモティブシンドロームのすべて】ロコモティブシンドロームを構成する疾患 上肢の障害 肘部管症候群. 日医師会誌. 2015 ; 144 (特別1) : S242-5.
 
13) Osborne G. The surgical treatment of tardy ulnar neuritis. J Bone Joint Surg 1957 ; 39-B : 782.
 
14) King T, Morgan FP. Late results of removing the medial humeral epicondyle for traumatic ulnar neuritis. J Bone Joint Surg British Volume. 1959 ; 41-B (1) : 51-5.
 
15) Caliandro P, La Torre G, Padua R, et al. Treatment for ulnar neuropathy at the elbow. Cochrane Database Syst Rev 2012 ; 7 : CD006839.
PubMed
16) Liu C-H, Chen C-X, Xu J, et al. Anterior Subcutaneous versus Submuscular Transposition of the Ulnar Nerve for Cubital Tunnel Syndrome : A Systematic Review and Meta-Analysis. Plos One 2015 ; 10 : e0130843-e.
PubMed
17) Bacle G, Marteau E, Freslon M, et al. Cubital tunnel syndrome : comparative results of a multicenter study of 4 surgical techniques with a mean follow-up of 92 months. Orthop Traumatol Surg Res 2014 ; 100 (4 Suppl) : S205-8.
PubMed
18) Kamat AS, Jay SM, Benoiton LA, et al. Comparative outcomes of ulnar nerve transposition versus neurolysis in patients with entrapment neuropathy at the cubital tunnel : a 20-year analysis. Acta Neurochir (Wien) 2014 ; 156 : 153-7.
PubMed
19) Soltani AM, Best MJ, Francis CS, et al. Trends in the surgical treatment of cubital tunnel syndrome : an analysis of the national survey of ambulatory surgery database. J Hand Surg Am 2013 ; 38 : 1551-6.
PubMed
20) Adkinson JM, Zhong L, Aliu O, et al. Surgical Treatment of Cubital Tunnel Syndrome : Trends and the Influence of Patient and Surgeon Characteristics. J Hand Surg Am 2015 ; 40 : 1824-31.
PubMed
P.655 掲載の参考文献
1) Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013 ; 65 : 1-11.
 
2) Sable-Fourtassou R, Cohen P, Mahr A, et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 2005 ; 143 : 632-8.
PubMed
3) Sinico RA, Di Toma L, Maggiore U, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum 2005 ; 52 : 2926-35.
PubMed
4) Vrancken AF, Gathier CS, Cats EA, et al. The additional yield of combined nerve/muscle biopsy in vasculitic neuropathy. Eur J Neurol 2011 ; 18 : 49-58.
PubMed
5) 尾崎承一, 牧野博史. ANCA関連血管炎診療ガイドライン 2014 改訂版 : 厚生労働省厚生科学特定疾患対策研究事業難治性血管炎に対する調査研究班, 編.
 
6) Cohen P, Pagnoux C, Mahr A, et al. Churg-Strauss syndrome with poor-prognosis factors : A prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Rheum 2007 ; 57 : 686-93.
PubMed
7) Goransson LG, Herigstad A, Tjensvoll AB, et al. Peripheral neuropathy in primary sjogren syndrome : a population-based study. Arch Neurol. 2006 ; 63 : 1612-5.
PubMed
8) Ramos-Casals M, Solans R, Rosas J, et al. Primary Sjogren syndrome in Spain : clinical and immunologic expression in 1010 patients. Medicine (Baltimore) 2008 ; 87 : 210-9.
PubMed
9) Mori K, Iijima M, Koike H, et al. The wide spectrum of clinical manifestations in Sjogren's syndrome-associated neuropathy. Brain 2005 ; 128 : 2518-34.
 
10) Griffin JW, Cornblath DR, Alexander E, et al. Ataxic sensory neuropathy and dorsal root ganglionitis associated with Sjogren's syndrome. Ann Neurol 1990 ; 27 : 304-15.
 
11) Asahina M, Kuwabara S, Asahina M, et al. D-penicillamine treatment for chronic sensory ataxic neuropathy associated with Sjogren's syndrome. Neurology 1998 ; 51 : 1451-3.
 
12) Chen WH, Yeh JH, Chiu HC. Plasmapheresis in the treatment of ataxic sensory neuropathy associated with Sjogren's syndrome. Eur Neurol 2001 ; 45 : 270-4.
 
13) Takahashi Y, Takata T, Hoshino M, et al. Benefit of IVIG for long-standing ataxic sensory neuronopathy with Sjogren's syndrome. IV immunoglobulin. Neurology. 2003 ; 60 : 503-5.
 
14) Pascual J, Cid C, Berciano J. High-dose i.v. immunoglobulin for peripheral neuropathy associated with Sjogren's syndrome. Neurology 1998 ; 51 : 650-1.
 
P.660 掲載の参考文献
1) Bird SJ. Diagnosis and management of critical illness polyneuropathy and critical illness myopathy. Curr Treat Options Neurol 2007 ; 9 : 85-92.
PubMed
2) Bednarik J, Vondracek P, Dusek L, et al. Risk factors for critical illness polyneuromyopathy. J Neurol 2005 ; 252 : 343-51.
PubMed
3) Schweickert WD, et al. ICU-acquired weakness. Chest 2007 ; 131 : 1541-9.
PubMed
4) Stevens RD, Marshall SA, Cornblath DR, et al. A framework for diagnosing and classifying intensive care unit-acquired weakness. Crit Care Med 2009 ; 37 : S299-308.
PubMed
5) Latronico N, Bolton CF. Critical illness polyneuropathy and myopathy : a major cause of muscle weakness and paralysis. Lancet Neurol 2011 ; 10 : 931-41.
 
6) Bolton CF. Neuromuscular manifestations of critical illness. Muscle Nerve 2005, 32 : 140-63.
PubMed
7) 畑中裕己, 園生雅弘, 清水輝夫. Critical illness polyneuropathy. Annual Review 神経 2002, 中外医学社, 東京, 2002, p244-50.
 
8) Bird SJ, Rich MM. Critical illness myopathy and polyneuropathy. Curr Neurol Neurosci Rep 2002 ; 2 : 527-33.
PubMed
9) Rich MM, Bird SJ, Raps EC, et al. Direct muscle stimulation in acute quadriplegic myopathy. Muscle Nerve 1997 ; 20 : 665-73.
PubMed
10) Goodman BP, Harper CM, Boon AJ. Prolonged compound muscle action potential duration in critical illness myopathy.Muscle Nerve 2009 ; 40 : 1040-2.
PubMed
11) Grimm A, Teschner U, Porzelius C, et al. Muscle ultrasound for early assessment of critical illness neuromyopathy in severe sepsis. Critical Care 2013 ; 17 : R227.
PubMed
12) Witt NJ, Zochodne DW, Bolton CF, et al. Peripheral nerve function in sepsis and multiple organ failure. Chest 1991 ; 99 : 176-84.
PubMed
13) Stevens RD, Dowdy DW, Michaels RK, et al. Neuromuscular dysfunction acquired in critical illness : a systematic review. Intensive Care Med 2007 ; 33 : 1876-91.
PubMed
14) Lacomis D, Petrella JT, Giuliani MJ. Causes of neuromuscular weakness in the intensive care unit : a study of ninety-two patients. Muscle Nerve 1998 ; 21 : 610-7.
PubMed
15) Bednarik J, Lukas Z, Vondracek P. Critical illness polyneuromyopathy : the electrophysiological components of a complex entity. Intensive Care Med 2003 ; 29 : 1505-14.
PubMed
16) Lefaucheur JP, Nordine T, Rodriguez P, et al. Origin of ICU acquired paresis determined by direct muscle stimulation. J Neurol Neurosurg Psychiatry 2006 ; 77 : 500-6.
PubMed
17) Lacomis D, Zochodne DW, Bird SJ. Critical illness myopathy : what's in a name-. Muscle Nerve 2000 ; 23 : 1767-72.
 
18) Campellone JV, Lacomis D, Kramer DJ, et al. Acute myopathy after liver transplantation. Neurology 1998 ; 50 : 46-53.
PubMed
19) Hirano M, Ott BR, Raps EC, et al. Acute quadriplegic myopathy : a complication of treatment with steroids, nondepolarizing blocking agents, or both. Neurology 1992 ; 42 : 2082-7.
PubMed
20) De Jonghe B, et al. Paresis acquired in the intensive care unit : a prospective multicenter study. JAMA 2002 ; 288 : 2859-67.
PubMed
21) Hough CL, Steinberg KP, Taylor Thompson B, et al. Intensive care unit-acquired neuromyopathy and corticosteroids in survivors of persistent ARDS. Intensive Care Med 2009 ; 35 : 63-8.
PubMed
22) Puthucheary Z, Rawal J, Ratnayake G. Neuromuscular blockade and skeletal muscle weakness in critically ill patients : time to rethink the evidence? Am J Respir Crit Care Med 2012 ; 185 : 911-7.
PubMed
23) Bolton CF. Neuromuscular manifestations of critical illness. Muscle Nerve 2005 ; 32 : 140-63.
PubMed
24) Latronico N, Shehu I, Seghelini E. Neuromuscular sequelae of critical illness. Curr Opin Crit Care 2005 ; 11 : 381-90.
PubMed
25) Fletcher SN, Kennedy DD, Ghosh IR, et al. Persistent neuromuscular and neurophysiologic abnormalities in long-term survivors of prolonged critical illness. Crit Care Med 2003 ; 31 : 1012-6.
PubMed
26) Herridge MS, Cheung AM, Tansey CM, et al. One-year outcomes in survivors of the acute respiratory distress syndrome. N Engl J Med 2003 ; 348 : 683-93.
PubMed
27) Latronico N. Neuromuscular alterations in the critically ill patient : critical illness myopathy, critical illness neuropathy, or both? Intensive Care Med 2003 ; 29 : 1411-3.
 
28) David WS, Roehr CL, Leatherman JW. EMG findings in acute myopathy with status asthmaticus, steroids, and paralytics : clinical and electrophysiologic correlation. Electromyogr Clin Neurophysiol 1998 ; 38 : 371-6.
PubMed
29) Guarneri B, Bertolini G, Latronico N. Long-term outcome in patients with critical illness myopathy or neuropathy : the Italian multicentre CRIMYNE study. J Neurol Neurosurg Psychiatry 2008 ; 79 : 838-41.
PubMed
30) Koch S, Wollersheim T, Bierbrauer J, et al. Long-term recovery In critical illness myopathy is complete, contrary to polyneuropathy. Muscle Nerve 2014 ; 50 : 431-6.
PubMed
31) Koch S, Wollersheim T, Bierbrauer J, et al. Long-term recovery In critical illness myopathy is complete, contrary to polyneuropathy. Muscle Nerve 2014 ; 50 : 431-6.
PubMed
32) Garnacho-Montero J, Amaya-Villar R, Garcia-Garmendia JL, et al. Effect of critical illness polyneuropathy on the withdrawal from mechanical ventilation and the length of stay in septic patients. Crit Care Med 2005 ; 33 : 349-542.
PubMed
33) Ali NA, O'Brien JM Jr, Hoffmann SP, et al. Acquired weakness, handgrip strength, and mortality in critically ill patients. Am J Respir Crit Care Med 2008 ; 178 : 261-8.
 
34) Brunello AG, Haenggi M, Wigger O, et al. Usefulness of a clinical diagnosis of ICU-acquired paresis to predict outcome in patients with SIRS and acute respiratory failure. Intensive Care Med 2010 ; 36 : 66-74.
PubMed
35) Williams S, Horrocks IA, Ouvrier RA, et al. Critical illness polyneuropathy and myopathy in pediatric intensive care : A review. Pediatr Crit Care Med 2007 ; 8 : 18-22.
PubMed
36) Van der Schaaf M, Beelen A, De Vos R : Functional outcome in patients with critical illness polyneuropathy. Disabil Rehabil 2004 ; 26 : 1189-97.
PubMed
37) Sladen RN : Neuromuscular blocking agents in the intensive careunit : a two-edged sword. Crit Care Med 1995 ; 23 : 423-8.
 
38) Murray MJ, Cowen J, DeBlock H, et al. Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient. Crit Care Med 2002 ; 30 : 142-56.
PubMed
39) National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network : Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med 2006 ; 354 : 1671-84.
PubMed
40) Novak F, Heyland DK, Avenell A, et al. Glutamine supple-mentation in serious illness : a systematic review of the evidence. Crit Care Med 2002 ; 30 : 2022-9.
 
41) Yu YM, Ryan CM, Fei ZW. et al. Plasma L-5-oxoproline kinetics and whole blood glutathione synthesis rates in severely burned adult humans. Am J Physiol Endocrinol Metab 2002 ; 282 : E247-58.
PubMed
42) Wijdicks EF, Fulgham JR. Failure of high dose intravenous immunoglobulins to alter the clinical course of critical illness polyneuropathy. Muscle Nerve 1994 ; 17 : 1494-5.
PubMed
43) Mohr M, Englisch L, Roth A, et al. Effects of early treatment with immunoglobulin on critical illness polyneuropathy following multiple organ failure and gram-negative sepsis. Intensive Care Med 1997 ; 23 : 1144-9.
PubMed
44) Brunner R, Rinner W, Haberler C, et al. Early treatment with IgM-enriched intravenous immunoglobulin does not mitigate critical illness polyneuropathy and/or myopathy in patients with multiple organ failure and SIRS/sepsis : a prospective, randomized, placebo-controlled, double-blinded trial. Crit Care 2013 ; 17 : R213.
PubMed
45) Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001 ; 345 : 1359-67.
PubMed
46) De Jonghe B, Sharshar T, Lefaucher JP, et al. Paresis acquired in the intensive care unit : a prospective multicenter study. JAMA 2002 ; 288 : 2859-67.
 
47) Van den Berghe G, Schoonheydt K, Becx P, et al. Insulin therapy protects the central and peripheral nervous system of intensive care patients. Neurology 2005 ; 64 : 1348-53.
PubMed
48) Hermans G, De Jonghe B, Bruyninckx F, et al. Interventions for preventing critical illness polyneuropathy and critical illness myopathy. Cochrane Database Syst Rev 2009 ; CD006832.
PubMed
49) Hermans G, De Jonghe B, Bruyninckx F, Van den Berghe G. Interventions for preventing critical illness polyneuropathy and critical illness myopathy. Cochrane Database Syst Rev 2014 ; CD006832.
PubMed
50) NICE-SUGAR Study Investigators, Finfer S, Chittock DR, Su SY, Blair D, et al. Intensive versus conventional glucose control in critically ill patients.N Engl J Med 2009 ; 360 : 1283-97.
 
51) Finfer S, Liu B, Chittock DR, et al. Hypoglycemia and risk of death in critically ill patients. N Engl J Med 2012 ; 367 : 1108-18.
PubMed
52) Schweichlert WD, et al. Early physical and occupational therapy in mechanically ventilated, critically ill patients : a randomised controlled trial. Lancet 2009 ; 373 : 1874-82.
 
53) Burtin C, et al. Early exercise in critically ill patients enhances short-term functional recovery. Crit Care Med 2009 ; 37 : 2499-505.
PubMed
54) Routsi C, Gerovasili V, Vasileiadis I, et al. Electrical muscle stimulation prevents critical illness polyneuromyopathy : a randomized parallel intervention trial. Crit Care 2010 ; 14 : R74.
PubMed
55) Maffiuletti NA, Roig M, Karatzanos E, et al. Neuromuscular electrical stimulation for preventing skeletal-muscle weakness and wasting in critically ill patients : a systematic review. BMC Med 2013 ; 11 : 137.
PubMed
56) Burke D, Gorman E, Stokes D, et al. An evaluation of neuromuscular electrical stimulation in critical care using the ICF framework : a systematic review and meta-analysis. Clin Respir J 2014 ; Oct 29.
 
57) Kress JP, Hall JB. ICU-acquired weakness and recovery from critical illness. N Engl J Med 2014 ; 370 : 1626-35.
PubMed
58) Hermans G, Van den Berghe G. Clinical review : intensive care unit acquired weakness. Crit Care 2015 ; 19 : 274.
 
P.664 掲載の参考文献
1) Kuwabara S, et al. Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome. Cochrane Database System Rev 2008 ; Oct 8 ; (4) : CD006828.
 
2) Nakanishi T, Sobue I, Toyokura Y, et al. The Crow-Fukase syndrome : a study of 102 cases in Japan. Neurology 1984 ; 34 : 712-20.
PubMed
3) 納光弘, 他. Crow-Fukase症候群の全国疫学調査 2004. 厚生労働省免疫性神経に関する調査研究班平成16年度報告書. p141-4.
 
4) Watanabe O, Arimura K, Kitajima I, et al. Greatly raised vascular endothelial growth factor (VEGF) in POEMS syndrome. Lancet 1996 ; 347 : 702.
PubMed
5) Abe D, Nakaseko C, Takeuchi M, et al. Restrictive usage of monoclonal immunoglobulin lambda light chain germline in POEMS syndrome. Blood 2008 ; 112 : 836-9.
PubMed
6) Kuwabara S, Hattori T, Shimoe Y, et al. Long term melphalan-prednisolone chemotherapy for POEMS syndrome. Neurol Neurosurg Psychiatry 1997 ; 63 : 385-7.
PubMed
7) 桑原聡, 三澤園子. Crow-Fukase症候群の新規治療展望. Annual Review 神経 2007, 中外医学社, p214-20.
 
8) Wong VA, Wade NK. POEMS syndrome : an unusual cause of bilateral optic disk swelling. Am J Ophthalmol 1998 ; 126 : 452-4.
PubMed
9) Jaccard A, Royer B, Bordessoule D, et al. High-dose therapy and autologous blood stem cell transplantation in POEMS syndrome. Blood 2002 ; 99 : 3057-9.
PubMed
10) Dispenzieri A, et al. Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome, and a review of the literature. Blood 2004 ; 104 : 3400-7.
 
11) Kuwabara S, et al. Autologous peripheral blood stem cell transplantation for POEMS syndrome. Neurology 2006 ; 66 : 105-7.
PubMed
12) Kuwabara S, et al. Neurologic improvement after peripheral blood stem cell transplantation in POEMS syndrome. Neurology 2008 ; 71 : 1691-5.
PubMed
13) Kuwabara S, et al. Thalidomide reduces serum VEGF levels and improves peripheral neuropathy in POEMS syndrome. J Neurol Neurosurg Psychiatry 2008 ; 79 : 1255-7.
PubMed
14) Dispenzieri A, et al. Lenalidomide therapy in a patient with POEMS syndrome. Blood 2007 ; 110 : 1075-6.
 
15) Kanai K, et al. Failure of treatment with anti-VEGF monoclonal antibody for long-standing POEMS syndrome. Intern Med 2007 ; 46 : 311-3.
PubMed

第14章 筋疾患

P.670 掲載の参考文献
1) 本村政勝, 他. 重症筋無力症の自己抗体. Brain Nerve 2013 ; 65 : 433-9.
 
2) Shiraishi H, Motomura M, Yoshimura T, et al. Acetilcholine receptor loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. Ann Neurol 2005 ; 57 : 289-93.
 
3) 村井弘之, 山下夏美. 重症筋無力症の疫学 厚生労働省免疫性神経疾患に関する調査研究班臨床疫学調査結果から. 脳 2008 ; 21 (11) : 55-9.
 
4) Gronseth GS, Barohn RJ. Practice parameter : thymectomy for autoimmune myasthenia gravis (an evidence-based review) : report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000 ; 55 : 7-15.
PubMed
5) Blalock A, Mason MF, Morgan HJ, et al. Myasthenia Gravis and tumors of the thymic region. Report of a case in which the tumor was removed. Ann Surg 1939 ; 110 : 544-61.
PubMed
6) Blalock A. Thymectomy in the treatment of myasthenia gravis. Report of twenty cases. J Thorac Surg 1944 ; 13 : 316-39.
 
7) Masaoka A, Yamakawa Y, Niwa H, et al. Extended thymectomy for myasthenia gravis patients : a 20 year review. Ann Thorac Surg 1996 ; 62 : 853-9.
PubMed
8) Lauriola L, Ranelletti F, Maggiano N, et al. Thymus change in anti-MuSK-positive and-negative myasthenia gravis. Neurology 2005 ; 64 : 536-8.
 
9) Leite MI, Strobel P, Jones M, et al. Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG. Ann Neurol 2005 ; 57 : 444-8.
PubMed
10) Mann JD, Johns TR, Campa JF, et al. Long-term administration of corticosteroids in myasthenia gravis. Neurology 1976 ; 26 : 729-740.
PubMed
11) Cosi V, Citterio A, Lombardi M, et al. Effectiveness of steroi treatment in myasthenia gravis : a retrospective study. Acta Neurol Scand 1991 ; 84 : 33-9.
 
12) Yamaguchi Y, Saito Y, Baba M, et al. Favorable results of thymectomy combined with prednisolone alternate-day administration in myasthenia gravis Jpn J Surg 1987 ; 17 : 14-20.
PubMed
13) Pascuzzi RM, Coslett HB, Johns TR. Long-Term corticosteroid treatment of Myasthenia Gravis : report of 116 patients. Ann Neurol 1984 ; 15 : 291-8.
PubMed
14) 新井洋, 伊藤直樹, 平山恵造. 全身型重症筋無力症に対するステロイド・胸腺摘除併用療法の長期効果. 神経治療 1995 ; 12 : 437-43.
 
15) Evoli A, Batocchi AP, Palmisani MT, et al. Long-term results of corticosteroid therapy in patients with myasthenia gravis. Eur Neurol 1992 ; 32 : 37-43.
PubMed
16) 若田宣雄, 根本博, 新妻正道, 他. 重症筋無力症とステロイド・ホルモン療法-減量, 投与時期の変更により改善する症例を含めて-. 臨床神経 1992 ; 32 : 131-7.
 
17) Truhan AP, Ahmed AR. Corticosteroids : a review with emphasis on complications of prolonged systemic therapy. Ann Allergy 1989 ; 62 : 375-91.
PubMed
18) Brown ES, Suppes T. Mood symptoms during corticosteroid therapy : a review. Harv Rev Psychiatry. 199 ; 5 : 239-46.
 
19) Masuda M, Utsugisawa K, Suzuki S, et al. The MG-QOL15 Japanese version : validation and associations with clinical factors. Muscle Nerve. 2012 ; 46 : 166-73.
PubMed
20) Masuda M, et al. Self-perceived quality of life and related clinical conditions in Japanese partients with myathenia gravis : a multicenter cross-sectionalstudy. Neurology 2013 ; 80 (Meeting Abstracts P02.198).
 
21) Nagane Y, et al. Impact of 'achieving minimal manifestrations or better status with predonisolon ≦ 5mg/day' in MG patients on self-perceived quality of life : amulticenter follow-up study. Neurology 2013 ; 80 (Meeting Abstructs P02.202).
 
22) Nagane Y, Suzuki S, Suzuki N, et al. Early aggressive treatment strategy against myasthenia gravis. Eur Neurol 2011 ; 65 : 16-22.
PubMed
23) 鬼島正典, 小宮山純, 平山恵造. 難治性眼筋型重症筋無力症小児例に対するmethylprednisolone pulse療法. 神経治療 1988 ; 5 : 383-8.
 
24) Tindall RS, Phillips JT, Rollins JA, et al. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann NY Acad Sci 1993 ; 681 : 539-51.
PubMed
25) Ciafaloni E, Nikhar NK, Massey JM, et al. Retrospective analysis of the use of cyclosporine in myasthenia gravis. Neurology 2000 ; 55 : 448-50.
PubMed
26) Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology 1998 ; 50 : 1778-83.
PubMed
27) Gajdos P, Chevret S, Toyka K. Plasma exchange for myasthenia gravis. Cochrane Database Syst Rev 2002 ; (4) : CD002275.
PubMed
28) Gajdos P, Chevret S, Toyka K. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev 2008 ; (1) : CD002277.
PubMed
29) Nelson RP Jr, Pascuzzi RM, Kessler K, et al. Rituximab for the treatment of thymoma-associated and de novo myasthenia gravis : 3 cases and review. J Clin Neuromuscul Dis 2009 ; 10 : 170-7.
PubMed
30) Chaudhuri A, Behan PO. Myasthenic crisis. Q J M 2009 ; 102 : 97-107.
 
31) Lawrence HP II, James CT. Epidemiologic evidence for a changing natural history of myasthenia gravis. Neurology 1996 ; 47 : 1233-8.
 
32) Murai H, Masuda M, Utsugisawa K, et al. Clinical features and treatment status of adult myasthenia gravis in Japan. Clin Exp Neuroimmunol 2014 ; 5 : 84-91.
 
P.674 掲載の参考文献
1) Titulaer MJ, Lang B, Verschuuren JJ. Lambert-Eaton myasthenic syndrome : from clinical characteristics to therapeutic strategies. Lancet Neurol 2011 ; 10 : 1098-107.
PubMed
2) Nakao YK, Motomura M, Fukudome T, et al. Seronegative Lambert-Eaton myasthenic syndrome : study of 110 Japanese patients. Neurology 2002 ; 59 : 1773-5.
PubMed
3) Wirtz PW, Sotodeh M, Nijnuis M, et al. Difference in distribution of muscle weakness between myasthenia gravis and the Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 2002 ; 73 : 766-8.
PubMed
4) Fukuda T, Motomura M, Nakao Y, et al. Reduction of P/Q-type calcium channels in the postmortem cerebellum of paraneoplastic cerebellar degeneration with Lambert-Eaton myasthenic syndrome. Ann Neurol 2003 ; 53 : 21-8.
PubMed
5) Zivkovic SA, Shipe C. Use of repetitive nerve stimulation in the evaluation of neuromuscular junction disorders. Am J Electroneurodiagnostic Technol 2005 ; 45 : 248-61.
PubMed
6) AAEM Quality Assurance Committee. American Association of Electrodiagnostic Medicine. Literature review of the usefulness of repetitive nerve stimulation and single fiber EMG in the electrodiagnostic evaluation of patients with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome. Muscle Nerve 2001 ; 24 : 1239-47.
PubMed
7) Shibayama T, Ueoka H, Nishii K, et al. Complementary Roles of pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC). Lung Cancer 2001 ; 32 : 61-9.
PubMed
8) Newsom-Davis J. A treatment algorithm for Lambert-Eaton myasthenic syndrome. Ann N Y Acad Sci 1998 ; 841 : 817-22.
PubMed
9) Maddison P, Newsom-Davis J. Treatment for Lambert-Eaton myasthenic syndrome. Cochrane Database Syst Rev 2005 ; 18 : CD003279.
 
10) McEvoy KM, Windebank AJ, Daube JR, et al. 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. N Engl J Med 1989 ; 321 : 1567-71.
PubMed
11) Sanders DB, Massey JM, Sanders LL, et al. A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome. Neurology 2000 ; 54 : 603-7.
PubMed
12) Newsom-Davis J, Murray NM. Plasma Exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome. Neurology 1984 ; 34 : 480-5.
PubMed
13) Bain PG, Motomura M, Newsom-Davis J, et al. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology 1996 ; 47 : 678-83.
PubMed
14) Pellkofer HL, Voltz R, Kuempfel T. Favorable response to rituximab in a patient with anti-VGCC-positive Lambert-Eaton myasthenic syndrome and cerebellar dysfunction. Muscle Nerve 2009 ; 40 : 305-8.
 
15) Tarr TB, Malick W, Liang M, et al. Evaluation of a novel calcium channel agonist for therapeutic potential in Lambert-Eaton myasthenic syndrome. J Neurosci. 2013 19 ; 33 : 10559-67.
 
16) Maddison P, Newsom-Davis J, Mills KR, et al. Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma. Lancet 1999 ; 353 : 117-8.
PubMed
17) Maddison P, Lang B, Mills K, et al. Long term outcome in Lambert-Eaton myasthenic syndrome without lung cancer. J Neurol Neurosurg Psychiatry 2001 ; 70 : 212-7.
PubMed
P.681 掲載の参考文献
1) Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975 ; 292 : 344-7.
PubMed
2) Hoogendijk J, Amato A, Lecky B, Choy E, et al. 119th ENMC international workshop : trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscular disorders : NMD 2004 ; 14 : 337-45.
PubMed
3) 難治性疾患等政策研究事業 厚, 自己免疫疾患に関する調査研究班, 多発性筋炎・皮膚筋炎文科会. 多発性筋炎・皮膚筋炎治療ガイドライン. 診断と治療社, 東京, 2015.
 
4) Dalakas MC. Inflammatory muscle diseases. N Engl J Med 2015 ; 372 : 1734-47.
PubMed
5) Luo YB, Mastaglia FL. Dermatomyositis, polymyositis and immune-mediated necrotising myopathies. Biochim Biophy Acta 2015 ; 1852 : 622-32.
 
6) van der Meulen MF, Bronner IM, Hoogendijk JE, et al. Polymyositis : an overdiagnosed entity. Neurology 2003 ; 61 : 316-21.
PubMed
7) Kassardjian CD, Lennon VA, Alfugham NB, et al. Clinical Features and Treatment Outcomes of Necrotizing Autoimmune Myopathy. JAMA Neurol 2015 ; 72 : 996-1003.
PubMed
8) Ernste FC, Reed AM. Idiopathic inflammatory myopathies : current trends in pathogenesis, clinical features, and up-to-date treatment recommendations. Mayo Clin Proc 2013 ; 88 : 83-105.
PubMed
9) Dalakas MC. Immunotherapy of myositis : issues, concerns and future prospects. Nature reviews. Rheumatology 2010 ; 6 : 129-37.
PubMed
10) Oddis CV, Sciurba FC, Elmagd KA, et al. Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet 1999 ; 353 : 1762-3.
PubMed
11) Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003 ; 362 : 971-82.
PubMed
12) Dalakas MC. Review : An update on inflammatory and autoimmune myopathies. Neuropathol Appl Neurobiol 2011 ; 37 : 226-42.
PubMed
13) Mastaglia FL, Zilko PJ. Inflammatory myopathies : how to treat the difficult cases. J Clin Neurosci 2003 ; 10 : 99-101.
 
14) Dalakas MC, Sonies B, Dambrosia J, et al. Treatment of inclusion-body myositis with IVIg : a double-blind, placebo-controlled study. Neurology 1997 ; 48 : 712-6.
PubMed
15) Cherin P, Pelletier S, Teixeira A, et al. Intravenous immunoglobulin for dysphagia of inclusion body myositis. Neurology 2002 ; 58 : 326.
PubMed
16) Dalakas MC, Rakocevic G, Schmidt J, et al. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain 2009 ; 132 : 1536-44.
 
17) Amato AA, Sivakumar K, Goyal N, et al. Treatment of sporadic inclusion body myositis with bimagrumab. Neurology 2014 ; 83 : 2239-46.
PubMed
18) Rose MR, Jones K, Leong K, et al. Treatment for inclusion body myositis. Cochrane Database Syst Rev 2015 ; 6 : CD001555.
 
19) Henriksson KG, Lindvall B. Polymyositis and dermatomyositis 1990-diagnosis, treatment and prognosis. Prog Neurobiol 1990 ; 35 : 181-93.
PubMed
20) Bunch TW, Worthington JW, Combs JJ, et al. Azathioprine with prednisone for polymyositis. A controlled, clinical trial. Ann Intern Med 1980 ; 92 : 365-9.
PubMed
21) Bunch TW. Prednisone and azathioprine for polymyositis : long-term followup. Arthritis Rheum 1981 ; 24 : 45-8.
PubMed
22) Schiopu E, Phillips K, MacDonald PM, et al. Predictors of survival in a cohort of patients with polymyositis and dermatomyositis : effect of corticosteroids, methotrexate and azathioprine. Arthritis Res Ther. 2012 ; 14 : R22.
 
23) Yu KH, Wu YJ, Kuo CF, et al. Survival analysis of patients with dermatomyositis and polymyositis : analysis of 192 Chinese cases. Clin Rheumatol 2011 ; 30 : 1595-601.
PubMed
24) Metzger AL, Bohan A, Goldberg LS, et al. Polymyositis and dermatomyositis : combined methotrexate and corticosteroid therapy. Ann Intern Med 1974 ; 81 : 182-9.
PubMed
25) Wedderburn LR, Rider LG. Juvenile dermatomyositis : new developments in pathogenesis, assessment and treatment. Best Prac Res Clin Rheumatol 2009 ; 23 : 665-78.
 
26) Hasija R, Pistorio A, Ravelli A, et al. Therapeutic approaches in the treatment of juvenile dermatomyositis in patients with recent-onset disease and in those experiencing disease flare : an international multicenter PRINTO study. Arthritis Rheum 2011 ; 63 : 3142-52.
PubMed
27) Joffe MM, Love LA, Leff RL, et al. Drug therapy of the idiopathic inflammatory myopathies : predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med 1993 ; 94 : 379-87.
 
28) Vencovsky J, Jarosova K, Machacek S, et al. Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol 2000 ; 29 : 95-102.
PubMed
29) Takada K, Nagasaka K, Miyasaka N. Polymyositis/dermatomyositis and interstitial lung disease : a new therapeutic approach with T-cell-specific immunosuppressants. Autoimmunity 2005 ; 38 : 383-92.
 
30) Kotani T, Takeuchi T, Makino S, et al. Combination with corticosteroids and cyclosporin-A improves pulmonary function test results and chest HRCT findings in dermatomyositis patients with acute/subacute interstitial pneumonia. Clin Rheumatol 2011 ; 30 : 1021-8.
PubMed
31) Kotani T, Makino S, Takeuchi T, et al. Early intervention with corticosteroids and cyclosporin A and 2-hour postdose blood concentration monitoring improves the prognosis of acute/subacute interstitial pneumonia in dermatomyositis. J Rheumatol 2008 ; 35 : 254-9.
PubMed
32) Ingegnoli F, Lubatti C, Ingegnoli A, et al. Interstitial lung disease outcomes by high-resolution computed tomography (HRCT) in Anti-Jo1 antibody-positive polymyositis patients : a single centre study and review of the literature. Autoimmun Rev 2012 ; 11 : 335-40.
PubMed
33) Wilkes MR, Sereika SM, Fertig N, et al. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum 2005 ; 52 : 2439-46.
PubMed
34) Hassan J, van der Net JJ, van Royen-Kerkhof A. Treatment of refractory juvenile dermatomyositis with tacrolimus. Clin Rheumatol 2008 ; 27 : 1469-71.
PubMed
35) Hollar CB, Jorizzo JL. Topical tacrolimus 0.1% ointment for refractory skin disease in dermatomyositis : a pilot study. J Dermatolog Treat 2004 ; 15 : 35-9.
 
36) Ando M, Miyazaki E, Yamasue M, et al. Successful treatment with tacrolimus of progressive interstitial pneumonia associated with amyopathic dermatomyositis refractory to cyclosporine. Clin Rheumatol 2010 ; 29 : 443-5.
PubMed
37) Mitsui T, Kuroda Y, Ueno S, et al. The effects of FK506 on refractory inflammatory myopathies. Acta Neurol Belg 2011 ; 111 : 188-94.
PubMed
38) Yamasaki Y, Yamada H, Yamasaki M, et al. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology (Oxford) 2007 ; 46 : 124-30.
PubMed
39) Riley P, Maillard SM, Wedderburn LR, et al. Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety. Rheumatology (Oxford) 2004 ; 43 : 491-6.
PubMed
40) al-Janadi M, Smith CD, Karsh J. Cyclophosphamide treatment of interstitial pulmonary fibrosis in polymyositis/dermatomyositis. J Rheumatol 1989 ; 16 : 1592-6.
PubMed
41) Rowin J, Amato AA, Deisher N, et al. Mycophenolate mofetil in dermatomyositis : is it safe? Neurology 2006 ; 66 : 1245-7.
PubMed
42) Majithia V, Harisdangkul V. Mycophenolate mofetil (CellCept) : an alternative therapy for autoimmune inflammatory myopathy. Rheumatology (Oxford) 2005 ; 44 : 386-9.
PubMed
43) Pisoni CN, Cuadrado MJ, Khamashta MA, et al. Mycophenolate mofetil treatment in resistant myositis. Rheumatology (Oxford) 2007 ; 46 : 516-8.
PubMed
44) Danieli MG, Calcabrini L, Calabrese V, et al. Intravenous immunoglobulin as add on treatment with mycophenolate mofetil in severe myositis. Autoimmun Rev 2009 ; 9 : 124-7.
PubMed
45) Gelber AC, Nousari HC, Wigley FM. Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis : a series of 4 cases. J Rheumatol 2000 ; 27 : 1542-5.
 
46) Edge JC, Outland JD, Dempsey JR, et al. Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis. Arch Dermatol 2006 ; 142 : 65-9.
PubMed
47) Rouster-Stevens KA, Morgan GA, Wang D, et al. Mycophenolate mofetil : a possible therapeutic agent for children with juvenile dermatomyositis. Arthritis Care Res (Hoboken) 2010 ; 62 : 1446-51.
PubMed
48) Waldman MA, Callen JP. Self-resolution of Epstein-Barr virus-associated B-cell lymphoma in a patient with dermatomyositis following withdrawal of mycophenolate mofetil and methotrexate. J Am Acad Dermatol 2004 ; 51 : S124-30.
 
49) Saketkoo LA, Espinoza LR. Experience of mycophenolate mofetil in 10 patients with autoimmune-related interstitial lung disease demonstrates promising effects. Am J Med Sci 2009 ; 337 : 329-35.
PubMed
50) Swigris JJ, Olson AL, Fischer A, et al. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest 2006 ; 130 : 30-6.
PubMed
51) Morganroth PA, Kreider ME, Werth VP. Mycophenolate mofetil for interstitial lung disease in dermatomyositis. Arthritis Care Res (Hoboken) 2010 ; 62 : 1496-501.
PubMed
52) Valiyil R, Casciola-Rosen L, Hong G, et al. Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies : a case series. Arthritis Care Res (Hoboken) 2010 ; 62 : 1328-34.
PubMed
53) Deligny C, Goeb V, Dueymes M, et al. Rituximab for patients with myopathy associated with anti-signal recognition particle antibodies : comment on the article by Valiyil et al. Arthritis Care Res (Hoboken) 2011 ; 63 : 460 ; author reply 461.
 
54) Whelan BR, Isenberg DA. Poor response of anti-SRP-positive idiopathic immune myositis to B-cell depletion. Rheumatology (Oxford) 2009 ; 48 : 594-5.
 
55) Arlet JB, Dimitri D, Pagnoux C, et al. Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP). Neuromuscul Disord 2006 ; 16 : 334-6.
 
56) Mahler EA, Blom M, Voermans NC, et al. Rituximab treatment in patients with refractory inflammatory myopathies. Rheumatology (Oxford) 2011 ; 50 : 2206-13.
PubMed
57) Mok CC, Ho LY, To CH. Rituximab for refractory polymyositis : an open-label prospective study. J Rheumatol 2007 ; 34 : 1864-8.
PubMed
58) Rios Fernandez R, Callejas Rubio JL, et al. Rituximab in the treatment of dermatomyositis and other inflammatory myopathies. A report of 4 cases and review of the literature. Clin Exp Rheumatol 2009 ; 27 : 1009-16.
PubMed
59) Oddis CV, Reed AM, Aggarwal R, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis : a randomized, placebo-phase trial. Arthritis Rheum 2013 ; 65 : 314-24.
PubMed
60) Aggarwal R, Bandos A, Reed AM, et al. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol 2014 ; 66 : 740-9.
PubMed
61) Levine TD. Rituximab in the treatment of dermatomyositis : an open-label pilot study. Arthritis Rheum 2005 ; 52 : 601-7.
PubMed
62) Cooper MA, Willingham DL, Brown DE, et al. Rituximab for the treatment of juvenile dermatomyositis : a report of four pediatric patients. Arthritis Rheum 2007 ; 56 : 3107-111.
PubMed
63) Chiu YE, Co DO. Juvenile dermatomyositis : immunopathogenesis, role of myositis-specific autoantibodies, and review of rituximab use. Pediatr Dermatol 2011 ; 28 : 357-67.
PubMed
64) Chung L, Genovese MC, Fiorentino DF. A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol 2007 ; 143 : 763-7.
PubMed
65) Labioche I, Liozon E, Weschler B, et al. Refractory polymyositis responding to infliximab : extended follow-up. Rheumatology (Oxford) 2004 ; 43 : 531-2.
PubMed
66) Efthimiou P, Schwartzman S, Kagen LJ. Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis : a retrospective study of eight patients. Ann Rheum Dis 2006 ; 65 : 1233-6.
PubMed
67) Dastmalchi M, Grundtman C, Alexanderson H, et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 2008 ; 67 : 1670-7.
 
68) Hengstman GJ, De Bleecker JL, Feist E, et al. Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate. Eur Neurol 2008 ; 59 : 159-63.
PubMed
69) Sprott H, Glatzel M, Michel BA. Treatment of myositis with etanercept (Enbrel), a recombinant human soluble fusion protein of TNF-alpha type II receptor and IgG1. Rheumatology (Oxford) 2004 ; 43 : 524-6.
PubMed
70) Iannone F, Scioscia C, Falappone PC, et al. Use of etanercept in the treatment of dermatomyositis : a case series. J Rheumatol 2006 ; 33 : 1802-4.
 
71) Group MS. A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol 2011 ; 70 : 427-36.
 
72) Ishikawa Y, Yukawa N, Ohmura K, et al. Etanercept-induced anti-Jo-1-antibody-positive polymyositis in a patient with rheumatoid arthritis : a case report and review of the literature. Clin Rheumatol 2010 ; 29 : 563-6.
 
73) Klein R, Rosenbach M, Kim EJ, et al. Tumor necrosis factor inhibitor-associated dermatomyositis. Arch Dermatol 2010 ; 146 : 780-4.
PubMed
74) Riolo G, Towheed TE. Anti-tumor necrosis factor inhibitor therapy-induced dermatomyositis and fasciitis. J Rheumatol 2012 ; 39 : 192-4.
PubMed
76) Thompson B, Corris P, Miller JA, et al. Alemtuzumab (Campath-1H) for treatment of refractory polymyositis. J Rheumatol 2008 ; 35 : 2080-2.
PubMed
77) Gordon PA, Winer JB, Hoogendijk JE, et al. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev 2012 ; 8 : CD003643.
PubMed
78) Narazaki M, Hagihara K, Shima Y, et al. Therapeutic effect of tocilizumab on two patients with polymyositis. Rheumatology (Oxford) 2011 ; 50 : 1344-6.
PubMed
79) Zong M, Dorph C, Dastmalchi M, et al. Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers : a mechanistic study with 12 months follow-up. Ann Rheum Dis 2014 ; 73 : 913-20.
PubMed
80) Elovaara I, Apostolski S, van Doorn P, et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases : EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol 2008 ; 15 : 893-908.
PubMed
81) Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993 ; 329 : 1993-2000.
PubMed
82) Kampylafka EI, Kosmidis ML, Panagiotakos DB, et al. The effect of intravenous immunoglobulin (IVIG) treatment on patients with dermatomyositis : a 4-year follow-up study. Clin Exp Rheumatol 2012 ; 30 : 397-401.
PubMed
83) Lam CG, Manlhiot C, Pullenayegum EM, et al. Efficacy of intravenous Ig therapy in juvenile dermatomyositis. Ann Rheum Dis 2011 ; 70 : 2089-94.
PubMed
84) Danieli MG, Malcangi G, Palmieri C, et al. Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis. Ann Rheum Dis 2002 ; 61 : 37-41.
PubMed
85) Cherin P, Pelletier S, Teixeira A, et al. Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis : an open study with thirty-five adult patients. Arthritis Rheum 2002 ; 46 : 467-74.
PubMed
86) Danieli MG, Pettinari L, Moretti R, et al. Subcutaneous immunoglobulin in polymyositis and dermatomyositis : a novel application. Autoimmun Rev 2011 ; 10 : 144-9.
PubMed
87) Suzuki Y, Hayakawa H, Miwa S, et al. Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis. Lung 2009 ; 187 : 201-6.
PubMed
88) Marie I, Menard JF, Hatron PY, et al. Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis : a series of 73 patients. Arthritis Care Res (Hoboken) 2010 ; 62 : 1748-55.
PubMed
89) Diot E, Carmier D, Marquette D, et al. IV immunoglobulin might be considered as a first-line treatment of severe interstitial lung disease associated with polymyositis. Chest 2011 ; 140 : 562-3.
PubMed
90) Bakewell CJ, Raghu G. Polymyositis associated with severe interstitial lung disease : remission after three doses of IV immunoglobulin. Chest 2011 ; 139 : 441-3.
PubMed
91) Manlhiot C, Tyrrell PN, Liang L, et al. Safety of intravenous immunoglobulin in the treatment of juvenile dermatomyositis : adverse reactions are associated with immunoglobulin A content. Pediatrics 2008 ; 121 : e626-30.
PubMed
92) Miller FW, Leitman SF, Cronin ME, et al. Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med 1992 ; 326 : 1380-4.
PubMed
93) Alexanderson H. Exercise in inflammatory myopathies, including inclusion body myositis. Curr Rheumatol Rep 2012 ; 14 : 244-251.
PubMed
94) Taborda AL, Azevedo P, Isenberg DA. Retrospective analysis of the outcome of patients with idiopathic inflammatory myopathy : a long-term follow-up study. Clin Exp Rheumatol 2014 ; 32 : 188-93.
PubMed
75 Brunasso AM, Scocco GL, Massone C. Dermatomyositis during adalimumab therapy for rheumatoid arthritis. J Rheumatol 2010 ; 37 : 1549-50.
PubMed
P.687 掲載の参考文献
1) 筋ジストロフィー治療のエビデンス構築に関する臨床研究班. 筋ジストロフィーの心不全治療マニュアル-エビデンスと戦略-. 2008.
 
2) 筋ジストロフィーの治療と医学的管理に関する研究班. 筋ジストロフィーにおける脊柱変形の治療・ケアマニュアル. 2004.
 
3) Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1 : diagnosis, and pharmacological and psychosocial management. Lancet Neurology 2010 ; 9 : 77-93.
PubMed
4) Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2 : implementation of multidisciplinary care. Lancet Neurology 2010 ; 9 : 177-89.
PubMed
5) デュシェンヌ型筋ジストロフィー診療ガイドライン 2014. 日本神経学会, 日本小児神経学会, 国立精神・神経医療研究センター監修, 医学書院, 2014.
 
P.693 掲載の参考文献
1) Hoffman EP, Brown RH, Kunkel LM. Dystrophin : the protein product of the Duchenne muscular dystrophy locus. Cell 1987 ; 51 : 919-28.
PubMed
2) Theadom A, Rodrigues M, Roxburgh R, et al. Prevalence of muscular dystrophies : a systematic literature review. Neuroepidemiology 2014 ; 43 : 259-68.
PubMed
3) Koenig M, Beggs AH, Moyer M, et al. The molecular basis for Duchenne versus Becker muscular dystrophy : correlation of severity with type of deletion. Am J Hum Genet 1989 ; 45 : 498-506.
PubMed
4) Aartsma-Rus A, Fokkema I, Verschuuren J, et al. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat 2009 ; 30 : 293-9.
PubMed
5) Monaco AP, Bertelson CJ, Liechti-Gallati S, Moser H, Kunkel LM. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 1988 ; 2 : 90-5.
PubMed
6) Tuffery-Giraud S, Beroud C, Leturcq F, et al. Genotype-phenotype analysis in 2,405 patients with a dystrophinopathy using the UMD-DMD database : a model of nationwide knowledgebase. Hum Mutat 2009 ; 30 : 934-45.
 
7) デュシェンヌ型筋ジストロフィー診療ガイドライン 2014. 日本神経学会, 日本小児神経学会, 国立精神・神経医療研究センター, 南江堂, 東京, 2014.
 
8) Summerton J, Stein D, Huang SB, et al. Morpholino and phosphorothioate antisense oligomers compared in cell-free and in-cell systems. Antisense Nucleic Acid Drug Dev 1997 ; 7 : 63-70.
PubMed
9) Hudziak RM, Barofsky E, Barofsky DF, et al. Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation. Antisense Nucleic Acid Drug Dev 1996 ; 6 : 267-72.
PubMed
10) Aoki Y, Nagata T, Yokota T, et al. Highly efficient in vivo delivery of PMO into regenerating myotubes and rescue in laminin-α2 chain-null congenital muscular dystrophy mice. Hum Mol Genet 2013 ; 22 : 4914-28.
 
11) Aoki Y, Nakamura A, Yokota T, et al. In-frame Dystrophin Following Exon 51-Skipping Improves Muscle Pathology and Function in the Exon 52-Deficient mdx Mouse. Mol Ther 2010 ; 18 : 1995-2005.
PubMed
12) Aoki Y, Yokota T, Nagata T, et al. Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery. Proc Natl Acad Sci U S A 2012 ; 109 : 13763-8.
PubMed
13) Yokota T, Lu QL, Partridge T, et al. Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. Ann Neurol 2009 ; 65 : 667-76.
PubMed
14) Yokota T, Nakamura A, Nagata T, et al. Extensive and prolonged restoration of dystrophin expression with vivo-morpholino-mediated multiple exon skipping in dystrophic dogs. Nucleic Acid Ther 2012 ; 22 : 306-15.
PubMed
15) Saito T, Nakamura A, Aoki Y, et al. Antisense PMO found in dystrophic dog model was effective in cells from exon 7-deleted DMD patient. PLoS One 2010 ; 5 : e12239.
PubMed
16) Voit T, Topaloglu H, Straub V, et al. Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II) : an exploratory, randomised, placebo-controlled phase 2 study. Lancet Neurol 2014 ; 13 : 987-96.
 
17) Goemans NM, Tulinius M, van den Akker JT, et al. Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med 2011 ; 364 : 1513-22.
PubMed
18) Mendell JR, Rodino-Klapac LR, Sahenk Z, et al ; Eteplirsen Study Group. Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol 2013 ; 74 : 637-47.
 
19) Ezzat K, Aoki Y, Koo T, et al. Self-Assembly into Nanoparticles Is Essential for Receptor Mediated Uptake of Therapeutic Antisense Oligonucleotides. Nano Lett 2015 ; 15 : 4364-73.
PubMed
20) 青木吉嗣, 武田伸一. デュシェンヌ型筋ジストロフィーに対するエクソンスキップ療法. In ; 生体の科学, 医学書院, 東京, 2011, p128-33.
 
P.699 掲載の参考文献
1) Fukuyama Y, Osawa M, Suzuki H. Congenital progressive muscular dystrophy of the Fukuyama type- clinical, genetic and pathological considerations. Brain Dev 1981 ; 3 : 1-29.
PubMed
2) Murakami T, Ishigaki K, Shirakawa S, et al. Severe muscle damage following viral infection in patients with Fukuyama congenital muscular dystrophy. Brain Dev 2012 ; 34 : 293-7.
PubMed
3) Nakano I, Funahashi M, Takada K, et al. Are breaches in the glia limitans the primary cause of the micropolygyria in Fukuyama-type congenital muscular dystrophy (FCMD) ? Pathological study of the cerebral cortex of an FCMD fetus. Acta Neuropathol 1996 ; 91 : 313-21.
PubMed
4) Kobayashi K, Nakahori Y, Miyake M, et al. An ancient retrotransposal insertion causes Fukuyama-type congenital muscular dystrophy. Nature 1998 ; 394 : 388-92.
PubMed
5) Godfrey C, Foley AR, Clement E, et al. Dystroglycanopathies : coming into focus. Curr Opin Genet Dev 2011 ; 21 : 278-85.
PubMed
6) Yoshida-Moriguchi T, Campbell KP. Matriglycan : a novel polysaccharide that links dystroglycan to the basement membrane. Glycobiology 2015 ; 25 : 702-13.
 
7) Kondo-Iida E, Kobayashi K, Watanabe M, et al. Novel mutations and genotype-phenotype relationships in 107 families with Fukuyama-type congenital muscular dystrophy (FCMD). Hum Mol Genet 1999 ; 8 : 2303-9.
PubMed
8) Murakami T, Hayashi YK, Noguchi S, et al. Fukutin gene mutations cause dilated cardiomyopathy with minimal muscle weakness. Ann Neurol 2006 ; 60 : 597-602.
PubMed
9) Taniguchi-Ikeda M, Kobayashi K, Kanagawa M, et al. Pathogenic exon-trapping by SVA retrotransposon and rescue in Fukuyama muscular dystrophy. Nature 2011 ; 478 : 127-31.
PubMed
P.703 掲載の参考文献
1) 川井充, 編. 筋強直性ジストロフィーの治療とケア, 医学書院, 2000.
 
2) Harper PS, van Engelen B, Eymard B, Wilcox DE, eds. Myotonic dystrophy : present management and future therapy. Oxford University Press, Oxford, 2004.
 
3) 筋ジストロフィー治療のエビデンス構築に関する臨床研究班. 強直性ジストロフィーにおける診断・治療マニュアル, 2008.
 
P.706 掲載の参考文献
1) Venance SL, Cannon SC, Fialho D, et al. The primary periodic paralyses : diagnosis, pathogenesis and treatment. Brain 2006 ; 129 : 8-17.
PubMed
2) Cleland JC, Griggs RC. Treatment of neuromuscular channelopathies : current concepts and future prospects. Neurotherapeutics 2008 ; 5 : 607-612.
PubMed
3) Finsterer J. Primary periodic paralyses. Acta Neurol Scand 2008 ; 117 : 145-58.
PubMed
4) Lehmann-Horn F, Jurkat-Rott K, Rudel R. Ulm Muscle Centre. Diagnostics and therapy of muscle channelopathies-Guidelines of the Ulm Muscle Centre. Acta Myol 2008 ; 27 : 98-113.
PubMed
5) Kung AW. Clinical review : Thyrotoxic periodic paralysis : a diagnostic challenge. J Clin Endocrinol Metab 2006 ; 91 : 2490-5.
PubMed
6) Lin SH. Thyrotoxic periodic paralysis. Mayo Clin Proc 2005 ; 80 : 99-105.
PubMed
7) Sansone V, Tawil R. Management and treatment of Andersen-Tawil syndrome (ATS). Neurotherapeutics 2007 ; 4 : 233-7.
PubMed
8) Kuhn M, Jurkat-Rott K, Lehmann-Horn F. Rare KCNJ18 variants do not explain hypokalaemic periodic paralysis in 263 unrelated patients.J Neurol Neurosurg Psychiatry. 2015 e-pub.
PubMed
9) Sansone V, Meola G, Links TP, et al. Treatment for periodic paralysis. Cochrane Database Syst Rev 2008 ; (1) : CD005045.
PubMed
10) Fournier E, Arzel M, Sternberg D, et al. Electromyography guides toward subgroups of mutations in muscle channelopathies. Ann Neurol 2004 ; 56 : 650-61.
PubMed
11) Arimura K, Arimura Y. Clinical electrophysiologic tests and genotype correlations in muscle channelopathies. Suppl Clin Neurophysiol 2004 ; 57 : 283-7.
PubMed
12) Tassone H, Moulin A, Henderson SO. The pitfalls of potassium replacement in thyrotoxic periodic paralysis : a case report and review of the literature. J Emerg Med 2004 ; 26 : 157-61.
PubMed
13) Lin SH, Chiu JS, Hsu CW, et al. A simple and rapid approach to hypokalemic paralysis. Am J Emerg Med 2003 ; 21 : 487-91.
PubMed
14) Links TP, Zwarts MJ, Wilmink JT, et al. Permanent muscle weakness in familial hypokalaemic periodic paralysis. Clinical, radiological and pathological aspects. Brain 1990 ; 113 : 1873-89.
PubMed
15) Tawil R, McDermott MP, Brown R Jr, et al. Randomized trials of dichlorphenamide in the periodic paralyses. Working Group on Periodic Paralysis. Ann Neurol 2000 ; 47 : 46-53.
 
16) Links TP, Zwarts MJ, Oosterhuis HJ. Improvement of muscle strength in familial hypokalaemic periodic paralysis with acetazolamide. J Neurol Neurosurg Psychiatry 1988 ; 51 : 1142-5.
PubMed
17) Matthews E, Portaro S, Ke Q, et al. Acetazolamide efficacy in hypokalemic periodic paralysis and the predictive role of genotype. Neurology 2011 ; 77 : 1960-4.
PubMed
18) Ligtenberg JJ, Van Haeften TW, Van Der Kolk LE, et al. Normal insulin release during sustained hyperglycaemia in hypokalaemic periodic paralysis : role of the potassium channel opener pinacidil in impaired muscle strength. Clin Sci (Lond) 1996 ; 91 : 583-9.
PubMed
19) Fiore DM, Strober JB. Treatment of hypokalemic periodic paralysis with topiramate. Muscle Nerve 2011 ; 43 : 127-9.
PubMed
P.710 掲載の参考文献
1) Afifi AK, Bergman RA, Havey JC. Steroid myopathy, clinical, histologic and cytologic observation. Johns Hopkins Med J 1968 ; 123 : 158-76.
 
2) Schakman O, Glison H, Thissen JP. Mechanisms of glucocorticoid-induced myopathy. J Endocrinol 2008 ; 197 : 1-10.
 
3) Shimizu N, et al. Crosstalk between glucocorticoid receptor and nutritional sensor mTOR in skeletal muscle. Cell Metab 2011 ; 13 : 170-82.
PubMed
4) 下畑享良, 他. %クレアチン尿の有用性の再検討. 脳と神経 2006 ; 58 : 39-42.
 
5) 上山秀嗣. 低カリウム血性ミオパチー. 骨間筋症候群 (第2版) 下巻. 別冊日本臨牀 2015 ; 新領域別症候群シリーズ 33 : 282-6.
 
6) Shintani S, et al. Glycyrrhizin (Licorice) -induced hypokalemic myopathy. Report of 2 cases and review of the literature. Eur Neurol 1992 ; 32 : 44-51.
PubMed
7) Singel GG, Brenner BM. Hypokalemia. Harrison's Principes of Internal Medicine 15th ed, McGraw-Hill, 2001, p279-81.
 
P.715 掲載の参考文献
1) Narita A, Yasunaga T, Ishikawa T, et al. Ca (2+) -induced switching of troponin and tropomyosin on actin filaments as revealed by electron cryo-microscopy. J Mol Biol 2001 ; 308 : 241-61.
PubMed
2) Endo M, Yagi S, Ishizuka K, et al. Changes in the Ca-induced Ca release mechanism in the sarcoplasmic reticulum of the muscle from a patient with makignant hyperthermia. Biomed Res 1983 ; 4 ; 83-92.
 
3) Endo M, Tanaka M, Ogawa Y. Calcium induced release of calcium from the sarcoplasmic reticulum of skinned skeletal muscle fibres. Nature 1970 ; 228 : 34-6.
PubMed
4) 菊地博達. 悪性高熱症の発症機序・検査法と治療. 医事新報 1997 ; 3812 : 11-6.
Medical*Online
5) 松井一幸, 菊地博達. 体温 (体温下降, 悪性高熱症). 最新麻酔科学 下巻 改訂第2版 (稲田豊, 藤田昌雄, 山本亨, 編), 克誠堂出版, 東京, 1995, p1639-45.
 
6) Wappler F. Malignant hyperthermia. Eur J Anaesthesiol 2001 ; 18 : 632-52.
PubMed
7) 中尾正和. 悪性高熱症の発生頻度は? 医学の歩み1989 ; 148 : 404.
 
8) 向田圭子, 弓削孟文. 臨床症状-疫学. 悪性高熱症 (菊地博達, 編), 克誠堂出版, 東京, 2006, p67-72.
 
9) 向田圭子, 弓削孟文. 骨格筋検査. 悪性高熱症 (菊地博達, 編), 克誠堂出版, 東京, 2006, p153-98.
 
10) Ibarra CAM, Wu S, Murayama K, et al. Malignant hyperthermia in Japan : mutation screening of the entire ryanodine receptor type 1 gene coding region by direct sequencing. Anesthesiology 2006 ; 104 : 1146-54.
 
11) 盛生倫夫, 菊地博達, 弓削孟文, 他. 悪性高熱症診断基準の見直し. 麻酔と蘇生 1988 ; 24 (別冊 19) : 104-10.
 
12) Larach MG, Localio AR, Allen GC, et al. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology 1994 ; 80 : 771-9.
PubMed
13) Gronert GA, Pessah IN, Muldoon SM, et al. Malignant hyper thermia. In ; Miller RD, ed. Miller's Anesthesia Vol1 Sixth edition. New York, Churchill Livingstone, 2005, p1187.
 
14) Bradom BW, Larach MG. North American MH Registry. Reassessment of the safety and efficacy of dantrolene. Anesthesiology 2002 ; 97 : A1199.
 
15) 前原康宏, 向田圭子, 久保田稔, 他. わが国の悪性高熱症の集計 (1991年). 麻酔と蘇生 1992 ; 28 (別冊27) : 79-83.
 
16) 小林雅子, 向田圭子, 右田貴子, 他. 我が国の悪性高熱症 (劇症型) の集計 (2007年). 第27回悪性高熱研究会プログラム・抄録集 14, 2007.
 
P.719 掲載の参考文献
1) Ayd FJ. Fatal hyperpyrexia during chlorpromazine therapy. J Clin Exp Psychopath 1956 ; 17 : 189.
PubMed
2) Delay J, Pichot P, Lemperier T, et al. Un neuroleptique Majeur non-phenothiazine et non reserpinique, I'haloperidol, dans le traitement des psychoses. Ann Med Psychol 1960 ; 118 : 145-52.
 
3) Toru M, Matsuda O, Makiguchi K et al. Neuroleptic malignant syndrome-like state folllowing a withdrawal of antiparkinsonian drugs. J Nerv Mental Dis 1981 ; 169 : 324-7.
 
4) Granner MA, WootenGF. Neuroleptic malignant sybdrome or parkinsonism hyperpyrexia syndrome. Semin Neurol 2010 ; 11 : 228-35.
 
5) Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am 1993 ; 77 : 185-202.
PubMed
6) Adityanjee, Aderibigbe YA, Mathews T. Epidemiology of neuroleptic malignant syndrome. Clin Neuropharmacol 1999 ; 22 : 151-8.
PubMed
7) American Psychiatric Association. Diagnostic and statistical manual of mental disorders, Fifth ed. American Psychiatric Association. Arlington, 2013, p709-11. (日本精神神経学会 : DSM-5 精神疾患の診断・統計マニュアル. 医学書院, 2014, p704-5).
 
8) 大平天平. 悪性症候群 (神経遮断薬悪性症候群) -その診断と治療. 医学の歩み 2014 ; 251 : 789-93.
 
9) 柴田護. 悪性症候群. Clin Neurosci 2013 ; 31 : 1329-30.
 
10) Gillman PK. Neuroleptic malignant syndrome : mechanisms, interactions, and causality. Mov Disord 2010 ; 25 : 1780-90.
PubMed
11) Kato D, Kawanishi C, Kishida I, et al. Effects of CYP2D6 polymorphisms on neuroleptic malignant syndrome 2007 ; 63 : 991-6.
PubMed
12) Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry 1985 ; 142 : 1137-45.
PubMed
13) Pope HG Jr, Keck PE, McElroy SL. Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am J Psychiatry 1986 ; 143 : 1227-33.
 
14) Gurrera RJ, Caroff SN, Cohen A, et al. An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. J Clin Psychiatry 2011 ; 72 : 1222-8.
PubMed
15) Berman BD. Neuroleptic malignant syndrome. A review for neurohospitalists. Neurohospitalist 2011 ; 1 : 41-7.
PubMed
16) Mills KC. Serotonin syndrome. A clinical update. Crit Care Clin 1997 ; 13 : 763-83.
PubMed
17) Gil-Navarro S, Grandas F. Dyskinesia-hyperpyrexia syndrome : another Parkinson's disease emergency. Mov Disord 2010 ; 25 : 2691-2.
PubMed
18) 田口宗太郎, 丹羽淳一, 衣斐進, 他. Dyskinesia-hyperpyrexia syndromeを合併したパーキンソン病の1例. 臨床神経 2015 ; 55 : 182-4.
 
19) Ikebe S, Harada T, Hashimoto T, et al. Prevention and treatment of malignant syndrome in Parkinson's disease : A consensus statement of the malignant syndrome research group. Parkinsonism Relat Disord 2003 ; 9 : S47-9.
 
20) 谷井久志. 悪性症候群. 臨床精神医学 2014 ; 43 : 1565-72.
Medical*Online
P.723 掲載の参考文献
1) Rosenberg I. Summary comments : epidemiological and methodological problems in determining nutritional status of older persons. Am J Clin Nutr 1989 ; 50 : 1231-3.
 
2) Cruz-Jentoft AJ, et al. Sarcopenia : European consensus on definition and disgnosis. Age Ageing 2010 ; 39 : 412-23.
 
3) Baumgartner R, et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 1998 ; 147 : 755-63.
PubMed
4) Jansen I, et al. Skeletal muscle cutpoints associated with elevated physical disability risk in older men and women. Am J Epidemiol 2004 ; 159 : 413-21.
 
5) Lauretani F, et al. Age-associated changes in skeletal muscles and their effect on mobility : an operational diagnosis of sarcopenia. J Appl Physiol 2003 ; 95 : 1851-60.
PubMed
6) Chen L-K, et al. Sarcopenia in Asia : consensus report of the Asian working group for sarcopenia. J Am Med Dir Assoc 2014 ; 15 : 95-101.
 
7) Frontera WR, et al. Strength conditioning in older men : skeletal muscle hypertrophy and improved function. J Appl Physiol 1988 ; 64 : 1038-44.
PubMed
8) Liu CJ, Latham NK. Progressive resistance strength training for impoving physical function in older adults. Cochrane Database Syst Rev 2009 ; 3 : CD002759.
 
9) Rasheed S, Woods RT. Malnutrition and quality of life in older people : a systematic review and meta-analysis. Ageing Res Rev 2013 ; 12 : 561-6.
PubMed
10) Rennie MJ. Anabolic resistance : the effects of aging, sexual dimorphism, and immobilization on human muscle protein turnover. Appl Physiol Nutr Metab 2009 ; 34 : 377-81.
PubMed
11) Kim HK, et al. Effects of exercise and amino acid supplementation on body composition and physical function in community-dwelling elderly Japanese sarcopenic women : a randomized controlled trial. J Am Geriatr Soc 2012 ; 60 : 16-23.
PubMed
12) Milne AC, Potter J, Avenell A. Protein and energy supplementation in elderly people at risk from malnutrition. Cochrane Database Syst Rev 2005 ; 1 : CD003288.
PubMed
13) Hamilton B. Vitamin D and human skeletal muscle. Scand J Med Sci Sports 2010 ; 20 : 182-190.
PubMed
14) Bischoff-Ferrari HA et al. Fall prevention with supplemental and active forms of vitamin D : a meta-analysis of randomized controlled trials. BMJ 2009 ; 339 : b3692.
PubMed
15) Bauer J, et al. Evidence-based recommendations for optimal dietary protein intake in older people : a position paper from the PROT-AGE Study Group. J Am Med Dir Assoc 2013 ; 14 : 542-59.
 
16) Biolo G, et al. Calorie restriction accelerates the catabolism of lean body mass during 2 wk of bed rest. Am J Clin Nutr 2007 ; 86 : 366-72.
PubMed
17) Wakabayashi H, Sakuma K. Nutrition, exercise, and pharmaceutical therapies for sarcopenic obesity. J Nutr Ther 2013 ; 2 : 100-11.
 
18) Witham MD, Sumukadas D, McMurdo ME. ACE inhibitors for sarcopenia- as good as exercise training? Age Ageing 2008 ; 37 : 363-5.
PubMed
19) Gale CR, et al. Grip strength, body composition, and mortality. Int J Epidemiol 36 : 228-235, 2007
PubMed
20) Gariballa S, Elessa A : Sarcopenia : prevalence and prognostic significance in hospitalized patients. Clin Nutr 2013 ; 32 : 772-6.
 

第15章 その他の脳神経疾患・治療法

P.731 掲載の参考文献
1) 島克司, 千ヶ崎裕夫. 3.1 頭蓋内圧のモニター法とその意義. In ; 坪川孝志, 植村研一, 端和夫, 他編. 最新脳神経外科のICU管理, 朝倉書店, 東京, 1993, p67-75.
 
2) 太田富雄. 2章. 頭蓋内圧亢進と脳ヘルニア. In ; 太田富雄, 松谷雅生, 編. 脳神経外科学 第9版, 金芳堂, 京都, 2004, p123-68.
 
3) 浅野孝雄. II. 脳浮腫. In ; 浅野孝雄, 編著. 脳虚血の病態学, 中外医学社, 東京, 2003, p292-319.
 
4) Rapoport SI. Roles of cerebrovascular permeability, brain compliance, and brain hydra ; ulic conductivity in vasogenic brain edema. In ; AJ, ed. Neural Trauma, Popp. Raven Press, 1979, p51-62.
 
5) Fishman. Brain edema. New Eng J Med 1975 ; 273 : 706-11.
 
6) 小原克之. 抗脳浮腫療法. 医学のあゆみ 1999 ; 191 : 721-4.
Medical*Online
7) 佐野圭司. 脳浮腫とその分類. 救急医学 1990 ; 14 : 269-72.
 
8) Klatzo I. Neuropathological aspects of brain edema. J Neuropathol Exp Neurol 1967 ; 26 : 1-14.
PubMed
9) 濱田潤一, 後藤文男. 脳浮腫の病態生理. 救急医学 1990 ; 14 : 273-82.
 
10) Vereno JL, Vizuete ML, Machado A, et al. Aquaporins in the central nervous system. Prog Neurobiol 2001 ; 63 : 321-36.
 
11) Zador Z, Bloch O, Yao X, et al. Aquaporins : role in cerebral edema and brain water balance. In ; Weber & Maas, eds. Progress in Brain Research 161, Elsevier Science, 2007, p185-94.
 
12) Wang W, Xie D, Zhou L, et al. The function of aquaporin4 in ischemic brain edema. Clin Neurol Neurosurg 2014 ; 127 : 5-9.
 
13) Hedana VS, Bidari S, Gubernick D, et al. Treatment of stroke related refractory brain edema using mixed vasopressin antagonism : a case report and revew of the literature. BMC Neurol 2014 ; 14 : 213
 
14) 日本神経外傷学会 重症頭部外傷治療・管理のガイドライン作成委員会. 重症頭部外傷治療・管理のガイドライン 第3版. 医学書院, 東京, 2013.
 
15) 池田幸穂, 松本清. 1. 意識障害の診断と治療 C. 頭蓋内圧亢進と脳ヘルニアの診断と治療. In ; 橋本信夫, 編. 脳神経外科臨床指針, 中外医学社, 東京, 2002, p10-5.
 
16) Major R, al-Salim W. Ultrasound of optic nerve sheath to evaluate intracranial pressure. Emerg Med J 2008 ; 25 : 766-7.
PubMed
17) Buki B, Giraudet F, Avan P. Non-invasive measurements of intralabyrinthine pressure changes by electrocochleography and otoacoustic emissions. Hearin Research 2009 ; 251 : 51-9.
 
18) 上原淳, 紙尾均, 堤晴彦. IX 救急疾患 救急処置. 頭蓋内圧管理. 脳神経外科周術期管理のすべて, メジカルビュー社, 東京, 2000, p534-40.
 
19) Biestro A, Alberti R, Galli R, et al Osmotherapy for increased intracranial pressure : comparison between mannitol and glycerol. Acta Neurochir (Wien) 1997 ; 139 : 725-32.
PubMed
20) 日本脳卒中学会 脳卒中治療ガイドライン委員会. 脳卒中治療ガイドライン 2015, 協和企画, 東京, 2015.
 
21) Muizelaar JP, Shahlaie K. Hypertonic saline in neurocritical care : Is continuous infusion appropriate? Crit Care Med 2009 ; 37 : 1521-3.
PubMed
22) Georgiadis AL, Suarez JI. Hypertonic saline for cerebral edema. Curr Neurol Neurosci Rep 2003 ; 3 : 524-30.
PubMed
23) Battison C, Hons BA, Andrews PJD, et al. Randomized, controlled trial on the effect of a 20% mannitol solution and a 7.5% saline/6% dextran solution on increased intracranial pressure after brain injury. Crit Care Med 2005 ; 33 : 196-202.
 
24) Vialet R, Albanese J, Thomachot L, et al. Isovolume hypertonic solutes (sodium chloride or mannitol) in the treatment of refractory posttraumatic intracranial hypertension : 2mL/kg 7.5% saline is more effective than 2mL/kg 20% mannitol. Crit Care Med 2003 ; 31 : 1683-7.
PubMed
25) Chapter 11. Use of hyperosmolar therapy in the management of severe pediatric brain injury. Ped Crit Care Med 2003 ; 4 (3 Suppl) : S40-4.
 
26) Brain trauma foundation, AANS, CNS : Guideline for the management of severe traumatic brain injury 3rd edition, 2007.
 
27) Bassin S, Blech T. Barbiturates for the treatment of intracranial hypertension after traumatic brain injury. Crit Care 2008 ; 12 : 185-6.
 
28) Lescot T, Abdennour L, Boch AL, et al. Treatment of intracranial hypertension. Curr Opin Crit Care 2008 ; 14 : 129-34.
PubMed
29) Cooper DJ, Rosenfeld JV, Murray L, et al. Decompressive craniectomy in diffuse Traumatic brain injury. N Eng J Med 2011 ; 364 : 1493-502.
 
30) Bernard SA, Gray TW, Buist MD, et al. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N Engl J Med 2002 ; 346 : 557-63.
PubMed
31) The hypothermia after cardiac arrest study group. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med 2002 ; 346 : 549-56.
 
32) Clifton GL, Miller ER, Choi SC, et al. Lack of effect of introduction of hypothermia after acute brain injury. N Engl J Med 2001 ; 344 : 556-63.
 
33) Krieger DW, DeGeorgia MA, Abou-Chebl A, et al. Cooling for acute ischemic brain damage (COOL AID) : an open pilot study of induced hypothermia in acute ischemic stroke. Stroke 2001 ; 32 : 1847-54.
 
34) Marmarou A : Pathophysiology of traumatic brain edema : current concepts. Acta Neurochir 2003 ; (Suppl) 86 : 7-10.
PubMed
P.739 掲載の参考文献
1) American Academy of Sleep Medicine. International classification of sleep disorders, 3rd ed. (ICSD-3). Darien, IL, 2014.
 
2) 三島和夫. 睡眠薬の適正使用・休薬ガイドライン. 三島和夫 (睡眠薬の適正使用及び減量・中止のための診療ガイドラインに関する研究班) 編. 東京, じほう, 2014.
 
3) 睡眠障害の診断・治療ガイドライン : 睡眠医療 2巻, ライフ・サイエンス社, 2008.
 
P.746 掲載の参考文献
1) 特発性正常圧水頭症診療ガイドライン 第1版 (日本正常圧水頭症研究会特発性正常圧水頭症診療ガイドライン作成委員会), メディカルレビュー社, 2004.
 
2) 特発性正常圧水頭症診療ガイドライン 第2版 (日本正常圧水頭症研究会特発性正常圧水頭症診療ガイドライン作成委員会), メディカルレビュー社, 2011.
 
3) Benzel EC, Pelletier AL, Palema GL. Communicating hydrocephalus in adults : Prediction of outcome after ventricular shunting procedures. Neurosurgery 1990 ; 26 : 655-60.
 
4) Black PM. Idiopathic normal-pressure hydrocephalus. Results of shunting in 62 patients. J Neurosurg 1980 ; 52 : 371-7.
PubMed
5) Hashimoto M, Ishikawa M, Mori E, et al. Diagnosis of idiopathic normal pressure hydrocephalus is supported by MRI-based scheme : a prospective cohort study. Cerebrospinal Fluid Res 2010 ; 7 : 18.
PubMed
6) Iddon JL, Pickard JD, Cross JJ, et al. Specific patterns of cognitive impairment in patients with idiopathic normal pressure hydrocephalus and Alzheimer's disease : a pilot study. J Neurol Neurosurg Psychiatry 1999 ; 67 : 723-32.
PubMed
7) Iseki C, Kawanami T, Nagasawa H, et al. Asymptomatic ventriculomegaly with features of idiopathic normal pressure hydrocephalus on MRI (AVIM) in the elderly : a prospective study in a Japanese population. J Neurol Sci 2009 ; 277 : 54-7.
 
8) Ishii K, Hashimoto M, Hayashida K, et al. A multicenter brain perfusion SPECT study evaluating idiopathic normal-pressure hydrocephalus on neurological improvement. Dement Geriatr Cogn Disord 2011 ; 32 : 1-10.
PubMed
9) Ishikawa M, Hashimoto M, Kuwana N, et al. Guidelines for management of idiopathic normal pressure hydrocephalus. Neurol Med Chir (Tokyo) 2008 ; 48 Suppl : S1-23.
PubMed
10) Ishikawa M, Hashimoto M, Mori E, et al. The value of the cerebrospinal fluid tap test for predicting shunt effectiveness in idiopathic normal pressure hydrocephalus. Fluids Barriers CNS 2012 ; 9 : 1. doi : 10.1186/2045-8118-9-1.
 
11) Kahlon B, Sundbarg G, Rehncrona S : Comparison between the lumbar infusion and CSF tap tests to predict outcome after shunt surgery in suspected normal pressusre hydrocephalus. J Neuorl Neurosurg Psychiatr 2002 ; 73 : 721-6.
 
12) Kawaguchi T, Hirata Y, Bundo M, et al. Role of computerized tomogramphic cisternaphy in idiopathic normal pressure hydrocephalus. Acta Neurochir (Wien) 2011 ; 153 : 2041-8.
PubMed
13) Kazui H, Miyajima M, Mori E, et al. Lumboperitoneal shunt surgery for idiopathic normal pressure hydrocephalus (SINPHONI-2) : an open-label randomised trial. Lancet Neurol 2015 ; 14 : 585-94.
PubMed
14) Kitagaki H, Mori E, Ishii K, et al. CSF spaces in idiopathic normal pressure hydrocephalus : morphology and volumetry. AJNR Am J Neuroradiol 1998 ; 19 : 1277-84.
 
15) Krauss JK, Droste DW, Vach W, et al. Cerebrospinal fluid shunting in idiopathic normal-pressure hydrocephalus of the elderly : effect of periventricular and deep white matter lesions. Neurosurgery 1996 ; 39 : 292-9.
PubMed
16) Kubo Y, Kazui H, Yoshida T, et al. Validation of grading scale for evaluating symptoms of idiopathic normal pressure hydrocephalus. Dement Geriatr Gogn Disord 2008 ; 25 : 37-45.
 
17) Li X, Miyajima M, Mineki R, et al. Analysis of potential diagnostic biomarkers in cerebrospinal fluid of idiopathic normal pressure hydrocephalus by proteomics. Acta Neurochir (Wien) 2006 ; 148 : 859-64.
PubMed
18) Marmarou A, Bergsneider M, Klinge P, et al. The value of supplemental prognostice tests for the preoperative assessment of idiopathic normal-pressure hydrocephalus. Neurosurgery 2005 ; 57 : S17-28.
 
19) Miyake H, Kajimoto Y, Tsuji M, et al. Development of a wuick reference table for setting programmable pressure valves in patients with idiopathic normal pressure hydrocephalus. Neurol Med Chir (Tokyo) 2008 ; 48 : 427-32.
PubMed
20) Raftopoulos C, Massager N, Baleriaux D, et al. Prospective analysis by computed tomography and long-term outcome of 23 adult patients with chronic idiopathic hyrdrocephalus. Neurosurgery 1996 ; 38 : 51-9.
 
21) Pujari S, Kharkar S, Metellus P, et al. Normal pressure hydrocephalus : long-term outcome after shunt surgery. J Neurol Neurosurg Psychiatry 2008 ; 79 : 1282-6.
PubMed
22) Relkin N, Marmarou A, Klinge P, et al. Diagnosing idiopathic normal pressure hydrocephalus. Neurosurgery 2005 ; 57 : S4-16.
PubMed
23) Sasaki H, Ishii K, Kono AK, et al. Cerebral perfusion pettern of idiopathic normal pressure hydrocephalus studied by SPECT and statistical brain maping. Ann Nucl Med 2007 ; 21 : 39-45.
 
24) Savolainen S, Hurskainen H, Paljarvi L, et al. Five-year outcome of normal pressure hydrocephalus with or without a shunt ; Predicitive value of clinical signs, neuropsychological evaluation and infusion test. Acta Neurochir (Wien) 2002 ; 144 : 515-23.
PubMed
25) Stolze H, Kuhtz-Buschbeck JP, Drucke H, et al. Comparative analysis of the gait disorder of normal pressure hydrocephalus and Parkinson's disease. J Neurol Neurosurg Psychiatry 2001 ; 70 : 289-9.
PubMed
26) Tokuda T, Koizumi H, Kondo M, et al. The usefulness of the ConvexityAPPArent Hyperperfusion (CAPPAH) sign in the perfusion SPECT study for the diagnosis of iNPH, The Fourth Meeting of the International Society for Hydrocephalus and Cerebrospinal Fluid Disorders (Hydrocephalus 2012 Kyoto) 2012 ; 1PS-5-01 (abstr).
 
27) Walchenbach R, Geiger E, Thomeer RT, et al. The value of temporary external CSF drainage in predicting the outcome of shunting on normal pressure hydrocephalus. J Neurol Neurosurg Psychiat 2002 ; 72 : 503-6.
PubMed
P.755 掲載の参考文献
1) 亀山忠典, 他編. 薬害スモン, 大月書店, 東京, 1977.
 
2) 片平洌彦. スモン. In ; 高倉公朋, 宮本忠雄, 監修. 最新 脳と神経科学シリーズ 5. 薬物が起こす神経障害. メジカルビュー社, 東京, 2000, p164-77.
 
3) 野元正弘. 中枢神経障害の機序. 日内会誌 2007 ; 96 : 1580-4.
 
4) Richens A, Dunlop A. Serum-phenytoin levels in management of epilepsy. Lancet 1975 ; 2 : 247-8.
PubMed
5) Udina M, Hidalgo D, Navines R, et al. Prophylactic antidepressant treatment of interferon-induced depression in chronic hepatitis C : a systematic review and meta-analysis. J Clin Psychiatry 2014 ; 75 : e1113-21.
PubMed
6) Tanaka Y, Nagaki M, Tomita E, et al. Psychoneurological symptoms during interferon therapy in patients with chronic hepatitis : prospective study on predictive use of Cornell Medical Index and electroencephalogram. Liver Int 2004 ; 24 : 407-12.
PubMed
7) Grill MF, Maganti RK. Neurotoxic effects associated with antibiotic use : management considerations. Br J Clin Pharmacol 2011 ; 72 : 381-93.
PubMed
8) 伊藤愛, 成田有吾. 薬剤による神経症状. 内科 2014 ; 113 : 899-902.
 
9) 澤田康文. 薬物相互作用. 日内会誌 2007 ; 96 : 1570-9.
 
10) Kepa L, Oczko-Grzesik B, Stolarz W, et al. Drug-induced aseptic meningitis in suspected central nervous system infections. J Clin Neurosci 2005 ; 12 : 562-4.
PubMed
11) Moris G, Garcia-Monco JC. The challenge of drug-induced aseptic meningitis revisited. JAMA Intern Med 2014 ; 174 : 1511-2.
PubMed
12) Vesquez VS, Escande M, Lancet C. A propos de psychose cortisoniques. Ann Med Psychol 1974 ; 1 : 523-31.
 
13) Ling MH, Perry PJ, Tsuang MT. Side effect of corticosteroid therapy. Arch Gen Psychiatry 1981 ; 38 : 471-7.
 
14) 池田久雄. ステロイド投与患者への抗精神病薬の投与. 神経精神薬理 1984 ; 6 : 545-51.
 
15) 本村政勝, 白石祐一, 吉村俊朗, 他. 神経・筋接合部に影響を及ぼす薬物. 日内会誌 2007 ; 96 : 1604-7.
 
16) 樋口逸郎. 筋肉に影響を及ぼす薬物. 日内会誌 2007 ; 96 : 1598-603.
 
17) Law M, Rudnicka AR. Statin safety : a systematic review. Am J Cardiol 2006 ; 97 (8A) : 52C-60C.
PubMed
18) Weise WJ, Possidente CJ. Fatal rhabdomyolysis associated with simvastatin in a renal transplant patient. Am J Med 2000 ; 108 : 351-2.
 
19) Alexandridis G, Pappas GA, Elisaf MS. Rhabdomyolysis due to combination therapy with cerivastatin and gemfibrozil. Am J Med 2000 ; 109 : 261-2.
PubMed
20) Penn AS. Myoglibiuria. In ; Engel AG, Franzini-Armstrong C, eds. Myology, Vol 2, McGraw-Hill, NewYork, 1994, p1679-96.
 
21) Patel J, Superko HR, Martin SS, et al. Genetic and immunologic susceptibility to statin-related myopathy. Atherosclerosis 2015 ; 240 : 260-71.
PubMed
22) Rosenson RS, Baker SK, Jacobson TA, et al. An assessment by the Statin Muscle Safety Task Force : 2014 update. J Clin Lipidol 2014 ; 8 : S58-71.
PubMed
23) 上山秀嗣. 低カリウム性ミオパチー. 別冊日本臨牀 骨格筋症候群 (第2版) 下, 日本臨牀社, 東京, 2014, p282-6.
 
24) 安澄文興. 微細小管. In ; 小川和朗, 他編. 細胞生物学-細胞の運動と形態変化, 理工学社, 東京, 1978, p39-81.
 
25) Victor M, Sieb JP. Myopathies due to drugs, toxins and nutritional deficiency. I ; Engel AG, Franzini-Armstrong C, eds. Myology, Vol 2, McGraw-Hill, NewYork, 1994, p1697-725.
 
26) Kuncl RW, Duncan G, Watson D, et al. Colchicine myopathy and neuropathy. N Engl J Med 1987 ; 316 : 1562-8.
PubMed
27) Bradley WG, Lassman LP, Pearce GW, et al. The neuromyopathy of vincristine in man. Clinical, electrophysiological and pathological studies. J Neurol Sci 1970 ; 10 : 107-31.
PubMed
28) Takahashi K, Ogita T, Okudaira H, et al. D-penicillamine-induced polymyositis in patients with rheumatoid arthritis. Arthritis Rheum 1986 ; 29 : 560-4.
PubMed
29) 堀之内英雄, 熊本俊秀. 毒素性炎症性ミオパチー. 別冊日本臨牀 骨格筋症候群, 日本臨牀社, 東京, 2001, p255-8.
 
30) Higuchi I, Izumo S, Kuriyama M, et al. Germanium myopathy : clinical and experimental pathological studies. Acta Neuropathol (Berl) 1989 ; 79 : 300-4.
PubMed
31) 田中恵子. 癌と脳神経疾患. 日内会誌 2012 ; 101 : 2249-56.
 
32) 水谷智彦. 白質脳症. 日本臨牀 2007 ; 65 : 372-6.
Medical*Online
33) 水谷智彦. 抗悪性腫瘍薬による白質脳症. Brain Nerve 2008 ; 60 : 137-41.
 
34) Lucato LT, McKinney AM, Short J, et al. Reversible findings of restricted diffusion in 5-fluorouracil neurotoxicity. Australas Radiol 2006 ; 50 : 364-8.
PubMed
35) 田村英二, 多田宣正, 大石実, 他. 投与中止により軽快したcarmofur脳症の2例. 神経内科治療 1990 ; 7 : 47-51.
Medical*Online
36) Ziereisen F, Dan B, Azzi N, et al. Reversible acute methotrexate leukoencephalopathy : atypical brain MR imaging features. Pediatr Radiol 2006 ; 36 : 205-12.
PubMed
37) 千葉厚郎. Reversible posterior leukoencephalopathy syndromeと薬物. 日内会誌 2007 ; 96 : 1657-63.
 
38) Plotkin SR, Wen PY. Neurologic complication of cancer therapy. Neurol Clin 2003 ; 21 : 279-318.
 
39) 濱田潤一. 抗がん薬と頭痛. Brain Nerve 2008 ; 60 : 149-55.
 
40) Jolles S, Sewell WA, Leighton C. Drug-induced aseptic meningitis : diagnosis and management. Drug Saf 2000 ; 22 : 215-26.
PubMed
41) Creel GB, Hurtt M. Cephalosporin-induced recurrent aseptic meningitis. Ann Neurol 1995 ; 37 : 815-7.
PubMed
42) Diener HC, Limmroth V. Medication-overuse headache : a worldwide problem. Lancet Neurol 2004 ; 3 : 475-83.
PubMed
43) Stovner LJ, Andree C. Prevalence of headache in Europe : a review for the Eurolight project. J Headache Pain 2010 ; 11 : 289-99.
PubMed
44) 日本神経学会・日本頭痛学会・慢性頭痛の診療ガイドライン作成委員会. 薬物乱用頭痛. 慢性頭痛の診療ガイドライン 2013, 医学書院, 東京, 2013, p264-70.
 
45) Evers S, Jensen R ; European Federation of Neurological Societies. Treatment of medication overuse headache-guideline of the EFNS headache panel. Eur J Neurol 2011 ; 18 : 1115-21.
PubMed
46) 馬場康彦, 井上展聡, 山田達夫. 薬物性過敏症症候群による神経障害. 日内会誌 2007 ; 96 : 1652-6.
 
47) Shiohara T, Inaoka M, Kano Y. Drug-induced hypersensitivity syndrome (DIHS) : a reaction induced by a complex interplay among herpesviruses and antiviral and antidrug immune responses. Allergol Int 2006 ; 55 : 1-8.
PubMed
48) Fujino Y, Nakajima M, Inoue H, et al. Human herpesvirus 6 encephalitis associated with hypersensitivity syndrome. Ann Neurol 2002 ; 51 : 771-4.
PubMed
49) Masaki T, Fukunaga A, Tohyama M, et al. Human herpes virus 6 encephalitis in allopurinol-induced hypersensitivity syndrome. Acta Derm Venereol 2003 ; 83 : 128-31.
PubMed
50) 伊藤高雄, 大石知瑞子, 千葉厚郎, 他. フェノバルビタールによるdrug-induced hypersensitivity syndromeに続発した辺縁系脳炎の1例. 臨床神経 2005 ; 45 : 495-501.
 
P.760 掲載の参考文献
1) Weimer LH, Sachdev N. Update on medication-induced peripheral neuropathy. Curr Neurol Neurosci Rep 2009 ; 9 : 69-75.
PubMed
2) Postma TJ, Benard BA, Huijgens PC, et al. Long-term effects of vincristine on the peripheral nervous system. J Neurooncol 1993 ; 15 : 23-7.
PubMed
3) Khrunin AV, Moisseev A, Gorbunova V, et al. Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharmacogenomics J 2010 ; 10 : 54-61.
PubMed
4) Grothey A. Oxaliplatin-safety profile : neurotoxicity. Semin Oncol 2003 ; 30 (4 Suppl 15) : 5-13.
 
5) Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 2006 ; 24 : 1633-42.
PubMed
6) Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer : high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994 ; 12 : 2654-66.
PubMed
7) Kuwabara S, Dispenzieri A, Arimura K, et al. Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome. Cochrane Database Syst Rev 2012 ; 6 : CD006828.
PubMed
8) Cavaletti G, Beronio A, Reni L, et al. Thalidomide sensory neurotoxicity : a clinical and neurophysiologic study. Neurology 2004 ; 62 : 2291-3.
PubMed
9) Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma : a comprehensive review of the literature. Blood 2008 ; 112 : 1593-9.
PubMed
10) Stuubgen JP. Tumor necrosis factor-alpha antagonists and neuropathy. Muscle Nerve 2008 ; 37 : 281-92.
 
11) Narita M, Tsuji BT, Yu VL. Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. Pharmacotherapy 2007 ; 27 : 1189-97.
PubMed
12) Gaist D, Jeppesen U, Andersen M, et al : Statins and risk of polyneuropathy : a case-control study. Neurology 2002 ; 58 : 1333-7.
PubMed
13) Davis TM, Yeap BB, Davis WA, et al. Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes : the Fremantle Diabetes Study. Diabetologia 2008 ; 51 : 562-6.
PubMed
14) Ii M, Nishimura H, Kusano KF, et al. Neuronal nitric oxide synthase mediates statin-induced restoration of vasa nervorum and reversal of diabetic neuropathy. Circulation 2005 ; 112 : 93-102.
PubMed
15) Kinoshita T, Abe R, et al. Peripheral sympathetic nerve dysfunction in adolescent Japanese girls following immunization with the human papillomavirus vaccine. Intern Med 2014 ; 53 : 2185-200.
PubMed
16) Snider DE Jr. Pyridoxine supplementation during isoniazid therapy. Tubercle 1980 ; 61 : 191-6.
PubMed
17) Gamelin L, Boisdron-Celle M, Delva R, et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions : a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 2004 ; 10 : 4055-61.
PubMed
18) Hochster HS, Grothey A, Childs BH. Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity. J Clin Oncol 2007 ; 25 : 4028-9.
PubMed
19) Grothey, D. A. Nikcevich, J. A. Sloan, et al. Evaluation of the effect of intravenous calcium and magnesium (CaMg) on chronic and acute neurotoxicity associated with oxaliplatin : Results from a placebo-controlled phase III trial. J Clin Oncol 2009 ; 27 : 15s (suppl ; abstr 4025).
 
20) Pace A, Savarese A, Picardo M, et al. Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. J Clin Oncol 2003 ; 21 : 927-31.
PubMed
21) Wolf S, Barton D, Kottschade L, et al. Chemotherapy-induced peripheral neuropathy : prevention and treatment strategies. Eur J Cancer 2008 ; 44 : 1507-15.
PubMed
22) Hensley ML, Hagerty KL, Kewalramani T, et al. American Society of Clinical Oncology 2008 clinical practice guideline update : use of chemotherapy and radiation therapy protectants. J Clin Oncol 2009 ; 27 : 127-45.
 
23) Kaley TJ, Deangelis LM. Therapy of chemotherapy-induced peripheral neuropathy. Br J Haematol 2009 ; 145 : 3-14.
PubMed
P.765 掲載の参考文献
1) Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases : a randomized controlled trial. JAMA 2006 ; 295 : 2483-91.
PubMed
2) Blonigen BJ, Steinmetz RD, Levin L, et al. Irradiated volume as a predictor of brain radionecrosis after linear accelerator stereotactic radiosurgery. Int J Radiat Oncol Biol Phys 2010 ; 77 : 996-1001.
PubMed
3) Boari N, Bailo M, Gagliardi F, et al. Gamma Knife radiosurgery for vestibular schwannoma : clinical results at long-term follow-up in a series of 379 patients. J Neurosurg 2014 ; 121 Suppl : 123-42.
 
4) Chang EL, Wefel JS, Hess KR, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation : a randomised controlled trial. Lancet Oncol 2009 ; 10 : 1037-44.
PubMed
5) Chen CJ, Lee CC, Ding D, et al. Stereotactic radiosurgery for intracranial dural arteriovenous fistulas : a systematic review. J Neurosurg 2015 ; 122 : 353-62.
PubMed
6) Chopra R, Kondziolka D, Niranjan A, et al. Long-term follow-up of acoustic schwannoma radiosurgery with marginal tumor doses of 12 to 13 Gy. Int J Radiat Oncol Biol Phys 2007 ; 68 : 845-51.
PubMed
7) Einstein DB, Wessels B, Bangert B, et al. Phase II trial of radiosurgery to magnetic resonance spectroscopy-defined high-risk tumor volumes in patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2012 ; 84 : 668-74.
PubMed
8) Flickinger JC, Kondziolka D, Lunsford LD, et al. Development of a model to predict permanent symptomatic postradiosurgery injury for arteriovenous malformation patients. Arteriovenous Malformation Radiosurgery Study Group. Int J Radiat Oncol Biol Phys 2000 ; 46 : 1143-8.
 
9) Flickinger JC, Kondziolka D, Maitz AH, et al. An analysis of the dose-response for arteriovenous malformation radiosurgery and other factors affecting obliteration. Radiother Oncol 2002 ; 63 : 347-54.
PubMed
10) Hanakita S, Koga T, Igaki H, Murakami N, et al. Role of gamma knife surgery for intracranial atypical (WHO grade II) meningiomas. J Neurosurg 2013 ; 119 : 1410-4.
PubMed
11) Hanakita S, Koga T, Shin M, et al. The long-term outcomes of radiosurgery for arteriovenous malformations in pediatric and adolescent populations. J Neurosurg Pediatr 2015 ; 16 : 222-31.
 
12) Hanakita S, Koga T, Shin M, et al. Role of Gamma Knife surgery in the treatment of intracranial dural arteriovenous fistulas. J Neurosurg 2012 ; 117 Suppl : 158-63.
PubMed
13) Hanakita S, Koga T, Shin M, et al. The long-term outcomes of radiosurgery for intracranial hemangioblastomas. Neuro Oncol 2014 ; 16 : 429-33.
 
14) Hasegawa T, Kida Y, Yoshimoto M, et al. Gamma Knife surgery for convexity, parasagittal, and falcine meningiomas. J Neurosurg 2011 ; 114 : 1392-8.
PubMed
15) Hasegawa T, McInerney J, Kondziolka D, et al. Long-term results after stereotactic radiosurgery for patients with cavernous malformations. Neurosurgery 2002 ; 50 : 1190-7 ; discussion 1197-8.
 
16) Iwata H, Tatewaki K, Inoue M, et al. Single and hypofractionated stereotactic radiotherapy with CyberKnife for craniopharyngioma. J Neurooncol 2012 ; 106 : 571-7.
PubMed
17) Iyer A, Kano H, Kondziolka D, et al. Stereotactic radiosurgery for intracranial chondrosarcoma. J Neurooncol 2012 ; 108 : 535-42.
PubMed
18) Jacob JT, Carlson ML, Schiefer TK, et al. Significance of cochlear dose in the radiosurgical treatment of vestibular schwannoma : controversies and unanswered questions. Neurosurgery 2014 ; 74 : 466-74 ; discussion 474.
 
19) Jezkova J, Marek J, Hana V, et al. Gamma knife radiosurgery for acromegaly-long-term experience. Clin Endocrinol (Oxf) 2006 ; 64 : 588-95.
PubMed
20) Kano H, Shuto T, Iwai Y, Sheehan J, et al. Stereotactic radiosurgery for intracranial hemangioblastomas : a retrospective international outcome study. J Neurosurg 2015 ; 122 : 1469-78.
PubMed
21) Koga T, Saito N : Efficacy and limitations of stereotactic radiosurgery in the treatment of glioblastoma. Neurol Med Chir (Tokyo) 2012 ; 52 : 548-52.
PubMed
22) Koga T, Shin M, Saito N. Treatment with high marginal dose is mandatory to achieve long-term control of skull base chordomas and chondrosarcomas by means of stereotactic radiosurgery. J Neurooncol 2010 ; 98 : 233-8.
PubMed
23) Kurita H, Sasaki T, Kawamoto S, et al. Chronic encapsulated expanding hematoma in association with gamma knife stereotactic radiosurgery for a cerebral arteriovenous malformation. Case report. J Neurosurg 1996 ; 84 : 874-8.
PubMed
24) Lee CC, Vance ML, Lopes MB, et al. Stereotactic radiosurgery for acromegaly : outcomes by adenoma subtype. Pituitary 2015 ; 18 : 326-34.
PubMed
25) Lee CC, Yang HC, Chen CJ, et al. Gamma Knife surgery for craniopharyngioma : report on a 20-year experience. J Neurosurg 2014 ; 121 Suppl : 167-78.
PubMed
26) Lee JY, Sandhu S, Miller D, et al. Higher dose rate Gamma Knife radiosurgery may provide earlier and longer-lasting pain relief for patients with trigeminal neuralgia. J Neurosurg 2015 ; 123 : 961-8.
PubMed
27) Leenstra JL, Tanaka S, Kline RW, et al. Factors associated with endocrine deficits after stereotactic radiosurgery of pituitary adenomas. Neurosurgery 2010 ; 67 : 27-32 ; discussion 32-23.
 
28) Lu XY, Sun H, Xu JG, et al. Stereotactic radiosurgery of brainstem cavernous malformations : a systematic review and meta-analysis. J Neurosurg 2014 ; 120 : 982-7.
PubMed
29) Maruyama K, Kawahara N, Shin M, et al. The risk of hemorrhage after radiosurgery for cerebral arteriovenous malformations. N Engl J Med 2005 ; 352 : 146-53.
PubMed
30) Mayo C, Martel MK, Marks LB, et al. Radiation dose-volume effects of optic nerves and chiasm. Int J Radiat Oncol Biol Phys 2010 ; 76 : S28-35.
PubMed
31) Minniti G, Clarke E, Lanzetta G, et al. Stereotactic radiosurgery for brain metastases : analysis of outcome and risk of brain radionecrosis. Radiat Oncol 2011 ; 6 : 48.
PubMed
32) Mohr JP, Parides MK, Stapf C, et al. Medical management with or without interventional therapy for unruptured brain arteriovenous malformations (ARUBA) : a multicentre, non-blinded, randomised trial. Lancet 2014 ; 383 : 614-21.
 
33) Nagano O, Higuchi Y, Serizawa T, et al. Transient expansion of vestibular schwannoma following stereotactic radiosurgery. J Neurosurg 109 : 811-816, 2008
PubMed
34) Niranjan A, Kano H, Iyer A, et al. Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era. J Neurosurg 2015 ; 122 : 757-65.
PubMed
35) Oyesiku NM. Stereotactic radiosurgery for Cushing disease : a review. Neurosurg Focus 2007 ; 23 : E14.
PubMed
36) Pollock BE, Nippoldt TB, Stafford SL, et al. Results of stereotactic radiosurgery in patients with hormone-producing pituitary adenomas : factors associated with endocrine normalization. J Neurosurg 2002 ; 97 : 525-30.
PubMed
37) Pollock BE, Stafford SL, Link MJ, et al. Single-fraction radiosurgery of benign intracranial meningiomas. Neurosurgery 2012 ; 71 : 604-12 ; discussion 613.
 
38) Sahgal A, Aoyama H, Kocher M, et al. Phase 3 trials of stereotactic radiosurgery with or without whole-brain radiation therapy for 1 to 4 brain metastases : individual patient data meta-analysis. Int J Radiat Oncol Biol Phys 2015 ; 91 : 710-7.
PubMed
39) Serizawa T : Radiosurgery for metastatic brain tumors. Int J Clin Oncol 2009 ; 14 : 289-98.
PubMed
40) Serizawa T, Hirai S, Ono J, et al. Treatment selection for small cerebral arteriovenous malformations with clinical decision analysis : observation, gamma knife surgery or microsurgery? Surg Cereb Stroke (Jpn) 2003 ; 31 : 81-6.
 
41) Sheehan JP, Lee Vance M, Xu Z, et al. 142 Stereotactic Radiosurgery for Medically and Surgically Refractory Acromegaly : Long-term Rates of Remission and Hypopituitarism. Neurosurgery 2015 ; 62 Suppl 1 : 211-2.
 
42) Sheehan JP, Starke RM, Mathieu D, et al. Gamma Knife radiosurgery for the management of nonfunctioning pituitary adenomas : a multicenter study. J Neurosurg 2013 ; 119 : 446-56.
PubMed
43) Sheplan Olsen LJ, Robles Irizarry L, Chao ST, et al. Radiotherapy for prolactin-secreting pituitary tumors. Pituitary 2012 ; 15 : 135-45.
PubMed
44) Shin M, Kawahara N, Maruyama K, et al. Risk of hemorrhage from an arteriovenous malformation confirmed to have been obliterated on angiography after stereotactic radiosurgery. J Neurosurg 2005 ; 102 : 842-6.
PubMed
45) Shin M, Kawamoto S, Kurita H, et al. Retrospective analysis of a 10-year experience of stereotactic radio surgery for arteriovenous malformations in children and adolescents. J Neurosurg 2002 ; 97 : 779-84.
PubMed
46) Shin M, Ueki K, Kurita H, Kirino T : Malignant transformation of a vestibular schwannoma after gamma knife radiosurgery. Lancet 360 : 309-310, 2002
PubMed
47) Sneed PK, Mendez J, Vemer-van den Hoek JG, Seymour ZA, Ma L, Molinaro AM, et al. Adverse radiation effect after stereotactic radiosurgery for brain metastases : incidence, time course, and risk factors. J Neurosurg 123 : 373-386, 2015
PubMed
48) Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme : report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys 2004 ; 60 : 853-60.
PubMed
49) Tanaka S, Link MJ, Brown PD, et al. Gamma knife radiosurgery for patients with prolactin-secreting pituitary adenomas. World Neurosurg 2010 ; 74 : 147-52.
PubMed
50) Wang X, Mei G, Liu X, Dai J, et al. The role of stereotactic radiosurgery in cavernous sinus hemangiomas : a systematic review and meta-analysis. J Neurooncol 2012 ; 107 : 239-45.
PubMed
51) Xu Z, Schlesinger D, Moldovan K, et al. Impact of target location on the response of trigeminal neuralgia to stereotactic radiosurgery. J Neurosurg 2014 ; 120 : 716-24.
PubMed
52) Yamamoto M, Serizawa T, Shuto T, et al. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901) : a multi-institutional prospective observational study. Lancet Oncol 2014 ; 15 : 387-95.
PubMed
53) Yang I, Kim W, De Salles A, et al. A systematic analysis of disease control in acromegaly treated with radiosurgery. Neurosurg Focus 2010 ; 29 : E13.
 
P.769 掲載の参考文献
1) Truong D, Comella C, Fernandez H, et al. Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm : a randomized, placebo-controlled, phase II trial. Parkinsonism Relat Disord 2008 ; 14 : 407-14 ; Epub 2008 Mar 5.
 
2) Jankovic J, Kenney C, Grafe S, et al. Relationship between various clinical outcome assessments in patients with blepharospasm. Mov Disord 2009 ; 24 : 407-13.
PubMed
2) Doi T, Akai M, Fujino K et al. Effects of Home Exercise of Quadriceps on Knee OA Compared with NSAIDS. Am J Phys Med Rehabil 2008 ; 87 : 1-12.
 
3) Shirado O, Doi T, Hoshino Y, et al. Multicenter randomized controlled trial to evaluate the effect on home-based exercise on patients with chronic low back pain : the Japanese low back pain exercise therapy study. Spine 2007 ; 32 : 3052-9.
 
3) Brashear A, Gordon MF, Elovic E, et al. Botox Post-Stroke Spasticity Study Group. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med 2002 ; 347 : 395-400.
 
4) McCrory P, Turner-Stokes L, Baquley IJ, et al. Botulinum toxin A for treatment of upper limbs spasticity following strokes : a multi-centre randomized placebo-controlled study of the effects on quality of life and other person-centred outcomes. J Rehabil Med 2009 ; 42 : 536-44.
 
4) 田代善久, 阪本桂造. 大腿骨頚部骨折予防に向けての片脚立ちの効果. 日骨形態誌 2003 ; 13 : 21-6.
 
5) Burbaud P, Wiart L, Dubos JL, et al. A randomised, double blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients. J Neurol Neurosurg Psychiatry 1996 ; 61 : 265-9.
PubMed
5) Kita K,Fujino K,Nasu T, et al. A simple protocol for preventing falls and fractures in elderly individuals with musculoskeletal disease. Osteroporos Int 2007 ; 18 : 611-9.
 
6) Yoshimura N, Muraki S, Oka H, et al. Prevalence of knee OA, lumbar spondylosis, and osteoporosis in Japanese men and women ; the ROAD study. J Bone Miner Metab 2009 ; 27 : 620-8.
PubMed
6) Mancini F, Sandrini G, Moglia A, et al. A randomised, double-blind, dose-ranging study to evaluate efficacy and safety of three doses of botulinum toxin type A (Botox) for the treatment of spastic foot. Neurol Sci 2005 ; 26 : 26-31.
PubMed
7) Hesse S, Reiter F, Konrad M, et al. Botulinum toxin type A and short-term electrical stimulation in the treatment of upper limb flexor spasticity after stroke : a randomized, double blind, placebo-controlled trial. Clin Rehabil 1998 ; 12 : 381-8.
PubMed
7) 星地亜都志, 木村敦, 紺野愼一, 他. 本邦におけるロコモティブシンドロームの疫学 (学会抄録). 運動器リハ 2015 ; 26 : 145.
 
8) Bakheit AM, Thilmann AF, Ward AB, et al. A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke 2000 ; 31 : 2402-6.
PubMed
9) Bakheit AM, Pittock S, Moore AP, et al. A randomized, doubleblind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke. Eur J Neurol 2001 ; 8 : 559-65.
 
10) 篠原幸人, 小川彰, 鈴木則宏, 他編. 脳卒中治療ガイドライン 2009, 協和企画, 東京, 2009, p195-7.
 
11) Verplancke D, Snape S, Salisbury CF, et al. A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clin Rehabil 2005 ; 19 : 117-25.
 
12) Ubhi T, Bhakta BB, Ives HL, et al. Randomised double blind placebo controlled trial of the effect of botulinum toxin on walking in cerebral palsy. Arch Dis Child 2000 ; 83 : 481-7.
PubMed
13) Baker R, Jasinski M, Maciag-Tymecka I, et al. Botulinum toxin treatment of spasticity in diplegic cerebral palsy : a randomized, double-blind, placebo-controlled, dose-ranging study. Dev Med Child Neurol 2002 ; 44 : 666-75.
PubMed
14) 根津敦夫, 他 : 脳性麻痺児の下肢痙縮に対するA型ボツリヌス毒素療法の試み. 脳と発達 2008 ; 40 : 15-9.
Medical*Online
15) Lowe K, Novak I, Cusick A. Repeat injection of botulinum toxin A is safe and effective for upper limb movement and function in children with cerebral palsy. Dev Med Child Neurol 2007 ; 49 : 823-9.
PubMed
16) Scholtes VA, Dallmeijer AJ, Knol DL, et al. The combined effect of lower-limb multilevel botulinum toxin type a and comprehensive rehabilitation on mobility in children with cerebral palsy : a randomized clinical trial. Arch Phys Med Rehabil 2006 ; 87 : 1551-8.
PubMed
17) Rameckers EA, Speth LA, Duysens J, et al. Botulinum toxin-a in children with congenital spastic hemiplegia does not improve upper extremity motor-related function over rehabilitation alone : a randomized controlled trial. Neurorehabil Neural Repair 2009 ; 23 : 218-25 ; Epub 2008 Dec 23.
PubMed
18) Trounq DD, Rontal M, Rolnick M, et al. Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia. Laryngoscope 1991 ; 101 (6 Pt 1) : 630-4.
 
19) Bielamowicz S, Squire S, Bidus K, Ludlow CL : Assessment of posterior cricoarytenoid botulinum toxin injections in patients with abductor spasmodic dysphonia. Ann Otol Rhinol Laryngol 2001 ; 110 (5 Pt 1) : 406-12.
 
20) Adams SG, Hunt EJ, Irish JC, et al. Comparison of botulinum toxin injection procedures in adductor spasmodic dysphonia. J Otolaryngol 1995 ; 24 : 345-51.
PubMed
21) 野寺裕之. ボツリヌス毒素による痛みの治療. Brain Nerve 2008 ; 60 : 503-8.
 
22) Shuhendler AJ, Lee S, Siu M, et al. Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches : a meta-analysis of randomized, double-blind, placebo-controlled trials. Pharmacotherpy 2009 ; 29 : 784-91.
 
23) Straube A, Empl M, Ceballos-Baumann, A et al. Pericranial injection of botulinum toxin type A (Dysport) for tension-type headache-a multicentre, double-blind, randomized, placebo-controlled study. Eur J Neurol 2008 ; 15 : 205-13.
PubMed
24) Padberg M, de Bruijn SF, de Haan RJ, et al. Treatment of chronic tension-type headache with botulinum toxin : a double-blind, placebo-controlled clinical trial. Cephalalgia 2004 ; 24 : 675-80.
PubMed
25) Ondo WG, Vuong KD, Derman HS. Botulinum toxin A for chronic daily headache : a randomized, placebo-controlled, parallel design study. Cephalalgia 2004 ; 24 : 60-65.
PubMed
P.774 掲載の参考文献
1) 坂田悍教. 運動器不安定症を有する地域高齢者に関する開眼片脚起立特性. 整・災外 2007 ; 50 : 17-25.
 
P.779 掲載の参考文献
1) Stern RA, Riley DO, Daneshvar DH, et al. Long-term consequences of repetitive brain trauma : chronic traumatic encephalopathy. PM R 2011 ; 3 (10 Suppl 2) : S460-7.
 
2) McKee AC, Daneshvar DH, Alvarez VE, et al. The neuropathology of sport. Acta Neuropathol 2014 ; 127 : 29-51.
PubMed
3) Meehan W 3rd, Mannix R, Zafonte R, et al. Chronic traumatic encephalopathy and athletes. Neurology 2015 ; pii : 10.1212/WNL.0000000000001893. [Epub ahead of print]
 
4) Bernick C, Banks S. What boxing tells us about repetitive head trauma and the brain. Alzheimers Res Ther 2013 ; 5 : 23.
PubMed
5) McKee AC, Stern RA, Nowinski CJ, et al. The spectrum of disease in chronic traumatic encephalopathy. Brain 2013 ; 136 (Pt 1) : 43-64.
 
6) Guskiewicz KM, Marshall SW, Bailes J, et al. Association between recurrent concussion and late-life cognitive impairment in retired professional football players. Neurosurgery 2005 ; 57 : 719-26.
PubMed
7) Guskiewicz KM, Marshall SW, Bailes J, et al. Recurrent concussion and risk of depression in retired professional football players. Med Sci Sports Exerc 2007 ; 39 : 903-9.
PubMed
8) Strain J, Didehbani N, Cullum CM, et al. Depressive symptoms and white matter dysfunction in retired NFL players with concussion history. Neurology 2013 ; 81 : 25-32.
PubMed
9) Stern RA, Daneshvar DH, Baugh CM, et al. Clinical presentation of chronic traumatic encephalopathy. Neurology 2013 ; 81 : 1122-9.
PubMed
10) Jordan BD. The clinical spectrum of sport-related traumatic brain injury. Nat Rev Neurol 2013 ; 9 : 222-30.
PubMed
11) Montenigro PH, Baugh CM, Daneshvar DH, et al. Clinical subtypes of chronic traumatic encephalopathy : literature review and proposed research diagnostic criteria for traumatic encephalopathy syndrome. Alzheimers Res Ther 2014 ; 6 : 68.
PubMed
12) Bernick C, Banks SJ, Shin W, et al. Repeated head trauma is associated with smaller thalamic volumes and slower processing speed : the Professional Fighters' Brain Health Study. Br J Sports Med 2015 ; 49 : 1007-11.
 
13) Singh R, Meier TB, Kuplicki R, et al. Relationship of collegiate football experience and concussion with hippocampal volume and cognitive outcomes. JAMA 2014 ; 311 : 1883-8.
PubMed
14) Gandy S, Ikonomovic MD, Mitsis E, et al. Chronic traumatic encephalopathy : clinical-biomarker correlations and current concepts in pathogenesis. Mol Neurodegener 2014 ; 9 : 37.
PubMed
15) Koerte IK, Lin AP, Willems A, et al. A review of neuroimaging findings in repetitive brain trauma. Brain Pathol 2015 ; 25 : 318-49.
 
16) Gajawelli N, Lao Y, Apuzzo ML, et al. Neuroimaging changes in the brain in contact versus noncontact sport athletes using diffusion tensor imaging. World Neurosurg 2013 ; 80 : 824-8.
PubMed
17) Small GW, Kepe V, Siddarth P, et al. PET scanning of brain tau in retired national football league players : preliminary findings. Am J Geriatr Psychiatry 2013 ; 21 : 138-44.
PubMed
18) Barrio JR, Small GW, Wong KP, et al. In vivo characterization of chronic traumatic encephalopathy using [F-18] FDDNP PET brain imaging. Proc Natl Acad Sci U S A 2015 ; 112 : E2039-47.
PubMed
19) Marchi N, Bazarian JJ, Puvenna V, et al. Consequences of repeated blood-brain barrier disruption in football players. PLoS One 2013 ; 8 : e56805.
PubMed
20) McKee AC, Stein TD, Kiernan PT, et al. The neuropathology of chronic traumatic encephalopathy. Brain Pathol 2015 ; 25 : 350-64.
PubMed
21) Jafari S, Etminan M, Aminzadeh F, et al. Head injury and risk of Parkinson disease : a systematic review and meta-analysis. Mov Disord 2013 ; 28 : 1222-9.
PubMed
22) Acosta SA, Tajiri N, de la Pena I, et al. Alpha-synuclein as a pathological link between chronic traumatic brain injury and Parkinson's disease. J Cell Physiol 2015 ; 230 : 1024-32.
PubMed
23) Chio A, Benzi G, Dossena M, et al. Severely increased risk of amyotrophic lateral sclerosis among Italian professional football players. Brain 2005 ; 128 (Pt 3) : 472-6.
PubMed
24) Lehman EJ, Hein MJ, Baron SL, et al. Neurodegenerative causes of death among retired National Football League players. Neurology 2012 ; 79 : 1970-4.
PubMed
25) McKee AC, Gavett BE, Stern RA, et al. TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy. J Neuropathol Exp Neurol 2010 ; 69 : 918-29.
PubMed
26) Giza CC, Kutcher JS, Ashwal S, et al. Summary of evidence-based guideline update : evaluation and management of concussion in sports : report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2013 ; 80 : 2250-7.
PubMed
27) Concannon LG, Kaufman MS, Herring SA. Counseling athletes on the risk of chronic traumatic encephalopathy. Sports Health 2014 ; 6 : 396-401.
PubMed
28) Montenigro PH, Bernick C, Cantu RC. Clinical features of repetitive traumatic brain injury and chronic traumatic encephalopathy. Brain Pathol 2015 ; 25 : 304-17.
PubMed
29) Levin B, Bhardwaj A. Chronic traumatic encephalopathy : a critical appraisal. Neurocrit Care 2014 ; 20 : 334-44.
PubMed
30) Sinnott R, Maddela RL, Bae S, et al. The effect of dietary supplements on the quality of life of retired professional football players. Glob J Health Sci 2012 ; 5 : 13-26.
PubMed

第16章 遺伝子診断と遺伝相談

P.785 掲載の参考文献
1) 日本神経学会. 神経疾患の遺伝子診断ガイドライン 2009.
 
2) 日本医学会. 医療における遺伝学的検査・診断に関するガイドライン.
 
3) 岡山大学神経内科における遺伝子検査 1,000件の臨床疫学的解析. 臨床神経 2011 ; 51 : 471-7.
 
P.790 掲載の参考文献
1) 日本神経学会. 神経疾患の遺伝子診断ガイドライン 2009, 医学書院, 2009. http://www.neurology-jp.org/guidelinem/sinkei_gl.html
 
2) 日本医学会. 医療における遺伝学的検査・診断に関するガイドライン. http://jams.med.or.jp/guideline/genetics-diagnosis.html
 
3) Bennett RL, Steinhaus KA, Ulrich SB, et al. Recommendations for Standardized Human Pedigree nomenclature. Am J Hum Genet 1995 ; 56 : 745-52. 日本語要約 : 小林公子, 濱口秀夫. ヒトの家系図作成法の標準化案の提唱. Jpn J Hum Genet 1996 ; 41 : 269-74.
 
4) 新川詔夫 監, 福嶋義光 編. 遺伝カウンセリングマニュアル 改訂第2版. 南江堂, 2003. (参考図書)
 
5) OMIM : Online Mendelian Inheritance in Man http://www.omim.org/ (ヒトの遺伝性疾患のデータベース)
 
6) Washington University Neuromuscular disease center http://neuromuscular.wustl.edu/ (神経筋疾患のデータベース)
 

書評

最近チェックした商品履歴

Loading...